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Abstract 
Pulmonary arterial hypertension is a chronic inflammatory condition of the peripheral 
pulmonary vessels which is thought to affect up to 52 in every million people. Vasoconstriction, 
proliferation and vascular remodelling mechanisms dominate which narrow and occlude 
pulmonary vessels, ultimately leading to right ventricular heart failure. Lung transplantation 
with all its associated complications remains the only cure. Prostacyclin mimetics are used as 
long-term therapy to slow disease progression and manage symptoms. Treprostinil is a 
clinically registered prostacyclin mimetic which is available in parenteral, oral and inhaled 
dosage forms, although the parenteral form provides the best treatment. Treprostinil shows 
some efficacy for PAH treatment, but is dose limited by adverse events that are a major burden 
to patients. 
The aims of the project were to develop a prodrug strategy to increase the maximum tolerated 
dose of treprostinil. A meta-analysis was first conducted using clinical data for prostacyclin 
and treprostinil treatments to determine which adverse events caused the greatest impact on 
the dose of treprostinil that could be given. The meta-analysis was also designed to 
understand the likely mechanistic causes for the most limiting adverse events. The dose 
limiting adverse event causing the greatest limitation to dosing is the pain at the site of 
administration that is associated with subcutaneously administered treprostinil. Prostanoid 
EP2 and DP1 receptors for which treprostinil has potent affinity are present in the vasculature 
in the skin which gives rise to the swelling, flushing and pain upon exposure to high 
concentrations of treprostinil present in subcutaneous infusion 
Although polymer-treprostinil prodrugs and their constituent components were examined, 
treprostinil N-acyl sulfonamide was first considered as a potential prodrug candidate. The N-
acyl sulfonamide was evaluated because it has the potential to undergo subsequent enzymatic 
degradation in the liver to release active treprostinil. Although the in vitro activity of the prodrug 
treprostinil N-acyl sulfonamide was found to be less than treprostinil, there was concern from 
the industry collaborators about the stability of this prodrug version of treprostinil.  
Since treprostinil is as an agonist, treprostinil N-acyl sulfonamide was also considered for a 
polyvalent strategy. Unfortunately linking treprostinil to a polymer without undue loss of activity 
did not appear to be feasible. So treprostinil was used as a monomer to be conjugated within 
a degradable polyacetal mainchain. Water-soluble polyacetals undergo accelerated 
degradation at mildly acidic pH values which may be present in PAH diseased tissue. 
Treprostinil was conjugated within the mainchain using divinyl ether ethylene glycol and 
poly(ethylene glycol) as co-monomers. Treprostinil oligoacetal was obtained and was found to 
degrade in acidic conditions. The use of treprostinil as a co-monomer for polyacetal synthesis 
requires further optimisation because the two secondary hydroxyl groups in treprostinil may 
not be reactive enough and better masking of the treprostinil carboxylic acid moiety during 
storage is required. 
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Developing a polymer-pendent drug conjugate strategy for the targeted release of treprostinil 
was also investigated. A targeting moiety, CAR peptide, was synthesised and investigated for 
the extent of specific localisation in disease cells over healthy cells. A treprostinil release linker 
based on tryptase which is an enzyme present in the PAH diseased lung was also examined 
in parallel. A method to prepare the tryptase substrate prodrug derivative of treprostinil on-
resin was pursued. The method outlined shows promise in forming the treprostinil linker 
derivatives via a scalable route. It is envisaged that such treprostinil-linker adducts could be 
used in a polymeric conjugate or potentially in an antibody-drug conjugate. 
Methods to derivatise treprostinil were identified highlighting routes that could be pursued 
further. Polymeric-derivatisation of treprostinil may be a promising strategy to overcome 
current existing limitations with prostacyclin mimetic therapies. It is hoped that the progress 
described in this thesis will aid and guide future investigations in polymeric derivatives of 
treprostinil.  
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Impact Statement 
Adverse events caused by off-target effects limit the tolerability and efficacy of treatments for 
many diseases. For chronic, progressive diseases such as pulmonary arterial hypertension 
(PAH), the negative impact adverse effects from treatment on quality of life and not slowing 
disease progression can be a considerable burden for patients and their caregivers. 
This CASE studentship funded by the BBSRC and Lung Biotechnology Ltd. (a subsidiary of 
United Therapeutics) focuses on improving the tolerability of the gold standard drug class for 
the treatment of PAH. Clinical data was consulted to understand the dose limiting adverse 
events associated with different therapies which were then interpreted in the context of 
different pharmacological behaviours. The understanding gained provided direction to develop 
a prodrug of treprostinil to reduce activity in healthy tissues while increasing drug exposure in 
the PAH lung. Much of the research described in this thesis focused on using polymeric 
prodrug strategies to improve the toxicity profile of treprostinil. 
The impact of the work presented in this thesis is that the increased understanding of methods 
to chemically modify treprostinil as a prodrug to treat PAH can also be applied to related 
prostacylin mimetics. Furthermore, the approach for design and the concepts that were 
considered could be applied for therapies that are not inherently toxic but exert unwanted 
biological activity in healthy tissues which limits therapeutic efficacy. The intended net impact 
to optimise the effect of each dose while limiting adverse events could potentially reduce cost 
of treatment for chronic diseases such as PAH.  
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 Introduction 
 Pulmonary arterial hypertension 
Pulmonary arterial hypertension is a rare but fatal inflammatory disease estimated to affect 10 
million people worldwide. It is clinically defined as a sustained pulmonary arterial pressure 
(PAP) >25 mm Hg at rest, with a mean pulmonary-capillary wedge pressure and left ventricular 
end-diastolic pressure of less than 15 mmHg.1 Pulmonary arterial hypertension (PAH) forms 
Group 1 of the classification system defined and updated at the World Pulmonary 
Hypertension Symposium, 2013.2 Group 1 PAH includes idiopathic (IPAH), heritable, 
toxin/drug-induced PAH and PAH secondary to diseases such as connective tissue disease, 
congenital heart disease and human immunodeficiency virus (HIV) as well as persistent PAH 
of new-born infants. Regardless of the underlying cause, all PAH types are characterised by 
vasoconstriction as well as vascular smooth muscle cell (VSMC), endothelial cell (EC) and 
fibroblast proliferation causing remodelling of the distal pulmonary arteries.3  
 
Figure 1-1. Change in vascular smooth muscle cells during progression of pulmonary 
arterial hypertension. (i) The endothelial cells become dysregulated and small 
pulmonary arterials become muscularised; (ii). Large pulmonary arteries become 
muscularised (medial hypertrophy) and the vessel contracts, narrowing the lumen; (iii) 
Smooth muscle cells proliferate and infiltrate the intimal layer (neointimal formation) 
narrowing the lumen further, and resulting in occlusion of vessels; (iv) Severe 
remodelling of arteries forming plexiform lesions within the vessels.4 
Pulmonary arterial hypertension effects females disproportionately at a ratio of 2:1 compared 
to males, although the prognosis if often better for women.5 Mean age of patients with PAH 
was 36 ±15 for the National institute of health (NIH) registry between 1981 -85.6 The mean 
age has increased to 50 years in the years since 1993, as PAH in elderly patients is better 
recognised.  
In the initial stages of PAH, patients are often asymptomatic and only as the disease 
progresses do patients present with breathlessness and fatigue when performing everyday 
tasks (e.g. climbing the stairs). Owing to its rarity, the time taken from initial contact with a 
general practitioner to referral for PAH investigation is often over 3 years.7 The diagnostic 
procedure for PAH involves catheterisation of the pulmonary artery to calculate pulmonary 
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arterial pressure (PAP) and vascular resistance (PVR). As the disease progresses, the vessels 
become narrower, more fibrotic and are under a higher pressure with higher resistance 
(Figure 1-1).8 The increased pressure puts strain on the right ventricle of the heart which 
becomes less elastic and more fibrotic in response. As a result of these effects on the heart, 
PAH patients ultimately die of right ventricular heart failure or sudden cardiac death.9 
As well as haemodynamic parameters, the severity of disease is determined using functional 
read outs, such as 6-minute walk test and patient-reported outcomes such as Borg-dyspnea 
score. Disease severity is stratified by the World Health Organisation/New York Heart 
Association (WHO/NYHA) classification increasing from class I to IV which is used to guide 
treatment strategies. NYHA class uses the symptoms experienced by patients to classify heart 
function. Class I, patient experiences no limiting symptoms during physical activity; Class II, 
patients experience some limitations when performing physical activities; Class III, patients 
experience marked limitations during even normal activities but are comfortable at rest; Class 
IV, patients experience discomfort even at rest. Disease severity is measured and assessed 
through the clinical measure 6-minute walk distance (6MWD). The 6MWD test is performed 
by calculating distance walked on a flat surface in 6 minutes. As well as at initial diagnosis, 
these methods allow for less invasive monitoring of patient health and effects of lifestyle and 
therapeutic interventions. 
 
Endothelial changes are the earliest understood step to initiate PAH10, and although the 
underlying mechanism in IPAH is unknown, there is evidence that mitochondrial malfunction 
could play a role.11 In all PAH cases, endothelial damage caused by a variety of factors, 
including sheer stress, genetic factors and hypoxia are considered to be initiators of the 
disease. In healthy tissues, the endothelial cell layer lining small vessels is known to regulate 
vascular function. In PAH tissue, however, their phenotype changes and cells release growth 
factors and cytokines. The dysfunction facilitates vasoconstriction, thrombosis and 
inflammatory cell infiltration.12 VSMCs become proliferative and anti-apoptotic which leads to 
their infiltration through the medial layer and into the intima.13 Alterations in the phenotype of 
endothelial and VSM cells, where thromboxane and endothelin are released causes 
constriction of the vessel and a characteristic increase in PAP because of a high pulmonary 
vascular resistance occurs.1 In response to the inflammatory environment created, 
angiogenesis is stimulated.14 However, vessel growth occurs in a disordered fashion which 
leads to vascular remodelling and the formation of plexiform lesions.15 This further disrupts the 
vessel haemodynamics and eventually leads to vascular pruning where the distal pulmonary 
arteries become completely occluded and lose function and/or undergo necrosis.16 This 
process puts more strain on the right ventricle of the heart causing hyperplasia, hypertrophy 
and fibrosis of cardiac muscle cells, eventually leading to right heart failure and ultimately 
death.17 
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Within PAH tissue, the dysregulation of growth factors, enzymes, cell surface receptors, 
nuclear receptors and chemokines have been reported.16,18 Cell proliferation is promoted via 
changes to the extracellular matrix (ECM) brought about in part by matrix metalloproteases 
(MMPs), elastases and proteases. Specifically, MMP 2 and 9 are upregulated in PAH, which 
drives proliferation by releasing extracellular matrix (ECM) proteases. During remodelling, 
serine elastase activity is also increased which degrades the ECM,19 as well as heparinase, 
responsible for the cleavage of heparan sulfate chains on the cell surface.20 As a result of the 
mast cell accumulation and activation during chronic inflammation,21 tryptase and chymase 
are also released into the surrounding tissue.22,23 
Mast cells are present at varying densities throughout the body but can migrate and 
accumulate in sites of chronic inflammation.24 Their pathogenic roles include immune 
modulation, pro-inflammation, pro-fibrotic and surprisingly anti-inflammation. Mast cells are 
granulated, and each granule contains a cocktail of enzymes including tryptase and chymase, 
histamine, cytokines such as TNF-α, vasoconstrictors including thromboxane and 
prostaglandin D2, platelet activating factors and reactive oxygen species. Whereas many 
inflammatory cells release or produce most of the contents of a mast cell, tryptase and 
chymase are entirely specific to mast cells. Furthermore, there are two types of mast cells 
(MCs); in addition to the other contents listed, MCT are found only in the lung, and contain only 
tryptase (Hence, T) whereas MCTC which are associated with connective tissue, contain 
tryptase and chymase (hence, TC). Therefore, wherever chymase is present, tryptase is there 
too, but not vice versa. Upon activation of the mast cells, the granule contents are released 
into the surrounding tissue.  
 
Figure 1-2. Mast cell degranulation. Enzymes are stored within granules in the mast 
cells. Upon stimulation, the mast cell undergoes degranulation, releasing the enzymes 
into the extracellular compartment. 
The lung tissue contains two types of mast cells; MCT is found in the lung parenchyma which 
is rich in mast cells; and MCTC are found surrounding the pulmonary blood vessels, associated 
with connective tissues.25 Mast cells populations have been shown to increase in fibrosis, 
notably chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis (IPF). In IPF 
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patients, mast cell numbers have been reported to increase,26 particularly in the lung 
parenchyma and in fibrotic bundles compared to healthy tissues.27 Tryptase-positive mast cells 
in IPF have also been detected in their degranulated state.26 It should be noted however, that 
another study has shown an increase in mast cell density but not in total mast cell number.28 
PAH is an inflammatory, fibrotic disease29 so it is highly possible that MCs are involved with 
the progression of PAH. Increased chymase has been detected in vascular lesions with intimal 
fibrosis, suggesting a role in tissue remodelling in PAH.30,31 
Because PAH is such a complex disease, a variety of animal models are used to replicate the 
different features of the disease. However these models indicate different levels of MC 
involvement.30 None-the-less, in human tissue, chymase- and tryptase- positive mast cells 
have been shown to accumulate in the lung parenchyma and the adventitia of small blood 
vessels.32 Furthermore, in hypoxic conditions, MCs were implicated in the muscularisation of 
peripheral vessel33, and activated perivascular MCs were upregulated in the tissues of IPAH.34 
Price et al. found that the MC increases are found in both IPAH as well as PAH associated 
with coronary heart disease.35  
An increase in chymase and mast cells was found in a rat monocrotaline model of PAH with 
an aorto-cavel shunt. Tissue remodelling was attenuated and haemodynamic improvements 
were observed when the rats were treated with mast cells inhibitors.36 Mast cell accumulation 
was also associated with a supra-coronic aortic band model of left heart disease.37,38 The 
movement of MCs was investigated in the days after hypoxia exposure. Accumulation began 
in the pre-alveloar regions after 4 days which migrated to the pulmonary vasculature with 
further hypoxia exposure.39 Hypoxia-induced mast cell accumulation has been reported by 
others, which increases the chymase and trypase production.22,34,40  
Once released the contents of the mast cell granules have been shown to play an important 
role in initiating hypoxic pulmonary vascular modelling.31,41 It is well understood that a number 
of the inflammatory markers released from MC granules are implicated in remodelling 
pathways.42 Tryptase has been shown to split collagen I which stimulates the proliferation of 
smooth muscle cells, and thus likely to contribute to PAH pathobiology.43 
The role of mast cells in fibrosis and PAH is still not elucidated and is a topic of debate,44 
however the accumulation of mast cells within the PAH tissue is evidenced. A role of enzymes 
in chronic inflammation and PAH is established which changes the phenotype of cells.4,16,42 
The extracellular matrix is degraded which stimulates pro-inflammatory, pro-thrombotic, 
proliferative and fibrotic pathways, ultimately driving remodelling and the progression of PAH.42 
 
Proliferative and pro-inflammatory mechanisms, glycolytic respiration and tissue remodelling 
are all characteristic features of cancer. The parallel between PAH and cancer in relation to 
the pathways implicated and pathophysiological features has been highlighted.45 The 
hallmarks of cancer were highlighted and described by Hanahan and Weinberg46 and have 
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since been used to describe many facets of PAH.45 Although treatment strategies differ 
between cancer and PAH, the delivery and targeting of therapies may share similar 
approaches. A downside to PAH treatments is that as an orphan disease, fewer attempts to 
treat and understand PAH have been made compared to cancer. On the other hand, the 
similarities between the diseases may suggest that PAH treatments can benefit from the 
research and lessons learnt in the cancer field.  
 
Figure 1-3. Hallmarks of cancer, originally described by Hanahan and Weinberg46 and 
later compared to PAH by Bouchater et al., from which this is adapted.45 Half of the cancer 
features overlap with PAH and only one the activation and invasion of metastatis is not 
seen in PAH. The bold arrow indicates a high degree of similarity between cancer and 
PAH and a dashed arrow indicates a low similarity. 
Similar to the rapid cell growth characteristic of cancer, as PAH smooth muscle cells proliferate 
rapidly47 and gas exchange becomes less efficient, oxygen is used up faster than it can be 
provided, particularly in the fibrotic regions.48 Under stimulation by growth factors and pro-
proliferative agents, cells switch to an anaerobic glycolytic pathway for respiration and thus 
survival.16 Employing glucose as the energy source, cells can continue proliferating and 
developing, producing lactate as a by-product.49 In areas of poor vascularisation and inefficient 
gas exchange, the lactic acid builds up, in a process known as lactic acidosis. The high 
concentration of lactic acid causes an increase in acidity which can reach pH 6.0.50 
 
The complexity of PAH combined with an unknown underlying cause means that the main 
implicated pathways are multiple and much debated.4,29,51 It is well understood that an 
imbalance in vasomediators resulting in increased vasoconstrictors (thromboxane, endothelin) 
and decreased vasodilators (nitric oxide, prostacyclin) is involved in the disease progression. 
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Figure 1-4. The endothelin, nitric oxide (NO) and prostacyclin pathways involved in 
the pulmonary arterial hypertension in smooth muscle cells and their targeting for 
therapeutic benefit. The yellow triangles indicate the endogenous vasomediators. 
Endothelin-1 (ET-1) is an agonist of the ETA and ETB receptors which activates 
phospholipase C and increases intracellular calcium. An increase in calcium leads to 
a constriction of the vessel. Inhibiting the endothelin pathway can be achieved by use 
of selective and dual endothelin receptor antagonists (ERAs) Phospholipase C can 
also be activated by agonism of the EP1, FP and thromboxane (TP) receptors. 
Prostacyclin (PGI2) and selective agonists are active at the prostacyclin (IP) receptor. 
Prostacyclin analogues also have affinity for the IP receptor as well as other prostanoid 
receptors; The agonism of IP, DP1 and EP2 receptors activates adenylate cyclase 
which converts adenosine triphosphate (ATP) to cyclic adenosine monophosphate 
(cAMP). An increase in cAMP inhibits the mobilization of calcium (Ca2+) causing a 
vasodilatory response. Some prostacyclin (PGI2) analogues have affinity at the EP3 
receptor which inhibits the activation of adenylate cyclase, resulting in the increased 
mobilization of calcium. The EP1 receptor can be activated by prostacyclin analogues 
causing a vasoconstrictive effect. NO activates guanylate cyclase which converts 
guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP) which 
inhibits the mobilization of calcium, resulting in vasodilation. Guanylate cyclase can 
also be activated by soluble guanylate cyclase (sGC) stimulators or the removal of 
cGMP can be inhibited by phosphodiesterase-5 inhibitors (PDE-5i) which extends the 
inhibition of calcium mobilization. Orange lines indicate vasoconstrictive effects and 
blue lines indicate vasodilating effects. Image adapted from Lang and Gaine.52 
Endothelin Pathway 
Endothelin-1 is a 21-amino acid peptide produced in endothelial (and smooth muscle) cells 
which activates its two native receptors (ETA and ETB) to activate phospholipid C which 
mobilises calcium. An increase in calcium results in heightened proliferative and 
vasoconstrictive effects.53 During PAH, production of endothelin-1 is increased leading to 
disease progression.54 Therefore, the therapeutic use of endothelin receptor antagonists 
(ERAs) was designed to block the actions of endothelin by competitively binding to its 
receptors which prevent the downstream effects and slow disease progression. Clinically, 
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bosentan, macitentan, and ambrisentan are endothelin antagonists used in the treatment of 
PAH. 
Nitric Oxide (NO) 
Within healthy tissues, a whole host of vasoactive mediators implicated in a variety of 
mechanistic pathways control the activity of the vasculature. Within PAH, vasodilators NO and 
prostacyclin are down-regulated which allows for vasoconstrictive mechanisms, involving 
endothelin and thromboxane to dominate. NO is synthesised in endothelial cells by the 
conversion of L-arginine to L-citrulline by endothelial nitric oxide synthase enzyme. NO acts 
locally on smooth muscle cells and platelets to activate guanylate cyclase which causes an 
increase in cyclic guanosine monophosphate (cGMP) which prevents calcium being mobilised 
and ultimately results in antiproliferative, anti-platelet and vasorelaxation effects. An increase 
in arginase is also thought to be responsible for the decrease in NO.55,56 
Phosphodiesterase pathway 
The phosphodiesterase-5 (PDE-5) enzyme is responsible for the inactivation of cyclic 
guanosine monophosphate (cGMP), the compound responsible for activating vaso-protective 
mechanisms, including vasodilation and antiproliferative.57 Upregulated in PAH, driving 
disease progression by reducing the downstream effects of NO which in itself activates 
guanylate cyclase to produce cGMP. The action of PDE-5 is a therapeutic target to inhibit 
using PDE-5 inhibitors (PDE-5is). Inhibitors such as sildenafil and tadalafil have been shown 
to improve functional class, the  6-minute walk distance (6MWD) and decrease pulmonary 
arterial pressure.58,59 PDE-5 inhibitors are often used in combination without classes of PAH 
treatment.60 
Prostacyclin  
Prostacyclin (PGI2) (1), is a vasoactive compound first identified by Sir John Vane for which 
he was later awarded the Nobel Prize. Prostacyclin is derived from arachidonic acid 
metabolism in the endothelial and smooth muscle cells of vascular tissue by the action of 
cyclooxygenase-2 and PGI2 synthase enzymes. PGI2 is the natural ligand for the G-protein 
coupled IP receptor, found on the surface of platelets, endothelial cells (ECs) and vascular 
smooth muscle cells (VSMCs). The structure of prostacyclin contains a vinyl ether which is 
susceptible to acid-mediated hydrolysis converting it to a less stable compound in less than 3 
minutes in blood. Owing to its chemical instability, PGI2 cannot be stored so can only exert its 
action locally.61 Upon binding to the IP receptor, the Gs protein becomes activated and initiates 
an intracellular cascade of reactions resulting in elevated concentrations of intracellular cyclic 
adenosine triphosphate (cAMP).  Increased concentration of cAMP causes the activation of 
protein kinase A which decreases intracellular calcium ions, leading to vasodilation as well as 
the inhibition of VSMC proliferation and platelet aggregation.62 
In healthy patients, the relative concentrations of PGI2, and resulting outcomes, are in balance 
with other members of the prostaglandin family which maintain optimal vascular tone. 
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However, in PAH patients, there is a significant decrease in PGI2 synthase expression as well 
as a down regulation of the IP receptor63,64 enhancing the effect of vasoconstrictive 
mechanisms and progressing the disease further. Introducing exogenous prostacyclin to 
agonise the IP receptor or transfer of the IP receptor gene into animal models of PAH have 
been shown to ameliorate disease progression.65 This mechanistic understanding has driven 
the development of prostacyclin mimetic (PM) therapies to agonise the PGI2 pathway in the 
treatment of PAH.  
 
Figure 1-5. Different prostacyclin mimetics have different prostanoid receptor 
affinity profiles and are able to activate therpeuically beneficial receptors (Blue) and 
receptor which aid disease progression (Green).  
As well as the IP receptor, other prostanoid receptors exist which possess very similar 
structures. Despite the similar binding domains of the receptors, the intracellular couplings can 
vary to stimulate different intracellular proteins. The Gs protein is coupled to the IP, EP2, EP4 
and DP1 receptors, leading to cAMP generation, a decrease in intracellular calcium promoting 
a vasodilatory effect. Alternatively, the prostanoid receptors, such the EP1, EP3 and TP 
receptors, may be coupled to a Gq or Gi protein which have the opposite effect by raising 
intracellular calcium levels. Many synthetic IP receptor agonists have been developed and 
several have reached the market. As a result of the similarities between prostanoid receptors, 
IP receptor agonists are not entirely specific and possess varying affinity towards the different 
receptors.29 Successful prostanoid mimetics used in the treatment of PAH include Iloprost (2), 
Beraprost (3), Treprostinil (4) and selexipag (5), the prodrug of ACT-333679 (6) which all have 
affinity and potency at the IP receptor with varying additional selectivity to other prostanoid 
receptors. ACT-333679 is unique in that its structure is not based on that of prostacyclin and 
does not activate other prostanoid receptors so is considered a non-prostanoid, highly 
selective IP receptor agonist. 
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Figure 1-6. Prostacyclin mimetics used in the treatment of pulmonary arterial 
hypertension (PAH). Prostacyclin (and Epoprostenol) 1; Iloprost 2; Beraprost 3; 
Treprostinil 4; Selexipag prodrug 5; Selexipag metabolite, ACT-333679, 6. Red shows 
the cleavable moiety to release active agonist. 
 Prostacyclin and Mimetic Therapies 
Epoprostenol (Same structure as 1) is synthetically produced PGI2 and was the first 
prostacyclin receptor agonist therapy to be approved for the treatment of PAH in the USA in 
1995. It has a systemic half-life of less than 3 minutes in the blood, mostly due to the 
susceptibility of the vinyl ether to hydrolysis66 which drastically limits the potential of the drug 
due to the difficulty surrounding administration. Due to the lability of the vinyl ether, 
epoprostenol 1 needs to be continuously infused intravenously via a portable pump67 and the 
drug formula cassette needs to be kept cold by the use of a cooling pouch which needs to be 
changed every ~12 hours.68 Despite the cumbersome delivery device, risk of sepsis and 
associated risks with jamming of the pump,67 epoprostenol 1 is considered the gold standard 
treatment for late stage PAH. It has shown to significantly improve 6MWD and haemodynamic 
parameters, and is still the only treatment available shown to improve survival.69  
To minimise the issue of poor stability, epoprostenol sodium (Veletri®) was reformulated in 
2008 for use with a diluent containing L-arginine at pH 11-13 by addition of sodium hydroxide 
to achieve thermostabililty.70,71 The presence of L-arginine is thought to improve NO 
bioavailability as well as adding to the basic nature of the diluent. This formulation reduced the 
acid-catalysed degradation and negated the need for cooling of the dose pack.  
Intravenous administration of bioactive compounds via a catheter provides an instant increase 
in drug plasma concentration and with continuous infusion can be tuned to supply a constant 
dose over time minimising the peak and trough concentration variations. Although 
epoprostenol 1 is efficacious in treating PAH, the chronic nature of PAH requires an easier 
4 5 
6 
2 1 3 
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method of therapy delivery. The central catheter delivery requires healthcare professionals to 
insert, maintain and remove which as well as being inconvenient for the patient. Not only is 
this a costly way to administer the drug, but the the risk of infection is high (particularly in 
tropical climates) with severe outcomes. Lastly, the device is bulky to carry around. Together 
all of these issues, have a significant impact on quality of life.72 
Despite its biological relevance in PAH and its efficacy in the clinic, the instability of 
epoprostenol 1 in vivo means administration by any route other than central IV line is not viable 
for long-term use. Nebulised epoprostenol has been used off-label in critically ill or paediatric 
patients with PAH in pre, during or post cardiac surgery.73 Epoprostenol sodium is 
reconstituted in glycine buffer at pH 10.2 - 10.8 and delivered via ventilation mask or 
endotraceal mask fitted to a ventilator continuously over a period of hours.74,75 The system 
must avoid direct sunlight as epoprostenol is light sensitive.68 Whilst a suitable option for 
hospitalised patients, it is not easy for patients to adopt over a long period of time and maintain 
a degree of independence. Attempts to overcome stability of epoprostenol have carved an 
evolutionary path of PGI2 mimetic therapies. Initially PGI2 therapy was given by continuous IV 
infusions, which then led to the development of subcutaneous, inhalable and oral for 
formulations before arriving to the present day in the beginning of the nanomedicine 
revolution.76 Recent formulations trialled in academia and industry involve liposome 
encapsulations,77,78 polymer prodrugs79 and slow release nanoparticles.80  
 
Treprostinil 4 was approved as a PAH treatment by the FDA in 2002. Its stable tricyclic 
benzindene structure is based broadly on the prostanoid structure without possessing the 
labile vinyl ether. Formulated as the sodium salt, treprostinil 4 has a neutral pH, is stable at 
room temperature and has a systemic half-life of 4 hours in blood.81 In vitro, 91 % of treprostinil 
was shown to bind to unspecified proteins in human plasma.82 Treprostinil 4 is metabolised in 
the liver mainly by the CYP2C8 enzyme66 and 79% is excreted as several urinary metabolites 
none of which possess any biological activity.83,84 Initially selected for its potent IP receptor 
agonist properties, treprostinil 4 has since been shown to have activity at the EP2, DP1 and 
peroxisome proliferator-activated receptors (PPAR) β receptors, which may contribute to drug 
efficacy in slowing disease progression.62 In addition to potent activity at the IP receptor, 
treprostinil 4 is 10-fold more active at the DP1 (venodilating) and EP2 receptors (vasodilating).85 
Marketed as Remodulin®, treprostinil 4 was developed as a subcutaneous formulation for 
continuous infusion without the need for pack-cooling. This was intended to give patients more 
freedom to continue daily routines with reduced risk of serious catheter related infections.86,87 
Furthermore, the reliance on healthcare professionals and hospital time was reduced, as 
insertion of the SC line can be carried out by trained patients. Remodulin® was approved for 
subcutaneous infusion matching the constant dosing provided by IV with 100 % absolute 
bioavailability yet with a less invasive entry route and reduced risk of infection. Despite this, 
slight biurnal fluctuations in treprostinil concentrations in the blood are still prevalent 
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throughout the day and if terminated (e.g. from a pump malfunction), blood drug concentration 
decreases rapidly with a half-life of 3 hours.88 Treatment with Remodulin® in PAH patients 
over 12 weeks improved 6MWD by 16 m (p = 0.006).89 The cost of Remodulin® treatment for 
patients using 60-69 ng/kg/min exceeds $142,350 per year.90  
Although patients receive a relatively constant dose of treprostinil and experience 
improvements in the symptoms of PAH, the adverse events at the site of administration are a 
major limitation. Patients reported significant adverse events related to the injection site that 
include, swelling burning sensations, vasodilation of the local vasculature and most 
significantly, pain.89 It is recommended that the infusion site is maintained for as long as 
possible before changing and non-opiate analgesics are prescribed to manage the infusion 
site pain.82 In addition the pump is cumbersome and inconvenient for everyday living91. 
Although not common, infusion pump malfunctions can occur which results in a decreased 
tolerated dose, restricting a patient’s progress and can cause serious side effects including 
death. 
To alleviate the site pain, Remodulin was reformulated and approved for intravenous infusion 
administration in 2004. Owing to the inconvenience of IV administration and the risk of catheter 
infections, it is used as an alternative to epoprostenol as a second line treatment for patients 
presenting group III and IV PAH or for those who have been hospitalised. 
The benefits of continuously infused parenteral therapy, either SC or IV is that a near constant 
dose can be maintained. Although there are slight variations resulting in changes in 
metabolism between activity during the day and resting fast states in the night, the fluctuations 
are kept to a minimum. Because of the 100% bioavailability of these routes, cost of treatment 
is optimised to utilise all the active pharmaceutical ingredient available. The direct route of 
administration results in higher doses being tolerated than for non-parenteral routes.  
Despite the efficacy of parenteral PM therapy, the restrictions discussed, including wearing a 
continuous pump and demanding maintenance requirements, are burdening for patients for 
long-term therapy. 
 
The next generation of therapeutics introduced were designed to widen the therapeutic 
window to overcome the systemic effects with the introduction of inhalable treatments directed 
towards the diseased tissue. Nebulised prostacyclin mimetics are a non-invasive and self-
administered dosage form which provides a titratable and localised dose to the target organ. 
Once administered, the active pharmaceutical ingredient (API) is absorbed through the 
alveolar membrane and diffuses into the pulmonary capillaries where it arrives directly at the 
pulmonary vasculature at a rate dependent on diffusion across the alveolar tissue.92 Re-dosing 
is required multiple times a day via a hand-held nebuliser, depending on the active analogue 
used. 
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Inhaled iloprost 2 was first approved in 2004 by the FDA under the trade name Ventavis.93,94 
Iloprost is a PGI2 analogue stable at room temperature and physiological pH.95 Non-invasive 
delivery was first achieved by aerosol inhalation. Bioavailability of iloprost entering the vascular 
compartment is approximately 80% with the maximal concentration reached within 5 
minutes.96 Although iloprost has a half-life of 20-25 minutes when administered 
intravenously,97 in the airways the half-life is decreased to 6.5–9.4 minutes owing to rapid β-
oxidation.98 As a result, 6-12 inhalations per day are required to maintain concentrations of 
iloprost that maintain clinical benefit.99 As well as the inconvenience to patients, this made 
treatment disproportionately expensive for the efficacy achieved. Inhalation time has been 
reduced from 15 to 4 minutes per dose by use of ultrasonic nebulisation for particle 
formation.100 Pharmacologically, Iloprost 2 is a potent IP receptor agonist, with an inhibition 
constant (Ki) of 3.9 nM. Although iloprost has low affinity for EP2, EP3 and DP1, it has the most 
potency at the EP1 receptor with Ki at 1.1 nM.62 Activation of the EP1 receptor leads to an 
increase in intracellular calcium which leads to vasoconstriction,101 working against the 
vasorelaxation brought about by IP agonism.85 Although inhaled iloprost is used clinically, 
improving haemodynamics and exhibiting fewer adverse events,95 its utility in the clinic as a 
first line treatment could be hindered by its conflicting pharmacological character. 
Treprostinil 4 was formulated into an inhaled nebulised form of the sodium salt and marketed 
as Tyvaso®. In 2009, Tyvaso® received FDA approval for treatment of PAH in patients with 
class III symptoms.102 When treprostinil was first used clinically on a compassionate basis in 
only three patients, an improvement in functional class was achieved with no reported adverse 
events,103 although this was not reflected in the results of Tyvaso in the pivotal clinical trial.104 
An increase in 6MWD and measure of quality of life was reported, but not improvement in 
functional class or time to clinical worsening. In addition, adverse events including coughing 
and flushing were experienced, which in 7 patients (out of total 115) receiving inhaled 
treprostinil, resulted in its discontinuation. In an open-label trial comparing inhaled iloprost and 
inhaled treprostinil, the maximal vasodilatory effect measured by PVR was experienced later 
(18 ±2 min versus 8 ±1 min, mean ± standard error of the mean (SEM), p<0.0001) and for a 
longer time period (>1 hour, p<0.0001) with treprostinil versus iloprost which returned PVR to 
baseline after 40 minutes.105  
The bioavailability of Tyvaso® is determined to be 64% and 72% for the respective single 
doses, 18 and 32 μg.102 Tyvaso® is a longer acting prostacyclin analogue than iloprost with a 
potentially more desirable receptor affinity profile, (EP2 affinity, which dilates bronchial smooth 
muscle in airways).106 The pharmacokinetics are still limited, requiring 4 doses during waking 
hours; 3 breaths approximately every 4 hours.102 The nebuliser is not a hand-held device and 
requires, power to operate, addition of an ampoule of Tyvaso® formulation and distilled water 
and daily cleaning.107 
Inhalable PM therapies achieve greater therapeutic effect with smaller doses compared to 
parenteral delivery although they have a lower maximum tolerated dose.108–110 Inhaled and 
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oral PM therapies are often prescribed as part of a dual therapy strategy with PDE-5is or 
ERAs. For treprostinil, it is as part of dual therapy that Tyvaso® was approved by the FDA in 
2009.102 Approval of Tyvaso® in Europe is yet to be granted. Administration requires a 
handheld portable nebuliser which is not as discrete as inhalation devices used by asthma 
patients. The short residence time of the drug in the alveolar region and its rapid metabolism 
means multiple doses each day are required. Between doses, large fluctuations in drug blood 
concentrations are experienced which are thought to exacerbate adverse events such as 
flushing, and headache. 
 
Being the most patient-compliant method of drug administration, the first oral PM was long-
awaited. Oral therapy does not require difficult and time-consuming drug administration. Unlike 
subcutaneous and inhalable formulations, additional training is not necessary for patients to 
deliver their treatment. Furthermore, the oral tablet option allows for discrete administration in 
any setting which is less burdening for the patient.  
Beraprost 3 was the first oral prostacyclin mimetic developed which received approval in Asia 
in 2003. In the Arterial Pulmonary Hypertension and Beraprost European Study (ALPHABET), 
an improvement in symptoms and exercise capacity (6MWD) were observed.111 Functional 
class and haemodynamic measurements did not show improvements after 12 weeks. A further 
study demonstrated improvements in 6MWD at early time points within the 12 month trial but 
efficacy was attenuated after 6 months.112 
Treprostinil diolamine (7) was approved by the FDA (2013) as the first orally available 
prostacyclin therapeutic for use in the USA. The alternative diolamine salt of treprostinil 7 is 
administered in an osmotic, laser-drilled tablet which becomes hydrated after ingestion and 
slowly releases active treprostinil from the laser-drilled hole at a near zero order release rate. 
Patients are prescribed a starting dose of 0.25 mg twice daily which is titrated incrementally 
dependant on patient tolerance. The bioavailability of the oral formulation is 17% so greater 
concentrations are administered than enter the blood stream. 
 
Figure 1-7. Structure of treprostinil diolamine salt 7 used in the oral formulation 
orenitram®. 
Following the first approvals for oral PMs, 2015 saw the first global approval (USA, Canada, 
EU, Japan) of selexipag (5), a pro-drug of the active compound, ACT-333679 (6).62 Marketed 
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as Uptravi, selexipag is a non-prostanoid, selective IP agonist.113 The half-life of the inactive 
pro-drug form is 1-2 hours which is hydrolysed by hepatic enzymes to the active metabolite, 
which has a half-life of 7-8 hours. The increased lifetime in the blood is attributed to the 99% 
binding to plasma proteins such as albumin and α-acid glycoprotein. 
 
Figure 1-8. The structure of selexipag (5), the pro-drug which cleaves to release active 
compound ACT-333679 (6) 
When developing a series of potential prostacyclin receptor agonists, it was found that using 
the N-acyl sulfonamide derivative (5) of what was later termed ACT-333679 (6), exhibited a 
130-fold lower affinity than its parent acid at the human IP receptor in radioligand binding 
studies (Ki 20 nM verses 260 nM). Furthermore, when measuring inhibition of platelet 
aggregation at the same receptor, the IC50 of the N-acyl sulfonamide derivative, was 26-fold 
greater compared to its parent acid.114,115 Following the observation of hepatic degradation of 
N-acyl sulfonamide 5 to release the acid, turned what was first an unexpectedly inactive 
structure into selexipag 5, the first globally approved prodrug formulation for PAH.116  
Selexipag (5, tradename UPTRAVI®) is the most recent orally administered IP receptor 
agonist, and the only pro-drug to be granted FDA approval for the treatment of PAH.117 
Compared to other prostacyclin mimetics (PMs) used to treat PAH, the selexipag structure is 
not derived from prostacyclin and is therefore considered a non-prostanoid agonist.  
 
Figure 1-9. The conversion of selexipag (5) to ACT-333679 (6) by carboxylesterases 
found in hepatocytes of rats, dogs, monkeys and humans, as well as the blood plasma 
of rats. 
 
 
Synthesis of prostacyclin in the pulmonary vessels of PAH patients is significantly reduced 
leading to the dominance of vasoconstrictive and proliferative pathways to drive the disease.63 
The disruption of the prostacyclin pathway is considered a key mechanism involved in the 
pathobiology of PAH.29 Therapeutic restoration of prostacyclin levels has been shown to slow 
disease progression, improve functional class and ameliorate symptoms.118  
Prostacyclin can be used in patients with all stages of PAH, but is specifically recommended 
in patients with class III or IV PAH.119 Clinical benefit of prostacyclin therapies are proven 
5 6 
5 6 
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although, only epoprostenol has been shown to increase survival in a placebo-controlled and 
randomised trial.120 Prostacyclin therapies are limited to the maximum tolerated dose which 
restricts the efficacy of treatment to the tolerability of the adverse events. Patients would 
benefit in two ways if adverse events were overcome; (i) pain and discomfort of treatment 
would be removed, increasing quality of life (ii) greater concentrations of treatment could be 
administered, increasing efficacy.  
Many attempts to overcome adverse events associated with current therapies have been 
made. Improvements to current formulations have been investigated to reduce adverse 
events. Oral treprostinil 7 was developed for twice daily dosing but patients who split the dose 
into trice daily achieved a steadier drug-blood concentration throughout the day.121 
Unfortunately adverse events were not reduced.122 Subcutaneous infusions are recommended 
to be moved every 2-3 days, but to reduce the pain, are generally left in for 2-3 weeks without 
increased infection.123 Furthermore, delivery of capsaicin to the infusion site by use of a patch 
was also shown to decrease site pain.124 Ideas to reformulate the PMs have also been 
investigated as will be discussed in the following section. 
 
Preclinical research by industry and academic groups is being undertaken to address the 
drawbacks of PMs. Examples include the introduction of new molecules to the drug class,125,126 
and assessing the benefits of cross-class combinations of PAH therapies alongside the 
application of nanomedicine approaches in the delivery of known drugs.77,90,127,128 Following 
successful and titratable release of prostaglandin E1 from encapsulating nanoparticles,129,130 
the sodium salt of beraprost (3) was similarly encapsulated into slow releasing particles.131 
The nanoparticles were made from either racemic or isotactic polylactic acid (PLA) and PEG-
PLA block co-polymers using iron chloride to help trap the hydrophobic drug into the 
hydrophobic polymer. Experimentation of rhodamine S nanoparticles in a monocrotaline and 
hypoxia model of PAH showed that in treated rats, accumulation occurred more in diseased 
tissue than control tissue and occurred even more so than free rhodamine over a period of 5 
days. Furthermore, monocrotaline-treated rats, intravenously injected with nanoparticles 
containing 20 μg /kg of beraprost once a week for 21 days, experienced a similar reduction in 
right heart hypertrophy as rats treated daily with 100 μg /kg oral dose of free beraprost sodium. 
A formulation which requires less frequent administration without compromising clinical 
efficacy has potential for clinical translation. 
Liposomal nanoparticles have been employed to encapsulate Iloprost (2) to improve 
pharmacokinetics.78 Iloprost 2 was encapsulated in various cationic PEG2000—lipid block co-
polymers via thin film rehydration methods to produce liposomes with 59% average 
encapsulation efficiency. The rate of iloprost 2 release was determined by measuring the 
ability of the supernatant to dilate the rat pulmonary artery using a myograph. The ability to 
relax pre-constricted small pulmonary arteries was measured using the empty liposome, 
iloprost encapsulated liposomes and free iloprost. These experiments showed that the use of 
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liposomes allowed the same extent of vasodilation to occur with half the amount of iloprost 
compared to free drug (p < 0.001). 
Liposomes have also been employed for the pulmonary delivery of treprostinil pro-drugs in 
rats with hypoxia-induced PAH.80,132 Cationic alkyl ester derivatives of treprostinil pro-drugs 
are encapsulated into PEG-lipid nanoparticles by surfactant molecules which after inhalation, 
slowly diffuse out into the alveolar cavity and cross the tissue into the pulmonary vasculature. 
The peak concentration measured is lower than that obtained by inhalation of free treprostinil 
and the release is sustained for a longer period of time.133 The liposomal approach has been 
shown to achieve sustained release of treprostinil 4 using a non-invasive delivery method 
direct to the target organ. Unfortunately, liposomal prostacyclin is expensive to be manufacture 
on large scale and difficult to sterilise. Maintaining stability and characterising liposomal 
prostacyclin are also major bottle-necks limiting the clinical translation of liposomal 
approaches. 
An alkylated prodrug derivative of treprostinil has similarly been incorporated into a liposomal 
delivery system for a nebulised delivery system. The drug is called INS1009, compound 8, in 
Figure 1-10.134 A 16-carbon linear alkyl chain was conjugated to treprostinil 4 acid group 
forming an ester bond that was designed to be hydrolysed by esterases. The alkyl treprostinil 
prodrug was combined with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000 to encapsulate the prodrug within a liposome. Upon 
intratracheal administration to dogs, a localised reduction in PAP was observed. A similar 
effect of PAP was observed with guinea pigs and additionally, no cough respiratory tract 
irritation or emesis was observed.134 In a phase I single dose study in humans, patients were 
administered either inhaled treprostinil or inhaled liposomal nanoparticle INS1009 
prodrug.135136 Blood plasma concentrations of the prodrug were extended compared to free 
treprostinil although a 30% reduction in total treprostinil exposure was observed. The lower 
measure of treprostinil indicates 30% of the prodrug in INS1009 is cleared before converting 
to treprostinil. Adverse events between the two groups were similar although details of adverse 
events were not reported. No further developments into phase II trials have been reported, so 
it is likely that the pharmacokinetic improvement did not outweigh the negligible decrease in 
adverse events and thus, clinical development of INS1009 for PAH was terminated. 
 
Figure 1-10. Structure of the prodrug treprostinil 8 used in INS1009 formulation.134 
8 
Introduction 
 
46 
 
Slow-release formulations delivered directly into the lung would potentially require less 
frequent administration and achieve localised drug release in the lung. Once treprostinil 4 
diffuses into the bloodstream it is free to activate systemic receptors, reducing the intended 
effect to reduce unwanted systemic activation of prostanoid receptors. For treprostinil 4 to 
have optimal effect in the treatment of PAH, its target receptors in the lung will need to be 
activated preferentially over systemic receptors. 
In 2012, a collaboration between United Therapeutics (UT) and Ascendis was initiated to 
develop a PEGylated treprostinil. Four treprostinil 4 molecules were conjugated to a 4-arm 
PEG of 40 kDa with the intention of later being released from the coonjugate.137 The structure 
utilised the TransCon system developed by Ascendis but the exact conjugation method was 
not disclosed. It is presumed that treprostinil was likely to have been conjugated through the 
acid based on the expected lack of specificity between the two secondary hydroxyls. The 
prodrug was developed as a subcutaneous formulation which would reduce pain at the site of 
administration with an extended half-life to facilitate a once daily dosing regimen. In 2015 a 
press release was published announcing the study termination.138 Despite “favourable 
pharmacokinetic effects”, the tolerability was still an issue. The activity of treprostinil at any of 
the receptors that it has potent affinity for (IP, EP2, DP1), is expected to be reduced upon 
conjugation to the PEG structure. The reported adverse events after administration likely 
resulted from premature degradation of the ester bond in the subcutaneous hypodermis 
environment before permeation into the circulation. Carboxylesterases are ubiquitous in the 
body so enzymatic cleavage is likely to be rapid,139,140 which may have degraded the 
compound more rapidly than expected.  
 
Figure 1-11. Proposed structure of 40 kDa 4-arm PEG with a treprostinil conjugated at 
each terminal. Ester bonds have been drawn although the exact conjugation method has 
not been revealed. 
In late 2017, UT announced it had initiated a collaboration with Corsair Pharma with the aim 
of developing a transdermal patch for the delivery of treprostinil using a prodrug derivative 
which has reduced activity upon administration but once in the blood stream is transported to 
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the liver where is it converted to active treprostinil.343 No further details have been released 
about the treprostinil prodrug structure or its pharmacokinetic profile.  
 Therapeutic Potential of Treprostinil (4) 
Treprostinil is a stable analogue of prostacyclin and the only prostacyclin mimetic available to 
be given via four routes of administration; subcutaneous infusion, intravenous infusion, inhaled 
and oral routes.141 All PMs are designed as IP receptor agonists, and all but selexipag exhibit 
affinity at other prostanoid receptors.62 Treprostinil 4 is unique in that its efficacy is likely to be 
mediated through multiple targets, including the EP2 receptor.62,142,143 The affinity exhibited by 
treprostinil for the EP2 receptor was first considered to be an off-target effect although it now 
has to be considered as a therapeutic target.144 The IP receptor is downregulated in PAH and 
the EP2 receptor has been shown to increase in expression, making the latter receptor a 
particularly relevant therapeutic target in PAH (Figure 1-12).29 
 
Figure 1-12. The relative changes in expression of IP and EP2 receptors in human 
pulmonary arterial smooth muscle cells derived from patients with pulmonary arterial 
hypertension and controls. Reported by Patel and colleagues.142 
Treprostinil (4) is a benzindene derivative possessing an aryl acid and two hydroxyls; one 
cyclic and one as part of the alkyl chain.145 Early structure activity relationship studies using a 
platelet inhibition assay to determine activity concluded that the acid was necessary for 
receptor binding and activity is reduced 10-fold by its derivatisation to a methyl ester.145 
Furthermore, the presence and stereochemistry of the hydroxyls are also required for anti-
platelet activity. 
Parenteral delivery of PMs remains the most effective treatment for alleviating symptoms and 
increasing disease severity measurements including 6MWD. In later stages of disease or if a 
patient’s health rapidly declines, the patient is often moved to subcutaneous infusions until 
their condition stabilises. Although there are many PM options for early stage PAH (non-PM 
therapies as well as treprostinil in oral and inhaled forms), there is no substitute for 
subcutaneous treprostinil in late stage disease other than IV infusion.  
Within the clinic, a universal maximum concentration that patients reach does not exist. 
Instead, patients are encouraged to reach and maintain the highest dose they can tolerate 
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before adverse events cannot be withstood. The therapeutic window is narrow, so most 
patients will experience adverse events when taking treprostinil. Despite the clinical benefits 
of treprostinil 4, adverse events still limit the maximum tolerated dose. Treprostinil therapy is 
hindered by toxicity at the site of injection as well as adverse events induced by systemic 
activation.146 
 Methods of drug optimisation 
Improving the pharmacokinetics and altering the biodistribution of an active pharmaceutical 
ingredient can improve efficacy and patient tolerability.147 A treatment can be improved to 
some degree by a judicious choice of formulation and route of administration. It is also possible 
to modify the drug structure to produce analogues with more optimal solubility, permeability 
and biodistribution while preserving sufficient biological activity.  
Drug compounds can also be covalently conjugated to small moieties such as an amino acid, 
or to large biologics including antibodies, proteins such as albumin, or polymers. Alternatively, 
drugs can be non-covalently encapsulated in larger structures such as hydrogels, polymeric 
nanoparticles or within particles such as liposomes, vesicles or nanoerythrosomes. Sustained-
release formulations of PMs have been investigated, some of which reached phase I 
trials.136,137 Only one pro-drug PM, selexipag (5), has been approved for the treatment of 
PAH.116 
 
A commonly employed method to improve pharmacokinetics of a drug molecule is to 
temporarily modify the structure to reduce its activity and enhance its pharmacokinetic 
properties.148 Covalent modification of an active drug to a small functional moiety to form 
prodrug, which then undergoes an in vivo reaction to regenerate the active drug, is a strategy 
used in ~20% of all newly approved small molecule drugs entering the market.148 Prodrugs 
are often used to decrease activity in non-specific tissues and allow for the distribution of the 
prodrug to a select tissue before the prodrug moiety is cleaved and the active drug released. 
Many different prodrug moieties have been examined. Hydrophilic pro-moieties such as 
sugars and phosphoesters can increase the solubility of a drug.149 Alkyl prodrugs (eg. methyl 
or propyl esters) can increase drug permeation, such as tafluprost for delivery to the eye for 
glaucoma treatment.150  
The reaction of a pro-drug to form the active drug molecule is dependent on the prodrug 
structure and the conditions required to cleave it. Some bonds require a chemical interaction 
to cleave the pro-drug (e.g. pH, redox), whereas other moieties require enzymatic degradation. 
A summary of the physiological conditions required to cleave commonly employed prodrug 
structures is listed in Table 1-1. 
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Table 1-1. Structures of a selection of prodrug structures in the clinic and their cleavage 
conditions. 
Prodrug Property 
Cleavage 
conditions 
Indication  Ref 
 
Increased 
lipophilicity 
and 
permeability 
Esterases Heart failure 151 
 
Increased 
stability of 
the boronic 
acid  
Hydrolysis in 
physiological 
conditions 
 
Multiple 
myeloma 
152 
 
Generates 
radical 
species 
Reduced by 
nitroreductases 
Chagas 
disease in 
children 
153 
 
Improved 
brain 
permeability 
Decarboxylation 
catalyzed by L-
aromatic-amino-
acid 
decarboxylase 
Neurogenic 
orthostatic 
hypotension 
154 
 
Improved 
solubility 
Plasma or 
intestinal 
phosphatases 
Acute skin 
infections 
155 
Depending on the medical application, the release site and rate for generating the active drug 
can in principle be tailored. For instance, 5-aminosalicylic acid is an oral anti-inflammatory 
agent used for the treatment of inflammatory conditions of the gastrointestinal tract (GIT) such 
as Crohn’s disease, ulcerative colitis and irritable bowel disease.156 To increase specificity to 
the GIT, 5-aminosalicylic acid is administered in the inactive prodrug form, balsalazide. When 
in the colon, bacterial enzymes cleave balsalazide by azoreduction to release the active parent 
compound 9 where it is able to locally interact in the inflamed colon (Table 1-1).  
Protein binding prodrug 
Another strategy to increase the circulation lifetime of bioactive compounds includes exploiting 
interactions with circulating proteins, such as the case of alkylated insulin (Levermir®) an 
approved treatment for the management of diabetes which exhibits a longer half-life owing to 
enhanced albumin binding.157 Albumin, which makes up 55% of the proteins in blood, interacts 
with neonatal Fc receptors which extends its half-life to 19-21-days. Drugs such as warfarin, 
diazepam and ibuprofen are able to bind to albumins and remain in the circulation longer than 
for other small molecules.158 α-Tocopherol is able to bind to albumin through hydrophobic 
interactions and has been considered in the conjugation of bioactive compounds to extend 
their half-lives.159,160 The concept of conjugating treprostinil 4 to a protein binding moiety such 
as α-tocopherol could increase the half-life of treprostinil to reduce the frequency of 
9 
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administration, although the distribution of drug across the body would still be wide spread. 
Treprostinil therapy is limited by its systemic exposure, so by only increasing half-life leaves 
the challenge of optimising biodistribution to the lung yet to be solved.  
 
Prostacyclin mimetics, like most small molecule drugs, exhibit short half-lives owing to their 
susceptibility to be renally excreted, metabolised and distributed to non-diseased tissues 
which is a result of their small size.161 To compensate, delivery strategies have included the 
conjugation of small drugs to large macromolecules, including, proteins, polymers and nano 
particles.162 Conjugation of a drug to a polymer can be used to mask activity, similar to a 
prodrug approach will additional macromolcular properties. In contrast, multiple drug 
compounds may be conjugated to a polymer whilst preserving the drug activity, to enhance 
activity using a polyvalent approach. In addition to either approach, the conjugation of other 
molecules may be desired to aid solubility or conjugate localisation.  
Conjugation of drugs to polymers, known as polymer drug conjugates (PDC), have been 
designed and investigated with different water-soluble polymers and drugs.163–166 Polymer 
conjugation has seen most success in the conjugation of proteins by poly(ethylene glycol) 
(PEG) in a process termed PEGylation. PEG is simple in design, easy to synthesise and obtain 
commercially with a variety of functional groups and exhibits a narrow molecular weight 
distribution.167,168 Since 1990, at least nine PEG-protein conjugates have received FDA 
approval, involving therapeutic proteins such as enzymes, antibodies, growth factors and 
cytokines.168 The PEG chains provide steric shielding of the protein to reduce immunogenicity, 
increase biological half-life which results in decreasing the frequency of dosing. For instance, 
when interferon-α2b (Intron® A) was PEGylated with a 12 kDa PEG molecule the resulting 
conjugate, PegIntron®, possessed a longer half-life than Intron® A.169 Following intravenous 
administration in humans, the serum concentration of Intron A rapidly decreased to 
untraceable amounts within 24 hours, whereas PegIntron® was detectable at a maximal 
sustained concentration for 48 to 72 hours.170 PegIntron® is dosed once weekly rather than 
once every other day for the non-PEGylated interferon (Intron®). The less frequent dosing also 
reduced the frequency of side effects suffered by the patient. The size of PEG has been shown 
to exhibit direct correlation with lifetime by avoiding renal excretion171 and other PEGylated 
proteins have also become first line treatments (e.g. PEG-Granulocyte colony stimulating 
factor (PEG-GCSF)) used to treat non-Hodgkins lymphoma. 
The concept of conjugating low molecular weight drugs to polymers was proposed by 
Ringsdorf in 1975 (Figure 1-13),172 which consisted of a polymer containing water solubilising 
pendant chains, targeting moieties and drug conjugated by a biodegradable linker. 
The first polymer-drug conjugate in Phase 1 trials for the treatment of cancer in 1994 (HPMA 
copolymer- doxorubicin (Dox) (FCE28068, PK1)).173 Since then, the progression into the clinic 
of polymer-drug conjugates derived from a cytotoxic agent has been more hindered than for 
Introduction 
 
51 
 
the PEG-protein conjugates.174 Polymer conjugates of low molecular weight drugs generally 
require that the drug be released from the polymer. PEG-proteins do not require release of the 
protein. For the case of cytotoxic drugs, and any drug with off-target effects, the site and 
specificity of release of the drug from the polymer is an important feature. 
 
Figure 1-13. Ringsdorf model of a multifunctional polymer proposed as a method to 
achieve site-specific delivery of drug compounds. The structure contains a hydrophilic 
polymer back bone with targeting moieties conjugated in a pendant fashion. The drug is 
also conjugated to the polymer via a biodegradable linker. 
In the case of oncology, conjugation of drugs to macromolecules exploit tissue permeability 
gradients where diseased tissue can often be more permeable than healthy tissue.175 
Permeability is often associated with angiogenesis and inflammation in cancer.176 Within 
malignant tissue, especially in rapidly growing tumours, there may also be decreased 
lymphatic drainage which can aid to retain a molecule after tissue uptake. These combined 
effects are known as the enhanced permeability and retention effect (EPR) and may also 
partially explain why macromolecules initially extravasate into malignant tissue.175–177 
Retention is established by the prolonged circulation time of a polymer drug conjugate to allow 
for extravasation into more permeable tissues by diffusion. The accumulation of 
macromolecules into permeable vasculature by the EPR effect results in passive targeting of 
malignant and often inflammed tissues.177–179 Given that endothelial disruption and 
inflammation are key features of PAH, it is possible to imagine targeting therapeutics to the 
PAH lung but exploiting the EPR effect.180,181 
The covalent conjugation of a drug to a polymer often causes the drug activity to be reduced, 
owing to the steric hindrance that the relatively large polymer provides.164 Drug cleavage is 
required from the polymer to restore activity and thus the polymer drug conjugate can be 
considered a polymeric prodrug; temporarily exploiting the properties of macromolecules to 
extend circulatory life time and passive targeting of permeable vessels.166 
The choice of polymers utilised also deserve consideration as the polymer must be water 
soluble to facilitate fluid-like interactions with physiological media.182 The polymer must also 
be inert, i.e. must not evoke a biological response such as toxicity or immunogenicity. 
Metabolism or excretion must be defined and accumulation of the polymer within cells should 
not occur. Particularly for hydrophobic drug compounds, the polymer must contain a 
hydrophilic backbone to facilitate fluid-like interactions with physiological media. 
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Both biodegradable and non-biodegradable polymers have been employed for polymer drug 
conjugates.165 An historical advantage has meant non-biodegradable polymers have received 
more attention which has led to their dominance in the clinic over biodegradable options. 
Biodegradable polymers for drug conjugates offer alternative materials, with less chance of 
bioaccumulation as well as the opportunity to conjugate the drug through the polymer 
mainchain.183,184 The most successful polymers employed for conjugation are poly(ethylene 
glycol) (PEG) and poly(2-(N-hydroxypropylmethacrylamide)) (pHMPA).165  
 
Table 1-2. Polymer-drug conjugates being clinically investigated 185 DOX = doxorubicin; 
CPT = camptothecin 
Polymer Conjugate Linker 
Clinical 
Status 
HPMA 
HPMA-copolymer-DOX PK1; FCE28068 Peptidyl Phase II 
HPMA copolymer-DOX-galactosamine 
PK2; FCE28069 
peptidyl Phase I 
HPMA copolymer-paclitaxel PNU166945 Ester 
Phase I/ 
discontinued 
HPMA copolymer-camptothecin MAG-
CPT 
Ester 
Phase I / 
discontinued 
HPMA copolymer malonato-platinate Malonate Phase I 
HPMA copolymer-DACH-platinate, 
AP5346 ProlindacTM 
Aminomalonate Phase II 
PGA 
PGA-camptothecin CT-2106 Amide Phase I/II 
PGA-paclitaxel Xyotax™ Ester Phase III 
Dextran 
Oxidised dextran-DOX AD70, DOX-OXD Schiff Base 
Phase I 
discontinued 
Carbomethyldextran-exatecan DE-310 Amide Phase I 
Dextrin Cyclodextrin-camptothecin IT-101 Amide Phase I 
PEG PEG-camptothecin Pegamotecan Ester 
Phase II 
discontinued 
PEG is a popular choice in polymer-drug conjugate mainly owing to its FDA approval.186 PEG 
is usually terminally conjugated and thus is limited in the number of drug molecules conjugated 
per polymer chain, although attempts to increase loading by forming multi-arm and branched 
PEG chains has been conducted.187–189 More recently, the inert nature of PEG has been called 
into question as anti-PEG antibodies have been identified in patients treated with 
macromolecules with PEGylated surfaces.190–192 The role and clinical implication of the 
antibodies is unknown190 and the observation has not deterred PEG conjugates from entering 
the clinical setting.193 
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Figure 1-14. Monomer of camptothecin (CPT) – cyclodextrin – PEG (CDP) conjugate 
which increases the solubility of CPT by 3-fold. Number of PEG monomers, n (average) = 
77 and PEG Mw is 3400. Number of CDP-CPT monomer per drug polymer, m (average) = 
18 ±5 and Mw is 85 ±23 kDa. 
One example of harnessing macromolecular attributes for a drug delivery is the conjugation of 
naturally occurring camptothecin (CPT) which is used in the treatment of cancer (10).194 
Camptothecin promotes apoptosis of tumour cells, but its low solubility and unstable structure 
limits its potential in the clinic. The cytotoxic nature of CPT is a significant problem as it is not 
tissue specific and exerts its effects in healthy tissue as well. Conjugation to a cyclodextrin-
based linear polymer via an ester bond to a glycine linker increased the hydrophilicity and 
solubility by 3-fold. Furthermore, the increased molecular weight prevented excretion by renal 
filtration, extending systemic half-life. Compared to free CPT, enhanced biodistribution to 
tumour tissue is observed which is a result of the enhanced permeation and retention (EPR) 
effect,195 where small aggregates accumulate in tumours. Despite the acid catalysed 
esterolytic cleavage of CPT from the polymer (between CPT and glycine linker) not being 
tumour specific, pre-clinicial trials showed the accumulation of the conjugate in the tumour 
tissue resulted in a greater proportion of CPT release in the tumour, meaning a higher 
maximum tolerated dose could be achieved with reduced systemic toxicity.196,197  
Clinically, polymer-drug conjugates have had limited success in cancer owing to minimal 
improvements in therapeutic outcome.185 Off-target effects have been reduced but 
improvements in survival have not been achieved. Without specific mechanisms for the 
release of the cytotoxic agents used in cancer, release can occur prematurely, and even small 
concentrations released in healthy tissues can cause serious off-target effects. 
 
One of the most significant drawbacks of prostacyclin therapies for PAH is the lack of 
specificity towards the lung tissue as synthetic prostacyclin and its analogues are active at 
prostanoid receptors (including EP1, EP2, EP3, EP4, DP1 receptors) expressed in the 
vasculature throughout the body.62,85 The activation of prostanoid receptors on the systemic 
endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) is understood to be the 
major cause of the characteristic side effects such as diarrhoea, flushing and nausea and 
gives rise to the risk of systemic hypotension, lowering blood pressure at higher doses.198 
10 
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These factors conspire to limit the maximum dose resulting in a narrow therapeutic window for 
many of the prostacyclin therapies. 
Pulmonary delivery 
The targeting of therapies to the PAH diseased lung can potentially be achieved by delivering 
pharmaceuticals via the pulmonary route. Pulmonary delivery has long been used to deliver 
therapeutic gases (e.g. nitrous oxide and ethers for anaesthetic).199 Methods to impart 
properties suitable for inhalation to drug compounds has received much attention in the form 
of nebulised drugs and drug powder formulations.200 Localised pulmonary delivery has been 
shown in to induce the same therapeutic effect at lower concentrations.201 
The lung is designed to facilitate absorption from the alveoli into the blood stream and as a 
result possesses an efficient mechanism to ensure foreign particles do not enter the alveoli. 
Thus, pulmonary delivery is restricted to particles between 2-5 μm and limited by the rapid 
clearance of particles from the lung by entrapment by mucociliary escalator or macrophage 
uptake.202 Many inhaled therapeutics have been successful, such as asthma therapies which 
deliver steroids to the airway receptors. 
The delivery of therapies which achieve a steady concentration by sustained release has been 
harder to achieve clinical success.92 Particles which reside in the alveolar regions, avoiding 
detection of clearance mechanisms, have been investigated. Steady release of drugs over 
time from the particles has been demonstrated in vitro and in vivo but none have entered 
phase II trials.200,201,203 One possible limitation is the fate of the particle carrier once the drug 
has been released. The accumulation of such particles in the alveoli have been linked to 
inflammatory responses such as granulomas,204 and inducing molecular pathways associated 
with inflammation, oxidative stress and fibrosis;205–207 all of which key characteristics of the 
PAH lung.51 
Delivery of PAH agents via the pulmonary route although offers direct organ targeting, was 
considered likely to exacerbate the inflammatory response and so for this reason, the 
pulmonary route was ruled out for this PhD project. 
Active targeting 
Since Ehrlich first developed the concept of the ‘magic bullet’,208 where drugs would be 
designed to be systemically delivered yet carry out their effect exclusively at the target site, 
much research has been focused on achieving this concept. Understanding the environment 
established within a diseased tissue and how it contrasts to normal tissues has been a key 
objective in designing responsive conjugates for achieving localised delivery of drug 
molecules. The expression of different antigens and enzymes vary for different cell types and 
this complementary binding can be exploited to target cell/tissue/organ. 
Clinically, active targeting approaches are best exemplified with the conjugation of drug 
compounds to antibodies (Figure 1-15), forming antibody drug-conjugates (ADC).209 
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Exploiting the body’s natural system for distinguishing between different tissues and cells, 
ADCs can be designed for a specific antigen found in the target tissue.  
 
Figure 1-15. General structure of an antibody, showing the Fab chains, the FC region and 
the hinge region, coloured dark blue. The tail-like Fc region is responsible for interacting 
with cell surface receptors which extends its biological half-life The chains are oriented 
and aligned with N-termini at the top and C-termini at the bottom. Chains are held together 
by disulfide bridges between the thiols of cysteine residues in the protein structure. Only 
the light blue regions are the site of antigen specific binding. 
Many of the ADCs investigated clinically  have been in development for the treatment of 
cancer.210 Highly cytotoxic drug molecules are covalently linked to antibodies which are 
targeted to specific epitopes overexpressed by tumour cells. This localises the cytotoxic 
compounds at the tumour sites where they are released. As important as choosing the 
antibody, is identifying a suitable releasable linker, which must exhibit stability in the blood 
plasma to allow for the ADC to get to its target without premature release of the drug. Once 
internalised by the cell or the tissue site, the linker must be degraded (either hydrolytically, 
oxidatively or enzymatically) to release the cytotoxic compound. It has been suggested that 
the withdrawal of ADCs BR96-DOX 11 and Mylotarg® were a result of poor linker stability. 
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Table 1-3. Features of a selection of antibody-drug conjugates (ADCs) clinically approved or under clinical review. 
AcBut = 4-(4-acetylphenoxy)butanoic acid 
ADCref Antibody Drug 
Linker 
bond 
Indication Stage 
Brentuximab 
vedotin 
(Adcetris®)211 
Anti CD30 
Monomethyl 
Auristatin E 
Valine-
citrulline 
amide bond 
Hodgkin’s lymphoma, 
systemic anaplastic 
large cell lymphoma 
(ALCL) 
Approved (2011) 
inotuzumab 
ozogamicin 
(Besponsa®)212 
Anti-(CD)-22 calicheamicin 
Hydrazone 
AcBut 
relapsed/ refractory 
acute lymphoblastic 
leukemia (ALL) 
Approved (2017) 
gemtuzumab 
ozogamicin 
(Mylotarg®)213 
Anti-CD33 calicheamicin 
Hydrazone 
AcBut 
CD33-positive acute 
myeloid leukemia 
(AML) 
Approved (2000), 
withdrawn (2010), 
reapproved (2017) 
Trastuzumab 
emtansine 
(Kadcyla®)214 
Anti-HER2 
emtansine 
(DM1) 
thioether 
HER2 metastatic 
breast cancer 
Approved (2015) 
 (IMMU)-110 
(hLL1-DOX)215 
Anti-CD74 Doxorubicin Hydrazone Multiple myeloma Phase I/II 
Lorvotuzumab 
mertansine 
(IMGN901)216 
Anti CD56- 
Maytansine 
(DM1) 
Disulfide 
Multiple myeloma, 
solid tumours 
Phase I/II (2009) 
Discontinued (2013) 
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Conjugation of antibodies to single drug molecules as for emtansine (Figure 1-16) or to drug 
carriers such as drug-polymers or nanoparticles,217 have proven their targeting ability in 
preclinical trials. However, in the almost 20-year period since the first market entry, only three 
more ADCs have successfully been clinically registered.218,219 Reasons for the ADCs not 
reaching the market include; non-specific release of drug, lack of specific antigen binding after 
conjugation to drug, insufficient expression of antigen on target cell and insufficient amount of 
drug released from ADC.  
 
Figure 1-16. Antibody-emtansine conjugate for the targeting and delivery of drug to tumour 
tissue. 
Additionally, the use of antibodies as targeting agents have limitations in respect to their 
stability. As with all proteins, the 3D-conformation is vitally important, as biological activity is 
dependent on the tertiary structure of the antibody. Modifying an antibody with a drug-linker, 
especially with hydrophobic drugs, can result in a greater propensity for protein aggregation. 
The interactions between the polypeptide chains in an antibody are also sensitive to 
temperature, pH, oxidative stress and the solvent they are exposed to. The stability of 
antibodies is limited between a narrow range of optimum conditions which limits the 
modification and reaction types employed to conjugate the drug.220 Conjugation of drug 
compounds can destabilise the structure further which adds to the instability of ADCs which 
results in a propensity to aggregate upon storage.221 
Methods to overcome the limitations of antibody targeting have led to the investigation of 
antibody-fragments (Fabs) as targeting motifs. Antibodies carry out many functions (antigen 
binding, neonatal Fc receptor binding, aggregation) so their structure is an amalgamation of 
all the parts necessary to carry out each function. The antigen binding region is relatively small 
compared to the whole antibody. To harness only the binding functionality, antibodies have 
been proteolytically cleaved by specific enzymes (e.g. pepsin) to obtain the Fab, which could 
then be used to conjugate to drug.222–225 In more commercial settings, the Fabs can be 
generated recombinantly.226 
The specificity of peptide-protein interactions, such as that of endothelin to its receptors, is a 
result of a small amino acid sequence with the large protein. The specificity possessed by the 
peptide has inspired investigations to find small peptide moieties which selectively bind to a 
protein target for use as a targeting moiety.227,228 The use of a highly specific peptide can 
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circumvent the limitations associated with antibodies by removing any non-essential binding 
structures. In addition, without a tertiary structure, many peptide targeting moieties are stable 
and less prone to aggregation.  
A downside to the smaller peptidic targeting is rapid clearance from the circulatory system by 
renal excretion.161 Peptides have a greater ability to permeate tissues more rapidly, which is 
less possible with macromolecules. In addition, peptides are susceptible to proteolysis by 
circulating enzymes.229 The circulation time can be extended by conjugating the target peptide 
to a macromolecule.230 Using a targeting peptide in a polymer drug conjugate may allow active 
targeting of the pulmonary vasculature to cause localised accumulation of prostacyclin 
mimetics and restrict their exposure at the IP receptors located elsewhere. 
Targeted polymer drug conjugate 
The design of a polymer drug conjugate can include; (i) a hydrophilic polymer backbone to 
increase solubility; (ii) drug bound by a biodegradable linker and: (iii) a moiety which actively 
targets the desired tissue. As discussed in 1.4.4, the release of the drug compound in the 
desired tissue relies on the polymer derivative getting into the tissue. The passive diffusion of 
polymeric structures even aided by the EPR effect is often not sufficient enough to achieve 
great enough drug concentrations to reach the therapeutic dose. In such instances, active 
targeting structures may be better employed within the PDC. 
Methods to achieve active targeting have employed antibodies and targeting peptides to 
localise the conjugate and subsequent pay-load release to the desired tissue. The inclusion of 
targeting moieties as ligands on polymer-drug conjugates have been employed to target 
various tissues (Table 1-4).  
Table 1-4. Targeting moieties used in the preclinical trials, including antibodies, 
peptides and peptidic linkers. 
Conjugates Targeting moiety Target Ref 
Anti-CD20 Multivalent HPMA 
Copolymer-Fab’ Conjugates 
Anti-CD20 
B-lymphocyte 
antigen 
231 
SP5-52-Lipo-Dox SVSVGMKPSPRP 
Tumor Blood Vessels 
of Lung Cancer 
232 
P-(Esbp)-DOX DITWDQLWDLMK E-selectin 233 
HPMA copolymer-PGE1 
conjugates 
Gly-D-Asp8 Cathepsin K in bone 234 
PAMAM-Ac-FITC-LCTP RCPLSHSLICY Lung cancer 235 
A targeted-polymer drug conjugate approach for the delivery of treprostinil 4 to PAH would 
combine many of the approaches discussed so far. The design of such a construct requires 
consideration of the drug conjugation site, the linker and targeting moiety to be employed, the 
polymer structure, polymer molecular weight and synthetic route to prepare a polymer 
treprostinil conjugate.  
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Only limited information on the PEG-treprostinil conjugates is publicly accessible and no 
information on using a targeting moiety to target any of the prostacyclin mimetics has been 
described. Therefore, the design of a target treprostinil polymer conjugate will require 
investigation into the individual components before a conjugate can be prepared. 
Site-specific Implantation 
A strategy used to overcome a lack of specificity to the diseased tissue and to avoid large 
systemic exposure is to physically place or implant the drug in the desired tissue or organ 
using a device or insert. For example, to help prevent a foreign body response and localised 
inflammation, drug eluting stents designed to slow the progression of restenosis are coated 
with a layer of a polymer-loaded with an anti-proliferative compound that is slowly released at 
the site of stent implantation at the vascular wall achieving a localised anti-proliferative 
effect.236,237 A drug-eluting stent is known as a combination device as it has a structural 
function in addition to drug release.  
Patients who have stents inserted are at a greater risk of stent-induced thrombosis, must also 
take a systemic anticoagulant therapy as a preventative measure.238 The effect of these 
treatments on non-target tissues carries the risk of adverse events so localising the anti-
proliferative drug release to the site of stent insertion using a drug-eluting stent further reduces 
the risk of coronary infarction or embolism.238 Investigations into the formulation of the stent 
coating, where and how the drug should be loaded, i.e. either a homogenous drug layer or 
loading drug into reservoirs in the stent structure239 and how to modify the rate and time period 
of release, have been described.240 
 
Methods to conjugate drug molecules to macromolecules (Figure 1-17) must allow linker 
function to increase blood circulation lifetimes, alter biodistribution, regulate cellular uptake, 
modify the drug release profile and to reduce unwanted activity e.g. at the administration site. 
Drug-conjugation can in principle be accomplished using linkers that are either degradable 
(releasable) or non-degradable (non-releasable).  
 
Figure 1-17. Basic structure of a drug conjugate; where the carrier (C) represents either 
a polymer or targeting moiety, B represents the biodegradable linker and D represents a 
drug. 
Linker degradation and subsequent drug release can be accomplished by hydrolysis which 
occurs by one of two mechanisms; auto hydrolysis (catalysed by acid) and enzymatic.241 
Alternatively, in the case of polymer drug conjugates that are inherently active, a non-
releasable linker is desirable. 
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Hydrolytic Cleavage 
Non-enzymatic degradation of esters, carbonates and carbamates occur at a slow rate at 
biological pH (~7.4) but increase with decreasing pH. The linkers employed are often acid-
sensitive242 and many features of linker structure can influence degradation rates.243  
The use of acid-sensitive linkages has been described to localise release at a tumour site and 
also within a lysosome for drugs requiring uptake by a cell.  Both sites are acidic environments. 
Acid-labile bonds that have been used include acetals, orthoesters, hydrazones, imines and 
cis-aconitryl bonds241 (Table 1-5). One example is the hydrazone-linked doxorubicin conjugate 
11, investigated for the tumour-specific release of doxorubicin. Following administration, the 
conjugate is designed to be stable in healthy tissues at pH 7.4, preventing drug release. Upon 
antibody binding to the tumour, the conjugate is internalised into lysosomes where the pH is 
lower (~5.5). The bond is cleaved, releasing the cytotoxic payload into the tumour cells. The 
conjugate exhibit activities similar to free doxorubicin at 1/8th of the dose equivalent and 
extended the lifetime of tumour-inoculated mice.244 
Table 1-5. Examples of acid-labile drug linkers employed in pre-clinical 
investigations. Dox=doxorubicin; mAb = monoclonal antibody; PEG = poly(ethylene 
glycol); BSA = bovine serum albumin. 
Structure Bond Description Ref 
 
Hydrazone 
Antibody 
doxorubicin 
conjugate 
conjugated by 
hydrazone 
245 
 
Orthoester 
PEGylated 
cholesterol 
conjugated by 
ortho ester 
246 
 
Acetal 
Estradiol 
conjugated to 
PEG via 
acetal bond 
247 
 
Imine 
Polymer-
bound 
doxorubicin 
conjugated by 
aromatic 
imine 
248 
 
Cis-
acetonitryl 
Doxorubicin 
conjugated to 
bovine serum 
albumin via 
cis-acetonitic 
bond 
249 
11 
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Recently, a silyl di-ether linker was used in an antibody-drug conjugate (Figure 1-18) which 
claimed to possess a slow release degradation profile which could be altered by modification 
of the silicon side chains to alter the degradation rate.250 In vitro results showed no drug 
release in solution at pH 7.4, while 80 % of the conjugated drug was released over 72 hours 
in solution at pH 5. Unlike linkers such as orthoesters, silyl di-ethers do not require strict 
anhydrous conditions for their synthesis and storage, which make them more practical.  
 
Figure 1-18. Acid sensitive degradation of silyl ether antibody conjugate prodrug to 
release gemcitabine 
Acid degradation offers a simple approach to target drug release in PAH given the acidic 
nature of the hypoxic lung.50,251 However, there is limited literature on the exact pH of the 
pulmonary environment and how localised that environment is. One concern would be that 
release would be triggered in tissues (such as muscles) by lactic acidosis caused by exercise 
or in areas of unrelated inflammation.  
Enzyme Degradation 
Some esters as well as amide bonds (present in peptidyl linkers) are not susceptible (or are 
weakly so) to non-enzymatic hydrolysis and so require the presence and action of esterases 
or proteases and peptidases respectively, for drug release. Less specific enzymes cleave their 
respective bonds providing there is minimal steric hindrance and the compound is hydrated. 
More specific enzymes require a particular peptide sequence in the linker for cleavage to 
occur. The specificity of enzymatic degradation can be altered to control and optimise drug 
release rate and site by careful selection of peptide linker. For example, doxorubicin has been 
conjugated to HPMA via a peptidyl linker specific for cleavage by cathepsin, Gly-Phe-Leu-
Gly.173 Employment of the peptide linker resulted in cathepsin-dependant release which 
achieved a 4-7 fold increase in doxorubicin concentration in the tumour compared to treatment 
with free drug. 
The upregulation of enzymes and metalloproteases in PAH is understood to occur, so 
employment of enzyme degradable linkers to activate treprostinil holds potential. Lytic 
enzymes which are disease-specific may not offer a cleavage method that is easily exploitable. 
For example, the enzyme matrix metalloprotease (MMP) 9 cleaves its substrate within the 
chain, between the two amino acids leucine and threonine.252 Such an enzyme does not 
facilitate a method of conjugation of a drug that can be released upon enzyme cleavage. 
Therefore, an exploitable enzyme would need to cleave a peptidyl chain at the terminus of the 
recognised substrate sequence. 
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To assist in cleavage, a drug molecule can be bound to its conjugate via a self-immolating 
spacer molecule to allow release after enzymatic cleavage253,254 (Figure 1-19). Self-
immolative spacers can undergo an intramolecular reaction upon a linker reaction or cleavage 
to release free drug. 
 
Figure 1-19. Example structure of a Tripartite conjugate undergoing 1,6-elimination to 
cleave a carboxylic acid terminated drug molecule.255 involving drug, linker and carrier. 
Green representing the drug; blue the linker and red the carrier.  
Polyvalent approach 
An established but less investigated route to utilise a polymer drug conjugate is to employ a 
polyvalent approach. Polyvalency takes its inspiration from bacterial interactions and antibody 
binding by conjugating multiple drug molecules to a macromolecule such as polymers, in a 
manner which retains receptor potency.256 Upon binding of a carrier-bound ligand to a 
receptor, the other ligands attached to the conjugate are then in close proximity of other 
receptors which using a co-operative approach to increase the likelihood of forming a binding 
interaction with other bound-ligands.257 Furthermore, some ligand targets are activated by 
receptor clustering, which can be induced by the polyvalent approach.256 
 
Figure 1-20. Structure of a polyvalent approach which possesses multiple non-
cleavable drug molecules on the same structure. The drugs are conjugated without 
the intention of release as a polyvalent approach requires the drug structures to be 
active upon conjugation. As the first drug ligand bind to the receptor, other ligands are 
in close proximity to other receptors which uses a co-operative binding effect in 
increase lreceptor activation. A targeting moiety can be employed to localise receptor 
binding. 
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Drug delivery using polyvalency aims to achieve greater receptor activation by using co-
operative binding. Such an approach has been attempted using polymers and liposomes as a 
carrier and is appropriate to consider when agonism of surface receptors is required.257 The 
polyvalent concept for drug delivery has been hypothesised and investigated preclinically, but 
is yet to demonstrate clinical efficacy.257,258 A limitation of a polyvalent approach is that it does 
not necessarily ensure effects are exerted in the correct tissues. A targeted polyvalent carrier 
may guide the conjugate to the desired site but could become quite complicated to design if a 
prodrug version was required so that activity was not present when the drug is administered. 
 The Project 
Prostacyclin mimetic therapy is used clinically to treat PAH in patients that do not respond to 
initial therapeutic approaches, usually oral. Clinical benefit is established but does not 
ultimately inhibit disease progression. Furthermore, the burden on patients is considerable 
owing to the adverse events. Chemical modification of active pharmaceutical agents is a 
common strategy to optimise therapy efficacy. The project was formed as part of a 
collaboration with Lung Biotechnology (Silver Spring, USA) who invest heavily in the PAH field 
and continue to seek new strategies for therapeutic improvements. Through the collaboration, 
treprostinil 4 sample was donated from their parent company United Therapeutics. Therefore, 
our approach focused on the improvement of treprostinil use, although the similarities in 
structure between treprostinil, beraprost and iloprost and to a lesser extent, selexipag, mean 
that many approaches could be applied to other prostanoid structures. 
Treprostinil 4 has proven to be a successful drug clinically, and its multiple mechanisms 
elucidated, might mean that it offers wider benefits over other single mechanism PAH 
treatments. Despite a desirable agonist profile (i.e. IP, EP2, DP1), treprostinil suffers (like all 
PMs) from poor specificity for the lung, which causes adverse events and limits the maximum 
tolerated dose and thus, the efficacy of the treatment. Overcoming the adverse events and 
increasing tolerability has served as motivation for many attempts to reformulate treprostinil.  
 
Pulmonary Delivery 
Delivery of PAH agents such as treprostinil 4 via the pulmonary route offers a method of direct 
organ targeting.201 Treprostinil and iloprost are available in nebulised form which achieve 
localised therapeutic effects to the pulmonary vasculature over the systemic circulation.259,260 
The limitation with treatment is the frequency and complexity of the dosing regimen. 
Furthermore, inhaled treprostinil is less efficacious than parenteral delivery and is therefore 
delivered as dual therapy.261 Suggested improvements to decrease the burden of treatment 
on patients include a portable delivery system and a sustained release formulation to reduce 
dosing frequency.262  
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Chemical approaches to develop a sustained delivery system could potentially utilise 
nanotechnologies to create inhalable particles which slowly releases treprostinil over time. The 
particle would need to exhibit properties to avoid premature clearance from the airways and 
achieve the correct particle dimensions to enter the alveoli. Treprostinil would be released 
from the particle allowing it to dissolve and diffuse across the alveolar epithelial cell layer. The 
particle would then require degradation to facilitate transportation across the epithelial cells to 
enter the blood stream to be excreted.  
The use of nanotechnologies in the lung is applied with caution as many particles have been 
associated with inducing inflammatory and fibrotic responses.263 The delivery of nanoparticles 
to the lung which is affected by an uncontrolled inflammatory pathway initiated in PAH was 
considered too likely to exacerbate the problem. The occlusion and muscularisation of the 
small vessels in PAH results in poor transfer of molecules across the alveolar membrane. 
Requiring a clearance mechanism which relies on the pathways affected by the disease may 
limit therapy to patients with less progressed PAH. For the reasons discussed, development 
of a treprostinil formulation delivered by the pulmonary route was ruled out. 
Pulmonary Vascular Stent 
The localised delivery of agents to the vasculature by insertion of a stent is an attractive 
concept for treating pulmonary arterial hypertension. Stents are usually used in the coronary 
arteries,236 although the insertion of a stent into the pulmonary artery may also be possible. It 
remains standard practice for patients with suspected PAH to undergo right heart 
catheterisation for diagnosis.8 The procedure is invasive and associated with risks, although 
may offer an opportunity to deliver a drug-releasing implant. Similar to a drug-eluting stent for 
the prevention of restenosis, a treprostinil-eluting stent could be hypothesised. Unlike the 
stents currently in the clinic, the stent would not be required for structural purposes, only to 
release drug in the pulmonary tissue. Treprostinil 4 could be conjugated to a polymer which 
could then be utilised to coat a stent inserted into the pulmonary artery. Overtime, treprostinil 
would be released from the polymer and transported into the smaller pulmonary vessels. After 
total treprostinil 4 had been released from the stent, the stent no-longer holds a purpose. To 
facilitate a second dose, a second stent would require insertion. Therefore, the stent would 
need to be biodegradable.240 Furthermore, the rate of degradation of the stent structure would 
ideally match the total drug release rate to reduce the time the patient is not receiving a 
localised drug dose before the next stent is inserted.  
A limitation with biodegradable stents is their difficulty in tracing to determine their structure 
integrity.240 The main limitation with any insertable device particularly of those which are 
embedded into the vasculature is the issue in removing them should adverse events occur.264 
Once inserted, the dose and release rate of the drug from the stent is not tuneable. Non-
tuneable delivery of treprostinil presents a limitation as PAH patients respond to and tolerate 
different doses of PMs. Therefore, realistically the dose provided by such a structure would be 
a baseline dose and more traditional forms of therapy would likely be required. Furthermore, 
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the drug eluting stent has a fixed dose of therapeutic so would require re-insertions, each of 
which, causes damage to the artery and imposes the additional risk, cost and burden 
associated with insertion. For a chronic illness repeated stent insertion did not seem like a 
better tolerated or less costly, in terms of both time and clinical resources, alternative. The 
risks associated with inserting a stent into the damaged vasculature of the PAH lung precluded 
further consideration to examine developing a treprostinil-releasing stent. 
Protein binding prodrug 
A technique to optimise the systemic lifetime of bioactive compounds includes exploiting 
interactions with circulating proteins, such as the case of albumin bound paclitaxel an 
approved treatment for breast, lung and pancreatic cancer.265 Albumin, makes up 55% of the 
proteins in blood which makes it an attractive protein to exploit. An alkyl-drug conjugate which 
binds to albumin could evade clearance by exploiting the abundance of albumin proteins in 
the blood. By interacting with neonatal Fc receptors, albumin exhibits an extended half-life to 
19-21-days. Drugs such as warfarin, diazepam and ibuprofen are able to bind to albumins and 
remain in the circulation longer than for other small molecules.158 α-Tocopherol is able to bind 
to albumin through hydrophobic interactions and has been considered in the conjugation of 
bioactive compounds to extend their half-lives.159,160 The concept of conjugating treprostinil 4 
to a protein binding moiety such as α-tocopherol could increase the half-life of treprostinil to 
reduce the frequency of administration, although the distribution of drug across the body would 
still be wide spread. Furthermore, treprostinil is 90% bound to blood proteins following 
administration,266 so an enhanced protein binding derivative may not best exploit the protein 
binding potential. A method to develop an albumin binding prodrug of treprostinil was therefore 
not considered further. 
Polyvalent approach 
A pro-drug conjugate with treprostinil (4) could act as a slow releasable depot and reduce 
administration site pain and the number of daily doses, however the systemic effects would 
not be avoided as once treprostinil is released, the activity of treprostinil is no longer local as 
the circulatory system will distribute the free drug to receptor targets systemically, which will 
also lead to rapid elimination.267 In contrast, non-degradable drug polymer conjugates are 
designed to maintain drug activity upon conjugation via a stable bond designed not to undergo 
degradation in vivo. Non-degradable conjugation of treprostinil would require activity at the IP, 
EP2 and DP1 receptors to be maintained after conjugation but if achieved, localised 
accumulation of treprostinil in PAH tissue could reduce side effects in the systemic 
vasculature. 
Treprostinil (4) displays a 10-fold decrease in activity when the carboxylic acid is derivatised 
to an ester, so conjugation through the acid would to be expected to reduce treprostinil activity 
even further. Although a polyvalent approach might mask this reduction in activity, there would 
be a need to ensure that treprostinil could also be conjugated with the carboxylic acid groups 
intact. This leaves conjugation through the hydroxyl groups as other options which are also 
Introduction 
 
66 
 
required for receptor binding. An alternative route might be to pursue a method of treprostinil 
derivatisation through parts of the molecule less vital to receptor binding, such as alkylation of 
the aromatic ring.  
Should it be possible to prepare polyvalent treprostinil structures that had some activity, then 
there would still be the side effects to contend with, e.g. site of administration pain. This could 
be overcome using a pro-drug approach by employing a degradable protecting group to 
deactivate the polyvalent treprostinil moieties. Presumably, if treprostinil were conjugated via 
the aromatic ring then the carboxyl terminus could be derivatised so the activity of treprostinil 
is restored upon site-specific degradation. A polyvalent strategy would require a prodrug 
version of a polyvalent treprostinil drug (Figure 1-21).  
 
Figure 1-21. Basic structure of a permanently conjugated treprostinil 4 molecule with 
reduced activity by virtue of a degradable carboxylic acid protecting group 
Such an approach would require many separate considerations; validation of a polyvalent 
approach for treprostinil therapy; macromolecular structure type, size and material; choice of 
prodrug masking group; conjugation of treprostinil to maintain activity; and finally combining 
the ideas to synthesise the final compound. Completion of such a venture without any prior 
results to act as a starting point is is likely beyond the scope of a single PhD project. None-
the-less, initial investigations into a polyvalent approach were considered, described in 
Appendix 8.3. 
Antibody targeting 
Antibody-drug conjugates offer a method of targeting which has achieved some clinical 
success.268 The targeting of treprostinil 4 to the lung using an antibody specific to an antigen 
expressed exclusively in the pulmonary vessels in PAH can be envisaged. Treprostinil 4 could 
be conjugated by a cleavable linker which is specific to the PAH lung so that once the ADC 
binds within the pulmonary vessels, treprostinil is released. The localised delivery of treprostinil 
would result in a localised therapeutic effect. To achieve such a compound both the antibody 
and linker require consideration. As described earlier, ADCs have received much attention but 
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only 4 have entered the clinic in the past 20 years.219 Finding an antibody for a verified target 
in PAH and then obtaining and derivatising the structure for an antibody drug conjugate has 
taken industrial teams decades to achieve so such an approach is likely beyond the scope of 
a PhD project. 
Prodrug 
Formation of prodrug derivatives of active pharmaceutical agents is a common procedure used 
to temporarily impart properties to a drug which can later be modified by a chemical or 
enzymatic reaction to reveal the active drug.148,269 A prodrug form of treprostinil 4 could be 
imagined which would exhibit reduced activity upon administration and once absorbed could 
then be converted to treprostinil by either hydrolytic or enzymatic degradation. Ideally, the 
cleavage mechanism, the site of cleavage and the rate of cleavage should be tailored to 
facilitate prodrug conversion in the PAH lung to achieve site specific drug release.148,149,270 
A treprostinil prodrug could conceivably have limited activity upon SC administration to reduce 
local adverse events. The mechanism by which treprostinil is released from the pro-drug 
structure could be imagined to be degraded by a systemic mechanism to facilitate a slow 
release and thus, less frequent dosing. Alternatively, the cleavage mechanism could be 
designed to exhibit specificity for the PAH diseased lung. The limitation of a prodrug approach 
for the localisation of treprostinil in the treatment of PAH is the non-specific permeation of 
small molecules into tissues which may still exert prostanoid receptor agonist effects if 
cleaved. 
Polymer drug conjugate 
Another prodrug strategy for treprostinil 4 could be to design a polymer-drug conjugate.165 As 
previously described, PEG-treprostinil derivatives have been investigated that have shown 
some activity and degradation preclinically, but failed to reduce adverse events in clinical trials, 
likely owing to premature release of treprostinil. The suboptimal results published do not 
suggest that all polymer-drug conjugates will be unsuccessful. None of the published attempts 
utilised a disease specific degradation mechanism. The choice of the drug linker is a key 
feature of polymer conjugate design. Therefore, polymer-treprostinil conjugate employing a 
disease specific linker can be envisaged to improve upon current treprostinil therapy and 
previous polymeric-treprostinil approaches. 
The conjugation of treprostinil 4 to a polymer would be expected to remove treprostinil activity 
by the act of conjugation. In addition, the macromolecular size of the conjugate is expected to 
reduce clearance rates to extend biological duration of action. Polymer-drug conjugates are 
available in a variety of configurations, but it could be imagined that treprostinil could be 
covalently conjugated to a linear polymer either as a pendant or terminus moiety or within the 
polymer backbone. For both concepts, a linking moiety is required for treprostinil. The linker 
must be cleavable. Incorporation of treprostinil within a polymer backbone, requires that the 
degradable element can be formed either during polymerisation or reside within a monomer. 
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Polymer conjugation offers many opportunities that can be modified; the choice in polymer, 
drug loading, conformation of polymer (i.e. linear, branched, dendritic), site of treprostinil 
conjugation, and size of the conjugate. Furthermore, targeting can be achieved either by 
careful design of a cleavable treprostinil-conjugation bond or by employing targeting moieties. 
 
The aim of this project is to develop prodrug strategies for treprostinil 4 with the view to 
reducing the adverse events associated with the use of PMs in the treatment of PAH. Prodrug 
derivatives reduce the activity of the parent compound and can be optimised to exhibit more 
favourable biological half-lives and distribution profiles. A benefit of the prodrug strategy is that 
the cleavage of the prodrug drug, to release active drug, can be tailored to the disease 
environment, localising the site of drug exposure.  
It is hypothesised that a method of reversibly conjugating treprostinil 4 can be developed in a 
manner that reduces the activity of treprostinil but will degrade to release active treprostinil 
either (i) once in the systemic circulation or (ii) by a mechanism specific to the disease to 
localise the activity of therapy. A well-designed prodrug strategy has the potential to decrease 
adverse events, increase the maximum tolerated dose and reduce the dosing frequency. 
 
Figure 1-22. Structure of treprostinil 4, to which this project is focused on improving the 
delivery for the treatment of pulmonary arterial hypertension (PAH). 
Initially, the limitations in current prostacyclin therapies will be quantified using trial data 
reporting adverse events in the published literature. A meta-analysis of combined data will 
allow for trends to be identified. Adverse events specific to each prostacyclin mimetic and their 
biological profiles will be determined. Moreover, the adverse event profiles will and analysed 
to consider the role in which administration route plays in the differences in tolerability. The 
results of the meta-analysis will be used to establish the qualities required of a prodrug 
derivative of treprostinil to overcome adverse events associated with the current formulations.  
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 Meta-analysis on the adverse events of 
prostacyclin mimetics. 
 Introduction 
Pulmonary arterial hypertension (PAH) is a rare but life threatening inflammatory remodelling 
disease of the small (< 500µm) pulmonary arteries.271 Pulmonary vascular resistance 
progressively increases, ultimately leading to right ventricular failure. The aetiology of the 
disease is unknown, but pulmonary vessels from PAH patients show reduced expression of 
prostacyclin (PGI2) synthase leading to reduced levels of prostacyclin as well as 
downregulation of its classical target, the IP receptor.272 One consequence of the loss of 
prostacyclin signalling is promotion of vasoconstriction of the pulmonary circulation. To 
circumvent a defective prostacyclin pathway, PAH patients are therapeutically targeted by the 
administration of synthetic prostacyclin (epoprostenol 1) or its stable analogues, such as 
iloprost 2, treprostinil 4, and beraprost 3. More recently, selexipag 5, a selective IP receptor 
agonist with a structure not based on prostacyclin, has been approved for PAH treatment.273 
Described collectively as prostacyclin mimetics (PMs, Figure 1-6), these agents are able to 
bind to and activate prostacyclin’s native receptor (IP) promoting vasodilatory, anti-proliferative 
and anti-thrombotic effects, which are likely to contribute to their clinical benefit.85,144,274–277 
However, administration of PMs are associated with adverse events (AEs) in patients, 
including headache, jaw pain, nausea, diarrhoea, cough, flushing and in the case of 
subcutaneous formulations, site pain. In general patients that tolerate higher doses derive 
most benefit, however in a number of patients the maximum tolerated dose is well below the 
optimal treatment dose.72  
PMs are also known to activate other prostanoid receptors. Some could contribute to 
therapeutic efficacy (DP1, EP2+4), because they couple to Gs and increase cAMP, whilst others 
may have a negative impact (EP1+3, TP) because they oppose the biological effects of IP 
receptor activation through activation of Gi and Gq inhibiting cAMP generation and/or raising 
calcium levels.85 Different compounds in this drug class have varying affinities for the above 
mentioned prostanoid receptors, including the IP receptor which may introduce variance in 
their overall activity (Table 2-1). The different receptor affinities of the PMs might therefore be 
expected to translate clinically to different efficacies, adverse events and tolerability in patients. 
For example, selexipag and its active metabolite, ACT-333679 has no reported biological 
activity at other prostanoid receptors.278 Consequently, it might reasonably be expected to be 
associated with fewer adverse events.198,279 
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To overcome adverse events and improve the patient’s quality of life, a variety of PM 
formulations have been developed which allow for dosing via different administrative routes 
(Table 2-2). Treprostinil 4 and iloprost 2 are available via more than one route. Different routes 
of administration possess inherent limitations and will vary the impact of quality of life for a 
patient. Additionally, different administrations expose different tissues to the PM which has the 
potential to cause localised adverse events. The different activity profiles, drug formulations 
and administration routes of the collective PMs (including synthetic epoprostenol sodium, 
iloprost, treprostinil sodium, treprostinil diolamine 7, beraprost sodium, and selexipag), could 
potentially translate into different clinical responses with varying tolerability. Therefore, the 
common practice of describing adverse events as “prostanoid” is too generalised to help guide 
either patients and doctors when choosing therapies or medicinal and formulation scientists 
when designing new therapies. 
  
Table 2-1. Binding affinity at human prostanoid receptors (Ki /nM), split into 
therapeutically beneficial receptors (blue) and therapeutically disadvantageous 
(green). ND = not determined. 
Prostacyclin 
mimeticref 
IP EP2 EP4 DP1 EP1 EP3 TP 
Epoprostenol62 2 ND ND ND >100 10-40 ND 
Iloprost280 3.9±0.6 1172±159 212±27 1016±63 1.1±0.3 208±26 6487±29 
Treprostinil280 
32.1±0.
2 
3.6±0.3 826±116 4.4±0.4 212±56 2505±263 NC 
Selexipag281 260±20 >10000 >10000 >10000 >10000 >10000 >10000 
ACT-333679  
 (Selexipag 
metabolite)281 
20±1 5800 4900 2600 >10000 >10000 >10000 
Beraprost282 16 >3300 >3300 >3300 >3300 110 >3300 
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The primary aim of this thesis is to explore strategies to improve the side effect profile of 
treprostinil therapy for the treatment of PAH. In order to target the most efficient method to 
achieve a better tolerated treprostinil therapy, the limitations of current therapies needed to be 
identified. Although a recent review has qualitatively explored the sources and management 
of different adverse events,72 the present analysis sought to investigate the effect 
quantitatively, using data gathered systematically from published randomised clinical trials.  
The primary objective of this systematic review and meta-analysis is to examine the tolerability 
of PMs. It was hypothesised that the different PMs and routes of administration would affect 
the AE profile and so this was explored. Furthermore, to appreciate the clinical benefit in the 
context of adverse effects, relevant outcome measures including: 6MWD, Borg score; 
haemodynamic parameters; discontinuation and fatalities were meta-analysed. 
 Results 
 
Initial searching highlighted 1802 papers which decreased to 297 after application of the RCT 
filter and search criteria (Figure 2-1). An abstract review identified 35 papers as relevant which 
Table 2-2. The different clinically approved prostacyclin mimetics are 
available in different formulations for delivery by different routes of 
administration.  
Prostacyclin 
mimetic 
Route of 
administration 
Description 
Epoprostenol Intravenous 
Flolan®; Epoprostenol sodium in glycine 
buffer diluent  
Veletri®; Epoprostenol sodium in sodium 
chloride diluent 
Iloprost 
Intravenous 
Ilomedin®; aqueous solution of iloprost 
trometamol 
Inhaled Ventavis®; Nebulised iloprost trometamol 
Beraprost Oral Beraprost sodium; Beraprost sodium tablet 
Treprostinil 
Subcutaneous 
Remodulin®; Treprostinil sodium in sodium 
chloride diluent delivered by ambulatory 
infusion pump via catheter under skin 
Intravenous 
Remodulin®; Treprostinil sodium in glycine 
diluent delivered by ambulatory infusion 
pump via central venous catheter  
Inhaled 
Tyvaso®; treprostinil sodium nebulised by 
portable nebuliser 
Oral 
Orenitram®; Treprostinil diolamine, 
extended osmotic release tablet 
Selexipag Oral Uptravi®; Prodrug form, film coated tablet   
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when reviewed in full outlined 15 papers of interest, published between 1990 and 2013, to be 
analysed. All studies included were multicentre trials. Included studies had a median trial 
length of 12 weeks, ranging between 8-156 weeks. Patients were given PMs via continuous 
SC infusion (treprostinil), continuous IV infusion (treprostinil, epoprostenol), repeated daily 
inhalation (treprostinil, Iloprost) or daily oral administration (beraprost, treprostinil, selexipag).  
 
Figure 2-1. Flow diagram of the selection process for identifying relevant trials. 
Assessment of the quality of the included papers show relatively high study quality except for 
a high risk in “other bias” owing to a potential conflict of interest by funding sources (Figure 
2-2). The high percentage of unclear risk arises from a majority of blinded studies not 
specifying whether the endpoint assessors were also blinded or not and the treatment of 
missing data due to high attrition rates. The Barst study for beraprost was a 12-month trial and 
although outcome data could be obtained after 12 weeks, adverse events were not.112 Data 
obtained for adverse event analysis were cumulative data over a 12-month period. Selexipag 
data from the GRIPHON trial was also obtained after 26 weeks for outcome data but after the 
end of the trial for adverse event data.283 This may exaggerate odds ratios for these trials. 
However, a majority of trials also found that most events occurred in the titration period at the 
beginning of trials, so we believe the trials to still be comparable.  
 
Figure 2-2. Assessment of bias results for the combined trials. 
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Within the studies, a total of 3541 patients were included in the meta-analysis; 1857 treated 
with PMs and 1684 given placebo. Patients enrolled were mostly female (76%) and of a similar 
age (mean = 46 years, standard deviation (SD) = 7). The aetiology of PAH of the patients were 
idiopathic PAH (66%) diagnosed with mostly class II (25%) or class III (68%) PAH. Within 
individual trials, adjustments for age, gender and disease severity between placebo and 
treatment cohorts were made. In all but one trial, patients were receiving non-specific therapy, 
including seven in which patients were also receiving PAH-specific treatment in the form of an 
ERA and/or a PDE-5i, described as combination therapy. Where necessary, clinical trial 
reports were referred to obtain data not published in the journal articles. All but one trial 
reported adverse events. A brief description of the trials basic characteristics is shown in Table 
2-3. 
Maximum daily doses were collected from published trial methods and supplementary 
materials. When maximum doses were given as per administration, the value was multiplied 
by the number of administrations per day. Where actual mean doses achieved for 
subcutaneous and intravenous administrations were not reported, estimates were calculated 
based on the mean doses reported per kilogram, by multiplying by the average worldwide 
weight (62kg).284 To consider the effects of the varying bioavailabilities of the different PMs 
and different routes of administration, we multiplied the daily dose by the reported 
bioavailabilities, taken from the packet inserts for each treatment. To obtain a single value, the 
two reported bioavailabilities for the two doses available for inhaled treprostinil (Tyvaso) were 
averaged.128 The dosing information for each trial is shown in Table 2-4.
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Table 2-3. Summary of trial and patient characteristics.  NYHA = New York Heart Association functional class; ERA = endothelin receptor antagonist; PDE-5i 
= phosphodiesterase -5 inhibitor. 
 Study  Drug Administration 
Study 
length 
/weeks 
Background 
therapy 
Pre-trial therapy 
Treatment 
patients 
Control 
patients 
%NYHA 
class III 
% 
female 
Mean 
age /y  
1 
Simonneau et 
al. 2002 
Treprostinil Subcutaneous 12 
adjunctive 
therapies** 
30 days no prostanoids 233 236 81 81 44.5 
2 
McLaughlin et 
al. 2003 
Treprostinil Subcutaneous 8 none conventional therapy 15 9    
3 
Rubenfire et 
al. 2007 
Treprostinil Subcutaneous 8 none 
Patients must have been receiving 
epoprostenol therapy for 3 months 
14 8 41 86 45.5 
4 
Hiremath et al. 
2010 
Treprostinil Intravenous 12 none conventional therapy 30 14 95 61 32 
5 
McLaughlin et 
al. 2010 
Treprostinil Inhaled 12 Bosentan bosentan 3 months 115 120 98 81 54 
6 
Tapson et al. 
2012 
Treprostinil Oral 16 
PDE-5i and/or 
ERA 
PDE-5 inhibitor and or ERA for 3+ 
months at a stable dose for 1 
month, no prostanoids 
174 176 74 82 51 
7 
Jing et al. 
2013 
Treprostinil Oral 12 none no specific treatments 233 116 66 73 39.4 
8 
Tapson et al. 
2013 
Treprostinil Oral 16 
PDE-5i and/or 
ERA 
PDE-5 inhibitor and or ERA for 3 
months + at a stable dose for 1 
month, no prostanoids 
157 153 73 78 54 
9 
Barst et al. 
2003 
Beraprost Oral 52 none conventional therapy 60 56 47.4 85.3 42 
10 
McLaughlin et 
al. 2006 
Iloprost Inhaled 12 Bosentan bosentan 4 months 34 33 94 79 50 
11 
Galie et. Al. 
2002 
Beraprost Oral 12 none 
Not prostanoid treatment for 1 
month 
65 65 50.8 61.5 45.5 
12 
Simonneau et 
al. 2012 
Selexipag Oral 17 
 ERA and or  
PDE-5i 
Stable dose ERA and PDE-5i for 12 
weeks 
33 10 60.5 81.4 54.6 
13 
Sitbon et al. 
2015 
Selexipag Oral 156 
 ERA and or  
PDE-5i 
Stable dose ERA and PDE-5i for 12 
weeks 
582 574 52.5 79.8 48.1 
14 
Olschewski et 
al. 2002 
Iloprost Inhaled 12 none conventional therapy 101 102 58.6 67.5 52 
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Table 2-4. Dosing information for each trial. PM = prostacyclin mimetic; BD = two dosings daily; QD = four dosing; * = Mean number of inhalations 
achieved during trial; + = weight based on international average (59 kg). 
Trial 
Administration 
route 
PM 
Dose per 
administration 
Daily Dosing 
regime 
Bio-availabilityref 
Daily dose 
/mg 
Simonneau et al. 2002 Subcutaneous Treprostinil 9.3 ng/kg/min Continuous 182 0.830+ 
McLaughlin et al. 2003 Subcutaneous Treprostinil 13 ng / kg/min Continuous 182 1.161+ 
Rubenfire et al. 2007 Subcutaneous Treprostinil 32.2 ng/kg/min Continuous 182 2.875+ 
Hiremath et al. 2010 Intravenous Treprostinil 72 ng/kg/min Continuous 182 4.769+ 
McLaughlin et al. 2010 Inhaled Treprostinil 50 μg 9 inhalations QD 0.78102 1.404 
Tapson et al. 2012 Oral Treprostinil - - - - 
Jing et al. 2013 Oral Treprostinil 3.4 mg  BD 0.17285 1.156 
Tapson et al. 2013 Oral Treprostinil 3.1 mg BD 0.17285 1.054 
Simonneau et al. 2012 Oral Selexipag 583 μg BD 0.49113 0.571 
Sitbon et al. 2015 Oral Selexipag 950.4 μg BD 0.49113 0.931 
Galie et al. 2002 Oral Beraprost 80 μg QD 0.6286 0.192 
Barst et al. 2003 Oral Beraprost 71 μg QD 0.6286 0.170 
McLaughlin et al. 2006 Inhaled Iloprost 26.8μg 5.6 inhalations* 0.893 0.120 
Olschewski et al. 2002 Inhaled Iloprost 4.8 μg 7.5 inhalations* 0.893 0.029 
Rubin et al. 1990 Intravenous Epoprostenol 7.1 ng/kg/min Continuous 1287 0.634 
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2.2.3.1 Overall, drug type and route of administration 
Nine adverse events were significantly increased compared to placebo. Site pain, jaw pain, 
flushing and headache demonstrated the highest ORs associated with PM therapies (OR 8.7, 
4.8, 4.0, 3.6, respectively), although heterogeneity between the results in each subgroup was 
present, ranging from 0 to 82%, indicating poor agreement in the overall result. 
Sub group analysis was performed with respect to PM drug type and administration route. A 
summary of the results is shown in Table 2-5 and Table 2-6. In brief, the likelihood of site 
pain was only increased in patients receiving parenteral (IV and SC) treprostinil vs. 
placebo89,288–290 (OR = 8.7; 95% CI: 1.6, 45.9; I2 = 79%). The high heterogeneity (I2 = 79%) 
indicates that there is considerable variability in the likelihood of site pain between trials. 
Furthermore, of the parenteral routes, site pain was most associated with the subcutaneous 
route of administration (OR =17.5; 95% CI: 11.1, 27.1; I2 = 0%). Thirteen studies89,112,127,283,289–
295 recorded headache as a common side-effect associated with PM therapies (OR = 3.6; 95% 
CI: 2.4, 5.4; I2 = 82%). Although headache was not associated with any particular PM drug 
type, the strongest association was observed with intravenous treprostinil290 (OR = 6.0; 95% 
Cl:1.1, 31.5; I2 not calculated) but in contrast, was not significantly measured for subcutaneous 
therapy. Vomiting was reported in eight studies89,127,283,288,289,291,294 and showed a significant 
increase in patients given PM treatment vs. placebo but again there was significant 
heterogeneity between studies (OR = 2.5; 95% CI: 1.4, 4.7; I2 = 79%). Sub-group analysis 
with regard to vomiting did not reveal any association with PM drug type but was most 
common with the intravenous route of administration (OR = 6.0; 95% CI: 1.1, 31.5; I2 not 
calculated) and was not significantly increased by subcutaneous administration (Table 2-5). 
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Table 2-5. Table showing likelihood of experiencing adverse events during trial period 
associated with prostacyclin mimetic therapy as meta-analysed by each mimetic (treprostinil, 
beraprost, iloprost and selexipag). OR = odds ratio; NS = non-significant; CI = confidence 
interval. 
Adverse 
Event 
Overall OR 
CI 
I2, p value 
Treprostinil OR 
CI 
I2, p value 
Beraprost OR 
CI 
I2, p value 
Iloprost OR 
CI 
I2, p value 
Selexipag OR 
CI 
I2, p value 
Site pain 
8.7 
(1.6, 45.9) 
79%, 0.003 
8.7 
(1.6, 45.9) 
79%, 0.003 
- - - 
Flushing 
4.0 
(3.0, 5.3) 
19%, 0.259 
4.4 
(2.7, 7.1) 
30%, 0.02 
5.3 
(2.3, 12.1) 
49%, 0.16 
3.7 
(1.8, 7.4) 
0%, 0.886 
2.7 
(1.7, 4.1) 
0%, 0.675 
Jaw Pain 
4.6 
(3.6, 5.8) 
0%, 0.571 
4.0 
(2.9, 5.6) 
0%, 0.421 
8.7 
(2.0, 37.2) 
50%, 0.159 
4.2 
(1.6, 10.8) 
0%, 0.885 
5.0 
(3.4, 7.3) 
0% 0.356 
Headache 
3.6 
(2.4, 5.4) 
82%, 0.000 
3.3 
(1.6, 6.8) 
88%, 0.000 
NS 
 
87%, 0.006 
2.4 
(1.0, 5.7) 
49%, 0.161 
3.9 
(3.0, 5.0) 
0%, 0.406 
Pain in 
extremity 
2.7 
(1.7, 3.5) 
0%, 0.480 
3.3 
(2.2, 4.9) 
0%, 0.421 
- 
NS 
 
- , - 
2.4 
(1.7, 3.5) 
0%, 0.354 
Diarrhoea 
2.6 
(2.0, 3.4) 
46%, 0.039 
2.7 
(1.9, 3.9) 
47%, 0.079 
3.1 
(1.4, 7.3) 
36%, 0.213 
NS 
 
- , - 
3.1 
(2.4, 4.1) 
0%, 0.698 
Vomiting 
2.5 
(1.4, 4.7) 
79%, 0.000 
2.6 
(1.1, 6.1) 
79%, 0.000 
- - 
2.4 
(1.7, 3.4) 
- , - 
Arthralgia 
1.5 
(1.1, 2.2) 
0%, 0.788 
NS 
 
0%, 0.628 
- - 
NS 
 
- , - 
Nausea 
2.2 
(1.7, 2.8) 
41%, 0.060 
2.0 
(1.3, 3.0) 
63%, 0.012 
3.4 
(1.7, 6.7) 
0%, 0.451 
NS 
 
0%, 0.588 
2.2 
(1.7, 2.9) 
0%, 0.386 
Peripheral 
Oedema 
NS 
 
59%, 0.024 
2.1 
(1.2, 3.8) 
18%, 0.297 
NS 
 
- , - 
NS 
 
0%, 0.889 
NS 
 
- , - 
Fatigue 
NS 
 
50%, 0.062 
NS 
 
0%, 0.726 
3.6 
(1.1, 11.8) 
- , - 
NS 
 
- , - 
NS 
 
- , - 
Cough 
NS 
 
68%, 0.005 
NS 
 
68%, 0.042 
- 
2.0 
(1.2, 3.5) 
0%, 0.042 
NS 
 
0%, 0.376 
Upper 
respiratory 
tract 
infection 
NS 
 
6%, 0.382 
NS 
 
0%, 0.486 
0.5 
(0.2, 1.0) 
- , - 
NS 
 
- , - 
NS 
 
0%, 0.726 
Dyspnea 
NS 
 
57%, 0.030 
NS 
 
59%, 0.046 
- 
NS 
 
- , - 
0.7 
(0.5, 1.0) 
- , - 
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The likelihood of diarrhoea was increased in patients as reported in twelve 
studies89,112,127,128,283,289–292,294–296 (OR = 2.6; 95% CI: 2.0, 3.4; I2 = 46%). Analysis by different 
drug types revealed a decrease in heterogeneity for the selexipag group (OR = 3.1, 95% CI: 
2.4, 4.1, I2 = 0%), indicating that the results for each selexipag trial are consistent with one 
another. Diarrhoea was more likely in patients treated with oral PM therapies (OR = 3.3; 95% 
CI:2.7, 4.0; I2 = 0%) and not significantly associated with inhaled therapies. Nausea was 
associated with thirteen studies89,112,127,128,283,289–296 with moderate heterogeneity (OR = 2.2; 
95% CI: 1.7, 2.8; I2 = 41%). When analysed by drug type, the magnitude was greatest for 
patients taking beraprost (OR = 3.4; 95% CI: 1.7, 6.7; I2 = 0%) and was non-significantly 
associated with iloprost therapy. Eleven studies recorded flushing as an adverse event 
112,127,128,283,289,291–296. Meta-analysis calculated a strong significant increase in OR with limited 
heterogeneity (OR = 4.0; 95% CI: 3.0, 5.3; I2 = 19%). Sub-group analysis showed the greatest 
association with beraprost (OR = 5.3; 95% CI: 2.3, 12.1; I2 = 49%) and inhaled therapy (OR 
= 4.7; 95% CI: 2.0, 11.1; I2 = 26%) compared to the least association with selexipag (OR = 
2.7; 95% CI: 1.7, 4.4; I2 = 0%) and no significant increase for subcutaneous administration. 
The thirteen studies89,112,127,128,283,289–296 reporting jaw pain showed a significant association 
with PMs vs. placebo (OR = 4.6; 95% CI: 3.6, 5.8; I2 = 0%). This association was greatest for 
treatment with beraprost (OR = 8.7; 95% CI: 2.0, 37.2; I2 = 50%) and oral PMs (OR = 5.1; 
95% CI: 4.0, 6.7; I2 = 0%) and lowest for treprostinil (OR = 4.0; 95% CI: 2.9, 5.6; I2 = 0%) and 
inhaled administration (OR = 2.7; 95% CI: 1.2, 6.0; I2 = 14%). Data shown in Table 2-6. 
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The eight studies127,283,289–291,293–295 reporting pain in the extremity showed significant and 
homogenous association with PM treatment (OR = 2.7; 95% CI: 1.7 3.5; I2 = 0%). Pain in 
extremities was mostly associated with intravenous administration of PMs (OR = 13.0; 95% 
CI: 1.5, 112.3; I2 not calculated) but was not significantly associated with subcutaneous and 
inhaled administrations. Arthralgia was reported in four of the studies127,283,291,294 featuring only 
Table 2-6. Likelihood of developing each adverse event during trial period associated 
with prostacyclin therapy as meta-anlaysed by different routes of administration 
(subcutaneous and intravenous infusion, inhaled formulation and oral tablet/capsule) 
Odds ratios of adverse events as meta-analysed by route of administration. AE = 
adverse event; OR = odds ratio; CI = confident interval; NS = non-significant. 
AE 
Overall OR 
CI 
I2, p value 
SC OR 
CI 
I2, p value 
IV OR 
CI 
I2, p value 
Inhaled OR 
CI 
I2, p value 
Oral OR 
CI 
I2, p value 
Site pain 
8.7 
(1.6, 45.9) 
79%, 0.003 
17.5 
(11.1, 27.1) 
0%, 0.915 
0.7 
(0.2, 3.6) 
- , - 
- - 
Flushing 
4.0 
(3.0, 5.3) 
19%, 0.259 
1.3 
(0.2, 7.4) 
- , - 
- 
4.7 
(2.0, 11.1) 
26%, 0.26 
4.0 
(2.9, 5.5) 
27%, 0.226 
Jaw Pain 
4.6 
(3.6, 5.8) 
0%, 0.571 
3.1 
(1.6, 6.2) 
0%, 0.929 
NS 
 
- , - 
2.7 
(1.2, 6.0) 
14%, 0.313 
5.1 
(4.0, 6.7) 
0%, 0.700 
Headache 
3.6 
(2.4, 5.4) 
82%, 0.000 
NS 
 
59%, 0.088 
6.0 
(1.1, 31.5) 
- , - 
2.4 
(1.0, 5.7) 
49%, 0.161) 
5.4 
(3.5, 8.2) 
73%, 0.001 
Pain in 
extremity 
2.7 
(1.7, 3.5) 
0%, 0.480 
NS 
 
- , - 
13.0 
(1.5, 112.3) 
- , - 
NS 
 
- , - 
2.7 
(2.1, 3.6) 
0%, 0.418 
Diarrhoea 
2.6 
(2.0, 3.4) 
46%, 0.039 
1.8 
(1.2, 2.9) 
0%, 0.915 
NS 
 
- , - 
NS 
 
0%, 0.474 
3.3 
(2.7, 4.0) 
0%, 0.659 
Vomiting 
2.5 
(1.4, 4.7) 
79%, 0.000 
NS 
 
12%, 0.322 
6.0 
(1.1, 31.5) 
- , - 
- 
2.5 
(1.4, 4.7) 
85%, 0.000 
Arthralgia 
1.5 
(1.1, 2.2) 
0%, 0.788 
- - - 
1.5 
(1.1, 2.2) 
0%, 0.788 
Nausea 
2.2 
(1.7, 2.8) 
41%, 0.060 
NS 
 
65%, 0.091 
NS 
 
- , - 
1.7 
(1.0, 2.9) 
0%, 0.766 
2.6 
(2.2, 3.2) 
0%, 0.433 
Peripheral 
oedema 
NS 
 
59%, 0.024 
3.8 
(1.5, 9.6) 
- , - 
- 
NS 
 
0%, 0.889 
NS 
 
45%, 0.141 
Cough 
NS 
 
68%, 0.005 
- 
NS 
 
- , - 
2.4 
(1.6, 3.5) 
0%, 0.537 
NS 
 
0%, 0.668 
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oral treprostinil and selexipag, and showed a strong increase in OR in the treatment groups 
with no heterogeneity (OR = 1.5; 95% CI: 1.1, 2.2; I2 = 0%). Seven studies89,112,127,283,291,293,296 
reported peripheral oedema although on meta-analysis this was not more frequent with active 
therapy when compared to placebo (OR = 1.3; 95% CI: 0.8, 2.1; I2 = 59%). However, on sub-
group analysis the likelihood of peripheral oedema was only significantly increased for 
patients treated with treprostinil (OR = 2.1; 95% CI: 1.2, 3.8; I2 =18%). Subcutaneous 
administration, which only included treprostinil treatment, was also the only administration 
route associated with an increase in peripheral oedema (OR = 3.8; 95% CI: 1.5, 9.6; I2 not 
calculated).  
Fatigue was reported in seven trials127,128,283,291,293,294 although no significant difference in 
incidence between placebo and treatment groups with significant heterogeneity was detected 
(OR = 1.2; 95% CI: 0.8, 1.8; I2 = 50%). When analysed by PM drug type, heterogeneity was 
eliminated and a significant increase in OR of fatigue in patients treated with only beraprost 
was observed (OR = 3.6; 95% CI: 1.1, 11.8; I2 not calculated). Seven trials reported cough as 
a side effect,128,283,290,291,293,295,296 which when meta-analysed, showed no significant difference 
between treatment and placebo groups (OR = 1.5; 95% CI: 0.9, 2.6 I2 = 68%). Sub-group 
analysis only revealed a significant increase in the combined OR of cough for patients taking 
inhaled PMs (OR = 2.4; 95% CI: 1.6, 3.5; I2 = 0%) and iloprost (OR = 2.0; 95% CI: 1.2, 3.5; I2 
= 0%). Despite showing no significant correlation in the overall meta-analysis, when compared 
by PM types, a decreased likelihood for upper respiratory tract infection (URTI) was shown 
only to be associated with beraprost treatment (OR = 0.5; 95% CI: 0.2, 1.0; I2 not calculated). 
A similar decreased association was found for patients experiencing dyspnoea when treated 
with selexipag (OR = 0.7; 95% CI: 0.5 to 1.0; I2 not calculated). 
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2.2.4.1 6-MWD, Borg score, haemodynamics and quality of life score 
Study interventions were overall effective at increasing 6MWD by 16.3 m (95% CI: 13.0, 19.7; 
I2 = 90%). Significant improvements were greatest for intravenously administered drugs 
(treprostinil and epoprostenol, WMD = 72.4 m; 95% CI: 8.4, 136.4; I2 = 0%). In comparison, 
orally administered PMs showed an increase of 15.3 m (95% CI: 11.1-19.5; I2 = 93%). Overall, 
patient-reported Borg score was decreased by PM therapies to a limited extent (SMD=-0.3 
95% CI: -0.4, -0.1). By subgroup analysis, this was significant for only beraprost112,292 (SMD 
= -0.4; 95% CI: -0.6, -0.1; I2 = 0%). The largest decreased Borg score was measured in trials 
using intravenous PMs (SMD = -1.0; 95% CI: -1.6, -0.3; I2 not calculated) although was also 
observed with oral therapies (SMD = 0.3; 95% CI: -0.6, -9.1; I2 = 0%) but not significantly for 
subcutaneous and inhaled therapies. Patients receiving monotherapy only89,128,288,290,293 were 
also associated with a decreased Borg score (SMD = -0.4; 95% CI: -0.6, -0.1; I2 = 32%). Four 
trials monitored quality of life which was increased overall (SMD = 0.2; 95% CI: 0.1, 0.3; I2 = 
0%). When analysed by route of administration, this was only significant for inhaled therapies 
(SMD = 0.3; 95% CI: 0.1, 0.6; I2=9%). Mixed venous saturation improvements were shown for 
inhalation therapies89,112,288,295,296 (WMD = 2.1; 95% CI: 0.1, 4.0; I2 not calculated) although a 
similar non-significant increased trend was observed for subcutaneous (WMD = 2.4; 95% CI: 
-0.6, 5.4; I2 = 57%) and oral (WMD = 4.7; 95% CI: -2.2, 11.6; I2 = 0%) therapies. Data for 
continuous outcome variables are shown in Table 2-7 and Table 2-8.
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Table 2-7. Standardised mean difference of clinical outcomes as meta-analysed by different prostacyclin 
mimetics (treprostinil, beraprost, iloprost , selexipag and epoprostenol). 
 
Overall SMD 
(CI) 
I2, p value 
Treprostinil 
SMD 
(CI) 
I2, p value 
Beraprost SMD 
(CI) 
I2, p value 
Iloprost 
SMD 
(CI) 
I2, p value 
Selexipag 
SMD 
(CI) 
I2, p value 
Epoprostenol 
SMD 
(CI) 
I2, p value 
6MWD 
1.1 
(0.6, 1.7) 
98%, 0.000 
1.2  
(0.9, 1.6) 
90%, 0.000 
0.9 
(0.0, 1.7) 
90%, 0.002 
0.4 
(0.2, 0.7) 
0%, 0.690 
NS 
 
98%, 0.000 
NS 
 
-, - 
Borg 
Dyspnea 
score 
-0.3 
(-0.4, -0.1) 
36%, 0.133 
NS 
 
60%, 0.040 
-0.4 
(-0.6, -0.1) 
0%, 0.356 
NS 
 
-, - 
NS 
 
-, - 
 
- 
Quality 
of Life 
Score 
0.2 
(-.1, 0.3) 
0%, 0.391 
NS 
 
62%, 0.106 
NS 
 
-, - 
NS 
 
-, - 
- 
 
- 
Mixed 
venous 
saturatio
n 
NS 
 
99%, 0.000 
NS 
 
99%, 0.000 
NS 
 
-, - 
0.3 
(0.0, 0.6) 
-, - 
NS 
 
- 
Right 
arterial 
pressure 
NS 
 
99%, 0.000 
NS 
 
99%, 0.000 
NS 
 
0%, 0.875 
NS 
 
-, - 
1.0 
(0.2, 1.7) 
-, - 
 
- 
Heart 
rate 
NS 
 
72%, 0.003 
0.40 
(0.22, 0.58) 
- , - 
NS 
 
-, - 
NS 
 
55%, 0.136 
NS 
 
-, - 
NS 
 
-, - 
Cardiac 
index 
NS 
 
99%, 0.000 
NS 
 
99%, 0.000 
NS 
 
49%, 0.161 
- 
1.1 
(0.4, 1.9) 
-, - 
 
- 
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2.2.4.2 Fatalities and discontinuation from adverse events 
Discontinuations due to adverse events were monitored in 11 trials, and occurred in 10 
trials.87,111,112,127,128,283,290,293,297,298 Common adverse events leading to discontinuation were 
headache, nausea, jaw pain, diarrhoea, and vomiting. Compared to placebo, patients were 
significantly more likely to discontinue therapy in trials involving orally administered 
PMs89,112,127,128,283,288,289,292,293,297 (OR = 2.1; 95% CI: 1.5, 3.0; I2 = 0%) and was not significantly 
associated with subcutaneous, intravenous or inhaled administrations. An increased trend was 
seen for all three of the oral PM trials analysed, although when considering PM type, this 
reached significance for only selexipag (OR = 2.2; 95% CI: 1.5, 3.3; I2 not calculated). Mortality 
was reported in 12 studies but OR could not be calculated for 2, in which no deaths were 
reported. Therefore, 10 studies were included in the analysis. Although the overall OR was 
not significant, the intravenous PM group, including treprostinil and epoprostenol, had 
significantly fewer fatalities in the treatment group than the placebo group during the trials (OR 
= 0.2; 95% CI: 0.1, 0.9; I2 = 0%). A similar non-significant trend was observed for inhaled 
therapies. When analysed by separating into PM type, PMs were not associated with any 
significant change in likelihood of fatality, lung transplant, rescue therapy and right ventricular 
heart failure, during the period of observation. Results are shown in Table 2-9 and Table 2-10.
Table 2-8. Standardised mean difference (SMD) of clinical outcomes 
associated with prostacyclin mimetic therapy as meta-analysed by route of 
administration. SC = subcutaneous; IV = intravenous; CI = confidence interval; 
6MWD = 6-minute walk distance; NS = non-significant odds ratio. 
 
Overall SMD 
(CI) 
I2, p value 
SC SMD 
CI 
I2, p value 
IV SMD 
CI 
I2, p value 
Inhaled SMD 
CI 
I2, p value 
Oral SMD 
CI 
I2, p value 
6MWD 
1.1 
(0.6, 1.7) 
98%, 0.000 
1.1 
(0.6, 1.7) 
47%, 0.152 
0.6 
(0.1, 1.1) 
0%, 0.584 
NS 
 
96%, 0.000 
1.4 
(0.4, 2.4) 
99%, 0.000 
Borg 
Dyspnea 
score 
-0.3 
(-0.4, -0.1) 
36%, 0.133 
NS 
 
17%, 0.300 
-1.0 
(-1.6, -0.3) 
-, - 
NS 
 
41%, 0.193 
-0.3  
(-0.6, -0.1) 
0%, 0.459 
Quality of 
Life Score 
0.2 
(0.1, 0.3) 
0%, 0.391 
NS 
 
-, - 
- 
0.3 
(0.1, 0.6) 
9%, 0.293 
NS 
 
-, - 
Mixed 
venous 
saturation 
NS 
 
99%, 0.000 
NS 
 
99%, 0.000 
- 
0.3 
(0.0, 0.6) 
-, - 
NS 
 
0%, 0.588 
Right 
arterial 
pressure 
NS 
 
99%, 0.000 
NS 
 
99%, 0.000 
- 
NS 
 
-, - 
NS 
 
99%, 0.027 
Heart rate 
NS 
 
72%, 0.003 
0.4 
(0.2, 0.6) 
-, - 
NS 
 
-, - 
NS 
 
55%, 0.136 
NS 
 
57%, 0.126 
Cardiac 
index 
NS 
 
99%, 0.000 
NS 
 
99%, 0.000 
- - 
NS 
 
66%, 0.052 
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Table 2-9. Different prostacyclin mimetics (treprostinil, beraprost, iloprost, selexipag, epoprostenol) possess different likelihoods of 
affecting various measures of clinical efficacy as measured by odds ratio. 
 
Overall OR 
(CI) 
I2, p value 
Treprostinil OR 
(CI) 
I2, p value 
Beraprost OR 
(CI) 
I2, p value 
Iloprost OR 
(CI) 
I2, p value 
Selexipag OR 
(CI) 
I2, p value 
Epoprostenol OR 
(CI) 
I2, p value 
Discontinuation from 
adverse event 
NS 
 
-, - 
NS 
 
74%, 0.002 
NS 
 
-, - 
NS 
 
-, - 
2.2 
(1.5, 3.3) 
-, - 
NS 
 
-, - 
Clinical deterioration 
0.4 
(0.2, 0.8) 
47%, 0.080 
NS 
 
65%, 0.036 
- 
NS 
 
-, - 
0.3 
(0.2, 0.5) 
0%, 0.440 
 
- 
Fatalities 
NS 
 
12%, 0.334 
NS 
 
0%, 0.511 
NS 
 
-, - 
NS 
 
-, - 
NS 
 
-, - 
NS 
 
-, - 
Lung transplant 
NS 
 
0%, 0.870 
NS 
 
0%, 0.610 
- - 
NS 
 
-, - 
 
- 
Rescue therapy 
NS 
 
0%, 0.695 
NS 
 
0%, 0.488 
NS 
 
-, - 
NS 
 
-, - 
NS 
 
-, - 
 
- 
Right ventricular heart 
failure 
NS 
 
0%, 0.485 
NS 
 
0%, 0.380 
NS 
 
-, - 
NS 
 
-, - 
- 
 
- 
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2.2.4.3 Publication bias and heterogeneity analysis 
The presence of publication bias was investigated using two methods; Begg’s test; Egger’s 
test. Publication bias arises when not all studies conducted are reported. Usually, the results 
or conclusions of unpublished studies differ from those published. A plot of effect size against 
sample size allows for a funnel plot to be analysed. The narrower and more symmetrical the 
plot the more consistent the data is and therefore it is less likely that publication bias exists. 
The Begg’s test subtracts the pooled estimate of effect size by each value of effect size and 
divides by the standard error of the deviation. The adjusted effect size is correlated with the 
meta-analysis weight using Kendall’s rank correlation coefficient. The Egger’s test is a 
measure of regression of study difference. The log of the odds ratio divided by standard error 
(difference/SE) is plotted by one divided by standard error (1/SE) and whether the intercept 
passes through zero is set as the null hypothesis. A p-value less than 0.05 indicates publication 
bias.  
No publication bias was detected for 6MWD (SMD and WMD), Borg score (SMD and WMD), 
mixed venous saturation (SMD and WMD), right atrial pressure (SMD and WMD), cardiac 
index (SMD and WMD), heart rate (SMD and WMD), fatalities, rescue therapy and 
discontinuation due to adverse events using funnel plot symmetry as well as Begg’s and 
Egger’s tests. However, these results are only backed up by funnel plots for Borg score, heart 
Table 2-10. The effect of route of delivery by which prostacyclin 
mimetics are administered on the likelihood of clinical efficacy as 
measured by odds ratio.  
 
SC OR 
CI 
I2, p value 
IV OR 
CI 
I2, p value 
Inhaled OR 
CI 
I2, p value 
Oral OR 
CI 
I2, p value 
Discontinuation 
from adverse 
event 
NS 
 
89%, 0.000 
NS 
 
46%, 0.175 
NS 
 
0%, 0.703 
2.1 
(1.5, 3.0) 
0%, 0.743 
Clinical 
deterioration 
NS 
 
88%, 0.004 
- 
NS 
 
-, - 
0.4 
(0.3, 0.5) 
0%, 0.485 
Fatalities 
NS 
 
-, - 
0.2 
(0.1, 0.9) 
0%, 0.785 
NS 
 
0%, 0.863 
NS 
 
0%, 0.691 
Lung transplant 
NS 
 
-, - 
- - 
NS 
 
0%, 0.712 
Rescue therapy 
NS 
 
0%, 0.866 
NS 
 
-, - 
NS 
 
-, - 
NS 
 
0%, 0.448 
Right 
ventricular heart 
failure 
NS 
 
-, - 
- 
NS 
 
4%, 0.309 
NS 
 
36%, 0.211 
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rate and discontinuation. Heterogeneity was not attributed to differences in percentage of 
patients with class III IPAH, gender or mean age for 6MWD (SMD and WMD), borg score 
(WMD), fatalities, rescue therapy and discontinuation due to adverse events. Data is shown in 
Table 2-11.  
 
Table 2-11. Meta-regression analysis was carried out to determine the 
effect of age, gender or aetiology on the outcomes measured. 
 
Meta-
regression 
Coefficient Standard error  p-value 
Clinical 
deterioration 
Mean age 0.0590 0.2755 0.8440 
% female 0.1150 0.2858 0.7140 
% IPAH 0.0092 0.1605 0.9580 
Adverse event 
discontinuation 
Mean age 0.0236 0.1938 0.9090 
% female 0.0279 0.1082 0.8090 
% IPAH 0.0897 0.0789 0.3190 
Fatalities 
Mean age 0.0033 0.0620 0.9600 
% female 0.0548 0.0465 0.2920 
% IPAH 0.0217 0.0312 0.5170 
6MWD (WMD) 
Mean age 0.5621 0.7830 0.491 
% female 0.5230 0.6427 0.437 
% IPAH 0.0094 0.4465 0.984 
6MWD (SMD) 
Mean age 0.0600 0.6275 0.364 
% female 0.0378 0.0396 0.364 
% IPAH 0.0300 0.0290 0.328 
Borg (WMD) 
Mean age 0.1440 0.0881 0.350 
% female 0.0729 0.0666 0.472 
% IPAH 0.0606 0.0577 0.485 
Borg (SMD) 
Mean age 0.0511 0.0266 0.306 
% female 0.6314 0.0329 0.306 
% IPAH 0.0368 0.0260 0.392 
Rescue 
therapy 
Mean age 0.1580 0.1148 0.262 
% female 0.0084 0.1104 0.944 
% IPAH 0.0828 0.0680 0.310 
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 Discussion 
The likelihood of experiencing an adverse event within the trial period was explored in this 
meta-analysis. It was anticipated that the administration route chosen would have some 
inherent adverse events associated, independent of the compound being administered. For 
example, subcutaneous catheter would be expected to induce pain and discomfort. To 
eliminate the inherent effect of each administration, the pain reported for each trial was 
interpreted as a ratio between the proportion of treatment receiving and placebo receiving 
groups, by use of the odds ratio. This allowed for a value of the likelihood of an adverse event 
to be ascribed to each trial and groups of trials, thus removing any inherent effect associated 
to administration route. 
This meta-analysis investigated the effects of different PMs, and route of administration on the 
likelihood of various side effects in the treatment of PAH. Using subgroup analysis, different 
trends were identified to help indicate the underlying cause. Here it is demonstrated that the 
adverse event rate continues to limit dose optimisation in all treatments targeting the IP 
receptor. Altering the route of administration and the receptor selectivity of PMs, does appear 
to change the side effect profile, but not to significantly reduce or prevent their overall 
incidence. The parenteral route of administration is considered the least patient compliant, 
which was reinforced by our analysis, showing the greatest likelihood of adverse events. 
However, they were associated with the fewest types of adverse events, and intravenous 
administration was the only route to decrease the patient Borg Dyspnea score and risk of 
mortality. On the other hand, oral administration is considered the most convenient form of 
administration but was found to be associated with the widest variety of adverse events, even 
in patients treated with a selective IP receptor agonist. 
 
The associated AEs significantly increased in PM therapy compared to placebo include; site 
pain, headache, jaw pain, nausea, vomiting, diarrhoea, nausea, cough, peripheral oedema 
and arthralgia, although their likelihoods varied greatly, depending on treatment ( 
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Figure 2-3). Treprostinil, (DP1, EP2 and IP agonist) displayed the greatest number of adverse 
events and was responsible for the most strongly drug associated adverse event, with site 
pain increasing nine-fold in the treatment group versus placebo. This finding is consistent with 
other published literature90 and is in line with clinical reports.299 Beraprost (IP and EP3 agonist) 
showed the least number of AEs but was associated with the largest likelihood of flushing, jaw 
pain and nausea. Selexipag (selective IP agonist) was associated with the highest likelihood 
of headache. Only inhaled iloprost (EP1 and IP agonist) increased likelihood of cough and, 
despite previous reports,300 showed no significant increase of gastrointestinal AEs than 
placebo. Inhaled treprostinil also reported cough, however the analysis between PM type 
combines the effect of all treprostinil treatments. 
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Figure 2-3. Likelihood of developing each adverse event during trial period associated 
with prostacyclin mimetics (treprostinil, beraprost, iloprost and selexipag) as 
determined by odds ratio.  
In regard to the route of administration, there was association between intravenous 
administration of PMs and pain in extremities, headache and vomiting. Cough was exclusively 
associated with inhaled therapies, although flushing, jaw pain, headache, nausea and cough 
were all significantly increased. Orally administered PMs were associated the greatest number 
of different AEs, including; flushing, jaw pain, headache, pain in extremities, vomiting, 
arthralgia and nausea. Adverse events associated with epoprostenol therapy could not be 
quantified and were therefore not included in the analysis but were described as 
photosensitivity, loose stools, jaw pain and cutaneous flushing when patients lay on their left 
side. 
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Figure 2-4. Likelihood, measured by odds ratio, of experiencing each adverse event 
during trial period associated with prostacyclin mimetic therapy as analysed by route 
of administration (subcutaneous infusion, intravenous infusion, inhaled therapy and 
oral tablet/capsule). 
The increased likelihood of nausea associated with oral route of administration may be 
attributed to local effects consequent to the route of administration. Gastrointestinal (GI) 
adverse events may be ameliorated by drug administration strategies. For example, selexipag 
is administered in its inactive pro-drug form. After absorption and metabolism to its more active 
form, ACT-333679, it can activate IP receptors with a 10 fold higher potency.278,281 The pro-
drug form was expected to achieve steady blood concentrations and reduce GI AEs,279 which, 
in contrast to the selexipag trial reports, may explain the lower likelihood of nausea in patients 
taking selexipag than other PMs. Conversely, no reduction in vomiting and diarrhoea 
compared to active PMs was observed, which suggests a systemic underlying mechanism. 
Cutaneous flushing was increased in patients taking inhaled and oral PM therapy ( 
Figure 2-4). Compounds such as nicotinic acid are known to cause flushing by activating the 
DP1 receptor, which is found in abundance in the skin. 301–303 The promiscuous activity of some 
PMs at different prostanoid receptors, makes it possible for the flushing effect experienced in 
PAH therapies to be in part driven by the DP1 receptor. Upon inhalation and subsequent 
exhalations of PMs, they may come into contact with the skin surrounding the mouth, leading 
to a flushing effect. Flushing effects were prevalent for the treprostinil group, which has the 
most potent DP1 activity, but less prevalence for the selexipag group, which has no reported 
DP1 activity.62 Conversely, oral beraprost and selexipag are also associated with flushing, 
despite having little or no potency at the DP1 receptor (beraprost; Ki>10 µM and selexipag 
metabolite; Ki = 2.6 μM).278,280 Treatment with epoprostenol reportedly causes cutaneous 
flushing when patients lay on their left side. Affinity of epoprostenol at the DP1 receptor has 
not been established, owing to the instability of epoprostenol. This opens the possibility that 
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the IP receptors drive the effect but might combine with the DP1 receptor to produce a greater 
effect. Furthermore, the low association of facial flushing with subcutaneous administration, 
which achieves near-constant blood concentrations, could also suggest flushing to be 
associated with DP1 and/or IP receptor agonism in response to fluctuations of drug in the 
blood, or might indicate receptor desensitisation. Affinity for epoprostenol at the IP and EP2 
receptors are established (Table 2-1). Treatment with epoprostenol is associated with 
photosensitivity, which is implicated with the EP2 receptor,304 although this effect is not 
reported in other PMs notably treprostinil, a potent EP2 agonist. 
Treprostinil is the only drug in this analysis to be administered parenterally, and hence, was 
the only PM to be associated with site pain. Additionally, treprostinil was the only PM to show 
an increase in peripheral oedema, which is particularly likely when administered 
subcutaneously. This may be a consequence of the vasculature in the skin being rich in IP, 
DP1, EP2 and EP4 receptors, all of which are linked to inflammatory reactions within the skin 
and to which treprostinil will bind with variable affinity. Furthermore, activation of EP2 receptors 
induce skin irritation upon UV exposure.304,305 Whether this is a unique side-effect to treprostinil 
is unknown, although could be further investigated with subcutaneous administration of other 
PMs. Our results suggest that on-going trials into prodrug formulations306 and implantable 
pumps307 for treprostinil are likely to possess a significant reduction in pain at the implantation 
site due to the reduction in skin tissue contacting active drug.   
There is considerable interest and clinical need for upfront combination therapies and clinical 
evidence suggests a clear benefit to combination PAH therapy.308–310 This meta-analysis 
shows ERAs and PDE-5i given alongside PMs were associated with increased headache and 
vomiting. 
 
Figure 2-5. Forrest plots of overall meta-analysed outcome data for prostacyclin 
mimetic therapy as determined by standardised mean difference (SMD), where A) an 
increased value favours treatment and B) a decreased value favours treatment. CI = 
confidence interval; 6MWD = 6-minute walk distance 
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Patient experience was interpreted using patient reported outcomes. The decrease in Borg 
score suggest patients experienced symptomatic relieve overall during the trials. However, the 
decrease was modest and when analysed by sub group by PM type, was only significant for 
patients receiving beraprost. Orally administered PMs were associated with a modest 
improvement; however, the most significant change was seen for those administered 
intravenously. Quality of life scores were measured using one of two questionnaires 
(Minnesota Living with Heart Failure Questionnaire or EuroQol visual-analogue scale) and 
showed an increase with inhaled therapies but not oral PMs, which is considered the 
administration route with the least patient burden. Limited changes in quality of life scores 
indicate that the benefits associated with more favourable treatment options are still hindered 
by treatment impact on day-to-day living. 
Discontinuation of treatment due to AEs is an indicator of tolerability. Our study found no 
overall significant increase in likelihood of discontinuation with PM therapies. However, 
selexipag was associated with a greater tendency for discontinuations, reported to be caused 
by headache, diarrhoea and nausea in these trials.283 When analysed by administration route, 
oral PMs also showed an increased likelihood of discontinuation. This may suggest a 
mechanism dependant on route of administration. As selexipag is a selective IP agonist, these 
results may further suggest that discontinuation in some cases may also be caused by adverse 
events driven by the IP receptor. 
 
Figure 2-6. Forest plot showing the overall changes in efficacy measures of 
prostacyclin mimetic therapy as determined by odds ratio (OR). 
6MWD is a cheap, easy and well-tolerated, standardised test to measure symptomatic 
improvement. Indeed, most of the therapies included gained approval based upon their ability 
to improve walking distance. 6MWD was reported for all the studies included in this analysis. 
PM therapy is effective at improving 6MWD in patients compared to placebo controls. This 
effect was greater for IV, consistent with previous meta-analysis.311 Although debates 
surrounding its validity as a measure of disease severity,312313 it was found that PMs improved 
6WMD by 16.3 m, less than previously calculated,69,314,315 and less than the reported minimal 
important distance (33 m)316 or distance associated with clinical benefit (41.8 m).317 The 
relevance in using 6MWD has recently been under question.318 Although some trials have 
shown improved survival outcomes with improved 6MWD,319 others have shown no correlation 
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between 6MWD and survival rates and long-term outcomes such as time to clinical 
worsening.313 Furthermore, a relationship between baseline 6MWD has been shown to be a 
better marker predictor of mortality than change in 6MWD.320 
A statistical difference in mortality between treatment and placebo group was only found for 
intravenously administered PMs. However, the few deaths reported, short trial periods and the 
intervention of rescue therapy, limits the accuracy of this trend  
All treatments were effective at improving exercise proficiency although none avoided the 
burden of adverse events. Sub-group analysis identified that administrative route had as much 
effect on the type and severity of AE reported as the PM type and a greater effect on quality 
of life improvements. The variation in AEs with different administration route indicates that a 
many of the effects are caused by local activation of receptors. Other AEs were similar across 
all administration routes, indicating that the systemic exposure of drug is the cause. 
Surprisingly, selectively activating the IP-receptor did not alter the AE profiles, implicating the 
IP receptor is predominantly driving the AEs. 
 Secondary meta-analysis: Treprostinil 
The main limitation with the analysis conducted is the inability for drug compounds, i.e. 
treprostinil, to be analysed by individual route of administration, additional to the drug 
compound. Therefore, the analysis conducted includes an average of either all treprostinil 
data, regardless of the administrative route or all therapies of one administrative route (i.e. 
“oral” subgroup includes beraprost, oral treprostinil and selexipag). Therefore, a secondary 
meta-analysis was conducted focusing only on treprostinil trials. Analysis of treprostinil trials 
provides an opportunity to explore the effect of administration route of one compound which 
would more accurately quantify the administration effect. The secondary investigation into 
treprostinil was carried out to explore the following aims;  
1) To better compare the effects of administration route on adverse event data 
2) To retrospectively compare the results with the general trends identified in the 
prostacyclin mimetic analysis. 
3) To explore the effect of an IP selective agonist and prodrug formulation on AE 
outcomes. 
 
Selecting only the trials involving treprostinil, a total of 1684 patients were enrolled in these 
studies; 891 were treated with treprostinil and 793 given placebo, additional to any predefined 
background therapy. Patient groups were comparable in terms of patient characteristics and 
within individual trials were adjusted for age, gender and disease severity between placebo 
and treatment cohorts. The aetiology of the majority of patients was idiopathic, familial or 
associated PAH and were in NYHA class III. In half of the trials patients were receiving non-
prostanoid PAH-specific treatment concomitantly, ERAs or PDE-5i. An overview of the trial 
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characteristics is shown in Table 2-12. The primary end point was 6MWD in all but one trial 
where 6MWD was observed but the time to clinical worsening was the primary end point. Other 
outcome measures reported included Borg score, haemodynamic effects, clinical worsening 
and fatalities. All trials reported adverse events and where available, the clinical trial report 
was referred to in order to obtain unpublished information. 
  
 
9
4
 
Table 2-12. Summary of treprostinil trial and patient characteristics. 6MWD = 6-minute walk distance; IPAH = idiopathic pulmonary arterial hypertension; 
NYHA = New York Heart association functional class; Specific therapy includes endothelin receptor antagonists and phosphodiesterase 5-inhibitors; Non-
specific background therapy includes oxygen, oral vasodilators, calcium channel blockers, anticoagulants and digoxin.  
Trial 
Administration 
Route 
No. 
treatment 
No. 
Placebo 
Primary end 
point 
Background 
Therapy 
Eitology (IPAH : disease 
associated PAH) 
NYHA 
Class 
Length of 
study /weeks 
Simonneau 
2002 
Subcutaneous 233 236 6MWD  Non Specific 
IPAH (58%) / Disease 
associated (42%) 
II/III/IV 12 
McLaughlin 
2002 
subcutaneous 17 9 6MWD None  
IPAH (73%) / Disease 
associated PAH (27%) 
III / IV 8 
Rubenfire 2007 Subcutaneous 14 8 
time to 
clinical 
deterioration 
Specific 
IPAH (73%), Disease 
associated PAH (27%) 
I, II, III 8 
Hiremath 2010 IV 30 14 6MWD  Non Specific 
IPAH (95%) / Disease 
associated PAH (5%) 
III / IV 12 
McLaughlin 
2010 
Inhaled 115 120 6MWD Specific 
IPAH (56%) / Disease 
associated PAH (44%) 
III / IV 12 
Jing 2012 Oral 151 77 6MWD  None  
IPAH (75%) / Disease 
associated PAH (25%) 
I/II/III 12 
Tapson 2012 Oral 174 176 6MWD Specific 
IPAH (66%) / Disease 
associated PAH (34%) 
I/II/III/IV 16 
Tapson 2013 Oral 157 153 6MWD Specific 
IPAH (65%)/ Disease 
associated PAH (35%) 
II/III/IV/ 
unknown 
(2) 
16 
 95 
 
 Adverse Events 
A meta-analysis of the likelihood of each adverse event was carried out to establish whether 
there was in significant increase in adverse events as a direct result of treprostinil, or if the 
route of administration also played a role in the events recorded. Overall, there were 19 side 
effects reported, out of which nine were significantly related to treprostinil (site pain, flushing, 
jaw pain, headache, pain in extremity, diarrhoea, vomiting, peripheral oedema, nausea) and 
the remaining 10 were not (dizziness, upper respiratory tract infection, insomnia, abdominal 
pain, arthralgia, fatigue, palpitations, chest pain, dyspnoea, cough). In terms of magnitude, the 
presence of any adverse event was ten times more likely in the treprostinil over placebo [OR 
10.3, (95% CI: 1.1, 92.8), p = 0.038; I2 = 51 %, p = 0.128] while site pain, flushing, jaw pain 
and headache were most the most likely AEs associated with treprostinil therapy (OR 8.7, 4.4, 
4.0, 3.3, respectively). However, heterogeneity was invariably present ranging from 0 to 88 %.  
 Sub group analysis 
To further investigate the effect of administration route on the overall likelihood of adverse 
event, the trial data was split into individual administration routes. Intravenous administration 
was significantly associated with headache, extremity pain and vomiting (OR = 6.0; 95% CI: 
1.1, 31.5; I2 = Not calculated), (OR = 6.0; 95% CI: 1.5, 112.3; I2 = Not calculated), (OR = 13.0; 
95% CI: 1.1, 31.5; I2 = Not calculated), respectively. Flushing was most significantly attributed 
to inhaled treprostinil (OR = 20.6; 95% CI: 2.7, 157.9; I2 = Not calculated). Unsurprisingly, the 
greatest odds ratio was seen for site pain associated with subcutaneous administration (OR = 
17.5; 95% CI: 11.1, 27.4; I2 = 0%). Jaw pain, diarrhoea and peripheral oedema were also 
increased by subcutaneous treprostinil. Patients receiving oral treprostinil experienced the 
most types of adverse events including flushing (OR = 4.6; 95% CI: 3.2, 6.6; I2 = 0%), 
headache (OR = 6.5; 95% CI: 3.4, 12.4; I2 = 76%), pain in extremities (OR = 3.1; 95% CI: 2.0, 
4.8; I2 = 7%), diarrhoea (OR = 3.6; 95% CI: 2.7, 4.9; I2 = 0%) and nausea (OR = 3.0; 95% CI: 
2.2, 4.0; I2 = 8%).  
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Table 2-13. Likelihood of developing each adverse event during trial period associated 
with treprostinil therapy as analysed by each route of administration. AE = adverse 
event; OR = Odds ratio; NS = not significant. 
AE Overall OR 
p-
value 
No. 
studies 
Oral Inhaled Intravenous Subcutaneous 
Any event 
10.3 
(1.1-92.8) 
51%, 0.128 
0.038 3 
26.2 
5.1, 
135.4 
0%,  
 
- 
NS 
-,- 
- 
 
- 
Site pain 
8.7 
1.6, 45.9 
79%, 0.003 
0.011 4 
 
- 
 
- 
NS 
-,- 
- 
17.5 
11.1, 27.4 
0% 
Flushing 
4.4 
2.7, 7.1 
30% 0.222 
< 
0.0001 
5 
4.6 
3.2, 6.6 
0% 
20.6 
2.7, 
157.9 
- 
 
- 
NS 
-,- 
- 
Jaw Pain 
4.0 
2.9, 5.6 
0%, 0.421 
< 
0.0001 
7 
4.9  
3.3, 7.4 
0% 
NS 
-,- 
 
- 
NS 
-,- 
- 
3.1 
1.6, 6.2 
0% 
Headache 
3.3 
1.6-6.8 
88%, 0.0001 
0.001 7 
6.5 
3.4, 12.4 
77% 
 
- 
6.0 
1.1, 31.5 
- 
NS 
-,- 
59% 
Pain in 
extremity 
3.3 
2.2, 4.9 
0%, 0.412 
< 
0.0001 
5 
3.1 
2.0, 4.8 
7% 
 
- 
13.0 
1.5, 112.3 
- 
NS 
-,- 
- 
Diarrhoea 
2.7 
1.9, 3.9 
47%, 0.079 
< 
0.0001 
7 
3.6 
2.7, 4.9 
0% 
NS 
-,- 
- 
NS 
-,- 
- 
1.8 
1.2, 2.9 
0% 
Vomiting 
2.6 
1.1, 6.1 
79%, 0.0001 
0.024 7 
NS 
-,- 
90% 
 
- 
6.0 
1.1, 31.5 
- 
NS 
-,- 
12% 
Peripheral 
Oedema 
2.1 
1.2, 3.8 
18%, 0.297 
0.013 3 
NS 
-,- 
0% 
 
- 
 
- 
3.8 
1.5, 9.6 
- 
Nausea 
2.0 
1.3, 3.0 
63%, 0.012 
0.002 7 
3.0 
2.2, 4.0 
8% 
NS 
-,- 
- 
NS 
-,- 
- 
NS 
-,- 
65% 
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The analysis highlighted the same nine adverse events associated with PM therapy as 
significantly related to treprostinil treatment; site pain, flushing, jaw pain, headache, pain in 
extremity, diarrhoea, vomiting, peripheral oedema and nausea. Adverse events which were 
reported but not found to be significant either at meta-analysis or sub-group analysis level, 
suggests the cause is a direct consequence of the administration and not specific to treprostinil 
therapy.  
Patients receiving intravenous administration of treprostinil received the greatest dose, yet 
patients experienced minimal site pain, presumably because fewer tissues were exposed to 
treprostinil entering the circulatory system. In the earlier period of intravenous PM therapy, 
catheter-related complications caused by infection, were common with IV administration, 
Table 2-14. Non significant likelihoods of developing each adverse event during trial 
period associated with treprostinil therapy as analysed by each route of administration. 
AE = adverse event; OR = Odds ratio; NS = not significant. 
AE Overall OR 
p-
value 
No. 
studies 
Oral Inhaled Intravenous Subcutaneous 
Dizziness 
NS 
-,- 
0%, 0.625 
0.172 7 
NS 
-,- 
53% 
NS 
-,- 
- 
NS 
-,- 
- 
NS 
-,- 
0% 
Upper 
respiratory 
tract 
infection 
NS 
-,- 
0%, 0.486 
0.923 4 
NS 
-,- 
0% 
NS 
-,- 
- 
 
- 
NS 
-,- 
- 
Insomnia 
NS 
-,- 
0%, 0.919 
0.131 3 
NS 
-,- 
0% 
 
- 
NS 
-,- 
- 
NS 
-,- 
- 
Abdominal 
pain 
NS 
-,- 
0%, 0.693 
0.579 3 
NS 
-,- 
- 
 
- 
 
- 
NS 
-,- 
- 
Arthalgia 
NS 
-,- 
0%, 0.628 
0.129 3 
NS 
-,- 
0% 
 
- 
 
- 
 
- 
Fatigue 
NS 
-,- 
0%, 0.726 
0.159 4 
1.5 
1.0, 2.2 
0% 
NS 
-,- 
- 
 
- 
 
- 
Palpitations 
NS 
-,- 
72%, 0.028 
0.595 3 
NS 
-,- 
79% 
NS 
-,- 
- 
 
- 
 
- 
Chest pain 
NS 
-,- 
3%, 0.357 
0.948 3 
NS 
-,- 
- 
NS 
-,- 
- 
NS 
-,- 
- 
 
- 
Dyspnoea 
NS 
-,- 
59%, 0.046 
0.830 5 
NS 
-,- 
87% 
NS 
-,- 
- 
NS 
-,- 
- 
NS 
-,- 
- 
Cough 
NS 
-,- 
68%, 0.042 
0.372 3 
NS 
-,- 
- 
2.8 
1.7, 4.9 
NS 
-,- 
- 
 
- 
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particularly in tropical environments although indwelling catheters have improved over the 
years to minimise the risk. Such events were described in the trial but not included in our 
statistical analysis. However, it is well understood that intravenous infusion is the least 
convenient method of drug delivery due to the reliance on the healthcare professionals and 
the risk of serious infection without maintenance procedures. 
The localised pain when treprostinil is subcutaneously administered appears to be a reaction 
of treprostinil with localised tissue. The role of prostanoid receptors such as EP2, EP4 and DP1 
in the swelling, irritation and inflammation of skin has been documented.304,305 The increase in 
flushing associated with only inhaled treprostinil is likely explained by the nebuliser of Tyvaso. 
It is possible that during inhalation and the subsequent exhalations, the skin surrounding the 
mouth and nose are exposed to small particles of active drug. Treprostinil is a known DP1 
receptor agonist found in skin which has been implicated in heat and flushing reactions.305 It 
seems plausible that the flushing effect seen in patients taking inhaled treprostinil is mediated 
by the local activation of DP1 receptors, which treprostinil activates at a 10-fold lower 
concentration than the IP receptor 280. The significant but weaker association between oral 
treprostinil and flushing might be explained by this theory if residual treprostinil remains on the 
skin of fingers after capsule administration which is further spread by touching other areas. 
However, as oral and inhaled treatments are both associated with fluctuating drug blood-
concentrations, the variance in drug concentrations experienced between dosings may also 
contribute to the prevalence of flushing. Thus, when a steady concentration is maintained by 
continuous infusion, flushing is reduced.
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Figure 2-7. Adverse event profile for treprostinil as analysed by routes of administration 
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Of the treprostinil therapies, only oral administration significantly increased cases of nausea 
suggesting that the local interaction of treprostinil with the gastrointestinal tract results in 
nausea. However, the association of nausea with selexipag treatment suggest that a systemic 
action also contributes, as the stomach tissue is exposed to the less active prodrug. Selexipag 
does have affinity for the IP receptor in its prodrug form, so nausea may be a result of the 
relative concentrations of selexipag prodrug and treprostinil released from the osmotic capsule 
found within the stomach. If the rate of absorption into the blood stream is comparable to the 
dissolution or capsule release time, then the short residence time may reduce local activation 
of prostanoid receptors. Interestingly, the trend for vomiting does not match that of nausea as 
vomiting was not associated with oral treprostinil but was with selexipag. 
Diarrhoea and jaw pain show a similar pattern in that they are both associated with SC and 
oral treprostinil. This overlap rules out the possibility that high doses or fluctuating drug blood 
concentrations explain the side-effects. In the case of diarrhoea, direct activation of local 
receptors is also rejected. This suggests that both events are caused by systemic exposure of 
treprostinil, which is backed up by the lack of association when given by inhalation. Both 
adverse events were reported with high OR for IV administration but were not found to be 
significant, which may be a result of IV administration being represented by only one trial. 
Only intravenous administration caused a significant increase in vomiting. With similar 
systemic exposure, bioavailability and final mean daily dose, it is surprising that this trend was 
not also seen for subcutaneous administrations. This may be a result of the rate of dose 
escalation. IV trial patients were initiated onto treprostinil at 3 times the starting concentration 
as the SC trial89 and yet had the lower incidence of vomiting. For IV infusion, the dose was 
increased by 8 ng/kg/min per week with a maximum permitted dose of 100 ng/kg/min, with 
patients tolerating a mean dose of 72 ng/kg/min.290 The Simonneau SC trial did not however 
specify a dose increase rate but the maximum dose was less than a quarter of the IV trial, at 
22.5 ng/kg/min. Another SC trial288 not included in this study, shared a similar initiation dose 
range at the IV trial (2.5-5.0 ng/kg/min) but had a maximum allowed dose of 20 ng/kg/min. 
One of the SC trials differed in its design as it involved a weaning period from epoprostenol, 
onto treprostinil. 87 The dose of treprostinil at transition was reported at 25.3 ng/kg/min and the 
mean maximum dose tolerated by patients was 32.2 ng/kg/min. Although the mean daily doses 
are comparable, with a maximum of 4.8-fold difference, IV is administered at a greatest dose, 
so it is possible that the dose crosses a concentration threshold which induces vomiting 
systemically. 
Extremity pain was increased in trials involving both IV and oral treprostinil, although to a 
greater extend with the former. It is unlikely that fluctuating drug blood concentrations are the 
cause, as IV achieves steady-state concentrations. Systemic exposure of treprostinil or the 
difference in achieved daily dose may provide an explanation, although in these cases, it might 
be expected that subcutaneous administrations may also be associated with increased 
extremity pain. Only one SC trial is included in the sub-group analysis as only one trial reported 
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extremity pain.87 Being an unexpected adverse event in early treprostinil trials, it is possible 
that the adverse event was experienced more than it was reported.  
Interestingly, only one SC treprostinil trial reported increased peripheral oedema, whilst IV did 
not report any cases. IV and SC are given in similar concentrations with the same 
bioavailability (Table 2-4). The only difference being the tissue in which SC treprostinil comes 
into contact with. However, the subcutaneous tissues exposed to treprostinil, are not local to 
the extremities where peripheral oedema occurs. Peripheral oedema is considered a nervous 
effect associated with EP3 signalling through binding of PGE2.305 Treprostinil has poor affinity 
for the EP3 receptor,62 but the combined observation of peripheral oedema with treprostinil 
therapy as well as the ability for treprostinil to bind high affinity of treprostinil at the EP2 receptor 
may suggest a similar mechanism to induce peripheral oedema.  
 
The primary analysis including all prostacyclin mimetics was hindered by the averaging of the 
treprostinil effects for all administration routes. With the added understanding of how route of 
administration effects the likelihood of treprostinil side effects, by splitting the treprostinil trials 
by their routes of administration, it is possible to better compare the prostacyclin therapies 
without conflation and averaging the effect of treprostinil.  
Although it was possible in the first meta-analysis to determine the effect of subcutaneous 
treprostinil (only drug to be given via subcutaneous infusion), the effect of inhaled or oral 
treprostinil were conflated with other drugs administered via that route. With the further 
analysis into treprostinil, it is possible to compare between the different oral and inhaled 
therapies and determine the effect of a prodrug formulation on adverse events.  
Compared to the combined calculated odds ratio for inhaled therapies, including treprostinil 
and iloprost, when inhaled treprostinil was analysed separated, fewer AEs were reported. The 
combined analysis highlighted jaw pain (OR = 2.7), headache (OR = 2.4) and nausea (OR = 
1.7) to be associated with inhaled therapy. However, none of these adverse events were 
significantly associated with inhaled treprostinil and in the case of headache, no incidences 
were reported. As a composite of all administration routes, treprostinil was not associated with 
cough and was mildly associated with flushing. Consistent with clinical reports,321 when only 
inhaled treprostinil is considered, cough was significantly associated with therapy (OR = 2.8), 
similar to that of iloprost. Analysis of inhaled treprostinil revealed a strong significant 
association with flushing (OR = 20.6), indicating flushing is primarily a treprostinil effect (Figure 
2-8). 
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Figure 2-8. Comparison between inhaled treprostinil and iloprost in their association 
in inducing flushing and cough in PAH patients as measured by odds ratio. 
Beraprost, selexipag and treprostinil are all offered as an oral formulation. Whereas beraprost 
and treprostinil are administered in their active form, selexipag is not. Selexipag prodrug 
exhibits weak IP binding affinity (Ki = 260 nM) until it is metabolised by the liver after absorption 
from the GI tract (Ki = 20 nM). Therefore, it would be expected for the GI-tract related AEs to 
be less likely in patients taking selexipag. However, only a modest decrease in likelihood was 
observed. 
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Figure 2-9. Comparative likelihoods of GI-related adverse events in oral prostacyclin 
mimetics therapies (treprostinil, beraprost and selexipag), as determined by odds ratio. 
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The overall analysis determined headache to be the most likely AE for oral therapies, when 
this is split into the different oral therapies it is clear that this is most likely to be an effect of 
treprostinil (Figure 2-10). Beraprost is less likely to induce headache and selexipag is least 
likely. Treprostinil is an agonist of the EP2 receptor which regulates blood pressure. Both 
beraprost and selexipag exhibit poor affinity for the EP2 receptor which might explain the 
increase in headache with treprostinil. 
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Figure 2-10. The relative likelihood of headache associated with oral prostacyclin 
mimetic therapies (treprostinil, beraprost and selexipag) as determined by odds ratio. 
Pain in extremities was most significantly associated with intravenous and not subcutaneous 
treprostinil although was associated to a lesser extent with oral therapies. When analysed by 
the different oral therapies, a similar likelihood was identified for oral treprostinil and selexipag 
(Figure 2-11). As selexipag is an IP selective agonist, is could be assumed that the extremity 
pain is driven through the IP receptor. However, no extremity pain was noted for beraprost, an 
IP and EP3 agonist, or any other drug types. 
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Figure 2-11. Comparative likelihood of inducing extremity pain for oral prostacyclin 
mimetic therapies (treprostinil, beraprost, selexipag) as determined by odds ratio. 
Similar to the comparison of oral therapies, inhaled treprostinil can be compared with inhaled 
iloprost as only inhaled delivery of iloprost was included in the original analysis. Flushing is 
mostly associated with inhaled and oral PM therapies (OR = 4.7 and 4.0, respectively) which 
is thought to be a result of activating the prostanoid receptors in the skin surrounding the face 
(Figure 2-12). However, the similar trend for inhaled and oral PMs identified by meta-analysis 
hides the trend.  
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Figure 2-12. Comparison of likelihood of experiencing flushing for all prostacyclin 
mimetics (treprostinil, iloprost, selexipag and beraprost) delivered as analysed by 
inhaled and oral routes. 
When analysed by the different drug types, flushing is more than four times more likely for 
inhaled treprostinil than for any other treatment (Figure 2-13). 
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Figure 2-13. Relative likelihoods of patients experiencing flushing during trial periods 
as analysed by odds ratio of each individual inhaled and oral prostacyclin mimetic 
therapies. Inhaled treprostinil is most associated with reports of flushing. 
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Whereas selexipag has been granted global approval, beraprost is only approved in Japan 
and south Korea. Oral treprostinil (Orenitram®) has FDA approval but has not been granted 
approval from European Medicine Agency. This decision lies on the unfavourable 
risk:benefit:cost ratio. It is likely that the increased likelihoods of side effects experienced with 
treprostinil may relate to its potent activation of EP2 and DP1 receptors. Indeed the 
antiproliferative effects of treprostinil in human pulmonary artery smooth muscle cells isolated 
from PAH patients is largely driven by  the EP2 and not the IP receptor, via a mechanism 
involving PPAR gamma activation.142,272 This could be of particular importance when the IP 
receptor is downregulated, as is known to occur in PAH.47,277 Comparison of trial data between 
treprostinil and selexipag show no considerable difference in likelihood of AEs, indicating that 
achieving IP receptor selectivity does not reduce AEs in the patient. As will be discussed in 
future chapters, attempts to improve treprostinil therapy by employing a pro-drug approach 
have been investigated, however by extrapolating the treprostinil and selexipag, this data 
suggests that a pro-drug approach which releases treprostinil systemically, is expected to 
exhibit a major benefit in reducing site pain and increasing half-life but not in alleviating 
systemically induced adverse events. For a marked decrease in systemic adverse events an 
element of tissue targeting will be required. 
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Figure 2-14. Comparison of likelihoods of experiencing adverse events during trial 
periods associated with selexipag, a selective IP receptor agonist administered as a 
prodrug, and oral treprostinil. 
 
Previous meta-analyses have included all types of PAH treatment or focused on survival and 
outcomes.315,322–324 To our knowledge, this is the first meta-analysis of the PM class, firstly to 
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include selexipag, and secondly to explore the effect of different IP receptor agonists and route 
of administration on the adverse event profile. We collected data from 15 blinded, placebo-
controlled, randomised clinical trials and analysed their reported results. After thesis 
submission and following advice from reviewers, one trial was removed from the analysis as 
it only provided outcome data.297 The quality of the trials overall was acceptable, and data was 
collected to the best of our abilities. The aim was to focus on the patient experience of PM 
therapy, so the approach included data on AEs reported as well as patient-reported outcomes, 
Borg score and quality of life scores. By including secondary analysis of the treprostinil subset, 
direct correlation between AE profiles and PM types with multiple administration routes could 
be drawn. Nonetheless, our analysis is not without limitations; most studies were funded by 
the drug manufacturer which may be a source of reporting and publication bias OR was used 
to report likelihood of events which does not take trial duration into consideration.310 
Inconsistent reporting of 6MWD and Borg score (mean vs. median, SD vs. SE) was overcome 
by assuming data to be normally distributed and converting medians and interquartile ranges 
to means and SE, respectively. For one study,283 discontinued patient data was reported as a 
zero change in 6MWD, which potentially hides negative effects. During review of a manuscript 
detailing this work, one reviewer noted that for one trial,283 the adverse event data for the total 
trial period was used when the three month titration phase data was available in the 
supplementary information, and would have been a better comparison with the other shorter 
trials. Although the secondary analysis of treprostinil increased the depth of the investigation, 
reducing the group sizes decreases the sensitivity of the meta-analysis, so caution is advised 
when drawing trends and conclusions from meta-analyses with limited samples.  
 
The purpose of this analysis was to gain understanding of the limitations of current prostacyclin 
therapies. The underlying causes of adverse events were suggested as a way of identifying 
methods to mitigate them. In summary, it was identified that treprostinil was limited by pain 
experienced at the site of injection administration and flushing which are primarily local effects. 
The remaining adverse events, with lower likelihoods are likely a result of systemic exposure 
of treprostinil. Selective IP receptor agonism did not avoid side effects. A prodrug strategy for 
oral delivery did not significantly reduce AEs relating the GI tract, presumably because the 
effects are systemically induced. In conclusion, this investigation identifies two approaches by 
which treprostinil therapy could be improved: 
No. Limitation Strategy 
1 Site pain 
Reduce activity upon subcutaneous administration of 
treprostinil using prodrug strategy 
2 Systemic Exposure 
Achieve targeted therapy or release localised to the 
diseased pulmonary tissue 
The following work described within this chapter, the thesis will focus on contributing ideas, 
strategies and suggestions in achieving one, or both, of the aims identified in this chapter. 
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 Treprostinil N-acyl sulfonamide prodrug 
strategy.  
 Introduction  
Prodrug derivatives can optimise the properties of an active pharmaceutical ingredient (API) 
to be better suited for use in a medicine. Solubility, biological stability, adsorption, metabolism, 
activity, excretion and release site are all factors which can be altered by introducing a prodrug 
strategy. Pro-drugs are derivatives of an API which are conjugated to other chemicals that 
serve to temporarily mask the activity of the API. Upon administration, the masking group is 
cleaved to convert the structure into that of the original API, thereby reactivating it. 
 
Figure 3-1. Concept of prodrug approach. Prodrug moiety changes property of drug 
structure which can hinder its ability to bind to its receptors. Upon degradation, the 
prodrug moiety is cleaved to release drug compound which is able to interact with 
receptors. 
Over the past 2 decades, prodrugs have made up ~20% of all new small molecule 
approvals.148 A variety of masking prodrug head groups have been described such as alkyl 
esters, acetyl groups, sugars, amino acids, phosphoesters and alkyl ethers (Figure 3-2). 
Depending on the API and the pro-drug group employed, structural properties can be 
optimised to best achieve the necessary efficacy.148 Esterification and amidation of a 
carboxylic acid have been employed to reduce the polarity of compounds to allow for better 
permeation into tissues or cells.325,326 The former type of chemical modification can in many 
instances be readily reversed by endogenous cell esterases. Increasing hydrophobicity of 
polar moieties, for example, by esterification of carboxylic acids, can increase permeation and 
bioavailability for oral and ocular formulations.150,327 Additionally, carboxylic acids and hydroxyl 
moieties have been conjugated to sugar structures and phosphoesters, respectively, to 
increase aqueous solubility.149,328 Amino acid conjugation can also increase systemic lifetime 
and allow for prolonged released.329–332 For example, the amide-conjugated alanine derivative 
of brivanib, 12 (BMS-540215) exhibits increased bioavailability and solubility in aqueous media 
as compared to its parent API.331 This can reduce dosing frequency and smooth peak and 
trough fluctuations in drug-blood concentration between dosings.333  
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Degradation of the pro-drug to release the API can be triggered by either chemical or 
enzymatic means. Most chemical release mechanisms rely on hydrolysis although oxidation 
has also been used.334 Enzymatic mechanisms that rely on endogenous enzymes include 
oxidoreductases like CYP450 and DT-diaphorase as well as hydrolytic enzymes like 
carboxylesterase and β-glucuronidase, which are able to cleave the masking group of a 
prodrug structure.148 Prodrug strategies have been used in a wide variety of therapeutic areas 
including hypertension, antibiotics, gastric ulcers, coagulation anti-inflammatories and 
cancer.148,335 Prodrugs encounter different environments before reaching their intended 
system, tissue or cell of degradation, so stability requires consideration of the route of 
administration. Furthermore, the degradation must be sensitive enough for efficient release of 
the active drug.  
 
Figure 3-2. Different prodrug groups (highlighted in blue) used to temporarily modify 
properties of drug compounds. Compound 12 is Brivanib alaninate, the L-alanine ester 
of anticancer drug, Brivanib. Compound 16 is the tyrosine-conjugated derivative of 
non-steriodal inflammatory drug, dexibuprofen. Compound 13 is the ethyl ester 
derivative of antiviral Oseltamivir. Compound 15 is the phosphate ester of adenosine 
A2A antagonist, MSX-2; Compound 14 shows conjugate of 9-aminocamptothecin and 
glucuronidic acid linked by carbamate spacer. 
Prodrugs of treprostinil have been made with several different strategies having been 
described in published literature and patents.79,80,132,134,306,336,337 However, no treprostinil-
derived prodrugs have so far been developed for clinical use. It is well established in the few 
early structure-activity relationship studies conducted on treprostinil, that removing or 
derivatising the acid group, or even moving its position around the treprostinil benzindene ring, 
drastically decreases the anti-platelet effects of treprostinil.145 Therefore, reversibly 
derivatising the acid group would decrease the activity, suitable for a pro-drug strategy. 
Previous attempts were made by United Therapeutics to make a 5kDa poly(ethylene glycol) 
(PEG) conjugate of treprostinil which had prolonged cardiovascular actions in vivo when 
delivered via the pulmonary route.338 When administered (3 mg) via intratracheal instillation to 
12 16 
13 
15 14 
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a hypoxia-induced rat model of PAH, a 5 mmHg decrease in pulmonary arterial pressure was 
observed over 5 hours, compared to free treprostinil and iloprost, which produced more 
transient effects. Following publication in 2000, no further advances were made to pursue 
preclinical or clinical testing. Although no information on tolerability of treprostinil-PEG has 
been described, it is known that pulmonary exposure to nanoparticles can cause inflammation 
so are not suitable for the treatment of chronic inflammatory diseases.263  
As described in Chapter 1, PEGylated-treprostinil conjugates and treprostinil prodrugs have 
been pursued previously without achieving the primary goal of reducing site pain upon 
administration of the subcutaneous infusion. 134,135,306,339Without knowing the linker structure 
employed for PEG-treprostinil, it is not possible to accurately assess the underlying reason for 
the site pain. However, given the size of the PEG structure in relation to the appended APIs, 
and the specificity and conformation of the binding pocket of the IP and EP2 receptors,340,341 it 
is reasonable to assume the conjugate exhibits negligible inherent activity. Such a large 
conjugate would hinder interaction at the receptor binding domains. Therefore, the activity at 
the administration site is likely a result of premature release of treprostinil. Esterases are 
ubiquitous throughout the body so it’s possible that the 4-star-PEG-treprostinil is a substrate 
for carboxylesterases found in the subcutaneous compartment. Although other acid-labile 
linkers have been investigated for conjugation to treprostinil,342 it is likely that those structures 
would also lead to premature release of treprostinil in a bolus subcutaneous formulation. 
The N-acyl sulfonamides, moiety (Figure 3-3) is considered a common bioisostere of the 
carboxylic acid since carboxylic acids are susceptible to rapid metabolic degradation either by 
glucuronidation or acyl-CoA thioester formation.344 For example, the anti-inflammatory agent, 
tolmetin, is rapidly metabolised to an acyl-coenzyme A thioester intermediate in rats.345 With 
similar volume, size and charge, N-acyl sulfonamides offer drug candidates a structure with 
similar physical properties to their parent acid with reduced metabolic degradation. By means 
of the acidic proton (highlighted in red in Figure 3-3) with similar pKa as the carboxylic acid 
derivative, drug activity is usually preserved.346  
 
Figure 3-3. Structure of N-acyl sulfonamide 
The use of sulphonamides as bioisosteres is indicative that receptor interaction is not usually 
hindered. However, some compounds such as TIPP-703 and venetoclax display different yet 
favourable receptor activities (Figure 3-4). Unlike other sulphonamides, which are acid 
labile,347 the nitrogen-carbon bond of N-acyl sulfonamide requires enzymatic cleavage by 
carboxyl esterases to degrade the N-acyl sulfonamide bond.346 Interestingly, when exposed 
to hepatic enzymes of rat microsomes, which contain cytochromes P450, monooxygenases 
R1 = CH3, Ph 
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and uridine glucuronide transferases, Asunaprevir 18 was not metabolised to its acid 
derivative.348 
 
Figure 3-4. Examples of N-acyl sulphonamides as bioisosteres of clinical interest. 
Asunaprevir, 18 which is in development for the treatment of hepatitis C; N-acyl 
sulfonamide derivative of TIPP-703 which is a pan agonist of the peroxisome 
proliferator-activated receptors (PPARs), 19; and venetoclax 20 for the treatment of 
chronic lymphocytic leukaemia. 
As discussed in Chapter 1, selexipag is the only prodrug strategy used to treat PAH. Selexipag 
5 is stable in blood plasma and as determined in healthy volunteers, has a terminal half-life of 
between 0.7 and 2.3 hours, depending on the dose received. Once exposed to the 
carboxyesterases of the liver, the N-acylsulfonamide is cleaved to release ACT-333679 (6) 
into the blood stream with a terminal half-life of 9.4–14.2 hours. 349 In the blood, the drug is 
able to act on IP receptors found throughout the body.274 Whilst this does not reduce the 
likelihood of systemic adverse events, it has the potential to reduce local adverse events at 
the in the gastrointestinal tract as well as achieving a steady release of active drug in the blood 
owing to albumin binding.350 By increasing the half-life, blood concentrations do not fluctuate 
so rapidly, so the number of dosing administrations per day can be reduced. Although, the 28-
fold reduction in activity of prodrug 5 potentially results in a reduction of local effects in the GI 
tract before absorption, our meta-analysis indicates that GI related AEs are systemically 
induced.  
The significantly reduced activity of the N-acyl sulfonamide at the IP receptor indicates that 
the carboxylic acid interaction with the receptor binding pocket is highly size dependent. 
Although the structures of ACT-333679 6 and treprostinil 4 are not analogous, interactions 
with the IP receptor are thought to be similar. Therefore, an N-acyl sulfonamide derivative of 
treprostinil 4 is hypothesised to exhibit similar prodrug properties. Furthermore, a prodrug 
formulation of treprostinil would substantially reduce the local adverse events associated with 
administration. Learning from previous prodrug ideas in the literature, requiring metabolism by 
hepatic enzymes would avoid premature treprostinil release in the subcutaneous tissue. N-
acylsulfonamide have been shown to exhibit slow degradation rates which, if the biological 
half-life of the pro-drug is suitable, will result in a slow release of active drug over time.351 
17 
18 
19 
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As described in Chapter 2, treprostinil therapy is associated with a range of adverse events. 
The most prevalent and hindering being administrative site pain upon subcutaneous 
delivery.352 To overcome this limitation, masking the activity of treprostinil via a pro-drug 
derivative was pursued. Previous attempts at devising prodrug formulations have been centred 
around acid degradability which have all been limited by the premature release of treprostinil 
leading to activation of prostanoid receptors in the subcutaneous tissue. 
The most recently approved drug introduced to the PAH market, selexipag, utilises an N-acyl 
sulfonamide pro-drug approach. We hypothesised that the similarly derivatised treprostinil, 
would avoid site pain upon administration to the subcutaneous tissue by expressing reduced 
IP receptor activity until degradation by hepatic enzymes. Removing activity at the IP receptor 
may also indicate a reduction in activity at other prostanoid receptors (notably the EP2 and 
DP1) receptors. The primary aim was to investigate N-acyl sulfonamide treprostinil as a 
prodrug. 
 The following objectives were set: 
1.) To prepare treprostinil N-acyl sulfonamide (21). 
2.) To determine the in vitro activity of treprostinil N-acyl sulfonamide 21 to induce 
cAMP elevation in a cell line expressing the IP receptor.  
3.) Determine the cleavage of N-acyl sulfonamide treprostinil 21 with hepatic 
enzymes to release free treprostinil 4  
 
 
Scheme 3-1. Proposed conversion of treprostinil 4 to its N-acyl sulfonamide 21 
  Results and Discussion 
 
Knowing the importance of the acid functional group of treprostinil for its IP receptor activity, it 
was hypothesised that an acyl sulfonamide derivative of treprostinil would have reduced 
activity. A sulfonamide prodrug moiety was similarly utilised in selexipag. The reduced activity 
of treprostinil acyl sulfonamide 21 would potentially be beneficial at the injection site as it would 
be expected to induce less severe pain and swelling. Preparation of treprostinil acyl 
sulfonamide 21 essentially involves the formation of an amide bond at the treprostinil 
carboxylic acid. There are many routes to form an amide bond from a carboxylic acid. A widely 
used method is to increase the electrophilicity of the carbonyl by using coupling agents to 
4 
 
20 
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activate the acid for nucleophilic attack by an amine.353 This is commonly utilised in peptide 
synthesis, to link amino acids together. 
 
Treprostinil 4 was successfully synthesised following a published method354 during a 3-month 
placement with United Therapeutics & Lung Biotechnology in Silver Springs, Maryland, USA 
(Scheme 3-2). The purpose for preparing treprostinil 4 was to learn about the synthetic routes 
that are used to prepare treprostinil 4 commercially as well as the common intermediates that 
could potentially be used in a prodrug strategy.  
Two methods Scheme 3-2 are used by United Therapeutics for preparing treprostinil 4. Route 
i shows the FDA approved route and route ii is an improved synthesis which uses the 
controlled epinepherine derivative as the chiral reagent to couple the two starting materials. 
During the placement both synthetic routes were followed and the stereomeric purities of both 
products were compared. Complete synthesis, isolation and characterisation (details provided 
in appendix section 2) took over 2 months to yield 67.8 mg of pure treprostinil 4.
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Scheme 3-2. Two synthetic routes to achieve treprostinil 4; route i uses a Grignard reagent 
to couple the aldehyde and alkyne to form a racemic product. The hydroxyl is converted 
to a ketone which is subsequently converted back with defined stereochemistry. Route ii 
achieves the same compound with defined stereochemistry of the hydroxyl in one step 
using a chiral epinephrine-derived chiral reagent. 
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A certain amount of purified treprostinil 4 was pledged towards the project saving time and 
money. Appreciating the complexity of synthesis, cost, and the generosity of UT to provide 
material, treprostinil 4 was used sparingly and small reaction scales (5-50 mg) were employed.  
The carboxylic acid in treprostinil 4 is a phenoxyacetic acetic acid. Considering the cost and 
limited supply of treprostinil 4 , a model phenoxyacetic acetic acid 22 was used to examine 
reaction conditions for preparing acyl sulfonamide derivatives. Clearly the use of a model 
phenoxyacetic acid 22 does not possess the two hydroxyls that are present in treprostinil 4. 
Use of a model compound generally carries some risk that its properties (e.g. solubility, 
reactivity) will vary compared to the parent compound, treprostinil 4. However, to preserve the 
supply of treprostinil 4, it was necessary to use phenoxyacetic acid 22 for synthetic studies. 
 
Figure 3-5. Structure of phenoxyacetic acid 22 which possesses the same acid 
moietyas treprostinil and was therefore selected as a suitable model drug. 
N-(methylsulfonyl)-2-phenoxyacetamide 
Initial reactions aimed to modify the phenoxyacetic acid 22 to the N-acyl sulfonyl derivative, 
by coupling to methyl sulfonamide 25 (Scheme 3-3). Several methods were attempted Table 
3-1, mainly utilising known coupling reagents to make amides and esters.355 Of the coupling 
agents that were examined, carbodiimides were the most widely used.  
 
21 
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 Table 3-1. Attempted reactions for formation of N-acyl sulfonamide using model drug, phenoxyacetic acid 22. tBOK 
= potassium tert-butoxide; CDI = carbonyldiimidazole; DBU = 1,8-Diazabicyclo[5.4.0]undec-7-ene; 
THF=tetrahydrofuran;  DCM=dichloromethane 
Model 
drug 
Conditions Solvent 
Scale 
(mg) 
Reaction 
time 
Temp 
Outcome 
Ref 
39 
Methane 
sulfonyl 
chlroide, tBOK 
THF 30 1 hours 0 C 
Change in TLC to lower Rf but when worked up minimal 
methylene resonance was not detected by 1H NMR. 356 
22 25, CDI (36) THF 100  16 RT   
22 
25, CDI (36), 
DBU (31) 
THF 200 48 hours 
RT → 67 → 
RT 
TLC indicated reaction progess but 1H NMR showed only 
20% product. 
357,358 
22 
25, EDCI (34), 
DMAP (32),  
DCM 50  16 hours RT 
Additional TLC spot but starting acid still present. 1H NMR 
confirmed 50% conversion. 
359 
22 
25, CDI (36), 
DBU (31) 
THF 200  90 hours 
RT → 67 → 
RT 
Starting material still detected on TLC. Work up showed 
impure product by 1H NMR which was purified by 
crystallisation from CHCl3 
357,358 
22 
Thionyl chloride, 
25 
DCM 100  3 hours 80 C 
TLC revealed starting acid was still present and no new 
product spots 
 
22 
Thionyl chloride, 
25 
THF 100  
3 hours - 
overnight 
70 C - RT 
TLC showed presence of starting acid and subsequent 
NMR confirmed that minimal (<20%) reaction had 
occurred. 
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These reagents activate the acid carbonyl by replacement of the electron donating acid 
hydroxyl with an electron withdrawing carbodiimide generated intermediate 23. Carbodiimides 
possess two weakly basic nitrogens which render the central carbon susceptible to 
nucleophilic attack by a carboxylic acid. The O-acylisourea generated, is susceptible to rapid 
nucleophilic attack by any nucleophiles present. In the presence of amines, the desired amide 
is generated. However, the reaction solution possesses multiple nucleophiles which facilitates 
several other possible reaction routes. In the presence of excess acid, the symmetrical 
anhydride is formed which can be subsequently cleaved to form one equivalent of the desired 
methane sulfonamide. The high reactivity of the O-acylisourea makes it able to undergo an 
irreversible, undesired rearrangement to form the N-acylurea, particularly in the presence of 
weak nucleophiles. 
 
Scheme 3-3. BLUE: Proposed conversion of phenoxyacetic acid to the N-
acylsulfonamide derivative 26, via the O-acylisourea 23. DCC: R1, R2 = cyclohexane; 
DIPC: R1, R2 = isopropyl; EDCI: R1 = ethyl and R2 = dimethylaminopropyl; GREEN: 
Alternative method of sulfonamide formation via anhydride; RED: Formation of N-iso-
acylurea 24 resulting from unwanted side reaction of carbodiimides. 
To reduce the propensity for the N-iso-acylurea formation 24, additives are added to diminish 
the activity of the O-acylisourea 23 by two mechanisms; (i) N-hydroxy additives (Figure 3-6) 
protonate the O-acylisourea 23, preventing the intermolecular reaction, and (ii) they form the 
active ester which is less reactive. Formation of N-hydroxy additives is favoured in the 
presence of tertiary amine. 
 
21 
21 
26 
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Figure 3-6. N-hydroxy additives to enhance coupling efficiency and avoid N-
acylurea formation; HOBt 27, HOAT 28, N-hydroxysuccinimide NHS 29. 
The formation of the active ester is especially necessary for the coupling of weak or hindered 
nucleophiles such as alcohols and aromatic amines. For such reactions, a catalyst is 
employed. Nucleophilic bases (Figure 3-7) are added to form the active ester which possess 
electron withdrawing properties. The carbonyl of the active ester is exceptionally electrophilic 
which facilitates attack by weak nucleophiles. Although 1-hydroxybenzotriazole hydrate 
(HOBt) 27 is an effective catalyst, it is costly and explosive.360 In certain cases, DBU 31 has 
been shown to increase rate of reaction more than DMAP 32 or HOBt.361 This is attributed to 
its ability to act as a nucleophilic base in a similar manner to that of DMAP or HOBt. 
 
Figure 3-7. Amide coupling catalysts; imidazole chloride 30, 1,8-
Diazabicyclo[5.4.0]undec-7-ene (DBU) 31, 4-(dimethylamino)pyridine (DMAP) 32. 
EDCI 34 is a carbodiimide which gives a water soluble by-product (33).355 This simplifies the 
extraction during work up. Other carbodiimides (DCC, DIC) produce ureas of varying solubility 
which can be difficult to remove completely. Using EDCI 34 in the presence of catalytic DMAP 
32, coupling of sulfonamide 25 with phenoxyacetic acid 22 using EDCI 34 was attempted,362 
resulting in incomplete conversion to the desired sulfonamide derivative 26 Complete 
depletion of phenoxyacetic acid 22 spot was not observed and 1H NMR confirmed a 1:1 ratio 
of acid 22 methylene (4.58 ppm) and sulfonamide 26 methylene (4.68 ppm). The coupling 
reaction was repeated, leaving the acid 22 to undergo reaction with EDCI 34 for longer (18 
hours) which achieved a 9:1 ratio of sulfonamide product 26 to starting acid 22 as determined 
by 1H NMR spectroscopy. Purification by basic liquid extraction yielded the desired acyl 
sulfonamide 26 in 33% yield.  
EDCI 34 was purchased as the hydrochloride salt. Upon the result that EDCI 34 yields lower 
coupling product in the presence of additional base, it was thought that EDCI 34 may need to 
be deprotonated to allow the tertiary amine to deprotonate the intermediate species. Following 
this hypothesis, the EDCI-mediated reaction was repeated on a 50 mg scale, with the addition 
of triethylamine to neutralise the hydrochloride salt. A TLC spot with Rf at 0.86 was seen 
(similar to the product spot of the previous reaction, Rf = 0.94) but the phenoxyacetic acid 22 
was not consumed after 5 days. 1H NMR did not show the presence of any sulfonamide 
product 26; no shift in methylene resonance or methyl singlet was observed.  
An additional attempt was conducted in the same manner, with the addition of N-
hydroxylsuccinimide (NHS) 29 to avoid formation of N-acylurea 24. NHS 29 was added to the 
29 31 
 
30 
28 27 
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solution at the same time as acid 22 and stirred for 30 minutes before addition of the 
sulfonamide 25 to allow for the NHS-ester to form. TLC revealed six product spots and the 1H 
NMR spectrum, following basic workup with sodium carbonate, confirmed the absence of 
sulfonamide product 22, NHS-ester or EDCI 34.  
Based on these results, it is likely that the protonation of EDCI 34 is required for the EDCI-
mediated coupling (Scheme 3-4). It is possible that the ammonium side chain facilitates 
protonation of the imide which helps to drive the nucleophilic attack by sulfonamide 25. 
 
Scheme 3-4. Mechanism for the N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDCI) 34 mediated amide coupling of phenoxyacetic acid 22 and 
methane sulfonamide 25 to form N-acyl sulfonamide derivative 26. 
The model acyl sulfonamide 26 was also prepared using carbonyl diimidazole (CDI) 36 as the 
coupling agent. CDI 36 was used for the synthesis of selexipag 5.115,363 Whilst not a 
carbodiimide, the coupling with CDI 36 proceeds in a similar manner. The sp3 nitrogens on the 
imidazole rings in CDI 36 are slightly basic and can serve to deprotonate the phenoxy acetic 
acid 22 resulting in the formation of the mixed anhydride imidazolide intermediate 38 (Scheme 
3-5). Imidazole is liberated as a result. Acyl imidazole 37 formation through the nucleophilic 
attack of the displaced imidazole is driven by the evolution of CO2 (Scheme 3-5). The 
innocuous by-products generated by CDI-mediated couplings make their employment for 
amide couplings favourable for pharmaceutical applications. 
 
Scheme 3-5. Mechanism of amide formation between phenoxyacetic acid 22 and 
methane sulfonamide 25 mediated by 1,1-carbonyldiimidazole (CDI) 36. Attack of the 
imidazole into the anhydride intermediate 37 is driven by carbon dioxide evolution to 
form the acyl imidazole 38. 
35 
21 
36 
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Upon addition of a nucleophile to the acyl imidazole 38, the imidazole is substituted for the 
nucleophile.364 The nucleophilic nature of both reactions means anhydrous conditions and 
protocols must be adhered to. Although the acyl imidazole 38 serves to activate the carbonyl 
and make it more susceptible to nucleophilic attack, reactions rates of hindered and weak 
nucleophiles, such as methane sulfonamide 25 can be slow. CDI-mediated coupling was 
carried out between phenoxyacetic acid 22 and methane sulfonamide 25 in the absence of 
DBU 31 and no coupling product could be detected by 1H NMR after 16 hours. In such cases, 
catalysts are employed (Scheme 3-6). 
.  
Scheme 3-6. Mechanism of 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) catalysis of 
carbonyldiimidazole (CDI)-mediated amide coupling. Once acyl imidazole 38 is 
formed, DBU 31 displaces the imidazole which facilitates nucleophilic attack of 
methane sulfonamide 25 to form N-acyl sulfonamide 26. DBU catalyst 31 is 
regenerated during displacement which can undergo reaction with further molecules 
of acyl imidazole 38. 
Following previous protocols, the CDI-mediated coupling of phenoxyacetic acid 22 and 
methane sulfonamide 25 was carried out on a 200 mg scale in the presence of DBU 31. 
Varying from the previous DBU-free protocol, the reaction was heated to 67 ᵒC. The reaction 
was difficult to track by TLC as only a slight shift down the TLC plate was observed from the 
Rf of phenoxyacetic acid 22 (Rf = 0.43) and N-acyl sulfonamide 25 (Rf = 0.35). However, a 
colour change from brown to green when stained with phosphomolybdic acid (PMA) was 
observed upon reaction progression. Following liquid extraction to remove base, unreacted 
acid 22 and CDI, crystals were observed in CDCl3 during 1H NMR spectroscopy of the crude 
sample. Purification was therefore carried out by repeat crystallisation from chloroform to yield 
N-acyl sulfonamide 25, which was a white powder. 
An alternative method to circumvent possible formation of N-acylurea 24 was to form the 
primary amide via a mixed anhydride (Scheme 3-7) followed by reaction with a methane 
sulfonyl halide (Scheme 3-8). Amination of phenoxyacetic acid 22 into its respective primary 
amide 39 was successfully achieved by treatment with ammonium chloride by activation of the 
37 
24 
25 
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acid using ethyl chloroformate.365 Reaction progression was monitored by TLC, showing an 
increased Rf value which stained mauve with ninhydrin and did not stain with bromocresol 
green. 1H NMR spectroscopy showed a shift in methylene resonance of 0.04 ppm. Spiking the 
NMR sample with the starting phenoxyacetic acid 22 confirmed the presence of two different 
methylene proton environments, suggesting the reaction had occurred. 
 
Scheme 3-7. Conversion of carboxylic acid 22 to primary amide 39 which can then 
displace chloride of methane sulfonyl chloride to form 26. 
Based on clean TLC and NMR spectra, 2-phenoxyacetamide 39 was taken to the next step 
without further purification. Coupling to methane sulfonyl chloride was attempted under basic 
conditions in the presence of 1,4,7,10,13,16-hexaoxacyclooctadecane (18-crown-6).356 The 
pKa of a primary amide such as 39 is ~25,366 and owing to the ability of the nitrogen electrons 
to resonate into the sulfonyl groups, possesses limited nucleophilicity. Alternative bases, such 
as DMAP 32 and sodium hydride, are also reportedly used for nucleophilic reactions of primary 
amides which may have helped this reaction succeed.367,368 However, the transfer of such 
conditions to an analogous reaction with treprostinil 4 was anticipated to be unsuccessful 
owing to the presence of the secondary alcohols. Furthermore, the carbodiimide synthetic 
route had proved successful and the transfer to treprostinil 4 seemed the next logical step. 
 
Scheme 3-8. Reaction of primary amide 39 with sulfonyl chloride to form N-
acylsulfonamide derivative 26 by displacement of chloride ion.  
There are many methods and reagents available for amide coupling all of which have their 
own advantages and disadvantages (i.e. cost availability, ease of handling, activity, solubility, 
ease of removal). Although the synthesis of 26 could have been optimised further, a method 
of synthesis was identified with the reagents available. It was considered more worthwhile to 
transfer the conditions identified and lessons learnt over to the derivatisation of treprostinil 
than to optimise the model coupling further. 
25 
38 
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N-acyl sulfonamide treprostinil 
The synthesis of N-acyl sulfonamide treprostinil 21 using the CDI 36 conditions identified for 
derivatising phenoxyacetic acid 22 were then explored. On a 50 mg scale, treprostinil 4 was 
coupled to methane sulfonamide in the presence of CDI 36 and DBU 31. After 18 hours, TLC 
revealed 6 PMA-staining spots, including the starting material treprostinil. 1H NMR 
spectroscopy of the crude sample without work up revealed only the treprostinil 4 carboxyl 
methylene resonance, indicating the reaction had not occurred. HPLC analysis confirmed an 
absorbance with the same retention time as treprostinil 4. 
Treprostinil 4 (50 mg) was then treated to the EDCI 34 and DMAP 32 conditions found to be 
successful with phenoxyacetic acid 22. TLC conducted after 48 hours revealed 7 spots of 
which, one corresponded to treprostinil 4. After liquid extraction from both acidic and basic 
aqueous layers, the TLC still possessed 6 UV active compounds. A preparative TLC was 
carried out using 10% methanol in ethyl acetate and each band collected by extraction into 
methanol. The signal to noise ratio for all fractions was low and none of fractions possessed 
both the methyl resonance and treprostinil resonances. The reaction was thus considered 
unsuccessful. 
 
Figure 3-8. Proposed N,N'-Dicyclohexylcarbodiimide (DCC)-mediated formation of 
treprostinil-N-hydroxysuccinimide (NHS) ester, which is then displaced by methane 
sulfonamide to form N-acyl sulfonamide treprostinil 21. NEt3 = triethylamine; DMAP = 
4-(dimethylamino)pyridine 32. 
One further attempt was made to pre-form the treprostinil-NHS ester 40 which could then be 
treated with methane sulfonamide 25 to achieve the desired sulfonamide 21. On a 5 mg scale 
in DMF, treprostinil 4 was treated with DCC, NHS and triethylamine in the presence of DMAP 
32 catalyst. To minimise the possibility of the interference of the secondary alcohols with the 
activated carbonyl, methane sulfonamide 25 was added after 15 minutes. Following 16 hours 
of stirring at RT, TLC detected 9 spots, including mostly starting material. The crude reaction 
mixture was analysed by 1H NMR which did not show any shift in resonance corresponding to 
the carboxyl methylene of treprostinil. 
For work described in appendix 8.3, other derivatives of treprostinil were attempted to be made 
however, with limited success (Table 3-2). In light of this, as well as the contrast between the 
successful sulfonamidations of the phenoxyacetic acid 22, and the unsuccessful attempts for 
that of treprostinil 4, it was concluded that the problem was a feature of coupling treprostinil 4. 
The number of spots formed for each reaction indicated that a variety of unwanted reactions 
were occurring, despite no observable differences in the solubility between phenoxyacetic acid 
24 
39 
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22 and treprostinil 4. The main difference appeared in the presence of the hydroxyl groups of 
treprostinil 4. Although secondary alcohols are less nucleophilic that their primary 
counterparts, they are still capable of attacking electrophiles, particularly when in the presence 
of an activated carbonyl, such as the O-acylisourea activated carbonyl of treprostinil formed 
during coupling reactions (Figure 3-9). To avoid possible competing side reactions, it was 
hypothesised that the treprostinil 4 hydroxyl groups will need to be protected before coupling 
to sulfonamide 25 so a suitable protecting group was sought 
 
Figure 3-9. O-Acylisourea derivative of treprostinil formed as an intermediate during 
carbodiimide or carbodiimidazole coupling reactions. Where R = isopropyl, imidazole, 
cyclohexyl or ethyl groups. 
.
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Table 3-2. Unsuccessful attempted reactions to protect Treprostinil (4). At either carboxyl acid (COOH) terminus or both COOH and 
hydroxyl termini (OH). Dmob = dimethoxybenzyl alcohol;  K2CO3 = potassium carbonate; MeI = methyl iodide; DIPC = diisopropyl 
cardodiimide; EDCI =  N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride; DMAP = 4-(dimethylamino)pyridine; BzBr = 
benzyl bromide; Cs2CO3 = caesium carbonate; DCC = N,N’-dicyclohexylcarbodiimide; NHS = N-hydroxysuccinimide; BTCA =benzyl-
2,2,2-trichloroacetimidate MeOH = methanol; CDCl3 = deuterated chloroform; DCM = dichloromethane; THF = tetrahydrofuran;  tBuOH 
= tert-butanol; RT = room temperature; TLC = thin layer chromatography. 
Protecting group 
Treprostinil 
moiety 
Conditions Solvent 
Scale 
(mg) 
Time Temp Outcome 
Methyl esterification 
COOH 
K2CO3, MeI MeOH 5 
20 
mins 
RT No reaction (TLC) 
Dmob esterification 
COOH 
DIPC, Dmob CDCl3 2 
2 
hours 
0 - RT No reaction by NMR 
Triethylene glycol 
esterification 
COOH DIPC, Triethylene 
glycol 
CDCl3 2 6 days RT 
Conversion of treprostinil but 
many spots - difficult to isolate. 
Dmob esterification 
COOH 
EDCI, Dmob, DMAP DCM 2 3 days 0 - RT 
TLC conversion of trep, 
terminated 
Tribenzylation OH + COOH BzBr, Cs2CO3 NaH 50 7 days  No reaction 
Benzyl 
esterification 
COOH DCC, NHS, benzyl 
alcohol, DMAP 
DMF 5 5 days RT Prep TLC, LCMS peak 
Tribenzylation OH + COOH BTCA, triflic acid DCM 10 5 days RT No reaction 
Tribenylation 
OH + COOH 
BTCA, triflic acid THF 10 
17 
hours 
RT negligable benzylation 
Esterfication 
COOH Di-tert-butylcarbonate, 
DMAP, 
tBuOH 20 
48 
hours 
RT 
Many spots by TLC, difficult to 
isolate by prep TLC 
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The possibility of forming a cyclic ketal bond between the two hydroxyls was considered, 
however this would form an unfavourable 9 membered ring, so was not anticipated to be 
straight forward. Therefore, methods to cyclise the hydroxyl groups together were abandoned. 
Alternative commonly employed hydroxyl protecting groups are shown in Table 3-3.  
Table 3-3. Commonly employed hydroxyl protecting groups. TBAF = tetra-n-
butylammonium fluoride; DBU = 1,8-Diazabicyclo[5.4.0]undec-7-ene. 
Protecting group Structure Cleavage conditions369 
tert-
Butyldimethylsilyl 
ether (TBDMS)  
Fluoride: TBAF, hydrofluoric acid, Lithium 
aluminium hydride 
Acid: Dowex 50W-X8, sulfuric acid, 
trifluoroacetic acid 
Base: Lithium aluminium hydride, 
Alkyl ether 
(tbutyl)  
Acid: 4 N hydrochloric acid, Trifluoroacetic 
acid, formic acid353,  
Benzyl ethers 
 
Hydrogen/palladium on carbon, 
sodium/ammonia, Iron chloride + acetic acid 
Acetal  
(tetrahydropyran) 
 
Acid: 0.01 N hydrochloric acid, acetic acid, pH 
5 
Acyl groups 
 
Potassium carbonate/methanol, DBU, lipase 
enzyme 
Ester and amide formation using coupling agents such as diicarbodiimides and uronium salts 
require basic conditions353 so hydroxyl protecting groups that are stable to base were sought. 
However, in the presence of the free acid of treprostinil 4, acid labile protecting groups are not 
appropriate as the treprostinil acid could cleave an acid labile protecting group prematurely.  
Protection of treprostinil 4 hydroxyls has been described in published patents,79,370,371 
however, all methods describe simultaneous protection of the acid. The acid protecting group 
is then replaced with either an amine or ester bond. Although this gave confidence that the 
hypothesis of requiring hydroxyl protection was correct, only the silyl ethers were reported 
which did not give much information on the relative reactivity of the hydroxyls. 
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Figure 3-10. Protected treprostinil structures within the patent literature.79,370–372 
Several attempts to protect either only the hydroxyls or both the hydroxyls and the acid of 
treprostinil 4 simultaneously were attempted Table 3-4 which were largely unsuccessful. For 
the future ester and amide formation reactions using coupling agents such as diicarbodiimides 
in basic conditions as well as considering work described in Appendix 8.3 hydroxyl protecting 
groups that are stable to base were sought.  
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Table 3-4. Summary of attempted reactions to protect the hydroxyl groups of treprostinil 4. TBDMS(Cl) = tert-butyl dimethyl silyl (chloride); 
DMAP = 4-(Dimethylamino)pyridine; BTA = N,O-Bis(trimethylsilyl)acetamide; BzBr = benzylbromide; NaH = sodium hydride; tBuOK = 
potassium tert-butoxide; Cs2CO3 = caesium carbonate; BTCA =benzyl-2,2,2-trichloroacetimidate; DCM = dichloromethane; DMF = 
dimethyl formamide; THF = tetrahydrofuran; DMSO = dimethylsulfoxide; RT = room temperature; TLC = thin layer chromatography (using 
silica) 
Intended protecting 
group 
Conditions Solvent 
Scale 
(mg) 
Time Temp Result 
Silylation 
TBDMSCl, 
DMAP, Imidazole 
DCM 50 
48 
hours 
0 - RT 
Unsuccessful: No change by TLC. 
Degraded or no reaction. 
Trisilylation BTA DMF 50 
16 
hours 
0 - RT 
Partial success: One pot methane 
sulfonamide coupling 
Trep benzylation BzBr, NaH THF 10 
16 
hours 
RT Unsuccessful: by TLC 
Trep benzylation BzBr, tBuOK DMSO 10.2 
2 
hours 
RT Unsuccessful: multiple products 
Trep tribenzylation BzBr, NaH THF 50 
7 
days 
 Unsuccessful: No reaction 
Trep tribenzylation BzBr, Cs2CO3 THF 20 
6 
days 
reflux 
Partial success: Multiples products 
including dibenzylated treprostinil 
Trep tribenzylation BTCA, triflic acid DCM 10 
5 
days 
RT Unsuccessful: No reaction 
Trep tribenzylation BTCA, triflic acid THF 10 
17 
hours 
RT Unsuccessful: negligable benzylation 
TBDMS ether 
TBDMSCl, 
imidazole 
DMF 50 
16 
hours 
0 - RT 
Partial silylation 
Free acid may cleave silyl groups 
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Following guidance from the patent literature, the synthesis of tri-silyl protected treprostinil was 
carried out using tert-butyl dimethylsilyl chloride (TBDMSCl). The stability of the silylated ester 
was anticipated to be poor, however masking of the acid head group was required for the 
stability of the silyl ethers. The reaction was carried out on treprostinil 4 (50 mg) under basic 
conditions and using DMF as solvent which is thought to drive coupling reactions.373 TLC 
showed no change in the Rf value from starting treprostinil. In hindsight, it is possible that the 
TLC plate was acidic enough to cleave the silyl groups and this could have been investigated 
by running a 2D TLC. With retrospect, alumina could have been used as a neutral TLC 
alternative. 
 
Scheme 3-9. Trisilylation of treprostinil 4 to form silyl ethers at the hydroxyls and a 
labile silyl ester at the acid using tertiary butyl dimethyl silyl chloride (TBDMS). 
The trisilylation of treprostinil 4 was repeated with three equivalents of TBDMSCl. Separation 
between ethyl acetate and aqueous layers during liquid extraction was poor and although 1H 
NMR showed resonances at 0.1 and 0.9 corresponding to the silylated groups, the resolution 
was poor and further extraction only reduced the sensitivity of 1H NMR analysis. The lability of 
the silyl ethers and the issues experienced during isolation led to the termination of efforts on 
the silylation reaction.  
The isolation of the silylated treprostinil presented an opportunity for degradation, so using a 
different patented procedure, the trimethylsilyl ether and ester bonds were formed and the 
ester reacted with a more stable nucleophile in a two-step, one-pot reaction. Following the 
success of the EDCI 34 reaction with phenoxyacetic acid 22, it seemed reasonable to attempt 
the same coupling with treprostinil 4, assuming the hydroxyls were silylated. A more reactive 
silylating agent N,O-bis(trimethylsilyl)acetimidate 41 was employed for the trimethylsilyl (TMS) 
protection of treprostinil 4 on a 50 mg scale in DMF (Scheme 3-10). After 12 hours, EDCI 34 
and DMAP 32 were added to the solution mixture. After cooling for 30 minutes, methane 
sulfonamide 25 added and the reaction left for 3 days.  
4 
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Scheme 3-10. Trisilylation of treprostinil 4 in situ with N,O-
bis(trimethylsilyl)acetimidate (BTSA) 41 before cleavage and coupling of carboxylic 
acid with methane sulfonamide 25 with EDCI coupling agent 34 to form silylated N-
acyl sulfonamide derivative. Cleavage of silyl ethers forms the desired N-acyl 
sulfonamide treprostinil derivative 21. 
TLC revealed treprostinil 4 was present but with an additional spot with higher Rf = 0.8). The 
solution was run through analytical HPLC column (mobile phase = 10-90% acetonitrile/ water 
over 20 minutes) to identify reaction progression. The HPLC chromatogram showed a peak at 
13.3 minutes, different from that of treprostinil 4. The 1H NMR spectrum (Figure 3-11) 
suggests that N-acyl sulfonamide 21 was present, based upon the shift in methylene 
resonance from 4.6 to 4.7 ppm, and the presence of a singlet at 3.8 ppm, corresponding to 
the sulfonamide resonance, compared to treprostinil 4. No TMS groups were observed which 
could mean that the protection did not occur, or silylated product 42 was produced, but silyl 
groups were subsequently cleaved during work up. A total yield of 12 mg (20%) of N-acyl 
sulfonamide treprostinil 21 was produced, greater than that of the EDCI-coupling of 
phenoxyacetic acid 22 (4%). Additionally, the reaction appeared by TLC to form over 6 
compounds, indicating that the reaction was involved with multiple unwanted side reactions. 
For any commercial application, the loss of treprostinil 4 must be kept to a minimum and 
unwanted side reactions are a source of inefficiency. For this reason, a more reliable synthetic 
route was sought. 
4 
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Figure 3-11. 1H NMR of N-acylsulfonamide treprostinil 21 derived from trimethylsilane-
treprostinil formed in a one-pot, two-step reaction. Blue shows the shifted methylene 
resonance and pink shows the presence of the sulfonamide methyl resonance 
Hydroxyl-benzylation (Scheme 3-11) is a protecting group strategy used in the synthesis of 
treprostinil 4 (Scheme 3-2) and is robust to both acid and base conditions. Benzylation of 
treprostinil 4 via a base catalysed mechanism was explored, using benzyl bromide (Scheme 
3-11).  
 
Scheme 3-11. Benzylation of nucleophile by nucleophilic displacement of bromide. 
Base is often employed to deprotonate the nucleophile. 
Owing to the electron withdrawing effects of bromine, the benzylic carbon is subject to 
nucleophilic attack by alcohols and amines. The benzylation of treprostinil 4 (10 mg) was 
attempted with four equivalents of benzyl bromide in the presence of potassium tertiary 
butoxide. TLC revealed the presence of 6 spots including those with Rf values of treprostinil 
and benzyl bromide. Carrying out benzylations in the presence of sodium hydroxide was 
carried out on a small scale (10 and 50 mg), but TLC revealed only treprostinil and benzyl 
bromide.  
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Scheme 3-12. Proposed benzylation of treprostinil hydroxyls by base-mediated 
nucleophilic displacement of bromide ion. 
One final attempt was made to achieve the di-benzylated treprostinil. Treprostinil 4 (20 mg) in 
THF was treated to 3 equivalents of benzyl bromide in the presence of a weaker base caesium 
carbonate. The reaction TLC showed 5 spots and a sample was analysed by LCMS. As well 
as the treprostinil mass ion, the dibenzylated hydroxy-ether product ion was detected [M+H]+ 
571.3 m/z. The number of product spots in the TLC indicated that the reaction was only 
partially successful. 
It was hypothesised that removing the possibility of interference from the acid group of 
treprostinil 4 would increase the success of the hydroxyl resonances. Despite the inefficiency 
of the proposed synthetic route (Scheme 3-13), methods to protect treprostinil were expected 
to have been previously explored and elucidated by UT and the sulfonamide coupling step 
was considered the novel and important step. Therefore, any route to allow sulfonamide 
coupling to be investigated was considered acceptable in the meantime and if deemed 
necessary, the protecting group strategy could be optimised post-hoc.  
 
Scheme 3-13. Proposed synthetic route to protect hydroxyl groups of treprostinil 4. 
Protecting the acid of treprostinil 4 and then subsequent protection of the alcohols. PG 
= protecting group. 
Fischer esterification was employed by refluxing treprostinil 4 in anhydrous ethanol with an 
acid catalyst for 16 hours. The excess of solvent statistically results in ethanol attacking the 
π* orbital of the carbonyl bond, and further acidification of the intermediate hydroxyl, by proton 
transfer, eliminates water, leaving the ethyl ester. The build-up of water in the reaction solution 
prevents completion of the reaction. To circumvent hydrolysis of formed ester, several 
measures were taken; i) ethanol was dried over molecular sieves prior to reaction; ii) A large 
excess of ethanol was used; iii) reaction solution was dried over sodium sulfate towards the 
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end of reaction; iv) The solution was neutralised before reaction solvent was concentrated in 
vacuo. 
 
Scheme 3-14. Proposed mechanism for the acid-catalysed Fischer esterification of 
treprostinil 4 to form the ethyl ester derivative 43. 
Fischer esterification was monitored by TLC (determined by UV/PMA stain). Trace remaining 
treprostinil 4 was removed by base (K2CO3) extraction and the 1H NMR spectrum (Figure 
3-12) showed the expected ethyl resonances at δ 4.23 and 1.27 ppm corresponding to the 
ester CH2 and CH3, highlighted orange and green in Figure 3-12 respectively (CDCl3). By 
comparison to the 1H NMR spectrum of starting treprostinil 4 in CDCl3, the methylene 
resonance also shifted from δ 4.66 to 4.58 ppm. Treprostinil ethyl ester 43 was afforded as a 
dry white powder in 88% yield.  
 
Figure 3-12. 1H NMR spectrum of treprostinil ethyl ester 43 showing a shift in 
methylene resonance in purple, and the presence of the ester methylene and methyl 
resonances in yellow and green respectively. 
With the treprostinil ethyl ester 43 in hand, hydroxyl group protection was attempted using 
acid-catalysed nucleophilic substitution of benzyl-2,2,2-trichloroacetimidate 44 (BTCA) in the 
presence of trimethylsilyl trifluoromethane sulfonate (TMS-OTf).374,375 Under these conditions 
4 
42 
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multiple spots were detected by TLC (UV/PMA detection). A preparative TLC was conducted, 
and the fractions extracted in methanol then analysed by NMR. None of the compounds 
separated contained both benzyl aromatic and treprostinil resonances.  
 
Scheme 3-15. Proposed mechanism for the benzylation of treprostinil ethyl ester 43 
with benzyl-2,2,2-trichloroacetimidate (BTCA) 44 to form the bis-benzylated ethyl ester 
product 45. TMS-OTf = trimethylsilyl trifluoromethanesulfonate. 
Benzyl protection of treprostinil free acid 4 using BTCA 44 in the presence of TMS-OTf in both 
DCM376 and THF377 were both unsuccessful. Reagents were insoluble in DCM so additional 
THF was added to the reaction to aid solubility. In both cases TLC showed predominately the 
presence of treprostinil 4 after 5 days. 1H NMR of the crude reaction product showed less than 
10% benzylation, as determined by the benzyl methylene resonance. Owing to the steric 
hindrance and lack of nucleophilicity of the treprostinil 4 hydroxyl moieties in an acidic 
environment, treatment of treprostinil ethyl ester 43 with two equivalents of BTCA 44 could not 
displace the trichloroacetamide to form the benzyl ethers of 45.  
The neutral benzylation agent, 2-benzyloxy-1-methylpyridinium triflate 46 (dubbed the Dudley 
reagent) offered an alternative method for benzylation (Scheme 3-16).378 Neutralisation of the 
positively charged pyridinium ion weakens the benzylic C-O bond to make the carbon more 
susceptible to nucleophilic attack by even weak nucleophiles, which ultimately drives the 
benzylation reaction. The hydroxypyridinium intermediate 48 is slightly acidic but the addition 
of magnesium oxide to the reaction mixture neutralises the intermediate as it forms, converting 
it to the N-Methyl-2-pyridone, 47. The Dudley reagent 46 has been used successfully to protect 
secondary,379 tertiary380 and hindered hydroxyls.381 Reactions are known to progress well 
when trifluoromethyl benzene solvent is employed,382 particularly when reagents are poorly 
soluble in toluene, such as treprostinil. Trifluoromethyl benzene has a boiling point 60 ᵒC 
higher than DCM, so it is able to facilitate reaction conditions with higher operating 
temperatures.383 Trifluoromethyl benzene has been reported to offer benefit to selective 
benzylation reactions compared to toluene. For example, the benzylation of a glucose 
derivative does not proceed in the presence of toluene solvent but achieves a yield of 93% 
when carried out in trifluoromethyl benzene.378  
43 
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Scheme 3-16. Benzylation of secondary alcohols of treprostinil ethyl ester 43 using N-
methyl pyridinium triflate 46 (Dudley reagent). Magnesium oxide 47 (MgO) is present 
to neutralise hydroxypyridinium by-product 48. The reaction was conducted in 
trifluoromethyl benzene solvent and refluxed for 24 hours. 
The benzylation of treprostinil ester 43 using the Dudley reagent 46 was investigated on a 280 
mg scale. After heating in trifluoromethyl benzene at 83 ᵒC for over a 24-hours, TLC indicated 
reaction success by the consumption of starting material 43 spot. Additionally, a product spot 
with higher Rf was seen, which is consistent with the reduced polarity expected of benzylated 
ester 45. The presence of a single TLC product spot suggested formation of either the mono 
or bis, but not a mixture of both the benzylated treprostinil derivatives.  
The heterogenous reagent magnesium oxide was removed by filtration and the filtrate dried in 
vacuo to yield 451 mg (>100%) of crude benzylated ester 45. 1H NMR analysis of the crude 
product 45 showed the presence of the benzyl groups at 7.42 – 7.16 ppm which integrated to 
10 protons, as well as showing resonances corresponding to the benzyl resonances; doublet 
of doublets at 4.55 – 4.39 ppm and a singlet at 4.49 ppm, which indicated there had been a 
successful bis-benzylation of treprostinil ethyl ester 43. A shift in the methine protons 
(highlighted in pink and purple in Figure 3-13) from 3.53 and 3.65 ppm, to 3.38 and 3.50 ppm 
was observed, indicating that the benzyl groups had attached to the alcohol moieties, as 
desired. 
With the treprostinil 4 carboxylic acid and hydroxyl groups protected as shown in structure 45, 
purification by chromatography was expected to be simpler. With reduced polarity, less 
interaction occurs with the polar solid phase and better partitioning between stationary and 
mobile phases results. Reduced solid phase interaction reduces the broadening of the product 
band of compound and increases the resolution of the product which reduces the likelihood of 
overlapping product with impurities. The increased resolution facilitated isolation by automated 
42 
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chromatography through normal phase silica in two batches to yield bis-benzyl ester 45, as a 
clear oil which forms a crystalline structure upon cooling, in 49% total yield.  
 
Figure 3-13. 1H NMR spectra of bis-benzyl treprostinil ethyl ester, 45 
Subsequent ester hydrolysis of bis-benzyl treprostinil ethyl ester 45 was carried out using basic 
hydrolytic conditions using lithium hydroxide to afford a 64% yield of bis-benzyl treprostinil acid 
49, a clear oil.  
 
Scheme 3-17. Ester hydrolysis of bis-benzyl treprostinil ethyl ester 44 to form bis-
benzyl treprostinil 49 using lithium hydroxide (LiOH) 
Hydrolysis was monitored by TLC, showing a reduction in Rf value, from 0.71 to 0.0 as the 
reaction progressed. The presence of the acid group was confirmed by bromocresol staining 
forming a yellow TLC spot. There were no 1H NMR resonances for the ethyl ester methylene 
or methyl protons. A downfield proton at δ 9.26 ppm was consistent with being the 
exchangeable carboxylic acid proton. The resonance corresponding to the α-carbonyl 
methylene protons shifted from 4.75 to 4.60 ppm (highlighted in pink in Figure 3-14). The IR 
spectra showed a change in absorption from 1759 to 1732 cm-1 consistent with ester having 
been hydrolysed to a carboxylic acid. The addition of the OH absorption at 2858 cm-1 is also 
consistent with ester hydrolysis having occurred. 
44 48 
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Figure 3-14. 1H NMR spectra of bis-benzyl treprostinil 49 following ester hydrolysis. A 
shift in methylene resonance is observed (shown in pink) and the acidic proton (shown 
in yellow) is also present. 
As each protection/deprotection is associated with yield loss, it was hoped a route to the bis-
benzyl treprostinil 49 could be achieved without the protection and subsequent deprotection 
of the acid. Having found suitable conditions to protect the hydroxyl groups of treprostinil ester 
43 with the Dudley reagent 46, the same benzylation conditions was trialled for treprostinil 4 
on a 50 mg scale. TLC showed the absence of treprostinil 4 spot (Rf = 0.1) and the presence 
of a new spot with higher Rf (0.4) after 18 hours. After filtration to remove magnesium oxide 
47, the concentrated filtrate was acidified and extracted from aqueous layer in DCM to retain 
treprostinil 4 for comparison to afford a yellow/brown gel-like material. The 1H NMR spectrum 
showed the presence of three methylene resonances; one singlet for the treprostinil α-
methylene protons; one singlet for the benzyl methylene attached via ether to the alkyl chain 
of treprostinil 4; and one doublet of doublets corresponding to the two environments of the 
benzyl methylene protons forming the cyclic ether. The doublet of doublets forms from the two 
distinct environments of the two methylene resonances as a result of the confined freedom of 
rotation associated with being bound to a cyclic structure with multiple stereocentres, also 
seen in spectra of bis benzyl ester 44 and bis-benzyl acid 49 formed by ester hydrolysis. The 
direct benzylation was carried out to investigate the route, and a large supply of bis-benzyl 
treprostinil 49 had already been synthesised through the ester protection-deprotection route, 
so the direct benzylated product was not purified further.  
The successful direct benzylation of treprostinil 4 eliminates the esterification and ester 
cleavage steps. The diagnostic resonance upon benzylation is a shift in methine resonance 
0.1 ppm upfield. Although the final bis-benzyl treprostinil 49 formed by direct benzylation of 
treprostinil 4 was not purified and a yield cannot be determined and compared, the acid work 
up should have retained all the treprostinil 4 starting material. No remaining methane 
resonance corresponding to treprostinil 4 were detected. The TLC and the lack of treprostinil 
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4 detected by 1H NMR suggests that the coupling was complete. The direct benzylation was 
meant to serve as proof that the esterification could be circumvented for the formation of the 
N-acyl sulphonamide as below. 
As described earlier, an efficient method to couple methane sulphonamide 25 to the free acid 
was optimised on phenoxyacetic acid 22. The conditions which proved successful were 
coupling agents EDCI 34, reported by Pelletier,384 and CDI 36, reported by Nakamura.115 In 
the case of CDI 36, the catalyst DBU 31 was necessary for coupling, and catalytic DMAP 32 
assisted EDCI 34 coupling, however, the presence of triethylamine or addition of NHS 29 
prevented the product forming.  
 
Figure 3-15. 1H NMR spectra of bis-benzyl N-acyl sulfonamide treprostinil 21 showing 
the shifted methylene resonance highlighted yellow and the additional methyl 
resonance of the sulfonamide group in pink. 
The successful conditions for forming the N-acyl sulfonamide derivative of phenoxyacetic acid 
22 were then employed for bis-benzyl treprostinil 49 on a 50 mg scale. CDI 36/DBU 31 
conditions in refluxing THF proved successful giving a 21% isolated yield of bis-benzyl 
treprostinil N-acyl sulfonamide 50 after purification over a silica column. Interestingly, a greater 
yield of 46% for bis-benzyl treprostinil N-acyl sulfonamide 50 was achieved by employing EDCI 
34/DMAP 32 when carried out on a smaller 20 mg scale. The isolation of bis-benzyl 
acylsulfonamide treprostinil 50 required three runs of column chromatography to achieve good 
separation. Initially, automated separation of the product was conducted on normal phase 
silica with mobile phase 20% ethyl acetate/hexane increasing to 100% over 13 column 
volumes with a flow rate of 3 mL/min. Apart from an initial peak at the void volume, no peaks 
were distinguished. An increase in absorbance was measured but it remained across the 
entire spectrum. The column was purged manually with 50% ethyl acetate/methanol and all 
fractions were collected. The column was repeated but with the same outcome. With the 
concentrated collected fractions, a manual column was run using mobile phase 50-100% ethyl 
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acetate over 4 column volumes. Separation was achieved although some overlap of the 
compound spots were observed by TLC. For purity, only clean fractions were collected and 
combined to afford colourless oil so the isolated yield of 47% is not optimised. 1H NMR showed 
the presence of a singlet at 3.38 ppm corresponding to the sulfonyl methyl singlet. There was 
also a small downfield shift for the α-carbonyl methylene protons of 0.02 ppm, although a 
greater shift had been anticipated. However, mass spectroscopy confirmed the product mass 
of [M+H]+ 468 m/z. The neglibable shift in methylene resonance is possibly a result of the 
similar pKa of the acid and N-acyl sulfonamide acidic protons. 
 
Scheme 3-18. Coupling of bis-benzyl treprostinil 49 to methyl sulfonamide 25 to form 
bis-benzyl N-acylsulfonamide treprostinil 50. 
Debenzylation was first attempted by treating bis-benzyl N-acyl sulfonamide 50 with AlCl3. 
These conditions were examined because of an earlier observation when attempting to acylate 
the bis-benzyl protected-treprostinil ethyl ester 44 which resulted in the unwanted removal of 
the benzyl groups (Appendix 8.3). Although AlCl3 is reported by others to cleave ethers and 
alkylated aromatic amines,385 debenzylation was not successful. 
 
Scheme 3-19. Debenzylation of bis-benzyl N-acyl sulfonamide treprostinil 50 to form 
desired product N-acyl sulfonamide treprostinil 21. 
Hydrogenation is widely used for debenzylation, so was conducted using hydrogen and 
palladium on carbon. There are restrictions that prohibit hydrogen storage at UCL, so it was 
not possible to use a hydrogen balloon to purge and run the reaction. One effective method to 
48 
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generate hydrogen in situ was to use purpose-designed glassware, known as “CO-ware” 
Figure 3-16.  
 
Figure 3-16. Reaction of the reductive cleavage of benzyl ethers using the two-
chamber "CO-ware" glassware. HCl = 4 M hydrochloric acid; Pd/C = palladium on 
carbon. 
The CO-ware consists of two chambers which are linked by a bridge near the top, above the 
solvent levels. In one chamber, HCl and zinc undergo reaction to form hydrogen which passes 
via the bridge to the second chamber where the hydrogenation reaction mixture is stirred. In 
our hands, reaction times for the small scale reactions were generally no longer than standard 
hydrogenation reactions although larger scale reactions required longer time periods. 
 
Figure 3-17. 1H NMR spectra of desired product N-acyl sulfonamide treprostinil 21 
following hydrogenation of the hydroxyl-protecting benzyl group. No benzyl groups are 
detected and a shift in the methine resonance shown in yellow and pink was observed. 
N-acyl sulfonamide treprostinil 21, named TRE-S, was ultimately synthesised (Scheme 3-20) 
but required protection of the hydroxyl groups. Original synthesis of N-acyl sulfonamide 
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treprostinil 21 was limited by the need to protect and deprotect both the carboxyl and hydroxyl 
groups (Shown in blue). However, a route was found to protect the hydroxyl groups without 
the need for esterification (shown in red). It also became apparent that the coupling reactions 
using methane sulfonamide were not efficient in their yields. These factors thus limited options 
for scaling up the preparation of TRE-S 21. 
 
Scheme 3-20. Scheme of the final synthesis of N-acylsulfonamide treprostinil 21 from 
treprostinil, 4 by two different methods to achieve the bis-benzylated treprostinil acid 
49. Isolated yields (labelled in blue) are reported. Yields reported in red were not 
isolated but are based on thin layer chromatography progress. i) Ethanol, sulfuric acid, 
86 ᵒC ii) Dudley reagent, magnesium oxide, trifluoromethyl benzene; iii) Lithium 
hydroxide, methanol/tetrahydrofuran’water, 18 hours; iv) carbonyldiimidazole, 
methane sulfonamide, diisopropylethylamine, dichloromethane; Palladium/carbon, 
hydrogen (zinc/HCl), ethanol. 
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Following the longer blue route in Scheme 3-20 showing the isolated yields, the total yield for 
TRE-S 21 was 11%. Negating the need to esterify by benzylating treprostinil directly to form 
intermediate 44 is thought to improve the overall yield of synthesis. No treprostinil 4 was 
detected by TLC or 1H NMR spectroscopy indicating 100% conversion, although isolation was 
not carried out. Recalculating the yield via the red route, using an optimistic yield of 100%, 
gives an overall yield of 29%. The step with the lowest yield via this route is the sulfonamide 
coupling which suggests further optimising is possible. However, the need to protect also 
contributes to the remaining losses, so a route to N- acyl sulfonamide treprostinil 21 which 
circumvents the need to protect was therefore sought. 
 
During the synthesis of treprostinil 4 , a precursor triol intermediate 51 undergoes reaction with 
the chloroacetonitrile 52 in acetone, using potassium carbonate base and butylammonium 
iodide as iodide metathesis reagent to give treprostinil 4 after nitrile hydrolysis in 
methanol/water with potassium hydroxide (Scheme 3-21). The precursor triol 51 undergoes 
alkylation at the phenolic hydroxy without undergoing reaction at either of the secondary 
hydroxyls. There is no need to protect the secondary alcohols in the precursor triol 
intermediate 51. It was hypothesised the triol precursor 51 could be used to prepare the 
treprostinil acyl sulfonamide 21. 
 
Scheme 3-21. Last steps of treprostinil synthesis taking the triol to treprostinil. 
Before triol 51 was requested from UT, an attempt was made to obtain the triol 51 from  
treprostinil 4 by aryl ether cleavage. Ethers are relatively chemically stable bonds but are also 
known to undergo cleavage when exposed to strong acid in the presence of a nucleophile. 
The resonance of oxygen’s electrons into the aromatic ring upon phenol formation was thought 
to aid the likelihood of cleavage. Model compound phenoxyacetic acid 22 was treated with 
one equivalent of hydroiodic acid in dimethyl sulfoxide on a 100 mg scale. Monitoring by TLC 
after one hour showed the spot for starting acid 22 as well as additional spots with higher Rf. 
The reaction solution was worked up by liquid extraction in ethyl acetate and analysed by 1H 
NMR spectroscopy. The spectrum revealed the presence of the methylene resonance as well 
as no shift in aromatic proton resonances, deeming the reaction unsuccessful. Improvements 
to the ether cleavage could have been made by using acidic solvent and heating the 
reaction.386 However, soon after the benzindene triol intermediate 22 was kindly donated by 
United Therapeutics. 
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Scheme 3-22. Proposed conversion of treprostinil triol precursor, 51, to TRE-S 21. 
Bromoacetyl bromide 53 (Scheme 3-24) was selected to be used in place of chloroacetonitrile 
52 to make the treprostinil acyl sulfonamide 21. Reaction of treprostinil triol 51 was first 
examined with triethylene glycol (TEG) with the intention of forming the ester. Forming the 
ester allowed for a test reaction with a primary nucleophile without the interference of 
resonance, such as that of methane sulfonamide 25. Reaction with a bromo acetyl bromide 
53 and triethylene glycol were allowed to react in the presence of 1 equivalent of triethylamine 
for 30 minutes producing bromoacetyl ester 54 as a colourless oil (yield 73 %).The reaction of 
the bromo ester 54 with the triol precursor 51 was based upon the conditions used by Kokotos 
et al,387 which required acetone reflux at 58 ᵒC in the presence of potassium carbonate for 4 
hours. The displacement of the chloride ion in the treprostinil synthesis, required the formation 
in the iodo derivitave in situ by addition of t-butylammonium iodide. Such activation was not 
required in the synthesis of the prodrug derivatives as the bromine intermediates (54 and 55) 
were employed.  
 
Scheme 3-23. Formation of prodrug precursors. Displacement of acyl bromide of 53 
with trietheylene glycol forms bromo triethyleneglycol ester 54 and bromide 
substitution with methane sulfonamide 25 forms bromo-N-acylsulfonamide 55. 
A higher Rf for the esterified triol 56 was expected, similar to the properties possessed by the 
ethyl ester treprostinil derivatives. After 4 hours TLC showed the presence of a new product 
spot (Rf = 0.58) and only a faint spot corresponding to the starting triol 51 (Rf = 0.48). Multiple 
spots were visible with Rf less than 0.17, so purification was expected to be easy by column 
chromatography. The reaction was filtered to remove potassium carbonate and the filtrate 
concentrated to afford a brown oil. Column chromatography was carried out but neither of the 
high Rf compounds were the desired TEG esterified treprostinil 56. A mobile phase with higher 
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polarity was used to elute and isolate the more polar compounds. Surprisingly, TEG ester 
treprostinil 56 was isolated as the compound with the lowest Rf. 1H NMR spectroscopy 
confirmed the presence of the methylene proton at 5.83 ppm and the presence of the methyl 
ether singlet at 3.33 ppm. A downfield shift in the resonance corresponding to the methylene 
protons of TEG originally neighbouring the hydroxyl was observed, from 3.48 to 4.28 ppm, 
upon ether formation. 
 
Scheme 3-24. Synthesis of treprostinil prodrugs (21 and 56) using triol intermediate 
51 and prodrug derivatives (54 and 55) of bromoacetyl bromide (53). 
Nucleophilic substitution at the acyl bromide 53 under basic conditions with triethylamine were 
not sufficient for the formation of bromo N-acyl sulfonamide 55. It was necessary to conduct 
the reaction in refluxing toluene in the absence of base for 5 hours then cooling on ice to 
induce crystallisation to obtain the desired bromo acyl sulfonamide 55 at a yield of  24%. 
Reaction of the desired bromo acyl sulfonamide 55 with triol 51 was not achieved using the 
mild potassium carbonate conditions used to synthesise treprostinil TEG ester 56. 
In a similar manner to the synthesis of treprostinil 4, 388 nucleophilic displacement of the halide 
was expected to be aided by the addition of an iodide phase transfer agent. The reaction was 
repeated with the addition of tetrabutylammonium iodide, but no reduction in the product spot 
nor increase in a product spot observed after 72 hours. Conditions described by Oslund et 
al.,389 employ much stronger bases, such as sodium hydride, for the substitution of bromine 
by weak or hindered nucleophiles, such as phenolic hydroxyls. Following the unsuccessful 
attempts with mild bases, sodium hydride was employed.  
The reaction between treprostinil triol 51 and bromo acyl sulfonamide 55 was completed in the 
presence of two equivalents of sodium hydride base in DMF. Since the reaction was conducted 
at a small scale (20 mg), care was taken to ensure excess NaH was not added to reduce the 
likelihood of deprotonating either of the secondary alcohols. Tracking by TLC indicated the 
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reaction was not complete after 30 minutes so additional sodium hydroxide (1.1 equivalents) 
was added until the reaction progressed to completion. The N-acyl sulfonamide treprostinil 21 
was isolated by column chromatography to afford a clear oil in 20% yield. 1H NMR 
spectroscopy confirmed the presence of a methylene carbonyl at 4.58 ppm as well as a singlet 
methyl peak at 3.36, consistent with the treprostinil-derived sulfonamide 21. 
 
Figure 3-18. 1H NMR spectrum of N-acylsulfonamide treprostinil 21, synthesised via 
the triol intermediate 51. Resonance in pink shows the methylene resonance and that 
in yellow shows the methylene resonance of the sulfonamide. 
Unlike the bromo ester 54, the bromo N-acyl sulfonamide 55 has an acidic sulfonamide proton. 
Once deprotonated, the negative charge resonates through the carboyl and sulfonyl bonds. 
This increases electron density at the bromomethyl carbon rendering it less susceptible to 
nucleophilic attack. Additionally, an extra equivalent of base is required as the sulfonamide 
proton (highlighted red in Figure 34) is the most acidic proton, so the second equivalent 
deprotonates the phenol. 
 
Figure 34. Triol 51 and bromosulfonamide 55 with their respective pKas 
The requirement of a strong base such as sodium hydride to alkylate the phenol of triol 51 with 
the alkyl bromide 55 which possesses an additional acid proton may explain why the 
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treprostinil 4 synthesis utilises a two-step approach; the first reaction of triol 51 with 
chloroacetonitrile 52, followed by hydrolysis to obtain the acid. A feasible, alternative route 
might be to obtain the acid in one step using a halo-acetic acid (Scheme 3-25). However, the 
milder, two-reaction route is preferred, suggesting that there is a downside when scaling up to 
using strong bases such as sodium hydride (NaH) in the presence of acids. Indeed, whilst 
investigating routes to a polyvalent structure (described in Appendix, Section 3) we observed 
multiple TLC spots upon treating treprostinil ethyl ester 43 with NaH, indicating there was some 
degradation. It is hypothesised that the methylene becomes deprotonated and forms a ketene 
intermediate structure of treprostinil, which may explain the low yield of the triol reaction with 
methane sulfonyl bromide. 
 
Scheme 3-25. Proposed alternative route to treprostinil 4 from triol 51 using 
chloroacetic acid. 
Treprostinil N-acyl sulfonamide 21 from both the triol 51 and treprostinil 4 methods were both 
compared. 1H NMR spectra show overlapping resonances (CDCl3) as shown in Figure 3-19. 
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Figure 3-19. Comparison of 1H NMR spectra of the two N-acyl sulfonamide treprostinil 
compounds 21 formed from treprostinil 4 (blue) and triol 51 (red). 
Treprostinil 4 and both samples of N-acyl sulfonamide treprostinil 21 were analysed by RP-
HPLC for comparison. The HPLC system used is able to detect 3 wavelengths simultaneously. 
A short wavelength of 217 nm was used to detect for compounds with higher sensitivity. A 
higher wavelength of 254 nm was used to detect for fluorescent compounds. 
The predicted increase in solubility suggests that TRE-S 21 would have a shorter retention 
time than treprostinil 4. Both N-acyl sulphonamides 21, regardless of their synthetic route 
should elute at the same time, although surprisingly this was not the case (Figure 3-20). 
Treprostinil 4 has a retention time of 19.7 minutes. Treprostinil-derived sulfonamide 21 had a 
retention time of 16.6 minutes and was present at a 70% purity as determined by relative peak 
area using 217 nm wavelength view. In comparison, the triol-derived sulfonamide 21 had fewer 
impurities and had a slightly extended retention time of 18.6 minutes.  
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Figure 3-20. HPLC traces for treprostinil 4 and the two TRE-S compounds 21; one 
derived from treprostinil 4 and the second via the triol 51. 
A possible explanation for the difference in retention times is that the samples were run several 
months apart, between which, the column had been run by multiple users with various 
compounds. A solution was made combining the two TRE-S compounds together in 
acetonitrile (0.25 mM) which was analysed by HPLC. The compounds eluted together after 18 
minutes, with no distinction between the two products. Thus, the two expected TRE-S 
compounds appear to be the same, still without the presence of treprostinil. 
 
 
Figure 3-21. Elutogram of the combined TRE-S 21 compounds. No distinction 
between the products by HPLC absorbance confirms structure similarity and indicates 
that the product of the TRE-S synthesis using treprostinil or triol, is the same. 
The accurate mass of both compounds were the same although interestingly, the triol 51-
derived acyl sulfonamide 21 was detected in the negative mode ([M-H]- 466 m/z), similar to 
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the N-acyl sulfonamide phenoxyacetic acid compound 26, whereas the treprostinil derived 
sulfonamide 21 was detected in the positive mode ([M+H]+ 468 m/z).  
Notably, all sulfonamides (except triol 51-derived N-acyl sulfonamide 21) were characterised 
as their [M-H]- ion, although the LCMS/MS detected the compounds most sensitively as their 
positive [M+H]+ ion. To investigate whether this was a result of the formic acid added to the 
LCMS/MS system, the mobile phase buffer was changed to ammonium acetate and the 
samples re-run. However, the detection was still more sensitive in positive mode.  
The N-acylsulfonamide treprostinil 21 structure derived from treprostinil 4 via the TMS 
protected intermediate isolated by HPLC during an investigation into the hydroxyl-protection 
was retrospectively compared against the 1H NMR spectra of the known N-acylsulfonamide 
structures 21. Interestingly, the methylene resonance and the proposed methyl resonances 
do not overlap with the confirmed structures of N-acylsulfonamide treprostinil 21. Although 
analysis of the TMS-derived sample was carried out in a different deuterated sample (MeOD), 
the resonances share fewer similarities that would be expected. The sample of the TMS-
derived sample could not be located so unfortunately no re-analysis could be carried out.  
 
Figure 3-22. 1H NMR spectra comparing the treprostinil 4 derived N-acylsulfonamide 
21 (Red) and the trimethylsilyl ether-derived isolated product (Blue). Neither methylene 
or methyl resonances overlap.  
In this section, among many attempts, three methods to obtain N-acylsulfonamide treprostinil 
21 were described, all with similar overall yields. Two of the methods described produce 
consistent characterisation. Derivatising treprostinil 4 via an acid and hydroxyl protection route 
and derivatising the trial intermediate, although similar yields were achieved for the two 
methods of making N-acyl sulfonamide treprostinil 21, the triol 51 method took significantly 
less time and resources. One-pot derivisation from treprostinil via the TMS-protected product 
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gave as great a yield of product 21 compared to the other two methods, despite the many side 
reactions which seemed to occur by TLC. However, there are inconsistencies with the product 
as it was not fully characterised and unfortunately post-hoc analysis was not an option. With 
two synthetic routes outlined for the synthesis, of N-acyl sulfonamide treprostinil 21, the 
compound was taken forward to investigate its biological activity.  
 
An effective pro-drug is required to be stable upon storage and when administered, which will 
degrade to release the active compound at the target site. The pro-drug should have reduced 
activity in comparison to the parent drug. Selexipag 5 had a 10-fold decrease in activity at the 
IP receptor in comparison to its metabolite, ACT-333679 6, as measured by cAMP 
generation.390 Selexipag 5 was stable when incubated in human blood plasma (although not 
in rat plasma owing to the many esterases present), but was degraded in a time-dependant 
manner when incubated in both human and rat hepatic microsomal assays.115 The stability 
and degradation of TRE-S 21 was investigated using selexipag 5 as a comparative control.  
The anti-proliferative and vasodilatory effects of prostacyclin mimetics (PMs) is established to 
be dependent on cAMP,276 although not exclusively.272 Upon binding of PMs to the IP receptor, 
a cascade of intracellular mechanisms is initiated which cause adenylate cyclase to convert 
ATP to cAMP. The stimulation of cAMP generation results in a vasodilatory, anti-proliferative 
and anti-thrombotic response.62 The dependence of the pathway on cAMP makes it an ideal 
indicator of pathway activation.391 The activity of the PMs was measured comparatively in their 
ability to stimulate cAMP generation in a stable cell line, HEK-298.  
To increase the sensitivity of comparative cAMP generation and reduce the effects of other 
receptors, cells stably transfected to over-express the IP receptor were used. Once generated, 
cAMP has a half-life of approximately 1 hour and the time course of cAMP generation with 
treprostinil has previously been carried out, showing levels to peak at between 15-30 mins in 
normal human arterial smooth muscles.276 
The concentration-dependent response of treprostinil was evaluated over the range 0.01 to 
1000 nM in HEK-293 cells exposed to the agonist for 15 mins. Intracellular cAMP levels began 
to be elevated at concentrations above 0.01 nM of treprostinil. The log concentration causing 
50% of the maximal response (log EC50) was calculated from the fit to be of -9.2, which equates 
to an EC50 value of 0.6 nM. This is very similar to the EC50 (1.9 nM) value for cAMP generation 
reported in CHO cells expressing the IP receptor,85 but 10-fold lower than that (reported EC50 
8.2 nM) in normal human pulmonary arterial smooth muscle cells.276 This may simply reflect 
the different nature of the cell systems reflect differences in the expression of the IP receptor 
and/or activity of the phosphodiesterase enzymes that break-down cAMP. In contrast to 
treprostinil, the response of TRE-S had a 30-fold lower potency at elevating cAMP compared 
to treprostinil (EC50 was 18nM), where cAMP levels did not start to become elevated until 
above the 1 nM concentration. Therapeutically, treprostinil is administered to patients to 
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achieve drug-blood concentrations between 10-40 nM. As shown in Figure 3-23, at 10nM, 
TRE-S exhibits a 11.5-fold decrease in activity compared to treprostinil, and for 100 nM, a 
1411-fold decrease. The difference in EC50 of TRE-S and its metabolite (30-fold) is greater 
than that of selexipag and ACT-333679 (15-fold difference) as measured using a similar cAMP 
assay.278  
 
 
Figure 3-23. Concentration–response relationship of intracellular cyclic AMP changes 
induced by the treprostinil pro-drug, TRE-S 21 compared with treprostinil. HEK-293 
cells, stably transfected with the human IP receptor, were grown in minimum Earle’s 
medium containing 9% serum and treated with treprostinil drugs for 15 mins over the 
concentration range of 0.01-1000nM. Cyclic AMP was extracted from cells and 
normalised to protein content. Data are presented as mean ± S.E.M. (n=4) and points 
fitted using the sigmoidal-curve fitting routine in GraphPad Prism where the Hill slope 
has been set to 1. The table gives the min (Bottom) and max (Top) and the log of the 
EC50 values for the two curves shown. 
 
The reduced potency of TRE-S 21 at the IP receptor suggests there is potential to avoid 
adverse events experienced upon administration of treprostinil 4. The prodrug degradation 
drastically effects the utility of the prodrug. To evaluate the utility of TRE-S 21 as a prodrug, 
the stability in blood plasma and its enzymatic degradation profile was assessed.  
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Scheme 3-26. Proposed degradation of TRE-S 21 to treprostinil 4 by 
carboxylesterases found in hepatic microsomes. 
Enzymatic degradation of selexipag 5 (Error! Reference source not found.) to ACT-333679 
6 metabolite was reported to occur by the action of carboxylesterases. Enzymatic activation 
of selexipag was evaluated using hepatic microsomes in vitro.392 To investigate whether 
treprostinil sulfonamide 21 was broken down in a similar manner, the same type of assay was 
used. Selexipag 5 was used as a positive control. A general microsome protocol393 was 
followed with recalculated concentrations to match that reportedly employed by Nakamura.115  
The liver is rich in metabolic enzymes and is the site of most drug metabolism so stability and 
degradation are often determined in vitro using hepatocytes.393 Enzymes responsible for drug 
degradation are stored on the endoplasmic reticulum of cells. By isolating particles of the 
endoplasmic reticulum, known as microsomes, its associated enzymes are isolated and from 
soluble enzymes in the spuernatant and retained. Using the microsomes in the presence of 
pharmaceutical compounds, offers a method to determine profiles of drug degradation and 
prodrug activation by intracellular, non-soluble enzymes. Removing the issue of cellular 
uptake, analysis of each assay requires only a quenching and protein precipitation step to 
prepare the samples for analysis by HPLC. For analysis by LCMS(/MS), buffer salts must also 
be removed. 
Microsomes are a specific fraction of homogenised hepatic cells which contain a high level of 
non-aqueously soluble enzymes. Collected from several samples of one species and pooled 
together, the fraction aims to represent the enzymatic activity of a generalised population of 
that species. Degradation of TRE-S 21 was evaluated in rat microsomes, in a similar manner 
to that reported for selexipag 5,115 owing to their known activity for the degradation of selexipag 
5 and their affordable cost and availability. Microsomes were supplied as a concentrated 
suspension with 20 mg/mL of protein. For the assay, total protein concentration was diluted to 
0.53 mg/mL. 
A nicotinamide adenine dinucleotide phosphate (NADPH)-generating system was included in 
the assay to replenish enzyme activity. Enzymes utilise NADPH as a co-factor so without the 
regeneration of NADPH, concentrations of NADPH decrease, reducing enzymatic activity. The 
enzyme glucose-6-phosphate dehydrogenase removes protons from glucose-6-phosphate, 
and in doing so, converts NADP+ into NADPH. The inclusion of this enzymatic reaction in the 
20 4 
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assay replenishes the NADPH which is consumed by enzymatic activity by the microsomes 
and thus, maintains the activity of microsomes over time. MgCl2 is also included to stimulate 
CYP activity.394 NADPH can be added directly to the system but without replenishing the 
NADPH concentration, the enzyme activity is expected to reduce over time as NADPH 
becomes depleted 
Potassium phosphate buffer (PPBS) at pH 7.4 was used to dilute the microsome solution and 
all constituents of NADPH regenerating system, except the magnesium chloride. The buffer 
concentration described by all protocols115,393–395 was 100 mM, approximately 10 times the 
concentration of buffer salts than used for isotonic cell preparations. The higher phosphate 
concentration is required to maintain CYP(3A) activity. All solutions were prepared prior to 
each assay and stored on ice prior to combining. Protocol variations exist about the order of 
addition. Most protocols indicated that following aliquoting of the microsomal suspension into 
assay vials labelled for each time point, the vials should be pre-incubated for 5 minutes. 
However, whether the NADPH-regenerating system or the study drug is added in this step 
varies between different protocols. The microsomal enzymes were expected to have some 
activity before NADPH is spent, which would affect the drug concentrations even within the 
pre-incubation period. For this reason, the NADPH-regenerating system was added in the 
preincubation step and the addition of pro-drug (TRE-S 21 or selexipag 5) marked the 
beginning of the timed incubation. Selexipag 5 was run as positive control for the 
carboxylesterases and indomethacin was run as a positive control for the PY450 enzyme, 
which served as an indicator that the microsomes were active.396 At designated time points, 
the samples were quenched by addition of ice cold organic solvent (150 µL) which precipitates 
proteins, then the sample was vortexed and centrifuged at 4 ᵒC at 14 000 g for 10 minutes to 
remove proteins and the supernatants collected. A negative control was determined for each 
concentration by addition of the quenching solution to the microsome and NADPH-
regenerating solution before the drug compound which was immediately vortexed and 
centrifuged to remove the proteins.  
Selexipag was reported to have been run in the microsome assay at 10 μM and quantified at 
10 minutes. Clearly, more time points were conducted in order to calculate a rate of 
degradation but the 10-minute starting point was a reasonable place to initiate a pilot 
microsome study. The study assay was designed to test selexipag at 10-fold above and below 
the 10 μM concentration (1 μM and 100 μM) and samples would be analysed at 5, 10 and 20 
minutes. Using these parameters, the assay was run following the protocol described by 
Ackley et al.393 A vial was prepared for each concentration and time point, which contained 
PBS (271 μL), NADPH-generating solution (18 μL) and rat microsomes (8 μL). After 5 minutes 
of preincubation, the respective concentration of selexipag was added (3 μL) to achieve a final 
concentration of 1, 10 or 100 μM. At each time point, ice cold methanol (150 μL) was added 
to the solution which was then vortexed, centrifuged and the supernatant retained (200 μL). 
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The samples were analysed by HPLC measuring UV absorbance at 217 nm using a UV 
detector and the analysing standards of selexipag and ACT-333679 (100 fm – 100 μM) 
immediately after. An isocratic mobile phase was emplyed of 55% acetonitrile/water spiked 
with 0.1% TFA over 20 minutes. Each sample was analysed in duplicate. Detectable 
absorbances were only observed for 100 μM standards and for assay samples originally 
containing 100 μM selexipag (Table 3-5). No observable absorbances were shown for lower 
concentrations.  
Table 3-5. Absorbance of selexipag were only detectable for samples containing 
100 μM of selexipag initially. A decrease in selexipag is observed, however, 
concentrations seems to rise after 20 minutes. 
Selexipag 
concentration 
100 μM 
Incubation 
time 
/minutes 
1st Analysis 2nd Analysis 
Retention 
time of 
peak 
AUC 
Retention 
time of 
peak 
AUC 
100  
5 9.4 753 9.3 807 
10 9.3 71 9.4 76.7 
20 9.3 174 9.3 173 
Without a standard curve, the concentration of selexipag cannot be determined. Providing the 
value after 5 minutes is true, a decrease in selexipag concentration is observed, although 
concentrations increase after 20 minutes. The increase in concentration sheds doubt on the 
values obtained after 10 or 20 minutes; possibly an error during the sample preparation or an 
instrumental error. 
 
Figure 3-24. Low UV absorbance of selexipag standards.(10 and 100 μM) was 
observed as analysed by HPLC using isocratic mobile phase 55% acetonitrile/water. 
At 10 μM, two absorbances are present but both at a very low absorbance. At 100 μM, 
only one peak was observed, with a different retention time which was less resolved. 
The same mobile phase was used but to be sure that selexipag was given enough 
time to elute, the analysis was run for a further 10 minutes. 
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As shown by the low absorbance of selexipag in (Figure 3-24) it appeared UV detection was 
not sensitive enough to determine the presence of any remaining prodrug in the assay 
supernatant. This was surprising considering the article reporting selexipag 5 degradation in 
microsomes used HPLC.115 The authors were contacted, who could not confirm the extinction 
coefficient of selexipag 5 but revealed that in more recent studies they had utilised LCMS/MS 
to quantify degradation. Based on the results obtained and the guidance from the authors 
LCMS/MS was pursued as a prodrug detection method. 
 
Figure 3-25. Principle of liquid chromatography tandem mass spectrometry. Following 
injection, the sample is separated by column chromatography. The eluent is ionised 
which is accelerated towards the first of the three blue quadrupole. The specified 
precursor ions (red) are identified and permitted into the fragmentation quadrupole 
where they are further fragmented and enter the third qudrupole. Product ions result 
which are detected and quantified. 
In LCMS/MS, the sample is separated into its different compounds by LC on a RP-column. 
Following separation, the separated samples are channelled to the MS which selects ions with 
the specified full ion mass. Once isolated, the mass ions are further fragmented into smaller 
ions. The most abundant ion, as well as the total mass ion, can both be used to quantify the 
amount of analyte in the sample.  
To determine the fragment ions an optimisation MS process was developed. A standard 
solution of each compound (selexipag, TRE-S and papaverine) was prepared and a full scan 
of each sample was conducted. Ions can be identified as either their positive ion, using positive 
mode, or the negative mass ion, using negative mode. Based on the acidic nature and stability 
as a negative ion, the sulfonamide compounds (selexipag 5 and TRE-S 21), were expected to 
be detected in their negative [M-H]- state. By analysis on the LCMS/MS, a more sensitive 
detection was observed using the positive ion detecting mode. 
The mass ion was identified for each drug compound; 497.01 m/z for selexipag and 467.6 m/z 
for TRE-S. Using the mass ion as the precursor ion, the sample was analysed to detect for the 
fragments produced from the precursor ion. Agilent Optimiser software was used to vary the 
collision energy and fragmentor voltage value to identify the method which produced the most 
sensitive detection of fragments. The most abundant ion (302.1 m/z for selexipag and 337.2 
m/z for TRE-S), was used to quantify the amount of compound present. Following product-ion 
identification, a multiple reaction monitoring (MRM) method was created which uses the same 
solvent system and selectively detects for the specified ions identified in the MS. 
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Once the fragments had been identified, an LC method measuring total ion count was 
determined which would identify each product peak without overlap. Gradient methods 
appeared to show considerable baseline shifts and therefore an isocratic solvent of 55% 
acetonitrile/water both spiked with 0.1% formic acid, was employed. Using the fragments ions, 
a standard concentration curve could be plotted. Whilst investigating a suitable protocol to be 
sure enzymatic activity was occurring and could be detected, initial studies only included 
selexipag 5. Therefore, a selexipag standard concentration curve was analysed and plotted 
(Figure 3-30). 
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Figure 3-26. Plot of known concentrations of selexipag standards vs. the quantity of 
selexipag-derived ions with mass 302.1 m/z, as measured by area under the curve 
(AUC) using LCMS/MS. 
Both the selexipag study115 and microsome protocol for LCMS/MS analysis393 made no 
mention of any further purification of samples, so supernatants (20 μL) were analysed directly 
by LCMS/MS. 
 
Figure 3-27. Microsome assay used to investigate rate of degradation of prodrug by 
hepatic enzymes. Nicotinamide adenine dinucleotide phosphate (NADPH) 
regenerating solution includes glucose-6-phosphate, glucose-6-phosphate 
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dehydrogense, β- nicotinamide adenine dinucleotide phosphate disodium salt, 
magnesium chloride. Samples were analysed by tandem LCMS 
The data were analysed by the amount of the 302.1 m/z  fragment ion of selexipag, which was 
converted to concentrations using the standard curve in Figure 3-26. The concentrations were 
plotted versus time for each concentration (Figure 3-28). The data for the 10 μM sample after 
5 minutes shown in Figure 3-28. A looked spurious, with a total concentration of 666 μM (60-
times greater than the concentration added). This outlying data point was removed (Figure 
3-28 B). The calculated concentration for the assay run at 1 μM was determined to be 3μM, 
three times greater concentration than the total. The concentration did not change over 20 
minutes. A decrease in selexipag was observed for the 10 μM assays between 10 and 20 
minutes. The concentrations expected for the 100 μM within the first 10 minutes was much 
lower than expected, given the reported half-life of selexipag. 
All time points for 100 μM assays were lower than the initial concentration although however, 
a lower concentration was observed after 5 minutes than expected based. An explanation for 
the detection of selexipag at greater concentrations than added into the assay, was not 
developed. 
 
Figure 3-28. Quantification of selexipag 5 in the microsomal assay over time. The 
assay was run using concentrations of selexipag 5 at 1, 10 and 100 μM over a 20-
minute period. Concentrations were determined using liquid chromatography mass 
spectroscopy/mass spectroscopy using multiple reaction monitoring searching for the 
conversion of product ion (467 →302 m/z. A) shows the concentration of selexipag 
determined in the samples. The concentration calculated for the 10 μM sample after 5 
minutes is 60 times greater than that the amount of selexipag added into the sample 
and on this scale other trends cannot ber determined. Therefore, B) shows the same 
data on a smaller scale, excluding the spuriously high concentration determined for 
the 10 μM sample after 5 minutes. 
The first assay was run as a pilot study to try to gather information such as time frame, 
concentration and whether the enzyme activity was verified. The study was limited by few time 
points and enzyme activity was still doubted. The trends shown in the data were inconsistent 
between HPLC (Table 3-5) and LCMS/MS analysis (Figure 3-28) which may have been a 
result of degradation upon freeze-thaw cycles. The source of the inconsistencies was not 
determined. Possible sources of error include; experimental error, instrumental error and lack 
of enzyme activity. The assay was repeated in duplicate and to obtain a better understanding 
of the changes in selexipag 5 concentration over time, the assay was conducted over a longer 
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time frame and a sample for the initial time point was also included. To exclude instrumental 
error upon analysis by LCMS/MS an internal standard was added to the quenching solution. 
 
Figure 3-29. Structure of papaverine 57 used as a standard to compare 
concentrations of produgs against. The structure consists of stable bonds and only the 
[M+H]+ ion forms by protonation of the nitrogen. 
To eliminate any instrumental error, a standard (papaverine 57) was added to each sample 
and a ratio between the standard and selexipag peak was calculated. Papaverine 57 (shown 
in Figure 3-29) is a common LCMS standard with a stable structure that primarily forms the 
[M+H]+ ion. Without many smaller fragments, papaverine is detected cleanly with sharp, well-
resolved resonance, minimising interference with other ions present. Before analysis, an 
optimiser was run to identify the most abundant ion for papaverine, 324.1 m/z. 
A new standard curve was ploted which quantified the ratio between the most abundant 
selexipag and most abundant papaverine ions detected in the LCMS. 
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Figure 3-30. Standard curve of selexipag 5 quantified as the area under the curve for 
the selexipag product ion (302.4 m/z) chromatogram as a ratio of the product ion 324 
of papverine. 
The assay was repeated using the same procedure over a longer time frame to better 
determine the change in selexipag 5 concentrations over time. Each sample was run in 
duplicate to identify any outlying results. Samples were quenched using methanol spiked with 
56 
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papaverine (1 ng/mL) then prepared and analysed using the same LCMS/MS method 
developed.  
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Figure 3-31. Concentrations of selexipag 5 detected in the microsomal assay. The 
assay was run at 100, 10 and 1 μM, and quenching aliquotes at time points between 
0-45 minutes. A decreasing trend was visible for 100 and 10 μM although values for 
100 μM varied. An outlying value for selexipag 5 concentration in the 1 μM microsome 
solution after 45 minutes skewed the data to show an increasing trend. For all values, 
starting selexipag 5 concentration detected were greater than the amount of selexipag 
5 introduced into the microsomal assay. 
A consistent decreasing trend was observed for the 100 μM and 10 μM assays. Variability was 
still present in the samples, particularly at the higher concentration of 100 μM. The 45-minute 
time point at 1 μM for one of the duplicates was spuriously high (41 μM) which skews the trend 
in a positive direction. The decreasing rate of concentrations was lower than expected which 
called into question the level of activity. Selexipag was run as a comparator control for the 
TRE-S which would be run when the assay method was established, but confirmation of the 
enzyme activity was not provided using selexipag. Therefore, a second positive control for 
enzyme activity was sought. 
 
Scheme 3-27. Metabolism of indomethacin 58 to its O-desmethyl derivative which is 
mediated by CYP enzymes found in hepatic microsomes. 
57 
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To be certain of enzymatic activity, a positive control for the CYP enzyme was added. 
Indomethacin 58 is a cyclooxygenase (COX) inhibitor which is rapidly metabolised to its O-
desmethyl derivative by CYP enzymes (Scheme 3-27).396,397 For this reason, indomethacin 
58 can be employed as a positive control to confirm enzyme activity in microsome assays. 
Furthermore, indomethacin 58 is detected by MS in the positive mode, similar to selexipag. 
Indomethacin 58 controls were run in parallel with selexipag with few time points. An 
optimisation protocol was run in a similar fashion to selexipag 5, TRE-S 21 and papaverine to 
identify the most abundant product ion for indomethacin, 138.9 m/z. Following collection of 
these data, it was decided that the assay would be repeated without the 100 μM concentration, 
using the assay constituent concentration described by Nakamura and colleagues for 
selexipag degradation.115 The assay was conducted using the revised concentrations of assay 
constituents, described in Table 3-6. 
Table 3-6. Comparison of the two assay protocols employed for microsome 
degradation of prodrugs. Initially, a general protocol for microsomal degradation of 
pharmaceutical agents was followed. The details of the assay utilised to report 
degradation of selexipag was considered for further degradation attempts. NADP = 
Nicotinamide adenine dinucleotide phosphate; MgCl2 = anhydrous magnesium 
chloride. 
Assay parameter Old assay115 New Assay390 
Total volume 300 μL 500 μL 
 NADP 1.3 mM 2.5 mM 
Glucose-6-phosphate 3.3 mM 25 mM 
Glucose-6-phosphate 
dehydrogenase 
0.4 U/mL 4 U/mL 
MgCl2 3.3 mM 10 mM 
Microsomes 0.53 mg/mL 0.4 mg/mL 
Although the same column is used for both HPLC and LCMS/MS the sensitivity of the mass 
spectrometer to salts, proteins and lipids is greatly increased. Accumulation of precipitated 
proteins or salts can be severely damaging to the MS system. Precipitation with acetonitrile 
only removes large proteins and not all the salts, thus, a more extensive work-up procedure 
was required.  
Liquid-liquid extraction is known to be time consuming and inaccurate, so a more practical 
method was sought. Solid phase extraction (SPE) is a simpler, yet more expensive method to 
remove salts, proteins and lipids from samples. SPE products exist specifically for the purpose 
of preparing biologically derived samples for analysis by MS. Various SPE products are 
available and we utilised one which could be utilised to remove salts and proteins using a 
syringe attachment that did not require a vacuum manifold. Oasis HLB Prime cartridges were 
employed which as advised in their brochure can prepare samples in a 3-step procedure.  
The addition of an extra step adds the potential for more inaccuracy and the work up needed 
to be verified to ensure that the drug compounds were interacting with the solid phase as 
expected. Prodrug losses in the wash step need to be minimised and the recovery from the 
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solid phase in the elution step needed to be determined. To test the efficacy and recovery of 
the SPE work-up, known concentrations of selexipag (390 nM, 6.25 µM and 100 µM) were 
prepared in water. Three samples of each concentration split were used (Figure 3-32). The 
first sample (300 µL) was analysed by LCMS/MS without any work up; a second sample (300 
µL) was filtered through the SPE cartridge; and the third sample was filtered through the 
cartridge and then rinsed with MeCN (450 µL). The samples were analysed by LCMS/MS in 
MRM mode detecting for papaverine and selexipag ions. Peak areas vs. concentrations for 
each of the three samples were plotted (Figure 3-33). A separate series of concentrations 
were prepared in PPBS to check for the removal of buffer salts. The presence of buffer salts 
would quickly be identified as precipitate would accumulate on the ion source.  
 
Figure 3-32. Verification of cartridge method to isolate selexipag solution whilst 
removing salts and lipids. 
Passing the aqueous selexipag 5 solution through the SPE cartridge resulted in a 56-88% loss 
in concentration peak area. Upon flushing through the sample with MeCN, approximately 96% 
of the sample was recovered. Samples made in PPBS were also detected at levels 
comparable to the water samples. No salt precipitate formation was visible on the ion source, 
indicating buffer salts had been removed successfully. This indicated that the SPE cartridges 
would be suitable for the work up the microsome samples without compromising the 
concentrations of the prodrug. 
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Figure 3-33. Log10 plot of the detected peak areas for selexipag concentration 
during each step of the solid phase extraction (SPE) cartridge procedure as 
detected by LCMS/MS (MRM mode = searching for 497+ ion. Selexipag 5 
concentration plotted as log10.; Blue = selexipag sample in water; Orange = 
selexipag in potassium phosphate buffer solution (PPBS); Purple = aqueous 
selexipag solution filtered through cartridge; Green = filtered through cartridge 
and then flushed with acetonitrile (MeCN). Similar concentrations are detected in 
water as in PPBS. After filtering with SPE cartridge selexipag concentration is 
reduced (purple) which is recovered by additional rinse of acetonitrile. 
In discussion with the cartridge suppliers, it was suggested that an additional step be included 
to the cartridge protocol. The suggestion was based on the mixture of aqueous solvent (PPBS) 
and organic solvent (acetonitrile) in the supernatant added to the cartridges. Having 
established that the drug interacts well with the cartridge layer and no salts are entered onto 
the column, plus the cost of each cartridge (£4 per single-use cartridge), the amended 
cartridge protocol was employed. 
Samples were assumed to contain a mixture of buffer salts, enzyme proteins and membrane 
lipids, as well as prodrug and active drug metabolite. Supernatant from the assay (500 µL) 
was immediately loaded onto the SPE cartridge by syringe. A solution of 5% methanol in 
HPLC-grade water (500 µL) was then added to wash the sample. In this step, the aqueous 
solvent should facilitate a better interaction of the drug and prodrug compounds with the solid 
phase and dissolve any salts which will be flushed through the column. Into a new vial, the 
small organic compounds were eluted from the solid phase by addition of MeCN (500 µL) 
spiked with papaverine (1 ng/µL). The filtrate from this step is retained for LCMS/MS.  
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Figure 3-34. Method employed to prepare samples for liquid chromatography mass 
spectroscopy (LCMS). At each time point, microsomal solution is quenched with 
acetonitrile (150 μL) and loaded onto the solid phase extraction (SPE) cartridge and 
the supernatant retained. Salts are flushed through with washing with 5% 
methanol/water solution (200 μL) and the supernatant retained separately. 
Hydrophobic drug components, including selexipag 5 and TRE-S 21, are eluted by 
flushing SPE cartridge with acetonitrile (200 μL). Supernatant (3) collected for analysis 
by LCMS. 
The assay was run as before only using the cartridge protocol once the microsome assay 
supernatant had been collected. The standards were treated in the manner to provide a direct 
comparison. To prevent residual salts reaching the MS ion source, solvent eluted during the 
first minute from the LC was sent to waste rather than to the MS. As all compounds are eluted 
after 1.5 minutes only residual salts were directed to waste. 
Unfortunately, the TRE-S 21 standards did not show any sensitivity significant above baseline, 
so a standard curve could not be plotted. However, the TRE-S concentrations determined in 
the samples were sensitively detected and showed a decreasing trend over time, suggesting 
first-order kinetics. When plotted against time an exponential curve is determined. 
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Figure 3-35. Quantification of TRE-S product ion 302.4 in microsomal solution at 
different time points. A shows the ion count chromatogram and B shows the integration 
of each curve plotted as a function of time. 
Surprisingly, analysis of selexipag and indomethacin in the same experiment showed 
negligible concentration even in the initial timepoints. Concentrations around baseline were 
detected for even the most abundant ions. The negligible concentrations of indomethacin and 
selexipag detected (Figure 3-36.) the data was not analysed and plotted.  
 
Figure 3-36. Total ion count spectra for samples containing A) indomethacin or B) 
selexipag. Both samples contain papaverine standard. Detection was negligible. 
The data shown in Figure 3-36 (A and B) were collected during the final weeks of experimental 
lab work and although promising data from TRE-S run in duplicate was obtained (Figure 3-35), 
the detection of selexipag 5 and indomethacin was unexpectedly insensitive (Figure 3-36). 
During discussions with our industry collaborators, United Therapeutics (UT), they confirmed 
that treprostinil sulfonamide 21 had been also synthesised, but via a different route utilising an 
unknown di-protected treprostinil. The sulfonamide degradation had been evaluated using a 
microsome assay by a contract research organisation (CRO). 
Treprostinil N-acyl sulfonamide prodrug strategy. 
165 
  
The microsome protocol used by UT was similar to both the standard protocol393 and the 
method used to report selexipag 5 degradation,115 however several minor differences were 
identified. The method employed by UT used a different system to regenerate the enzyme. 
Instead of including an enzyme system to generate NADPH, their protocol added NADPH 
directly. The end result of NADPH presence is theoretically the same so is potentially unlikely 
to feature as the underlying cause for the failed attempts. Whether the NADPH-generating 
enzyme was functioning as expected was not determined. Instead of aliquoting time points 
out, the assay used by UT was carried out in one solution and at each time point aliquots 
removed, quenched with ice cold acetonitrile. Solutions were centrifuged to pellet the proteins 
and the supernatant frozen at -80 ᵒC until analysis. There was no mention of an extraction 
procedure to remove salts, so a solvent divert method (sending the eluted solvent to waste 
initially) was probably used. It is not thought the differences in the microsome assay protocol 
described in this chapter and used by UT account for the ambiguous results shown in Figure 
3-28, Figure 3-31, Figure 3-36. The data obtained for TRE-S indicates that there was enzyme 
activity in the assay (Figure 3-35) and the recovery of sample from the SPE cartridge was 
verified so it is likely that the LCMS/MS method requires further optimisation to increase 
sensitivity. A great deal of effort was committed to optimise the microsome assay. Since UT 
have confirmed that microsomes do cause sulfonamide cleavage of TRE-S 21 to treprostinil 
4, further work to optimise the microsome assay was postponed. Furthermore, it was also 
recently revealed that UT conducted a functional assay of receptor activation, with a difference 
in specific activity values when compared to the assay used in this work. 
HPLC analysis of the TRE-S 21 sample was run to determine if treprostinil 4 or other 
degradation products were present. A slow gradient was employed to avoid any overlapping 
of the TRE-S and treprostinil peaks and a treprostinil standard was run immediately afterward 
for comparison (Figure 3-37). Analysis of treprostinil 4 standard produced an absorbance with 
retention time 19.7 minutes. The TRE-S 21 sample produced a peak after 16.8 minutes with 
no absorbances at or around 19.7 minutes which suggest the presence of treprostinil. 
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Figure 3-37. Comparison of the HPLC elutograms of the TRE-S 21 sample used in 
the cAMP assays and treprostinil 4, run consecutively. No indication that TRE-S 21 
had degraded to treprostinil 4 was presented. 
This suggested that no degradation had occurred and the 100-fold difference in activity 
between treprostinil 4 and TRE-S 21 that had been determined (Figure 3-23) is accurate. The 
variation between the company calculated activity and that reported in this work may be a 
result of the different cells used and a different assay used to determine activity. The 
decreased activity of TRE-S 21 suggested it to be an encouraging structure for prodrug 
formulation. 
 
. 
 
This work offers a method of enhancing treprostinil therapy for PAH using pro-drug approach. 
Although the N-acyl sulfonyl derivatisation of treprostinil required a 5-step synthesis, the final 
structure was achieved using two different coupling agents. We were fortunate to obtain a 
precursor intermediate which permitted the synthesis in two-steps. The samples of treprostinil 
and benzindene triol were used sparingly and a cheaper model was used where possible to 
obtain reaction conditions. 
Despite our best efforts, this study was not without limitations. In our quest to economise on 
treprostinil and benzindene triol use, small scale reactions were employed which are inherently 
associated with considerable error and difficulty in controlling reaction conditions which made 
synthesis more challenging. Work up of reactions was challenging and often resulted in loss 
of compound. Consequently, the results from the early, small-scale reactions (<20 mg) are 
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less reliable and should be interpreted with more caution. The complexity of mechanistic 
pathways in PAH and PM therapy is well appreciated and thus is yet to be fully understtod. 
Therefore, it is not possible to accurately predict whether TRE-S will reduce adverse events 
induced by other receptors in other tissues. What is demonstrated is a decrease in IP receptor 
binding for TRE-S. Despite our best and continuous attempts to conduct a microsomal assay, 
it remains to be determined whether TRE-S is metabolised to active treprostinil in a similar 
manner to selexipag. Several protocols were consulted, and methods attempted, however the 
coherent data was not obtained. 
Activity was tested and shown to reduce at the IP receptor but activity at the DP1 and EP2 
receptors was not investigated. Treprostinil is a potent agonist of both receptors and has 
recently been shown to act principally through the EP2 receptor which is upregulated in the 
PAH arteries. The IP receptor agonism is a known and established concept, whereas the role 
played by the EP2 receptor has been identified but is not yet widely recognised. Thus, the IP 
receptor agonism of TRE-S was tested first with the intention of testing other receptors should 
time permit, which it unfortunately did not. For any continuing studies on the prodrug TRE-S, 
the activity at all active receptors should be investigated. 
 
In conclusion the N-acyl sulfonamide derivative of treprostinil (TRE-S) 21 was synthesised via 
two routes. The reduced activity of the TRE-S prodrug compared to treprostinil per se, having 
a more favourable ratio than licensed prodrug Selexipag (as shown in IP-expressing HEK 
cells), suggests that the N-acyl sulfonamide is a suitable pro-drug structure for further 
investigation towards clinical development. With reduced IP receptor activity, it is hypothesised 
that the present treprostinil prodrug strategy will translate clinically to a reduction in side effects 
and adverse events experienced upon administration. The requirement for enzymatic 
degradation by enzymes specific to the liver suggests that release of TRE-S in the 
subcutaneous tissue will not lead to premature release of free treprostinil.  
An additional advantage over Selexipag, which is a pure IP-receptor agonist, is that treprostinil 
additionally and predominantly activates EP2 receptors to achieve its therapeutic effects. Thus, 
one could conceive of the combined use of Treprostinil prodrug with Selexipag, providing a 
more broadly-based, potentially synergistic pharmacotherapy of PAH, additionally allowing 
dose-sparing of Selexipag to ameliorate its gastric side effects. 
A particular advantage of the present strategy is that it potentially avoids the release of free 
treprostinil upon parenteral administration. A reduction in adverse events would therefore be 
expected in IV infusion or sc depot modes of administration. In the case of infused treprostinil 
(Remodulin), injection site pain is the most prevalent AE for treatment. Likewise, local 
injection-site reaction may have been a factor in the termination of previous attempts to 
develop a PEGylated pro-drug of treprostinil as a subcutaneous depot.138 Moreover, the 
‘delivery ratio’ of the present prodrug (wherein 75% of the prodrug substance is treprostinil) is 
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markedly better than the PEGylated form (where this was less than 4%),79 i.e. a potential 18-
fold advantage for dosing purposes (i.e. lesser, more manageable, volume of injectate or 
infusate), depending on efficiency and rate of release of free treprostinil systemically. 
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 Treprostinil as a co-monomer 
 Introduction 
Polymer conjugation has been a successful clinical strategy to extend circulation time for 
proteins that rapidly clear from the body following administration (e.g. protein conjugation to 
poly(ethylene glycol), termed PEGylation). While conjugation of low molecular drug molecules 
to polymer structures have been evaluated clinically, particularly using cytotoxic molecules in 
the treatment of cancer, they have been less successful in achieving clinical registration.  
 
Figure 4-1. Proposed concept of incorporating a drug (D) along the mainchain of a 
polymer mainchain via biodegradable elements (B). For hydrophobic drugs, 
solubilising monomers or functions are included within the design. 
The overall strategy of conjugating toxic low molecular weight drugs to polymers is to impart 
macromolecular properties to low molecular weight actives. For example, macromolecules are 
able to remain in the blood compartment to avoid systemic distribution, which can be one 
strategy to increase the maximum tolerated dose of a drug. Tissue uptake at diseased sites 
can occur by passive (e.g. enhanced permeability and retention (EPR)) or active targeting. 
Upon conjugation of a small drug molecule to a polymer, biological activity is reduced. 
Therefore, a challenge for the polymer conjugation of drugs is the need to release the intact 
drug to restore biological activity. One way to conjugate a drug to a polymer is to use the drug 
as a co-monomer to become incorporated into the polymer mainchain (Figure 4-1). 
Subcutaneous (SC) administration of treprostinil 4 is an effective prostacyclin therapy 
associated with significant site pain at the injection site which negatively impacts patients' 
quality of life.72,299 Site pain limits the maximum tolerated dose (MTD) of treprostinil reducing 
the potential for therapeutic benefit.398 As discussed in Chapter 3, polymeric derivatives of 
treprostinil 4 have been examined.79,306,338,339,399 However the major limitation with previous 
treprostinil-polymer derivatives for subcutaneous delivery has been that persistent site pain 
has not be alleviated. Conjugation of a drug to a polymer often reduces the activity and toxicity 
of a drug. Pain is likely the result of either free treprostinil 4 in the preparation or premature 
release of treprostinil within the hypodermis prior to diffusion into circulation. An improved 
strategy would be to design a polymeric pro-drug with either a faster diffusion rate (smaller 
polymeric structure) or a slower drug release rate (more stable or site-specific conjugation 
bond).  
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As a potential co-monomer, treprostinil 4 possesses two secondary alcohols and one 
carboxylic acid. Acid degradable elements were limited to these moieties if treprostinil 4 was 
to be used without further derivatisation. The water solubility of treprostinil is influenced by the 
acid group which is deprotonated at physiological pH (>10 mg/mL). Therefore, conjugation 
through the treprostinil acid could potentially compromise solubility of oligomers during 
polymer degradation. Acid labile, biomedical degradable polymers include poly(ortho esters) 
and polyesters, although these polymers have been investigated for implant applications 
rather than as water-soluble polymers for drug conjugation. 
Biomedical polyesters are typically used for implants (e.g. microsphere or devices fabricated 
from poly lactic-co-glycolic acid (PLGA)) rather than for soluble applications such as for drug-
polymer conjugation as described here. Previous treprostinil-polymer conjugations have 
utilised ester bonds which are enzymatically labile by the ubiquitous esterases in the body. 
This results in non-specific conjugate degradation. Furthermore, depending on co-monomer 
composition, if both hydroxyl groups were to participate in a polymerisation, esterification of 
treprostinil into a polymer mainchain could result in a hyperbranched structure. Such a 
structure would have the advantage of reduced viscosity, however structural heterogeneity 
would be high and maintaining solubility could be challenging. Although no difference in the 
reactivity between the hydroxyls was observed from the hydroxyl protection reactions 
(Chapter 3), it is possible that in a polymerisation reaction, one hydroxyl group might be 
favoured requiring relatively harsh conditions or coupling reagents to give polymeric material. 
During chronic inflammation in pulmonary tissue of the PAH lung, the environment becomes 
acidic as a result of lactic acidosis which occurs in the hypoxic tissues.251 Therefore, a polymer-
drug strategy could be applied to release treprostinil in the diseased lung tissue. Reduced 
toxicity upon subcutaneous administration and through systemic exposure of the drug could 
potentially be achieved.  
Drug-linkers were described in Chapter 1, although not all are suitable as the biodegradable 
element within a polymer backbone. For polymerisation, a biodegradable element must 
possess characteristics outlined in Table 4-1. In addition to the limitations described above, 
polyesters as water soluble polymers may not be sensitive enough to the hydrolytic conditions 
at mildly acidic pH that can exist in some diseased tissues. Poly(ortho esters) require highly 
anhydrous synthetic conditions using hydrolytically labile and often chemically complex cyclic 
monomers.400  
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Table 4-1. Criteria for conjugation linkers 
Requirements of polymer conjugation bond 
Must facilitate incorporation of treprostinil via the mainchain in a linear polymer 
Must be sensitive to acid hydrolysis 
Must be stable at physiological pH 
Must be soluble or facilitate incorporation of soluble monomers 
Must not require specialised equipment for synthesis.  
Acetal bonds undergo hydrolysis in acidic environments and remain broadly stable at 
physiological pH. Water-soluble polyacetal co-polymers derived from drug monomers have 
been studied (Table 4-2).401,402 Although they are hydrolytic, the dry conditions required for 
formation are less stringent than that of poly(ortho esters). Polyacetals are more simple 
molecules to make than poly(ortho esters) as they have two oxygens at the hydrolytically labile 
carbon instead of 3 oxygens that are present in poly(ortho esters). Polyacetal structures are 
described which possess drug monomers in the form of diols as well as solubilising diol 
monomers which under reaction with divinyl ether compounds form a tert-polymer (Scheme 
4-6).401,402 Smaller polymers are isolated when drug monomers are included than without. 
Polyacetals are acid labile and display a pH dependent degradation profile that correlates with 
decreasing pH. 
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Table 4-2. Mainchain polyacetal structures reported in the literature which utilise 
diol drug compounds as co-monomers. PEG = poly(ethylene glycol). 
No
. 
Polyacetal structures in the literature Description 
Re
f 
 
 
Mainchain 
incorporation of 
diethylstilboestrol 
(DES) in  
poly(PEG-DES 
acetal) 
402 
 
 
Mainchain 
incorporation of 
methylhydroquion
e into PEG 
polyacetal 
401 
 
 
Pendantly 
conjugated 
Doxorubicin to 
poly(PEG acetal) 
mainchain 
403 
 
 
Polyacetal of DES  402 
Polyacetals can be prepared by the acid catalysed condensation of a diol and aldehyde such 
as acetaldehyde 63 (Scheme 4-1). A mole of water by-product is formed which must be 
removed to achieve a high degree of polymerisation and avoid acetal degradation. Water can 
be removed by distillation, but the high boiling point limits the choice of solvent used and 
makes removal challenging. 
 
Scheme 4-1. Polyacetal formation by condensation reaction between aldehyde and diol 
which forms water as a by-product. To achieve a high degree of polymerisation, the water 
must be removed by distillation of water. 
Acetal exchange reactions can be conducted using pre-formed acetals derived from a low 
molecular weight alcohols (eg. methanol) which have a lower boiling point (Scheme 4-2). The 
acid catalysed reaction is an equilibrium, so to drive the reaction and avoid the reverse 
58 
60 
59 
61 
62 
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degradation, anhydrous conditions are employed and the alcohol is removed by distillation as 
the polymer form formation. Without complete removal of the hydroxyl condensation product, 
acetal degradation makes reproducibility of the polymer product challenging. 
 
Scheme 4-2. Polyacetal formation with pre-made acetal structures, displacing 
methanol. The methanol by product must be removed from the reaction mixture by 
distillation to drive polymerisation. 
In the 1980s, Heller devised an alternative method to form acetals without forming a by-product 
by the reaction of a alcohol and vinyl ether (Scheme 4-4).404 Conjugation is acid catalysed 
which occurs presumably by protonation of the vinyl ether allowing hydroxy addition to form 
the acetal without generation of a hydroxylic by-product that must be removed.  
 
Scheme 4-3. Mechanism for acetal formation from the acid catalysed reaction of a 
vinyl ether with an alcohol. 
The formation of polyacetals can be conducted using bis-functional monomers; containing an 
alcohol and vinyl ether, known as an A-B monomer (Scheme 4-4). Since each monomer 
possesses a 1:1 ratio of each polyacetal precursor moiety, addition of any number of A-B 
monomers in an acidic, anhydrous environment will result in polyacetal formation. Limitations 
of this method involve synthesising a highly pure monomer and preventing spontaneous 
polymerisation during work-up and storage. Alternatively, two monomers can be employed; 
one containing two hydroxyls, and one containing the two vinyl ethers (Scheme 4-5). The 
structures are described as A-A and B-B monomers. 
 
Scheme 4-4. Mechanism for polyacetal formation from the acid catalysed 
polymerisation of an A-B type monomer with both vinyl ether and hydroxyl 
functionalities. Provided the monomer is pure and anhydrous reaction conditions are 
employed, polymerisation would be expected to occur in the presence of an acid 
catalyst. 
A potential limitation of using vinyl ether-based monomers to prepare polyacetals is the need 
to avoid the presence of water in the reaction. The presence of water at acidic pH can 
hydrolyse vinyl ethers to an alcohol. Loss of stoichiometric equivalence would result in dead 
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chain ends to terminate polymer growth. Additionally, although the polymerisation is catalysed 
by acid, the presence of water in an acidic environment also causes acetal degradation in situ. 
Thus, despite successful polyacetal formation, if water is present in the polymerisation 
reaction, acetal degradation can occur before it is possible to isolate the polymer. 
 
Scheme 4-5. The formation of a polyacetal by step growth polymerisation using an A-
A and B-B monomers. One monomer has two vinyl ethers and the other monomer has 
two hydroxyl moieties. No by-products are produced during polymerisation, but the 
monomers must be pure and added in exact 1:1 stoichiometry to achieve a high 
degree of polymerisation. 
Since polyacetal formation is a step polymerisation reaction, it is critical to maintain a 1:1 
stoichiometry if A-A and B-B monomer system is being used. As monomers form dimers and 
then oligomers and eventually polymer chains, the number of reactive end groups decreases. 
If a 1:1 monomer stoichiometry is not maintained, then polymer growth will be inhibited. 
To improve solubility, many polyacetals previously described include PEG diol as an A-A 
monomer.402,403,405 Low and moderate molecular weight poly(ethylene glycol) (PEG) diols (400 
to 3400 Da) have been used as a co-monomers for making water-soluble polyacetals.402,403,405 
Although many monomeric diols possess solubilising properties, PEG is a water soluble non-
ionic diol which is generally, but not always,192,406 considered non-toxic and biocompatible, 
especially at molecular weights above ~400 Da.407 Many PEG derived molecules have been 
used as excipients in widely used parenteral, oral and topical healthcare products.167 PEG is 
also utilised clinically in polymer protein conjugates408–410 and PEG toxicity has been 
extensively evaluated.168,411  
PEG molecular weight is often chosen to be large enough to reduce number of acetal bonds 
and therefore the number of aldehyde molecules released upon degradation, but also small 
enough to facilitate a reasonable amount of drug loading. 
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Scheme 4-6. Synthesis of polyacetal 59 containing diethylstiboestrol 66 (DES). 
Poly(ethylene glycol)3400 65 was employed as a co-monomer to aid solubility of 
hydrophobic DES and the polymerisation was conducted in the presence of triethylene 
glycol divinyl ether 64 under acidic conditions using para-toluene sulfonic acid (pTSA). 
Use of PEG diol macromonomers requires consideration of the polydispersity of PEG, which 
is often narrow, but not homogenous. The preparation of monodisperse, discrete PEG 
molecules of low–molecular weight is challenging thus, they are expensive to purchase. If the 
PEG is not mono-dispersed, then maintaining 1:1 stoichiometry from the outset of the 
polymerisation is difficult. Diol and divinyl ether monomers must be pure and anhydrous, 
otherwise polyacetal formation can be difficult to reproduce.  
Once a drug polymer is localised in the tissue, release of the drug is required. Degradation of 
acetal bonds is achieved by acid hydrolysis. The pH-dependent degradation make polyacetals 
an attractive delivery system for drug release in acidic environments such as chronically 
inflamed tissues. Involving the degradable element in the mainchain of a drug polymer allows 
for fast clearance of monomers once the drug has been released which avoids issues of 
polymer accumulation in the disease tissue.  
Hypothesis 
Owing to the two secondary alcohols present in treprostinil 4 it was reasoned that treprostinil 
could be incorporated into a polyacetal along the mainchain to overcome the limitations of 
continuous dosing and site pain associated with subcutaneous. An acetal structure would 
hopefully maintain an acceptable rate of diffusion from the hypodermis into circulation 
exhibiting a slow enough rate of degradation at physiological pH. If treprostinil forms part of 
the mainchain of an oligomeric (or polymeric) acetal, little activity from the bound treprostinil 
is expected, so such a structure would theoretically reduce site pain. 
58 
63 
64 
65 
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Scheme 4-7. The proposed ter-polymerisation of treprostinil 4 and poly(ethylene 
glycol)3400 (65) as A-A monomer and triethylene glycol divinyl ether (64) as the B-B 
monomer. The step growth polymerisation product 67 was expected to incorporate 
treprostinil in the main chain via acid-degradable acetal bonds. 
To prepare a treprostinil 4 containing polyacetal structure with a viscosity suitable for injection, 
large molecular weight polymers are not desirable. To minimise the possibility of hydrolysis in 
the subcutaneous compartment, a high enough rate of diffusion from the subcutaneous tissue 
into circulation is required. Therefore, small oligomeric polyacetals were sought.  
To begin to determine the potential of an acetal treprostinil macromolecule the following aims 
were: 
• To use treprostinil 4 as a co-monomer by utilising the secondary alcohols to prepare 
a polyacetal copolymer with treprostinil in the mainchain.  
• To investigate and compare the degradation profiles of a treprostinil polyacetal at 
physiological and acidic pH values. 
 Results and Discussion  
To overcome the activity of treprostinil at the site of subcutaneous infusion, it was 
hypothesised that a soluble drug conjugate of treprostinil 4 which could diffuse into the blood 
stream would reduce pain. Poly- or oligoacetals which incorporate treprostinil 4 into the 
mainchain can undergo degradation in an acidic environment such as what may exist in the 
inflamed tissue of the PAH lung251,412,413 to release treprostinil 4. A common synthetic route to 
prepare drug containing acetal macromolecules is to allow the diol containing drug to act as a 
co-monomer with a water solubilising PEG3400 65 and triethylene glycoldivinyl ether 64 in the 
presence of an acid catalyst. In this chapter, methods to link treprostinil 4 to an acetal 
macromolecule were explored. The intended product from the acetal polymerisation with 
treprostinil was poly(PEG-treprostinil acetal) 67 (shown in Figure 4-2). 
4 
66 
63 64 
Treprostinil as a co-monomer 
177 
  
 
Figure 4-2. Proposed structure of the expected polymerisation product, 
polyacetal(PEG-Trep) 67. 
In the presence of a diol acting as an A-A monomer and a divinyl ether acting as a B-B 
monomer, polyacetal formation can result via a step-polymerisation mechanism (Scheme 
4-10). Inclusion of treprostinil 4 as a diol A-A monomer offers the opportunity for inclusion into 
an acetal oligomer or polymer by reaction with a divinyl ether B-B monomer. Addition of each 
monomer in a 1:1 ratio will result in a homopolymer (Scheme 4-8), which often results in 
reduced solubility.402 Furthermore, with small oligomers forming early on in the step 
polymerisation, cyclisation products are possible (Scheme 4-9). Cyclisation is less of a 
problem when longer monomers are included in the synthesis at the two termini at each end 
of the monomer are less likely to interact. Therefore, additional water-soluble diols such as 
PEG macromonomers are included as a co-monomer. 
 
Scheme 4-8. Possible polymerisation product 68 using treprostinil as the A-A 
monomer and triethylene glycol divinyl ether 64 as the B-B monomer. Such drug 
polymers often exhibit poor polymerisation.402 
The reactivities of the two secondary hydroxyls in treprostinil 4 appear to be poor. As discussed 
in Chapter 3 in the context of hydroxyl protection, the treprostinil hydroxyls were weakly 
nucleophilic in SN2 displacement reactions of benzyl bromide in mild basic conditions. A similar 
result was observed when attempting to benzylate the hydroxyls of treprostinil ethyl ester by 
the triflic acid catalysed nucleophilic attack of benzyl-2,2,2-trichloroacetimidate 44 (BTCA). 
Attempts to achieve the protected hydroxyls were more successful when the acid was 
protected, although treprostinil acid 4 was successfully benzylated when the highly reactive 
66 
63 
4 
67 
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Dudley reagent was employed in neutral conditions (Chapter 3). It was anticipated that the 
reactivity of the treprostinil hydroxyls could differ from a primary alcohol derived from PEG in 
the formation of an acetal macromolecule containing treprostinil 4 in the mainchain such as 
the proposed structure 67. 
Whilst the rate of acetal formation at the PEG termini was expected to be fast, the rate of 
acetal formation at the treprostinil hydroxyl termini was expected to be relatively slower. With 
differing rates of acetal formation, it was anticipated that the rates could be manipulated by 
stepwise addition of the two diol monomers; treprostinil and PEG3400. One strategy is to add 
the treprostinil monomers and divinyl ether monomers together to form bis-functional 
treprostinil-vinyl ether intermediates to which PEG can later be added. However, the 
intermediate dimers, such as 69 possess the potential to cyclise (Scheme 4-9). Without any 
evidence to indicate the relative differences in rate of acetal formation, the preliminary reaction 
was carried out by simultaneous addition of treprostinil and PEG. 
 
Scheme 4-9. Possible cyclisation of reactive acetal dimer formed as an intermediate 
when pre-forming treprostinil reactive monomers for polymerisation by addition of 
PEG. The cyclisation product is non-reactive and less likely to form when longer chain 
monomers are present as the likelihood of the vinyl ether and hydroxyl moieties of the 
same molecule reacting is reduced. 
PEG3400 65 was chosen as the solubilising diol macro co-monomer. The number of acetal 
bonds in the polymer should be low owing to the release of acetaldehyde 63 upon degradation. 
Unnecessary acetal bonds, which serve only to link solubilising PEG monomers together, can 
be avoided by using longer PEG chains. Using PEG3400 65 in a 1:1 molar ratio with treprostinil 
4, theoretically reduces the possibility of two PEG chains neighbouring each other and 
achieves a treprostinil 4 percentage incorporation of 9%, which is a similar drug loading to 
other drug acetals.402 Guided by work previously reported by Vincent and colleaugues, 
triethylene glycol divinyl ether 64 (TEGDVE) was utilised as the divinyl monomer. 401–403,414 In 
addition to being hydrolytically labile, vinyl ethers are susceptible to homolytic fission when 
exposed to UV radiation, so light sensitive conditions were employed.  
An additional challenge in the formation of a treprostinil-containing polyacetal is the presence 
of the treprostinil acid moiety. Although several compounds have been linked to a polyacetal 
(Table 4-2) either within the mainchain or in a pendant fashion, none have possessed a free 
acid moiety. Acetals bonds are degraded in the presence of acid and water so to prevent self-
degradation by the treprostinil acid, scrupulous anhydrous conditions must be employed, and 
neutralisation is required to isolate the polymer as the carboxylate salt. 
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Polymerisation by acetal formation between diols and divinyl ethers occurs by a step growth 
polymerisation mechanism (Scheme 4-10). Step growth polymerisations rapidly consume 
monomer to form dimers which then undergo reaction to form oligomers that grow in a step 
wise fashion to form polymeric material. Typically, as the polymerisation progresses, the 
viscosity increases, and the number of chain ends decreases. The fast rate of monomer 
consumption in addition to the slow rate of larger polymer formation make tracking the reaction 
progression by monomer consumption irrelevant. 
 
Scheme 4-10. Possible outcomes of polyacetal formation during step-growth 
polymerisation of A-A divinyl ether and B-B diol monomers. Hydrolysis of the vinyl 
ether moieties results in dead chain ends and produces acetaldehyde 63 as by-
product. For complete polymerisation, the ratio of vinyl ether to hydroxyl moieties must 
equal 1:1. Imprecise stoichiometry of the monomers will result in dead chain ends and 
prevent chain growth. 
Possible side reactions include the cyclisation of small intermediate oligomers, which is most 
likely with smaller chains. High concentration of reagents in the reaction solution with 
continuous stirring can prevent intramolecular reactions occurring. To prevent the formation of 
dead-chain ends by vinyl ether hydrolysis, the acetal polymerisation reactions were carried 
out in anhydrous conditions removing traces of water from PEG3400 65 and hydrated pTSA by 
azeotropic distillation with toluene using Dean-Stark apparatus (Figure 4-3).  
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Figure 4-3. Image of the Dean-Stark apparatus used to dry acid and PEG3400 before 
polymerisation. 
After distillation of toluene, the Dean-Stark apparatus was removed and the reaction solution, 
containing PEG3400 65, treprostinil derivative (when used) and pTSA, was dissolved in 
anhydrous tetrahydofuran (THF) and the TEGDVE 64 was added slowly. When polymerisation 
results, the solution can become viscous and in the case of high molecular weight 
polymerisation, a gel-like solid is formed. Excess solvent is sometimes required to keep the 
reaction solution stirred. For the treprostinil 4 and treprostinil ethyl ester 43 containing 
polymers, a cloudiness was observed after 2-3 hours. Acid was neutralised by addition of 
triethylamine and polymers were isolated by precipitation into hexane. All monomers and 
expected products are insoluble in hexane so its choice as a precipitation solvent collects all 
components from the reaction mixture. Hexane precipitation does not offer the opportunity for 
reaction purification or removal of by-products, such as the catalytic acid salt. However, it does 
provide information on the whole reaction mixture, so following previous protocols,402,403,405 
polymerisation reaction mixtures were precipitated into hexane. Once collected under reduced 
pressure the polymers were dried under vacuum. To reduce the chance of degradation during 
storage, all polymerisation products were neutralised during work up, dried and stored at -20 
°C. 
After dying in vacuum, the isolated products were characterised by 1H NMR to determine the 
degree of acetal formation and in the case of drug polymers, the percentage of treprostinil 
incorporation. Deuterated water, with potassium carbonate to prevent degradation, was used 
as a solvent for NMR spectroscopy. Gel permeation chromatography (GPC) was used to 
estimate the polyacetal molecular weight characteristics by measuring refractive index. The 
weight distribution, known as the polydispersity index (PDI) is calculated as a ratio between 
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weight average molecular weight and the number average molecular weight, Mw/Mn. A value 
closer to one indicates uniformity of the molecular weight. Molecular weight characteristics 
were estimated by GPC using poly(methyl methacrylate) (PMMA) calibrants. 
Poly(PEG acetal) 
Anticipating lower reactivity of the treprostinil hydroxyls compared to the PEG hydroxyls, 
poly(PEG acetal) 70 was first synthesised to be certain that the conditions described in the 
literature resulted in polyacetal formation (Scheme 4-11).  
 
Scheme 4-11. Proposed polyacetal 70 formation by reaction between PEG3400 65 with 
triethylene glycol divinyl ether 64 in the presence of para-toluene sulfonic acid (pTSA).  
Polymerisation of PEG3400 65 with TEGDVE 64 to form poly(PEG acetal) 70 (Scheme 4-12) 
was carried out on a 3 g scale. Analysis by 1H NMR spectroscopy (Figure 4-4) shows the 
acetal methine and methylene resonances in a 1:3 ratio; a quartet at 4.77 ppm integrating to 
2 protons (highlighted in pink), and a doublet at 1.25 ppm integrating to 6 protons (highlighted 
in green). The PEG proton resonances between 3.45-3.74 ppm have a combined integration 
of 340 protons. Each PEG chain has an average of 77 repeat units, each with 4 methylene 
resonance thus 308 protons. Each TEGDVE monomer has 3 ethylene glycol repeat units so 
a total of 12 methylene resonance. The total expected number of protons is 320 and the total 
seen in the 1H NMR spectrum is 340. Comparing the ratio between one PEG chains to every 
two acetal bonds, indicates PEG was fully incorporated into a polyacetal mainchain.  
 
Figure 4-4. 1H NMR spectra of Poly(PEG acetal) 70. The acetal resonances are 
detected in the expected 1:3 ratio between the methine (highlighted in pink) and the 
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methyl resonance (highlighted in green). The ratio of acetal resonances to PEG 
resonances indicate a high degree of PEG incorporation into the polycetal mainchain. 
Poly(PEG acetal) 70 was analysed by GPC running DMF with 5 mM NH4BF4 additive, and the 
elutogram (Figure 4-5) estimated a weight average molecular weight (Mw) of 48 kDa 
(compared to polymethyl methacrylate (PMMA) standards) with a polydispersity index (PDI) 
of 2.0. A Mw of 48 kDa is consistent with a degree of polymerisation of 13 PEG 65 units. The 
1H-NMR and GPC data gave confidence that polyacetal formation with treprostinil 4 as co-
monomer could occur. 
 
Figure 4-5. Gel permeation chromatography elutogram of poly(PEG acetal) 70 
displaying a molecular weight of 48 kDa (PDI = 2.0). The GPC was conducted in 
DMF using PMMA calibrants at 70 °C. 
Oligo(PEG-treprostinil acetal) 
A 1:1 molar ratio of treprostinil 4 to PEG3400 65 was used to prepare the treprostinil polyacetal 
67 (Scheme 4-12). TEGDVE 64 was added dropwise to the dry THF solution of acidified diols 
(65 and 4) over 5 minutes and left to stir while shielding from light. The viscosity of the solution 
increased to form a gel-like solid consistent with polyacetalisation having occurred. The 
polymer was isolated after 3 hours by first adding more THF to the solution. Erroneously the 
neutralisation of the reaction mixture was conducted after precipitation into hexane had been 
initiated. Therefore, the neutralisation occurred during the precipitation, by addition of 
triethylamine (5 equivalents) to the remaining polymer solution and a further 2 equivalents to 
the hexane mixture. The precipitate was collected and dried. 
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Scheme 4-12. Proposed acetal forming reaction between triethylene glycol divinyl 
ether 64 and diols; poly(ethylene)glycol3400 65 and treprostinil 4. Based on previous 
studies using diol drugs,401–403,405,415 the poly(PEG-Treprostinil acetal) 67 was 
expected. pTSA = para-toluene sulfonic acid. 
1H-NMR can be used for end-group analysis for relatively low molecular weight polymers. 1H-
NMR can also provide an estimate of the relative incorporation of monomers in a co-polymer. 
Initial analysis of the 1 H NMR was carried out using phase and baseline correction functions 
within the analysis software (Figure 4-6) to obtain better resolution between the acetal methine 
(highlighted blue in Figure 4-7) and the water resonance. This was achieved using phase 
correction which skewed the baseline (Figure 4-6). The spectrum indicated a ratio of 1:2 for 
one aromatic treprostinil and acetal methine proton, which suggested treprostinil 4 had been 
incorporated as predicted into the oligoacetal macromolecular mainchain. On this basis, 
degradation assays were conducted without further purification.  
Only upon re-analysis of the 1H NMR data during the write up, did it become apparent that 
using the software analysis correction functions provided an inaccurate insight into the reaction 
success. Using the integrations calculated from Figure 4-6, a ratio of 2:14 was found for the 
acetal methine and methyl peaks, respectively. The acetal resonances cannot exist in a ratio 
other than 1:3. Thus, it was assumed that the conclusion of full treprostinil 4 incorporation into 
the main chain was not an accurate interpretation of the true polymerisation product. Using 
this insight, the raw 1H NMR data was re-analysed without using phase correction functions. 
However, by this point the degradation assays were completed with impure samples. Without 
time or sample to repeat the assays, the data obtained originally was retrospectively analysed 
to account for the updated structure analysis.  
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Figure 4-6. 1H NMR spectrum of the product obtained from the attempted polyacetal 
polymerisation with poly(ethylene glycol)3400 65, triethenylene glycol divinyl ether 64 
and treprostinil 4. To distinguish between the acetal methine proton peak (highlighted 
in blue), phase correction functions within the Mestrenova software were employed. 
This indicated a 1:2 ratio between treprostinil 4 and acetal groups. However, this 
skewed the integration of the acetal methine (blue) and methylene (yellow) resonances 
away from the possible 1:3 ratio. Therefore, this spectrum is not an accurate 
representation of the relative proton environments in the isolated product. 
Similar to that of the poly(PEG acetal) 70, the 1H NMR spectra for the polymerisation product, 
expected to be poly(PEG-treprostinil acetal) 67 showed the presence of a doublet at 1.25 ppm 
corresponding to the methyl of the acetal (highlighted in orange) and a quartet corresponding 
to the neighbouring lone acetal proton at 4.78 ppm (highlighted in blue). Treprostinil 4 
resonances were observed at their expected chemical shifts but owing to the overlap of PEG 
resonances no shift could be observed for the methine protons (highlighted red) on the 
hydroxyl carbons expected to have undergone reaction.  
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Figure 4-7. 1H NMR spectrum of oligo(PEG-Treprostinil acetal) 71 in D2O formed from 
polymerisation reaction. Acetal methine (blue) and methyl (orange) resonances are 
present in the expected ratio of 1:3. The p-toluene sulfonic acid (pink and purple) is 
present in equal ratio to the tritheylamine resonances (green and yellow) indicating 
neutralistaion. Although treprostinil resonances are present, the diagnostic methine 
resonances (red) are located under the PEG resonance at 3.5 ppm. 
The ratio of acetal methine:methyl resonances fit the expected ratio of 1:3 although the 
resolution is less clear than the spectrum for poly(PEG acetal) 70 (Figure 4-4). Notably, the 
acetal resonance of treprostinil acetal (highlighted in blue, in Figure 4-7) is less distinguished 
from the water peak, which makes integration less accurate. The ratio of integration between 
the acetal methine resonance and an aromatic doublet (6.7 ppm) resonance of treprostinil is 
1:5, which can occur when two PEG groups are present in a repeat unit. As PEG3400 65 has 
been shown to undergo acetal formation (polyacetal 70), and the treprostinil hydroxyls 
probably possess reduced reactivity compared to the PEG 65 hydroxyls. Therefore, it is 
possible that the PEG 65 rapidly formed acetal bonds with the TEGDVE 64 to form oligo(PEG 
acetal) chains which then react with treprostinil 4 at the oligomer terminus (Figure 4-8). With 
a treprostinil at the terminus, two PEG chains and five total acetal bonds, three vinyl ethers 
would be required. Thus, ending the oligomer with the reactive vinyl ether (Figure 4-8). Vinyl 
ethers are highly reactive so are unlikely to remain intact in the presence of the PEG 65 primary 
alcohols. Therefore, a terminal vinyl ether suggests that it possesses a dead chain end. 
However, no acetal, or aldehyde resonance was detected by 1H NMR, although it might be 
expected that if vinyl ether degradation had occurred, the acetaldehyde 63 was removed 
during isolation.  
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Figure 4-8. Formation of the proposed structure of polymerisation product based on 
the ratio of one aromatic treprostinil 4 peak to 5 acetal methine resonances visible in 
the 1H NMR spectrum. With 5 acetal bonds, the sequence ends in a triethylene glycol 
divinylether monomer 64. However, neither the vinyl ether proton peaks or the peaks 
corresponding to the degradation product, acetaldehyde 63 were visible, which lead 
to the conclusion that this was not the structure of the product isolated. 
The lack of terminal vinyl ether resonances visible in the 1H NMR spectrum suggests that 
perhaps two treprostinil 4 groups are present per oligomer at each terminus, with four PEG 
chains and ten acetals in total (Figure 4-9). An oligomer possessing treprostinil 4, PEG 65 
and TEGDVE 64 with ratio 1:2:3 (Figure 4-8) would have an expected Mw of 7.4 kDa, and an 
oligomer 71 with double the PEG and treprostinil groups (Figure 4-9) would possess a Mw of 
15 kDa.  
 
Figure 4-9. Proposed structure of the isolated product from the polymerisation reaction 
using treprostinil 4 as a co-monomer. Treprostinil 4 end groups are likely as their 
presence reduced the degree of acetal formation expected. The ratio of treprostinil 4, 
PEG 65 resonances indicates 5 acetal bond which would leave a terminal vinyl ether, 
which is not observed. Therefore, the structure must possess treprostinil at each 
terminus in oligo(PEG-treprostinil acetal) 71, which is supported by the Mw of 17 kDa 
estimated by gel permeation chromatography. 
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The GPC of oligoacetal 71 (Figure 4-10) estimated a modest Mw of 17 kDa (based on PMMA 
calibrants), supporting the 1H NMR interpretation of a bis-treprostinil oligomer 71. The Mw is 
considerably less than the Mw 43 kDa measured for poly(PEG-DES acetal) 59,402 implying 
treprostinil is a less efficient monomer than DES. While the PDI of oligoacetal 71 at 1.8 is 
comparable to other poly(PEG-drug acetals)402,403,405 the GPC displays several multiple peaks, 
suggesting many oligomeric species are present.  
 
Figure 4-10. Gel permeation chromatography elutogram of poly(PEG-treprostinil 
acetal) 71 displaying a molecular weight of 17 kDa (PDI = 1.8). The GPC was 
conducted in DMF using PMMA calibrants at 70 °C. The numerous peaks indicate a 
heterogeneous product. 
Based upon the predicted oligo(PEG-treprostinil acetal) 71, the theoretical inclusion of 
treprostinil 4 is 5% wttreprostinil/wtpolymer. The expected polyacetal 67 included treprostinil 4 within 
the mainchain with a 1:1:2 ratio of treprostinil, PEG and TEG, respectively. Theoretical 
inclusion of treprostinil 4 based upon full polymerisation would be 9%. 
Determination of the oligomer structure does not account for all the PEG protons detectable 
in the 1H NMR spectra.  
Total TEG/PEG protons in the oligo(PEG-trep acetal):  
= ((77 PEG repeat units x 4 protons per repeat unit) x 4 PEGs per oligomer) + (12 
TEG protons x 5 TEGs in the oligomer)  
= 1232 TEG/PEG protons 
Total PEG protons in spectra = 2818 protons 
Remaining PEG protons = 21818 – 1232 = 1586 protons 
 protons per monomer = (1586/4)/77 = ~5 PEG chains worth remaining. 
Mass % of soluble treprostinil 4 in a sample 
 = (390.5 × 2)/ [(390.5 × 2) + (3400 × 9) + (202.25 × 5) + 172.2 + 101.19 
 = 781 / (781 + 30600 + 1011.25 + 172.2 + 101.19) 
 = 2.4% wttreprostinil/wtsample. 
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The conclusion that treprostinil 4 incorporation is limited to one or two treprostinil compounds 
per oligomer, in the context of a successful polymerisation of PEG, may suggest poor 
dissolution of the oligomer 71 during the reaction. Whilst not an issue in the formation of 
polyacetal 70, the reaction solution for poly(PEG-treprostinil acetal) 67 formed a highly viscous 
gel after 3 hours. The lack of fluid behaviour may have hindered the possibility of the chain 
ends interacting to form larger polymers, resulting in the isolation of smaller oligomer chains. 
However, it is unlikely that oligomers would result in a viscous material. A gel-like material is 
usually consistent with the formation of high molecular weight polymer. One possible 
explanation is that a polyacetal compound with a greater degree of polymerisation formed 
initially, but degraded upon isolation, which is made plausible considering the error in delayed 
neutralisation. 
Oligomer 71 formation may be explained as a function of the hydroxyl reactivity. If the 
treprostinil 4 molecules were incorporated as terminal groups, this may indicate a difference 
in the reactivity of the two hydroxyls, as only one hydroxyl is able to either form or maintain an 
acetal bond. Unfortunately, no diagnostic resonances are visible to confirm or reject this 
interpretation that a terminal treprostinil 4 selectively conjugates through one hydroxyl. 
Treprostinil 4 was added in a 1:1 ratio with PEG 65, although only 27% of the total treprostinil 
expected is accounted for by 1H NMR spectroscopy (Figure 4-7). Furthermore, HPLC (Figure 
4-11) was conducted on an aqueous solution of the polymer sample isolated (5 mg/mL) and 
showed no free treprostinil 4 (retention time of treprostinil 4 is 9.6 minutes). The presence of 
treprostinil was measured by UV absorbance at 217 nm, following previous treprostinil 
detemination.354 This was initially interpreted as there was no free treprostinil 4 present in the 
polymeric solution. Free treprostinil 4 which was not accounted for in the 1H NMR spectrum 
(Figure 4-7) would have been expected to be isolated during precipitation in hexane.  
 
Figure 4-11. Overlapping HPLC chromatograms of the oligomeric product 71 in pH 
7.4 buffer (pink) and a sample of treprostinil 0.5 mg/mL (grey). No treprostinil 
absorbance is observed in the polymer solution.  
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Based on the weight of treprostinil added to the reaction compared to the total weight of all 
polymer-forming reagents added, theoretical percentage of treprostinil, either conjugated or 
non-conjugated, is 9%. The maximum amount of total treprostinil visible in the 1H NMR was 
calculated to be 2.4%, which suggests that the 6.6% of the treprostinil added is unaccounted 
for. The NMR solvent used was deuterium oxide in the presence of potassium carbonate, an 
aprotic base not detected by 1H NMR analysis. Its presence was included to reduce in situ 
degradation of the acetal bonds but would have also aided solubility of any unconjugated 
treprostinil. Furthermore, when analysed by HPLC in buffer at pH 7.4, the chromatogram of 
oligo(PEG-treprostinil acetal) 71 showed no evidence of treprostinil. Therefore, it is unlikely 
that the treprostinil unaccounted for had precipitated. 
Treprostinil, PEG3400 and p-toluene sulfonate triethylamine salt are all insoluble in hexane, 
owing to the high polarity and charge. Therefore, it is expected that all of the reagents present 
in the reaction mixture were isolated by precipitation into hexane. The delayed neautralisation 
of the polymerisation solution may have meant that protonated treprostinil was added into 
hexane which may have exhibited solubility given the large volume of solvent. Following the 
initial incorrect interpretation of the 1H NMR, the hexane layer was discarded. 
The 1H NMR spectrum of oligomer 71 (Figure 4-7) shows the pair of downfield aromatic 
doublets visible at 7.35-7.68 ppm corresponding to the presence of residual pTSA in a molar 
ratio of 2:13 with PEG. The triplet and quartet at 0.99 and 2.57 ppm, respectively, indicate that 
triethylamine is also present in equal equivalents to pTSA so it’s likely that they are present as 
the salt which precipitated out in hexane. To help ascertain whether the pTSA is present in a 
protonated or deprotonated form, an independent 1H NMR of pTSA in D2O with and without 
the addition of excess potassium carbonate base was conducted. However, no shift in the 
aromatic resonances was observed. 
Oligo(PEG-treprostinil ethyl ester acetal) 
Use of a drug co-monomer with a free carboxylic acid and secondary hydroxyls for 
incorporation into a polyacetal has not been previously described. In principle the treprostinil 
free acid 4 is capable of catalysing the degradation of acetal bonds, although this was not 
attempted. Treprostinil 4 solubility in toluene was poor even in the protonated form and 
required heating to over 50 °C. With residual toluene in the reaction solution at room 
temperature, it was assumed that a protonated treprostinil 4 would aid solubility and thus the 
solution was acidified. The secondary hydroxyls may contribute to a lower degree of 
polymerisation. In addition to the concern about the difference in the treprostinil hydroxyl 
reactivity, there was concern that the treprostinil 4 carboxylic acid would catalyse degradation 
during polyacetal synthesis.  
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Scheme 4-13. The proposed synthesis of poly(PEG-treprostinil ethyl ester acetal) 72 
formed by the ter-polymerisation using treprostinil ethyl ester 43 as a co-monomer. 
The success of the polymerisation was investigated in the absence of treprostinil acid. 
pTSA = para-toluene sulfonic acid. 
To investigate the effect of the free acid on acetal formation, the polymerisation was repeated 
using treprostinil ethyl ester 43 as a co-monomer (Scheme 4-13). The reaction was carried 
out with 50 mg treprostinil ethyl ester 43, using 0.03 equivalents of pTSA catalyst and more 
than 4 times the amount of solvent as used for treprostinil 4 to aid solubility. Upon addition of 
the divinyl ether 64, the reaction solution soon became cloudy. The solution was neutralised 
by addition of 16 equivalents of triethylamine. After precipitation and drying, GPC (Figure 
4-12) indicated the average molecular weight as 8 kDa, corresponding to approximately two 
PEG3400 65 chains per structure, with a narrow PDI of 1.1. 1H NMR showed the presence of 
treprostinil ethyl ester 43, acetal and PEG 65 protons in a ratio of 1:4:5088, indicating a low 
conversion of acetal. The 5088 PEG 65 methylene protons correspond to 15 units of 
macromonomer PEG 65 for every one treprostinil ethyl ester 43 and 4 acetals. Therefore, only 
2 of the 15 PEG 65 chains detected in the NMR have undergone acetal formation. The 
expected structure of poly(PEG-treprositnil ethyl ester acetal) 72, was not obtained. 
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Table 4-3. 1H NMR spectrum of polymerisation product in the attempt to form 
polyacetal(PEG-treprostinil ethyl ester) 72. Only small quantities of treprostinil ethyl 
ester 43 were present compared to the PEG 65 protons. Additionally, the para-
toluene sulfonic triethylammonium salt was present and unreacted vinyl ether 
chains were also obtained. Where R is any number of PEG3400 macromonomers. 
 
Proton environments identified 
 
 
 
The 1H NMR spectrum (Table 4-3) showed the ethyl ester moiety of treprostinil ethyl ester 43 
remained intact during the reaction, as concluded by the presence of the methylene resonance 
(highlighted in yellow) and the terminal methyl resonance of the ester (highlighted green). The 
treprostinil aryl carbonyl methylene peak is not observed as it lies under the broad peak for 
the PEG 65 methylene protons. Treprostinil ethyl ester 45 exhibits poor solubility in water 
compared to its free acid parent compound. Therefore, the detection of treprostinil ethyl ester 
43 resonances suggests they are included within the acetal structure. 
To prevent any degradation in the deuterium oxide solvent during 1H NMR analysis, potassium 
carbonate was added. Interestingly, the vinyl ether moiety was detected in its intact form, 
rather than the degraded acetaldehyde product 63. Ordinarily, vinyl ethers undergo hydrolysis 
in the presence of primary alcohols and mildly acidic water, which implies that in the presence 
of treprostinil ethyl ester, only a proportion of the vinyl ethers underwent nucleophilic addition. 
The poor acetal forming reactivity of treprostinil ethyl ester 43 also supports the interpretation 
that the treprostinil 4 secondary alcohols are only modestly reactive for incorporation into a 
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polyacetal using the reaction conditions which have been tried. Furthermore, interference of 
the treprostinil acid 4 in acetal formation is also ruled out. 
 
Figure 4-12. Gel permeation elutogram for the product of the acetal polymerisation 
reaction of treprostinil ethyl ester 43 and poly(ethylene glycol)3400 65 Only a small 
degree of acetal formation occurred with an average Mw of 8 kDa corresponding to 
only two PEG chains. The small Mw resulted in a narrow polydispersity index (1.1) 
Low efficiency for acetal formation using the treprostinil ethyl ester 43 may also be caused by 
its poor solubility in the reaction solution. During the reaction, a cloudy solution was formed 
upon addition of treprostinil ethyl ester 43, which remained slightly pearlescent until work-up. 
Solubility was also a factor which could be investigated further through optimising the solvent 
system used to better suit treprostinil ethyl ester 43. Despite the unsuccessful reaction, the 
detection of unreacted vinyl ethers is consistent to the anhydrous conditions employed. 
 
 
Scheme 4-14. Mechanism of acetal degradation. Acid catalysed mechanism for acetal 
hydrolysis is driven by protonation of one of the acetal oxygens to allow facile 
nucleophilic attack by water to cleave the acetal into two moles of alcohol and a mole 
of aldehyde 63. 
Polyacetals are known in the literature to exhibit pH dependent degradation.401–403,405,416  In 
the presence of protons, an acetal oxygen becomes protonated (Scheme 4-14). This drives 
the donation of electrons from the neighbouring acetal oxygen resulting in the formation of an 
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alcohol and an alkylated aldehyde intermediate. Water attacks the carbonyl by nucleophilic 
additional to form a hemiacetal which again donates electrons to facilitate the production of an 
alcohol and acetaldehyde. One limitation is the formation of 1 mol acetaldehyde upon 
degradation which may cause issues relating to its toxicity. 
Several studies have shown that polyacetals are hydrolytically stable at physiological pH and 
degrade at reduced pH to release drug. Degradation of the acetal bonds is acid catalysed with 
the release of the hydroxyl monomers as diols. For every vinyl ether derived acetal bond, one 
mole of acetaldehyde is also produced upon acetal hydrolysis. Acetaldehyde, the metabolite 
to ethanol, is a known carcinogen but has also shown to stimulate prostacyclin release in 
tissues and cells by stimulating prostacyclin synthase.417,418  
The hypoxic conditions formed in chronic PAH causes a switch in metabolism from oxidative 
phosphorylation to glycolysis, resulting in an acidic tissue.49 To evaluate pH dependent 
degradation, oligomers were incubated in aqueous environments at different pHs and the 
amount of treprostinil released over time was quantified. Oligo(PEG-treprostinil acetal) 71 
were evaluated in buffers adjusted to pH 7.4 and 6.6-5.5 to mimic physiological and acidic, 
diseased tissue respectively. Following previous studies,402,405 oligomer degradation studies 
were conducted using a concentration of 5 mg/mL at 37 °C with gentle agitation. The 
concentration of free treprostinil was analysed by HPLC at time points during the study. 
An initial degradation study was conducted at pH 7.4 and 5.5. An aqueous solution (1 mL) of 
oligo(PEG-treprostinil acetal) 71 (5 mg/mL) was analysed by HPLC at designated time points 
without neutralising the sample. To prevent further acid-mediated degradation during elution, 
the mobile phase comprised only acetonitrile (30% to 80% gradient) and water without any 
TFA. The UV absorbance of the eluted sample was analysed at 217 nm using a UV detector, 
which is sensitive enough to detect most pi bond electrons. Time points were taken between 
0 and 48 hours, and any free treprostinil was expected to elute at approximately 9.6 minutes 
(Figure 4-14). No change in the HPLC was observed at pH 7.4 (Figure 4-13 A). In contrast at 
pH 5.5, the chromatograms changed with time with a broad peak for treprostinil appeared by 
the end of the study (Figure 4-13 B).  
 
Figure 4-13. HPLC chromatograms of oligo(PEG-treprostinil acetal) 71, incubated at 
A) pH 7.4 and B) pH 5.5. No treprostinil was detected at pH 7.4 whereas absorbances 
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were detected for the oligo(PEG-treprostinil acetal) 71 at pH 5.5. The retention time of 
the peaks changed with time.  
The solubility of treprostinil sodium salt used for parental delivery is 10 mg/mL.266 For the 
subcutaneous formulation, each 1mL of solution contains 4.0 mg sodium chloride, 3.0 mg 
metacresol, 6.3 mg sodium citrate. Despite the solubility of treprostinil, direct analysis of the 
degradation mixture at pH 5.5 did not unambiguously show treprostinil (Figure 4-13), even for 
treprostinil standards (Figure 4-14). Furthermore, real time monitoring of the degradation, 
without a quenching step, meant measurements could only be taken when the HPLC 
apparatus was free, i.e. not during analytical run time. Therefore, the run time of the HPLC (40 
minutes) limited the frequency of analysis.  
Even with quantifiable treprostinil peaks, the absence of the TFA-buffer in the mobile phase 
created an inconsistent peak shape for the treprostinil standards (Figure 4-14) in comparison 
to when standards are run in a TFA-spiked mobile phase (Figure 4-16). 
 
Figure 4-14. HPLC chromatograms of treprostinil standards run in the absence of 
TFA. Peaks have multiple shoulders and are slightly inconsistent. 
The remaining sample solutions were incubated for a total of 6 days whilst the data was being 
analysed and interpreted. Consulting previous protocols,402 a method to quantify drug 
compound by liquid-liquid extraction was investigated. Neutral treprostinil (free acid) is soluble 
in ethyl acetate whereas PEG3400 was still insoluble after vortexing and sonication in ethyl 
acetate. Therefore, ethyl acetate was considered suitable for extraction of unconjugated 
treprostinil. For each of the remaining oligomer solutions, 880 μL was extracted with an equal 
volume of ethyl acetate (3×) which were combined, washed with brine, dried by passing 
through a glass pipette plugged with cotton wool and magnesium sulfate and the filtrate dried 
over a stream of air. The residue was dissolved in acetonitrile (150 μL) and analysed by HPLC 
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using steeper TFA-spiked solvent gradient (40-90% acetonitrile/water) and shorter analysis 
time (11 minutes). 
 
Figure 4-15. HPLC chromatograms for treprostinil detected in pH 7.4 (turquoise) and 
pH 5.5 (black) oligomer samples after 6 days. The samples were extracted using ethyl 
acetate and analysed using trifluoroacetic acid-spiked acetonitrile (40-90%) and water 
over 11 minutes 
For the two different pHs (7.4 and 5.5), the amount of treprostinil detected varied drastically 
(Figure 4-15). Using a treprostinil calibration curve and the shortened HPLC analysis method 
(Figure 4-16), the peaks were better resolved and allowed for quantification of the treprostinil 
in each sample. 
 
Figure 4-16. Analysis of treprostinil standards using mobile phase spiked with 
trifluoroacetic acid (TFA) is absorbed with better resolution and sensitivity than without 
TFA. A) HPLC chromatograms for treprostinil standards using TFA-buffered mobile 
phase and shorter method. B) Treprostinil concentrations were used to plot a standard 
curve. 
Using the HPLC standard curve determined for treprostinil using a TFA-spiked mobile phase 
(Figure 4-16), the peak areas of treprostinil detected by working up the degradation assay 
after 6 days were converted to concentration of treprostinil.  
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With a differing amount of treprostinil released for the neutral and acidic solutions, the reaction 
was repeated using the extraction method using a pH more relevant to inflamed tissue (pH 
6.6).251,412,413 A method of neutralising the test solutions before extracting the lipophilic 
components with ethyl acetate has been used in previously reported studies.402 However, the 
pKa of treprostinil acid (pKa 4.5)419 means treprostinil solubility in the organic layer is only 
facilitated at lower pH values. At neutral pH, treprostinil is expected to be in its deprotonated 
form rendering it poorly soluble into the organic layer. Therefore, neutralisation of acidic 
solutions would prevent treprostinil from partitioning effectively into an organic extraction 
solvent. Unfortunately, acidification during extraction would be expected to degrade acetal 
bonds further resulting in an increased concentration of treprostinil being extracted to cause 
an over estimation of polymer degradation. Thus, the oligo(PEG-treprostinil acetal) solutions 
were worked up directly at the pH of the buffer used for each degradation experiment. For this 
reason, the liquid extraction was carried out at each time point as quickly as possible. The 
reconstituted solutions were stored at -20 °C until all samples had been collected and then 
thawed before HPLC analysis 
 
Figure 4-17. Method for extraction of treprostinil 4 from degradation assay samples. 
Once a solution of oligo(PEG-treprostinil acetal) 71 has been made up at 5 mg/mL, 
aliquots of 1 mL are portioned immediately which are then incubated at 37 ᵒC. At each 
time point, the solution is extracted with ethyl acetate (EA; 200 μL ×3) which is then 
Table 4-4. The conversion of peak area to concentrations of treprostinil 4 
extracted from the degradation assay at pH 7.4 and 5.5. AUC, area under the 
curve as analysed by HPLC. 
pH AUC 
Concentration 
μg/mL 
% drug released 
from total drug in 
sample 
7.4 322611 4 0.48 
5.5 4135539 85 10.0 
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dried under a stream of air and reconstituted in acetonitrile (MeCN). The sample is 
analysed by HPLC using a TFA-spiked acetonitrile/water mobile phase. 
A further consideration of the known poor solubility of treprostinil 4, was the possibility of 
treprostinil aggregation or precipitation upon release from the oligomer. Thus, removal of an 
aliquot from the degradation experiment for the first time point and an aliquot for the last time 
point may contain differing proportions of insoluble treprostinil 4. To reduce this effect and 
attempt to achieve an equal concentration of treprostinil 4 and oligomer for each time point, 
once the treprostinil oligoacetal 71 solutions in the respective buffers for each pH were 
prepared for the degradation study, the solutions were immediately aliquoted into vials of equal 
volumes designated for each time point (Figure 4-17). A 10 mL degradation solution was 
prepared with oligo(PEG-treprostinil acetal) 71 at a concentration of 5 mg/mL in buffers at pH 
7.4 and 5.5. At each hour between 0 and 6 hours, a sample (1 mL) was taken and worked up 
as already described by extraction in 200 μL ethyl acetate (×3) which was washed with brine 
and dried over magnesium sulfate, and then reconstituted in 200 μL of solvent. A solvent of 
water, acetonitrile and methanol solution (5:2:1) was chosen which minimised the organic 
content and facilitated sample dissolution. The calibration curve obtained by dissolving 
treprostinil 4 in acetonitrile and analysing using TFA-mobile phase, shown in Figure 4-16 was 
used to determine treprostinil 4 content for each sample. A mix of dissolving solvents was 
designed to solubilise treprostinil 4 using a primarily aqueous solution to maximise interaction 
with the HPLC column. 
 
Figure 4-18. Release of treprostinil from oligo(PEG-treprostinil acetal) 71 over time 
when incubated at pH 7.4 (purple) and pH 6.6 (Green). Treprostinil was extracted into 
ethyl acetate from aliquots of aqueous sample and reconstituted into solvent mix of 
water/acetonitrile/methanol (5:2:1). The HPLC absorbances of treprostinil extracted 
from pH 7.4 (Graph A) and pH 6.6 (Graph B) The first sample to be analysed 
possessed a baseline greater than all other points; C) The integration of each peak 
was plotted as a function of time to each pH. A spurious data point was calculated 
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after 6 hours at pH 7.4, which was erroneously not washed with brine after extraction; 
D) The data was re-plotted without the spurious data point to observe the more 
consistent trend. 
The degradation experiment was conducted once appeared to show a difference in 
degradation between pH 7.4 and 6.6. Variability was observed although, on average, greater 
concentrations of treprostinil were detected in the more acidic aqueous buffer. Surprisingly, 
the gradient of the data collected at pH 6.6 was shallower than expected and amount of 
treprostinil collected over time remained fairly constant. One spurious result was detected after 
6 hours at pH 7.4 (Figure 4-18 C), but when removed from the data set (Figure 4-18 D), no 
overall change in treprostinil concentration was overserved over 6 hours. During the extraction 
of the sample at 6 hours in pH 7.4 buffer, the brine organic layer wash layer was erroneously 
skipped before filtering through the magnesium sulfate, which when analysed produced a 
much higher absorbance than expected. Interpretation of the effect of missing the brine step, 
may suggest that extracted treprostinil located in the ethyl acetate layers is subsequently lost 
to the aqueous layer upon brine wash. The slight variation in data observed could be due to 
the extraction process, particularly the drying step, or instrumental error (i.e. varying amounts 
of sample being collected by the autosampler for analysis). To mitigate any instrumental error 
an internal was added to the solvent used to dissolve the dried extracted treprostinil. 
 
Scheme 4-15. Para-nitrophenol and the resonant forms of the deprotonated form. 
Upon deprotonation the UV absorbance changes. 
An internal standard was added to the reconstituting solvent to reduce variability. The 
presence on an internal standard would identify if the variability was an instrument error (e.g. 
inaccuracies in the autosampler volume) and if so, allow for exact quantification by quantifying 
the ratio of treprostinil to internal standard. Initially, p-nitrophenol (Scheme 4-15) was 
investigated as an internal standard in the solvent mix of acetonitrile, water and methanol. 
Several dilutions were made to achieve a concentration of p-nitrophenol that remained in the 
detectable range when detected at 217 nm. When re-analysing the solution of p-nitrophenol 
after 24 hours, the solution was noticeably more yellow and the absorbance at the same 
concentration had increased in intensity and slightly increased retention time. The 
concentration of the day-old sample was diluted by a factor of 20, and the absorbance was 
still greater than the original sample analysed the day before (Figure 4-19). The change in 
absorbance it likely a result of p-nitrophenol becoming deprotonated (Scheme 4-15). The 
resonance forms of the deprotonated forms result in greater UV activity resulting in larger 
absorbances detected. The requirements of an internal standard are that they produce a 
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consistent measurement for the sample of interest can be compared against. Based on the 
variation in absorbance observed over time, p-nitrophenol was not a suitable internal standard.  
 
Figure 4-19. Comparison of HPLC chromatograms of p-nitrophenol. When freshly 
prepared at 0.84 mg.mL (pink), p-nitrophenol elutes after 3.9 minutes with an 
absorbance within the detectable limit. After 24 hours, a diluted solution (0.42 mg/mL) 
has a longer retention time and absorbance increases above the detectable limit 
(blue). 
With a similar structure to treprostinil 4, phenoxyacetic acid 22 was investigated as an internal 
standard by measuring absorbance at 217 nm. Without resonances involving the π-bond 
electrons of the aromatic ring, phenoxyacetic acid showed reproducible absorbance over time. 
As an internal standard, phenoxyacetic acid 22 in acetonitrile had a retention time of 3.6 
minutes which was sufficiently different from treprostinil with a retention time of 7.1 minutes 
(Figure 4-20). Baseline resolution between the two compounds was achieved while being 
sufficiently long enough to elute after the solvent peak. Therefore, acetonitrile was used for 
the reconstitution step. 
A standard curve of treprostinil was made using treprostinil concentrations made by serial 
dilution in MeCN of 0.5 mg/mL – 2 μg/mL (Figure 4-20). Each concentration solution was 
diluted in a stock solution of 1 mg/mL phenoxyacetic acid 22 in acetonitrile and 20 μL injected 
and analysed in duplicate by HPLC. The treprostinil peak areas were analysed as a ratio to 
the internal standard and plotted against concentration. The small amount of drug release 
observed in the preceding degradation studies (Figure 4-18) when compared to other 
polyacetals described in the literature suggests the hydrolysis is not occurring at a comparable 
rate.  
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Figure 4-20. Results of the standard treprostinil 4 concentrations when analysed in 
the presence of internal standard, phenoxyacetic acid 22. A) Comparison between the 
area of treprostinil absorbance and that of phenoxyacetic acid 24 removes any 
variation as a result of instrumental error. B) A plot of the ratio versus concentration of 
treprostinil 4 produces a reliable standard curve.  
The effect of oligoacetal 71 dilution on hydrolysis rate was then investigated. In addition, it was 
necessary to investigate whether the small concentrations of treprostinil detected were a result 
of slow oligoacetal degradation or an inefficient extraction process. Therefore, alongside the 
extraction process, the change in weight of the polymers was monitored by GPC. A solution 
of the oligomer product was made up at 2.5 mg/mL in buffers at pH 7.4, 6.0 and 5.5 and 
aliquots were portioned in duplicate. To preserve the sample, a smaller aliquot size of 400 μL 
was used instead of 1 mL. At timepoints 0-24 hours, two aliquots were removed from 
incubation; one was flash frozen in an acetone/dry ice bath and stored at -20 °C before 
lyophilisation and GPC analysis; and the other sample was worked up as usual by triple ethyl 
acetate extraction (200 μL), reconstituted in phenoxyacetic acid 22/acetonitrile solution and 
analysed by HPLC. Peak areas were multiplied by 2 to standardise the data obtained from a 
2.5 mg/mL solution of oligo(PEG-treprostinil acetal) 71 to previous and future data obtained at 
5 mg/mL and shown in Figure 4-21. 
 
Figure 4-21. Treprostinil released from oligo(PEG-treprostinil acetal) 71 over 24 hours 
when incubated at 37 ᵒC in buffers at pH 7.4, 6.0 and 5.5. Treprostinil was slowly 
released at pH 7.4 and 6.0 but no treprostinil was detected at any time point from the 
pH 5.5 buffer. 
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Peak area was plotted as a ratio between that of treprostinil 4 and phenoxyacetic acid 22 and 
converted to concentration using the standard curve in Figure 4-20. Surprisingly, the lowest 
concentrations of treprostinil 4 were detected for the most acidic buffer, which seemed to 
slightly decrease over 24 hours (Figure 4-21). The pH of the buffer used was reconfirmed to 
be pH 5.5, suggesting that perhaps the samples vials had been mixed up. However, upon 
consulting the raw data, the same values were obtained. Furthermore, the lack of an identified 
trend (Figure 4-22), implied an error occurred during the assay preparation. The gradient over 
24 hours was similar to the previous data over 6 hours and so it was concluded that the 
concentration of the oligomer solution was not reducing the rate of degradation. 
 
Figure 4-22. Chromatograms showing treprostinil 4 release from oligo(PEG-
treprostinil acetal) 71 solution in aqueous media (2.5 mg/mL) over time in different pH 
environments. Top row shows full scan and bottom row is the treprostinil absorbance. 
The assay was conducted in three different pH buffers, shown in each column; A) pH 
7.4; B) pH 6.0; C) pH 5.5 
GPC analysis was carried out by a colleague for a preliminary investigation and only time 
points at T0 and T6 hours were analysed. No detectable change was observed over 6 hours for 
either the neutral and acidic environments. Data for pH 7.4 and pH 5.5 shown in (Figure 4-23). 
This provided reassurance that the low concentrations of treprostinil detected by HPLC were 
accurate. In a published study, degradation of poly(PEG acetal) as calculated by molecular 
weight loss, achieved 60% over 100 hours at pH 5.5.405 The disparity in degradation properties 
between poly(PEG acetal) and oligo(PEG-treprostinil acetal) provided further evidence that 
treprostinil must be present within the oligomer in order to alter behaviour. 
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Figure 4-23. GPC traces showing degradation of oligo(PEG-treprostinil acetal) 71 
after 6 hours at pH 7.4 and 5.5. RI = refractive index 
Evidence of minimal degradation was determined by the concentration of treprostinil extracted 
as well as the GPC weight of the oligoacetal 71 structure after 6 hours. Thus, an investigation 
was carried out to investigate if the minimal degradation exhibited at pH 5.5 was reproducible. 
Fresh citrate buffer was made, and the assay repeated at 5.mg/mL in pH 5.5 only (Figure 
4-24).  
 
Figure 4-24. Repeat degradation of oligo(PEG-treprostinil acetal) 71 conducted at pH 
5.5, extracting treprostinil from the aliquots at each time point using ethyl acetate. The 
absorbance of treprostinil detected was more sensitive and followed a consistent trend 
in concentration over time that the previous attempt did not. 
The concentrations of treprostinil released from oligo(PEG-treprostinil acetal) 71 in buffer at 
pH 5.5 over 24 hours were calculated using the standard curve in Figure 4-20. The repeated 
assay data (Figure 4-24) was compiled with the previous data obtained for pH 7.4 and 6.0 
(Figure 4-21) to determine if a trend could be identified. Degradation occurred at a greater 
rate at pH 5.5 than of pH 6.0 and 7.4. 
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Figure 4-25.Plot of concentration of treprostinil 4 over 24 hours when incubated at 
different pHs. Following a poorly sensitive result for pH 5.5 previously, the degradation 
assay was repeated at pH 5.5 and combined with the original data for pH 7.4 and 6.0. 
Concentration of treprostinil 4 showed pH-dependent nature, with more treprostinil 4 
detected at lower pHs. 
Liquid-liquid extractions can be inefficient if there are solutes that can partition into both liquids, 
although was considered necessary based on earlier data (Figure 4-13) which suggested that 
direct analysis of the aqueous oligo (PEG-treprostinil acetal) 71 solution to determine the 
extent of treprostinil release was insensitive. While considering the limitations of extraction, 
each extraction and dissolution step was carefully controlled. Liquid-liquid extractions are 
made less accurate when carried out on a small scale, such as extraction from a 200 μL 
sample. Drying of the ethyl acetate layer was achieved by passing a stream of air over the 
liquid and was harder to control. Fluctuations in the air flow rate meant a consistent stream of 
air was not always achieved. It is not inconceivable that the solution splashed, altering the 
amount of treprostinil left as a residual solid. To reduce any effect the drying process had on 
treprostinil concentrations, a different method of drying was sought. Removal of ethyl acetate 
solvent was attempted using a vacuum centrifuge. 
With the overlapping concentrations of the previous results for pH 7.4 and 6.0, the degradation 
study was repeated using only pH 7.4 and 5.5 using returning to the higher oligomer 
concentration of 5 mg/mL. The original higher concentration was anticipated to have fewer 
errors in detection. Each aliquot contained a volume of 500 μL. 
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Figure 4-26. Standard concentration curve of treprostinil using the peak area of 
treprostinil absorbance directly. The wrong internal standard was used which maxed 
out the detector so a ratio between treprostinil and internal standard could not be used. 
The dried, extracted samples and treprostinil standards were erroneously reconstituted in a 
solution of para-nitrophenol in a 5:2:1 solution of water, acetonitrile and methanol (0.42 
mg/mL) instead of the phenoxyacetic acid solution (1 mg/mL in acetonitrile). The absorbance 
for p-nitrophenol reached above the maximum absorbance so a ratio between treprostinil 
could not be accurately determined. Therefore, the AUC of the treprostinil absorbance was 
directly plotted (Figure 4-26).  
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Figure 4-27. A plot of treprostinil concentration extracted from solutions of oligo(PEG-
treprostinil acetal) in buffers at pH 7.4 and 5.5 over 6 hours. A greater concentration 
of treprostinil was detected when incubated at pH 5.5 than at pH 7.4. Using vacuum 
centrifugation to dry the samples produced less varied concentrations of treprostinil. 
Using a larger volume and vacuum method of drying produced less varied results which follow 
a clear and defined trend over 6 hours. A baseline level of treprostinil is detected at all time 
points in buffer at pH 7.4, which does not increase over a 6-hour period. Consistent with 
published reports, at pH 5.5 the amount of treprostinil increases over time. The discrepancy 
between the initial relative concentration of treprostinil in solution may suggest some 
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degradation occurs immediately although is most likely a result of the different solubility of 
treprostinil at different pHs and is discussed later.  
In order to describe the in context of the maximum amount of treprostinil released from the 
oligomer product, a solution (500 mL, 5mg/mL) was exposed to a TFA environment, shown in 
an earlier 1H NMR investigation to degrade the acetal bonds. The oligomer solution was 
heated to 50 °C for 2 hours. After 1 hour at RT a precipitate was visible. Extraction with ethyl 
acetate appeared to remove the precipitate and the sample was prepared for HPLC in 
acetonitrile (200 μL) with phenoxyacid acid internal standard.  
 
Figure 4-28. HPLC chromatogram of TFA-degraded oligo(PEG-treprostinil acetal) 71 
(blue) compared to standard sample of treprostinil 4 (red). Both samples were 
prepared with phenoxyacetic acid internal standard. 
Surprisingly, no absorbance corresponding to the retention time of treprostinil was observed. 
Although the height of the phenoxyacetic acid HPLC absorbance was comparable to that in 
the treprostinil standard, the width, and hence the integrated area was larger. Interestingly, 
when consulting the 1H NMR spectra of oligo(PEG-treprostinil acetal) before and 60 minutes 
after incubation with TFA, as well as the acetal resonances being removed, so is the methylene 
resonance, highlighted in Figure 4-29, providing further evidence that treprostinil is unstable 
in strong acid. 
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Figure 4-29. Overlapping 1H NMR spectra of poly(PEG-trep) before (In red), and after 
incubation with TFA in D2O (in blue). 
It was queried whether the acidified treprostinil was eluting at the same retention time as 
phenoxyacetic acid 22, so the reaction was repeated without the addition of internal standard. 
Upon addition of acetonitrile (200 μL) a cloudy solution formed which was solubilised by 
addition of methanol (200 μL). Interestingly, no absorbance was observed, indicating that the 
treprostinil had either not been extracted or solubilised sufficiently.  
 
Figure 4-30 Overlapping chromatograms of treprostinil standard with phenoxyacetic 
acid (pink) and the elutogram of the sample extracted from oligo(PEG-treprostinil 
acetal) incubated with trifluoroacetic acid (blue). 
The presence of strong acid may have been enough to cleave the aromatic ether, however 
the 2-hydroxyacetic acid cleaved would still likely possess a methylene resonance in the same 
region of the 1H NMR spectrum. Furthermore, formation of the triol compound (51) does not 
fit the observation of poor solubility in either ethyl acetate (during extraction) or acetonitrile 
(during resolubilising). 
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Scheme 4-16. Proposed mechanism of acid catalysed ether cleavage, degradting 
treprostinil 4 to form the triol intermediate 51. 
An alternative method was used to quantify the maximum amount of treprostinil 4 in released 
from a sample of oligomeric product. Oligo(PEG-Treprostinil acetal) 71 (5 mg/mL), was 
incubated in a similar fashion in HCl (0.155 M), a pH 1 buffer used to mimic the degradative 
environment of the stomach. The change in treprostinil 4 concentration was analysed over 3 
hours. Sample aliquots (200 μL) were extracted, dried by a passing stream of air and 
reconstituted in phenoxyacetic acid spiked acetonitrile (200 μL). Samples were analysed by 
HPLC to quantify the amount of treprostinil present. Peak areas were converted to 
concentration using the phenoxyacid acid standard curve (Figure 4-20).  
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Figure 4-31. Plot of concentration of treprostinil 4 detected over 3 hours when 
incubated at pH 1 and extracted into ethyl acetate.  
The concentration of treprostinil 4 was observed to plateau after 1 hour which suggests that a 
maximum concentration, which can be extracted and detected, is reached. Therefore, this can 
be interpreted as the maximum amount of treprostinil 4 in a given sample. Conversion of the 
average peak area for hours 1-3 indicate that every 1 mL of oligomeric solution at 
concentration 5 mg/mL, 73 μg (1.4%) is treprostinil. Using 73 μg/mL as the maximum, previous 
data could be reanalysed in the context of the maximum amount of treprostinil possible. 
Most of the data from the two studies which were conducted using the extraction method 
(Figure 4-25 and Figure 4-27) were combined to analyse duplicate data to try to better 
understand assay reproducibility. The data obtained from the first extracted assay conducted 
at pH 7.4 and 6.6 was not used because of the variability in the concentrations over time. 
Several differences in the assay design set limitations in the overall trends observed. First, 
between the studies two different methods to dry the samples were used (air drying and 
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vacuum filtration), although the concentrations should not be altered, only variability. Second, 
only data obtained from buffer 7.4 and 5.5 and data obtained up to 6 hours, are duplicated. 
Lastly, the volumes of the aliquots worked up differ. The first study used an aliquot volume of 
500 μL and the second 400 μL. The volume of ethyl acetate used to extract (200 μL) was kept 
constant. Although the volume of sample extracted from was taken into consideration when 
calculating concentration of treprostinil 4, the effect the differences has on the partition of 
treprostinil into the organic layer cannot be discounted. As previously discussed, the first study 
used a dilute concentration of 2.5 mg/mL where all other studies were conducted at 5 mg/mL. 
The peak area was multiplied by a factor of two to standardise the result for comparison with 
other data. 
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Figure 4-32. Combined data showing the pH-dependant release of treprostinil 4 from 
oligo(PEG-treprostinil acetal) 71, as a percentage of the total treprostinil 4 released at 
pH 1. 
Treprostinil 4 release from oligo(PEG-treprostinil acetal) appears to occur in a pH-dependent 
fashion. Almost 100% of treprostinil was released after 6 hours when incubated in pH 5.5 
buffer, whereas the concentration increase of treprostinil at pH 7.4 was much lower for the first 
6 hours. The one aliquot analysed after 25 hours was comparable to treprostinil release from 
lower pH buffers. With only one repeat for each of the incubations after 25 hours, a limitation 
is met in drawing any conclusions. The study would benefit from repeated measurements. 
A base-level of treprostinil is detectable even at the initial time point at pH 7.4. The 
concentration of treprostinil released over a 24 hour period increases negligibly which implies 
that oligo(PEG-treprostinil acetal) is stable. Therefore, the detection of treprostinil 4 at the first 
time point suggests that some treprostinil was either never incorporated into the acetal of had 
prematurely degraded upon storage.  
One of the noticeable features of the degradation assays is the varying concentrations 
detected for at the initial time point. One limitation of the assay is the time lag between addition 
of the polymer to the buffer and aliquoting into an extraction solvent. Approximately 20 
seconds are given to facilitate dissolution and efficient mixing by vortexing, and the preparation 
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is conducted as rapidly as possible. The premature degradation of acetal bonds to release 
treprostinil during the sample preparation is expected to be more pronounced in highly acidic 
buffers and less so at pHs which exhibit little acetal degradation. The results obtained (Figure 
4-32) show a much greater difference in concentration than might be expected based on 
reported results.402  
 
Figure 4-33. Process of preparing assay sample for initial time point. Following 
dissolution of oligo(PEG-treprostinil acetal) 71 in aqueous buffer (5 mg/mL) by 
vortexing, the first aliquot is removed and added to a prepared vial containing ethyl 
acetate (200 μL). The extraction solutions are vortexed and allowed to separate and 
the extraction repeat three time total. The combined organic layers are then prepared 
for HPLC. Between the addition of polymer to aqueous buffer and the final extraction, 
approximately one minute passes which when acidic buffers are used may be enough 
time to degrade the acetal and release treprostinil. 
The difference in treprostinil 4 concentration at the initial time points when incubated in 
different buffers may be a result of the treprostinil acid group. At low pH values the treprostinil 
acid is protonated and in an environment with higher pH will exist in the deprotonated form. At 
different pHs, treprostinil will have different interactions with its solvent meaning the 
concentrations in each layer of an extraction conducted at different pH values will possess 
different concentrations of treprostinil. At high pH, the acid exists in the deprotonated, anionic 
form which facilitates stronger interactions with the polar aqueous phase and interact weakly 
with the ethyl acetate layer. At lower pH values, treprostinil exists as the cationic protonated 
form which with its reduced polarity interacts weakly with the aqueous phase and is more 
soluble in the ethyl acetate layer. Poor extraction of treprostinil is expected to occur at pH 
above 4.5, when the partition coefficient of treprostinil favours the aqueous layer over the 
organic layer.  
The extraction step was deemed important to ensure all treprostinil released was quantified. 
The first degradation assay suggested poor solubility of treprostinil in aqueous solution as 
direct analysis by HPLC showed minimal amount of treprostinil 4. However, when extracted 
24 hours later, a much greater concentration was obtained. An extraction method using ethyl 
acetate was successfully employed by Tomlinson and colleagues to quantify the hydrophobic 
hormone drug, diethylstilboestrol from poly(PEG-DES acetal) 59. Extraction allows for 
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treprostinil to be solubilised but carries its own limitation in the variation in extraction at different 
pHs. Additionally, following extraction the drying and reconstituting of the organic layer 
introduces variability in the results, as determined by the differing results for duplicate samples.  
It was expected that the limitation of the varying partition coefficients as well as the large 
variation in results could be overcome by removing the extraction step. A degradation study 
was designed which used samples prepared as before, except at each time point, the sample 
is neutralised by addition of ammonium phosphate buffer to further prevent degradation. After 
which free treprostinil would be solubilised by addition of an equal volume of acetonitrile to the 
neutralised degradation solution. Samples would be collected and frozen before analysis, 
without removing the polymer. To prevent degradation during analysis on the column, mobile 
phases would be used without TFA buffer.  
 
Figure 4-34. Proposed method of analysing degradation of oligo(PEG-treprostinil 
acetal 71 without the need to extract samples at each time point. A solution of 
oligo(PEG-treprostinil acetal) 71 in aqueous buffers at varying pH at 5 mg/mL would 
be prepared. Aliquots would be prepared and incubated at 37 ᵒC. At each time point a 
sample will be neutralised by the addition of ammonium phosphate buffer and diluted 
by a factor of 2 by the addition of acetonitrile. Samples can then be frozen until HPLC 
analysis. To prevent degradation during analysis, HPLC mobile phase will we used in 
the absence of trifluoroacetic acid. 
As mentioned previously, the presence of treprostinil 4 in initial samples may suggest 
degradation had occurred in the 4 months since original synthesis, despite the neutralisation 
of the acid and storage at -20 ᵒC. Indeed, the initial amount of treprostinil detected at pH 7.4 
increased over time. Therefore, an investigation was conducted to establish the extent of any 
premature degradation. To avoid the issues surrounding the extraction which had been 
identified, oligo(PEG-treprostinil acetal) 71 was dissolved in MeCN at 5 mg/mL and analysed 
directly by HPLC in the absence of TFA using the original method employed for the direct 
analysis of the aqueous degradation (Figure 4-13). One broad absorbance was observed with 
a retention time of 14.3 minutes, marginally earlier and much broader than that of a treprostinil 
standard used for comparison, with absorbance after 14.4 minutes.  
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Figure 4-35. HPLC chromatograms comparing absorbance of oligo(PEG-treprostinil 
acetal) 73 after 4 months of storage at -20 °C (shown in pink) and the absorbance of 
a treprostinil standard (orange). A larger, broader resonance is observed. 
Assuming the absorbance corresponds to only treprostinil, the concentration detected is 
greater than that obtained from the pH 1 degradation data by 174% (Figure 4-36). The 
concentration of treprostinil detected, accounts for 2.5% of the weight of the whole sample, 
which matches the amount of treprostinil calculated to be present in the 1H NMR spectrum. 
Which indicates that the oligo(PEG-treprostinil acetal) has fully degraded, at least at the termini 
where treprostinil was estimated to be conjugated. 
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Figure 4-36. Treprostinil 4 release measured by HPLC over 3 hours when incubated 
in buffer at pH 1 (shown in green), in the context of the amount of treprostinil 4 detected 
in the stored sample of oligo(PEG-treprostinil acetal) 71 when dissolved in acetonitrile 
and analysed by HPLC directly. Degradation was measured only once and the 
corresponding treprostinil 4 concentration indicated by the purple dashed line. 
Oligo(PEG-treprostinil acetal) 71 had degraded upon storage to release the same 
amount of treprostinil detected by 1H NMR after synthesis. Despite maximum 
degradation occurring at pH 1, indicated by the plateau, the concentration extracted is 
less than total treprostinil 4 released upon storage when analysed directly. 
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Degradation upon storage had been confirmed and the greater amount of treprostinil 
measured than the total amount extracted from buffer at pH 1 provided further evidence that 
the extraction method was limited for the quantification of treprostinil. Both a new method of 
accurately quantifying degradation and a new batch of oligo(PEG-treprostinil acetal) were 
required.  
Repeat synthesis was anticipated to give an opportunity to implement lessons learnt from the 
first synthesis, including; using a larger volume of reaction solvent, neutralisation of the 
reaction before precipitation, removal of the acid salt before storage. Optimising the synthesis 
was anticipated to achieve a better degree of polymerisation with a higher average molecular 
weight polymer, narrower PDI and exhibit greater stability upon storage. In more recent 
descriptions of polyacetal formation in the literature,420 precipitations were carried out in diethyl 
ether twice, re-dissolving in THF, and then lyophilised from water to remove traces of acid.  
Consideration was given to the mechanism by which the step growth polymerisation occurs, 
specifically the effect of the stoichiometry between the divinyl ether and diol monomers. When 
stochiometric amounts of vinyl ether and alcohol groups are not employed dead chain ends 
can arise. With more of one reactive monomer than the other, conjugation of the oligomers is 
inhibited, preventing larger chains from forming. The use of polydisperse PEG chains means 
the stoichiometry is estimated based upon the reported average molecular weight. Achieving 
stochiometric amounts of vinyl ether is therefore impossible but can overcome by addition of 
an underestimation of vinyl ether. After sufficient time for small oligomers to form, small 
amounts of vinyl ether are titrated in. The conjugation of oligomers to form polymers is deemed 
complete by an increased viscosity. The intended neutralisation before exposure work-up was 
anticipated to preserve a higher degree of oligomerisation. 
The synthesis was repeated using the same batches of materials. Variations included using 
rotary evaporation for drying the PEG and acid, addition of more solvent, as well as using the 
recommended equivalents of pTSA (0.03 eq). The scales were also varied and the ratios of 
monomers were kept constant. An increase in viscosity was not observed. 1H NMR confirmed 
minimal acetal formation. 
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Figure 4-37. 1H NMR spectrum of a repeat attempt to synthesise oligo(PEG-
treprostinil acetal) 71, using the same procedure proven successful before. The ratio 
of acetal methine resonances (blue) compared to the PEG resonances indicate that 
minimal acetal formation has occurred. 
A repeat of the first reaction was attempted on the same scale as before. To avoid the issue 
of the reaction becoming too viscous, anhydrous THF was only slightly increased above the 
original reaction (4 mL vs. 3mL). The purity of the vinyl ether was confirmed by NMR and 90% 
of the calculated amount added. Based on the reaction time of the first reaction, the reaction 
was left for 3 hours to form the oligomers. Addition of a further 5% did not alter the viscosity. 
Two more portions of 5% were titrated in without affecting the reaction progression. It was 
feared that an excess of vinyl ether would result in chain ends. Addition of a diol would offer 
the opportunity to conjugate the chains together. Although any diol compounds can be used, 
to keep the characterisation easy, A solution of PEG 3400 and pTSA.H2O in toluene was dried 
by azeotropic removal of water using rotary evaporation. Under argon, anhydrous THF was 
added and 10% of PEG 3400 was added to the reaction mixture. Although a subtle increase 
in viscosity was observed initially, no further change was seen after 24 hours stirring. The only 
remaining difference with the first reaction is the equivalents of catalytic acid. Despite being 
catalytic, the reaction may progress slowly in its absence. Addition of pTSA monohydrate 
would introduce competing water into the reaction so as an alternative the pyridinium salt was 
added. Pyridinium toluene sulfonate salt is a weak acid, employed for catalysing polyacetal 
formation.415,421 Without the bound water molecule, it does not require drying so carries less 
risk of driving polyacetal degradation. In total, 5 repeats were carried out with  each repeat 
consuming treprostinil and time, yet no indication that polymerisation had occurred was given.  
Several attempts were carried out to accurately study the degradation of oligo(PEG-treprostinil 
acetal) 71 and quantify the treprostinil released. Through the iterations, a method was created 
to quantify treprostinil by extraction of the aqueous solution and subsequent HPLC analysis. 
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Using this method, it was shown that the stability of oligo(PEG-treprostinil acetal) 71 at pH 7.4 
is consistent over a period of 24 hours, with 19% amount of treprostinil released. 
Comparatively, at pH 6.0 higher concentrations of treprostinil are detected, although the 
concentration measured after 24 hours is similar to the value at pH 7.4 for the same time point. 
When oligo(PEG-treprostinil acetal) 71 was incubated at pH 5.5, the rate increases sharply to 
over 80% release over 5 hours.  
Incorporation of poorly soluble diol drugs into polyacetal mainchains has been reported 
previously,401–403,405,416 however, none possessing an additional acid group. In comparison to 
literature reports, the treprostinil release from the oligo(PEG-treprostinil acetal) occurs at a 
faster rate than larger polyacetals which incorporate hydrophobic drugs in the main chain. The 
reported degradation of poly(PEG-DOX acetal) 59 achieved 65% of DOX release in 96 
hours,402 comparable to the 60% Mw reduction of poly(PEG acetal) over 100 hours in the same 
acidic conditions.405 Release of DES from poly(PEG-DES acetal) 59 was measured at 85% 
after 100 hours in pH 5.5 buffer, and deemed completely degradation after 145 hours. In 
contrast, oligomeric treprostinil was fully degraded after 6 hours at pH 5.5. The consistency of 
the degradation rates for mainchain polyacetals of similar loading and Mw, suggests that the 
type of alcohol contributing to the acetal bond plays a minimal role in the degradation. The 
slightly faster degradation rate of poly(PEG-DES acetal) 59 may be explained by the phenolic 
acetal formed. Phenolic hydroxyls resonate into the aromatic ring which weakens the oxygen 
bond into the acetal and make better leaving groups which ultimately increase the rate of 
hydrolysis. Extrapolating of the trend for hydroxyl stability affecting acetal degradation, it would 
be expected that an acetal bond comprised of a secondary alcohol might have increased 
stability. However, conjugation to treprostinil revealed a faster rate of degradation. The size 
difference between an oligomer of Mw 17 kDa in comparison to a 43 kDa polymer, previously 
described,402,414 will have a smaller volume and therefore a larger proportion of the structure 
will interact with the solvent. Additionally, as opposed to the mainchain incorporation of DES 
in poly(PEG-DES acetal) 59 the 1H NMR suggests treprostinil is most likely conjugated at 
PEG-acetal termini.  
Although pH 5.5 was investigated, pH 6.0 is more relevant in the context of the chronically 
inflamed tissue of PAH patients. Thus, the degradation at pH 6.0 was investigated. After 6 
hours, 40% of treprostinil had been released, which did not show much further release after 
24 hours. The reported degradation of poly(PEG acetal) at the similar pH of 6.5 showed 20% 
degradation after 100 hours. When DES was incorporated within the back bone, 30% of DES 
had been released after 100 hours at pH 6.5. 
 
The difficulty in producing a polyacetal polymer of oligomer, demonstrates the poor reactivity 
of the treprostinil hydroxyls in an acid environment. The reactivity of nucleophiles is often 
increased by the presence of a base which can deprotonate either the nucleophile or the 
intermediate formed. To overcome the poor reactivity of treprostinil hydroxyls, a base 
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catalysed polymerisation of treprostinil to form an acis-cleavable linker may be better suited. 
Based on work published by DeSimone and colleagues (Chapter 1, Figure 1-18),250 we 
designed a PEG-treprostinil polymer which was hypothesised to degrade in an acid 
environment. Instead of using the linker to conjugate two structures in a pendant fashion, we 
looked at utilising the linker in a similar method to the polyacetal, to link the drug into the 
polymer mainchain via the alcohols.  
 
Scheme 17. Proposed reaction for the incorporation of treprostinil monomer into a 
polymer backbone using silyl ethers as the biodegradable element. The reaction is 
conducted under basic conditions which was expected to facilitate nucleophilic 
substitution of the chloride ions by the treprostinil hydroxyls. 
Polymerisation is carried out by a substitution reaction, where the chloride is displaced by 
nucleophiles including the hydroxyl groups of PEG and treprostinil. Although the nucleophilicity 
of treprostinil alcohols is weak, their reactivity at chlorinated silyl groups has been published 
and proven in our hands (Chapter 3).  
Reactions were kept anhydrous to minimise hydrolysis of the dichloroisopropyl silane which is 
susceptible to nucleophilic attack by water. Trace water bound to PEG was removed by 
azeotropic removal of toluene using dean-stark apparatus and anhydrous solvents were used. 
Following the same procedure as for the polyacetal, the alcohol species was stirred in the 
presence of the catalyst, in this case, pyridine, and the polymerising agent was added slowly 
with vigorous stirring. Much like polyacetals, silyl ethers are susceptible to acid degradation. 
The requirement of base catalyst for silyl ether formation removes the problem of self-
degradation in situ provided enough base is added to deprotonate the acid group. 
Silyl ether polymerisation was attempted using treprostinil as a co-monomer with PEG in a 1:1 
ratio. To confirm the silyl ether is polymer can be formed, a drug free polymerisation was 
attempted using only PEG3400 as the control. In the case of polysilyl-PEG, no visual change 
Treprostinil as a co-monomer 
216 
  
occurred upon addition of dichloroisopropylsilane. However, the polysilyl-treprostinil-PEG 
reaction became cloudy immediately upon addition of diisopropylsilyl chloride. The reaction 
was stirred for 18 hours to allow enough time for the reaction to proceed. The polymerisation 
reaction solution was precipitated by addition into cold hexane. 
The 1H NMR of both compounds was inconclusive. In addition to the treprostinil hydroxyl 
methine resonances residing under the PEG peak, so did the silyl methine. Therefore, no 
diagnostic resonances for the reaction could be observed. GPC using PMMA calibrants 
estimated the PEG silyl compound to be 10 kDa, consistent with a trimerization. Based on the 
lack of polymerisation, the GPC of the treprostinil silyl ether was not conducted. 
The polysilyl ether treprostinil was attempted as a pilot reaction in the final days within the lab 
to test the hypothesis that a basic polymerisation would facilate polymerisation of treprostinil. 
Polymerisation of PEG3400 and treprostinil through silyl ether bonds was unsuccessful as 
determined by the low molecular weight estimated by GPC. The 1H NMR does not provide 
clear diagnostic resonances upon formation of the silyl ether which limits the information 
obtained. The reactivity of the hydroxyls may require a stronger base in stoichiometric amounts 
or longer reaction times. In future attempts, these factors could be considered.  
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  Strengths and limitations 
Treprostinil was incorporated into an oligomeric acetal conjugate of 17 kDa, containing two 
terminal treprostinil moieties This is the first drug monomer used in polyacetal conjugation 
featuring an acid moiety. Anhydrous conditions were employed and verified by the isolation of 
intact vinyl ethers. Upon polymerisation with treprostinil, the polyacetal signals appeared less 
sharp than the control polyacetal. Upon contribution of the hydroxyl oxygen to the acetal bond, 
a down field shift in the neighbouring methine proton peak would have been expected. 
Unfortunately, the methine proteins bound to the trep hydroxyl could not be seen in the NMR 
due to the overlapping chemical shift with the PEG signal. Incorporation of treprostinil into the 
acetal oligomer was inferred by the small amount of treprostinil detected at neutral pH and a 
pH-dependant increase in treprostinil detection over time. Methods to accurately quantify 
treprostinil were considered. Extraction into ethyl acetate proved more successful than direct 
analysis of the aqueous system. Clinically, the use of acetal biodegradable elements are 
limited by the release of acetaldehyde product, although this may provide an additional 
therapeutic benefit as acetaldehyde induces prostacyclin synthesis.  
None-the-less, this work was not without limitations. It should be highlighted that suitable 
quantities of treprostinil were not immediately available and as a result the work described in 
this chapter was conducted in the last months of the project. Upon confirmation that enough 
treprostinil was available, the tert-polymerisation was conducted. The limitations of treprostinil-
conjugated oligoacetals are proven evident. Successful polyacetal synthesis between A-A and 
B-B monomers is inherently intricate owing to the strict stoichiometry required to achieve full 
polymerisation. Using polydisperse PEG monomer further complicated the synthesis as 
stoichiometric quantities cannot be achieved.  
Although an oligoacetal was isolated, treprostinil was not incorporated into the mainchain as 
expected, which produced a similarly low Mw oligomer when repeated with the ethyl ester 
derivative, suggesting acetal formation was hindered by the poor reactivity of the hydroxyls. 
The viscosity of the reaction solution indicated a higher degree of polymerisation than that 
obtained, potentially suggesting acetal degradation upon isolation. An error was made which 
meant the neutralisation of the product was not conducted until after precipitation into hexane 
had been initiated, providing a time window for degradation to occur.  
Although the oligomer was formed initially, the problems surrounding reproducibility were also 
demonstrated. Furthermore, despite efforts to deprotonate residual acid, degradation occurred 
upon storage at -20 °C. Due to the system available, GPC characterisation of polymers was 
carried out using PMMA standards, which decreases the accuracy of measured characteristics 
of PEG-based polymers, although provided an estimate for the oligomeric structure to be 
determined. Although 13C NMR analysis often show broad peaks for polymers, it may have 
been possible for changes in the methine carbons neighbouring the acetal to confirm 
treprostinil inclusion upon polymerisation. Direct HPLC analysis of an aqueous solution of 
oligo(PEG-treprostinil acetal) 71, following synthesis, did not indicate the presence of 
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treprostinil. However, HPLC using an extraction method after 2 weeks from the date of 
isolation, shows the presence of treprostinil, which suggests not all treprostinil was 
incorporated in the oligomer. The extraction method detected treprostinil by HPLC more 
sensitively than directly from the aqueous assay solution. Despite the improvement, the 
extraction was inherently limited by the solubility of treprostinil in aqueous solutions above pH 
4. Furthermore, the partition coefficient of treprostinil in buffers of different pH was expected 
to vary. However, the neutralisation of the aliquots was anticipated to hinder the extraction of 
treprostinil into ethyl acetate and the acidification was expected to further degrade the acetal 
bonds, skewing any data obtained. Therefore, no adjustments were made to standardise the 
pH of the buffers before extraction. 
pH-dependent degradation was observed although the analysis would benefit from additional 
repeats conducted over a longer time period. Results from the degradation profile were varied 
and although efforts were made to reduce losses, including using vacuum centrifugation to dry 
the samples. Limitations with the work up were present and attempts were made to overcome 
them. An optimised protocol to study the degradation was designed, although its efficacy could 
not be put to test owing to the lack of reproducibility of the polymerisation. The demonstrated 
inherent issues surrounding reproducible synthesis, highlighted the issues this approach has 
commercially. Thus, an investigation into oligoacetal treprostinil conjugates was not continued 
further. 
 Conclusion 
Treprostinil was successfully incorporated into an oligoacetal. The relatively poor reactivity of 
the two treprostinil hydroxyl groups limited polymerisation, though one hydroxyl placed the 
treprostinil moiety at the oilogmer termini. Degradation was observed to be pH-dependent. 
The rate of treprostinil release was greater than that reported in the literature for DES, which 
is likely a result of the small oligomer formed and terminal treprostinil groups. Compared to 
the release profiles of other therapeutics reported in the literature (DES and DOX), we 
observed that the position of the secondary alcohols on a hydrophobic drug compound (such 
as treprostinil) can affects the degradation of the acetal bonds. Limitations in the degradation 
assay protocol were identified and methods were proposed to produce more reproducible 
degradation data. Although the study would benefit from optimised storage results and repeat 
degradation analysis, the inability to reproduce the polymerisation hindered this. An 
explanation into the poor reproducibility of the synthesis was not determined.  
Clinically, the small oligomer obtained is expected to have a faster rate of permeation from the 
subcutaneous tissue into the circulation with a longer residence time in the blood compartment 
than free treprostinil. The stability observed at pH 7.4 indicates minimal treprostinil release in 
healthy organs and a slow degradation of oligomer poly(PEG-treprostinil acetal) at pH 6.0 
suggests that oligomer 71 would exhibit a greater release of treprostinil in acidic tissues than 
those at physiological pH. 
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The polymerisation of treprostinil using a silyl ether approach was expected to be successful 
owing to the basic conditions employed preventing in situ degradation. One attempt was made 
to form poly(PEG treprostinil silyl ether) which was unsuccessful. For future attempts, a longer 
reaction time and stronger base would be expected to aid polymerisation.  Another approach 
is to derivatise each treprostinil diol such that a diacetal treprostinil monomer with more 
reactive polymeric functionality (e.g. amine) could be used for making a treprostinil containing 
acetal polymer. In this scenario, the treprostinil monomer would possess the acetal degradable 
elements and polymerisation could be better controlled using monomers that could be purified 
as solids (e.g. diamino-diacetal treprostinil and diacids). 
Treprostinil-drug conjugates have the potential to reduce both site pain and systemic site pain 
as well as increasing systemic half-life. Mainchain incorporation of other diol drugs offers a 
method to easily synthesise a polymer drug conjugate with high drug loadings. Treprostinil as 
a monomer has several limitations (i.e. secondary alcohols and an acid) which for polyacetals 
prevents polymerisation. Further investigations are required to determine a strategy to 
optimise treprostinil as a monomer for a polymerisation which possesses degradation sensitive 
to the PAH lung. 
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 Targeting of drug release 
 Introduction 
The practice of administering neutral synthetic polymers along with bioactive-compounds 
(drugs, proteins, genes and peptides) is used widely to alter distribution, biorecognition and 
site specificity of accumulation.162–164,422–424 The basic concept of polymer drug conjugates was 
proposed by Ringsdorf (Figure 5-1).425 The structure includes a hydrophilic polymeric 
structure which is able to actively target the disease site and result in localised accumulation. 
The drug is conjugated via a biodegradable linker which is stable in healthy tissues and also 
specific to the disease site. Conjugation forms a prodrug derivative with reduced activity which 
upon reaching the disease site results in release of the active drug. 
 
Figure 5-1. Generic structure of polymer drug conjugate proposed by Ringsdorf, which 
consists of a polymer backbone with solubilising groups, targeting moieties and drug 
molecules conjugated by a biodegradable linker.425  
A majority of polymer-drug conjugates explored and approved to date are designed to exploit 
enhanced permeation and retention (EPR) effects of malignant tissue. While it has been 
possible to increase the maximum tolerated dose of cytotoxics and achieve greater tumour 
uptake of drug in preclinical models, there has been little clinical improvement in mortality. 
The EPR effect is a feature of chronically inflamed tissue such as that of the PAH lung and 
PAH therapies are limited by lack of specificity for the disease tissue. To overcome the 
limitations of PM therapy, a drug-polymer conjugate was sought which would avoid site 
injection toxicity at the same time achieving localised release of treprostinil in the diseased 
pulmonary vasculature. Such a treprostinil polymer conjugate requires consideration of (i) the 
targeting moiety to localise a treprostinil polymer-drug conjugate to the lung, (ii) the linker used 
to conjugate treprostinil to the polymer and (iii) the water-soluble polymer to be used.  
For i) the conjugate is required to be located in the pulmonary tissue outside the cell where 
the IP, EP2 and DP1 receptors are located. The conjugate must not accumulate in other 
tissues. For ii) the linker must be stable in serum until the target tissue is reached and then 
must be cleaved in the extracellular compartment of the pulmonary vessels to release 
treprostinil. 
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Two general approaches to target a polymer-treprostinil conjugate to the PAH lung; addition 
of an active targeting moiety to the polymer as well as the use of PAH specific linkers to 
conjugate treprostinil to the polymer. 
 
Targeting of drug compounds is best exemplified by the antibody drug conjugates in the clinic. 
Exploiting the natural targeting method our immune systems utilise to protect us from disease, 
antibodies can be conjugated to drug compounds to allow for targeted drug delivery. 
Antibodies which compliment a variety of disease expressing antigens can be produced 
efficiently using recombinant methods. Employing a suitable linker for the conjugation of the 
antibody and a potent drug molecule offers a method to localise drug compounds and their 
effects at the desired site.426 
Several antigens upregulated in PAH were considered for potential use as a targeting moiety 
for a polymer-drug conjugate (Table 5-1). Within PAH, the expression of pro-inflammatory 
markers, growth factors and mediators of vascular remodelling are increased. One such 
growth factor is vascular endothelial growth factor (VEGF) which is responsible for mediating 
angiogenesis, shows increased expression in the plexiform lesions of human PAH vessels 
above basal.427,428 The exact role of VEGF is still not elucidated as evidence in conflicting,429,430 
which makes it a poor protein to target. Within the vascular lesions, production of hypoxia-
inducible factor-1 is also upregulated, driving anaerobic respiration, vascularisation and 
proliferation. Targeting of intracellular HIF-1 has the potential to be hindered by the expression 
in non-disease cells.431–433. However, HIF-1 is also expressed in a variety of other cells 
including macrophages, drenditic cells and lyphmocytes. Platelet (P-) and Endothelial (E-) 
selectins as well as intracellular cell adhesion molecule-1 (ICAM-1) are all detected in greater 
quantitites in patients with PAH than in healthy patients,434–438 however in their soluble forms. 
Therefore, targeting proteins released into the circulatory system, would not achieve 
pulmonary localisation. 
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Table 5-1. Summary of changes in expression of the following possible 
antigens in PAH and controls. PAH – pulmonary arterial hypertension. 
Proteins upregulated  
in PAH 
Pros Cons 
Hypoxia induible factor-1 
Increased in PAH within 
plexiform lesions427,439 
Also present in 
macrophages,431 
drendritic cells432 and 
lymphocytes433 
intracellular adhesion 
molecule 1 (ICAM) 
Increased expression in plasma 
of children with PAH440 
Basally expressed in all 
endothelium441 
Exisits in soluble forms in 
plasma so present 
systemically440 
Vascular endothelial 
growth factor (VEGF) 
Increased expression in 
plexiform lesions of PAH 
vasculature427,428 
Conflicting evidence of 
role in PAH429,430 – not 
recommended for 
therapeutic 
applications442 
P-selectin 
Increased levels of soluble P-
selectin434,435 
Soluble release means 
systemically expressed. 
E-selectin 
Increased in endothelium in PAH 
and released in soluble 
form438,443 
Increased by microparticles 
released from PAH tissue444 
Present in hematopoietic 
tissues435,436 
As described in Chapter 1, antibodies have achieved success in the clinic although wide 
spread use of ADCs has been hindered by limitations. The recombinant production of the 
chosen antibody and reproducable modification to synthesise the final ADCs is very 
expensive.445 In addition, toxicity can still be problem as a result of the bystander effect,446 and 
through non-specific uptake and subsequent release of cytotoxic compounds in healthy 
tissues.219,268 The ability of ADCs to initiate immunogenic responses in patients has also been 
reported.219 From a production view point, the biggest issues with employing antibodies as 
targeting moieties is their limited stability and and their propensity to aggregate which presents 
a limitation on the long-term storage of ADCs.221,222 
The antigen binding region is relatively small compared to the whole antibody. To harness only 
the binding functionality, antibodies have been metabolised by enzymes to release the fab 
chain, which could then be used to form a stable targeted-drug conjugate.222,223 The quest for 
stable and potent binding moieties has led investigations further to develop peptides which 
can bind to specific targets and assist in drug localiseation using peptide-drug conjugates.445  
Over 60 therapeutic peptides have entered the market,447 although in the context of interacting 
with therapeutic targets, rather than targeting moieties for the delivery of drug molecules. 
However, the precise nature of peptides used endogenously and therapeutically demonstrate 
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the potential targeting abilities that peptide possess. The use of peptides as targeted drug 
carriers has been explored preclinically, with one having completed phase II trials.448 
ANG1005 (formerly, GRN1005) is the conjugated product of the brain-permeating peptide 
Angipeptin-2 which targets tumour expressing receptor, lipoprotein protein 1, and the cytotoxic 
drug, paclitaxel.449 Combining the targeting and permeating abilities of the peptide allows for 
paclitaxel accumulation in metastasised brain tumours, which are notoriously difficult to 
treat.448 
Peptidic targeting moieties offer several advantages over ADCs, including, stablilty, cost, 
easier synthesis and modification. Peptides can be made synthetically so do not require 
extraction and purification from biological sources which makes them easier and cheaper to 
manufacture.445 Furthermore, their simplified structure is expected to reduce the adverse 
events associated with ADC conjugates, described above.  
Employing targeting peptides in polymer drug conjugates combines the targeting ability of 
peptides with the longer circulation times and reduced systemic distribution of 
macromolecules.164,450 In addition, greater drug loadings are often tolerated. Owing to the size 
ratio between polymer and targeting peptide, multiple targeting moieties are often required on 
each polymer chain to maintain binding affinity.  
Pre-clinically, an E-selectin targeting peptide (namely, Esbp) has been evaluated as a 
targeting moiety for polymer drug conjugate. When Esbp peptide and fluorescein were 
conjugated to a poly(hydroxypropyl methacrylate) backbone, binding to TNF-α activated 
vascular endothelial cells was increased 7-fold compared to a scrambled peptide polymer 
derivative.233 Esbp was then incorporated into a doxorubicin (DOX) containing HPMA to form 
the polymer drug conjugate P-Esbp-DOX (Figure 5-2).451 When admisitered in a single IV 
dose (15 mg/kg DOX equivalent dose) to mice with 3LL foot pad tumour, tumour growth was 
inhibited for 27 days, compared to a non-targeted polymeric DOX. Furthermore, following a 
single injection (45 mg/kg DOX equivalent) of P-Esbp-DOX in mice inoculated with a B16–F10 
lung metastasis model, survival was greater than 50% after 120 days. In comparison, mice 
treated with the scrambled peptide drug polymer did not survive beyond 44 days. When a 
second dose of P-Esbp-DOX was given, survival was increased to 80% after 95 days. When 
conjugated with a visualising agent, IR783, P-Esbp was shown to accumulate in metastatic 
tissues.  
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Figure 5-2. Structure of E-selectin binding polymer shown preclinically to reduce 
colonic tumours. The backbone is made up of non-biodegradable methacrylate 
monomers. A majority of which are hydroxypropyl methacrylate to aid solubility. The 
targeting moiety, Esbp, is selective for E-selesctin and is conjugated through a gly-gly-
cys linker. The presence of the thiol is necessary for thioester rearrangement to 
facilitate the conjugation of Esbp, post-polymerisation. Doxorubicin is conjugated to a 
gly-gly linker via pH sensitive hydrazine linker.233 
Similar to the Esbp targeting moiety, a peptide has been described which appears to exhibit 
selective binding to inflamed tissues.452 The 8 amino acid peptide, namely CARSKNKDC 
(CAR), (10) was found to exhibit selective binding in wounded vasculature452 including in the 
pulmonary tissue of a sugen/hypoxia mouse model of PAH which replicates the remodelling 
and altered haemodynamic aspects of PAH.453 Determined in a tendon wound model, phage 
binding of sequences where the basic amino acid side chains of CAR were exchanged for 
neutral side chains resulted in a loss of binding.452 Binding studies indicated that CAR is a 
ligand for heparin and heparan sulfate expressed on the surface of cells452 which become 
altered due to an increased release of heparanase, an enzyme that degrades polymeric 
heparan sulfate.454 PAH is associated with an increased expression in genes encoding 
heparanase enzyme and a heparan sulfate (HS) moiety, IdoA2S-GlcNS, to which heparanase 
is resistant to.455 The IdoA2s-GlcNS moiety is the likely receptor for CAR peptide which 
mediates cell endocytosis by micropinocytosis. which increases cellular internalisation. 
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Figure 5-3. Structure of CAR peptide which exhibits selective binding for inflamed 
tissue, including lung tissue in an experimental rat model of pulmonary arterial 
hypertension.453 
Co-administration of CAR (3 mg/kg) sublingually with intravenous imatinib, a broad spectrum 
tyrosine kinase inhibitor, (5 and 20 mg/kg), increased the localisation of therapeutic action as 
measured by an 8% reduction in right ventricular systolic pressure after 1 hour compared to 
no change when given imatinib alone.456 Furthermore, CAR peptide has been conjugated to 
liposomes and nanoerythosomes (vesicles derived from red blood cells) as surface targeting 
moieties which have aided in the specificity of drug release.77,457,458 The half-life of CAR-
liposomal fasudil was 34-fold higher than that of plain fasudil, and resulted in a 35-40% 
decrease in mean pulmonary arterial pressure with no change to the mean systemic arterial 
pressure.458 Some concern was raised about the lack of interest shown by the scientific 
community in the 4 years since the CAR publications but we sought to verify the results to 
determine its suitability as a targeting moiety. 
The homing properties reportedly possessed by the CAR peptide offer a potential method to 
target a polymer-treprostinil conjugate to the inflamed PAH lung. The high dose of CAR 
employed may be required to overcome rapid clearance which is often experienced with small 
peptides or a result of the poor bioavailability when administered sublingually. Conjugation 
onto a polymer for subcutaneous delivery may offer a route to overcome these limitations. We 
sought to confirm the CAR binding findings by labelling CAR with fluorescein and visualising 
the binding to inflamed endothelial cells (HUVEC) in vitro, employing TNF-α to stimulate an 
inflammatory response. The possibility of using the CAR peptide targeting moiety to aid 
localisation and thus, promoting localised drug release was envisaged.  
 
Drug delivery at a target site can be achieved by a passive targeting approach, employing a 
disease-specific drug release mechanism. Particularly for toxic drugs or drugs which exhibit 
many off-target affects, the premature release of the drug compound results in off-target 
effects and negates the purpose of the conjugate. Only once the conjugate has reached the 
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site of release, must the linker be cleaved to release the active drug with a potent therapeutic 
response.218,459 
As well as pro-inflammatory markers, disease-mediating enzymes are also upregulated in 
PAH, which might serve as a targeting strategy. By nature, enzymes exhibit specific activity 
for a unique structure of sequence of amino acids, for example ribozymes in the translation of 
RNA into the respective proteins for which they code.460 For metabolic enzymes, this activity 
involves a cleavage step, which depending on the enzyme and substrate, can occur at different 
bonds along a primary amino acid sequence. For example, the precursor for atrial natriuretic 
peptide is synthesised endogenously as a chain of 126 amino acids with low activity.461 It is 
cleaved between a specific serine and threonine bond by the protease corin to release the 
active 28 amino acid carboxyl terminus atrial natriuretic peptide which reduces blood 
volume.462 As well as endogenous enzyme substrates, many enzymes have been shown to 
possess specificity for exogenous peptidic substrates.463 Many peptide substrates are 
commercially available conjugated to a chromophore which releases a coloured compound 
upon cleavage by the respective enzyme. Chromogenic substrates are often used in either 
bench top or in vitro assays to quantify the amount of enzyme present in a system (e.g. cell 
culture or tissue isolation).464 
The conjugation of a drug to the substrate in place of a chromophore to form an enzymatically 
degradable peptide prodrug can be envisaged. Such a prodrug linker could be employed to 
link a drug to a polymer-drug conjugate which would exhibit minimal receptor activity upon 
administration and systemic circulation. Upon interaction with the specific enzyme located at 
the target site, the linker is cleaved to release the active drug compound. 
Tissue remodelling is a distinctive feature of PAH which implicates many pathways and 
mechanisms to drive the changes seen in this disease. As part of the pro-inflammatory 
mechanism, mast cells have been shown to accumulate around the small blood vessels of 
adult patients with PAH and in monocrotaline treated rats with induced PAH.31,37,40 Mast cells 
characteristically contain enzyme-filled granules which when stimulated degranulate to 
release the enzymatic contents. Within the granules two mast cell specific, serine proteases, 
tryptase and chymase, are released. Tryptase and chymase have unknown endogenous 
substrates but are known to cleave exogenous substrates at the N-terminus.463 Both tryptase 
and chymase are thought to drive progression of PAH, even in the early stages of disease.34,465 
Tryptase stimulates collagen 1 synthesis and fibroblast proliferation,39 while chymase is 
implicated in development of bleomycin-induced lung fibrosis30, the mechanism for which is 
likely to involve activation of MMPs.466  
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Figure 5-4. Proposed concept of employing peptidic substrates for tryptase and 
chymase as a linker which would be cleaved in the pulmonary arterial hypertensive 
lung. 
We hypothesised that the specific nature and locality of tryptase and chymase as well as their 
N-terminal substrate cleavage point, make their substrates suitable prodrug appendages to 
achieve PAH specific drug release in the pulmonary tissue (Figure 5-4). We sought to 
investigate CARSKNKDC as a targeting moiety and tryptase substrates as an enzyme 
degradable linker which could be later employed on a polymeric structure. Thus, we aimed to: 
• Obtain and test the utility of CAR as a homing peptide in pulmonary arterial smooth 
muscle cells with tumour necrosis factor alpha (TNF-α) induced inflammation. 
• Develop a method to synthesise a prodrug comprised of treprostinil bound to the C-
terminal of a peptidic substrate for tryptase and chymase. 
 
Figure 5-5. Proposed Polymer drug conjugate which features CARSKNKDC as a 
targeting moiety and an enzyme substrate linker to conjugate treprostinil via the aryl 
acid. 
 Results and Discussion 
The design of a successful polymer-drug conjugate (PDC) necessitated consideration of 
method to target localisation of treprostinil in the pulmonary vessels. For any drug conjugate, 
moieties to be considered include; tissue or cell to be targeted, drug to be released, suitable 
linker to carry and release drug, strategy to target the desired tissue and polymer system 
employed to optimise pharmacokinetics and dynamics of PDC.242,267,467 Targeting of the drug 
to a tissue can be achieved directly using an active targeting moiety, where the entire PDC 
possesses specificity to the target tissue; or indirectly by achieving site specific drug release 
where the PDC itself does not exhibit any specific affinity for the target tissue. The approaches 
are not mutually exclusive and thus, both approaches were pursued.  
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Exploiting the EPR effect does not completely avoid systemic exposure and therefore, 
targeting moieties can also be employed to increase localisation. The prostanoid receptor 
target for treprostinil exists on the surface of platelets, vascular endothelial and smooth muscle 
cells. Therefore, prostanoid receptor binding would be advantaged by the localisation of 
polymer drug conjugates in the pulmonary tissue. Targeting of the extracellular compartment 
is less explored than internalised target, although the extracellular environment is has been 
proven to cleave proteolytic ADC linkers to achieve desired therapeutic effects.468,469 Several 
antigens to which an antibody could target are presented in PAH (Table 5-1), however the 
issues associated with extracting, conjugating and purifying led our attention to small targeting 
peptides. CARSKNKDC (CAR) was identified as a potential moiety which could be 
incorporated into the design of a polymer drug conjugate.  
The importance of the drug releasable linker even in targeted therapies such as antibody drug 
conjugates is established.459 The requirement for a linker to be stable during storage, injection, 
circulation and releasable at the desired site of action is just as necessary for the design of 
polymer-drug conjugates.470 From the earliest efforts to develop PDCs, it is clear the linker is 
a key feature in the design of any conjugate or pro-drug structure.470 In the case of treprostinil, 
release is required at the surface of endothelial cells, platelets and smooth muscle cells where 
prostanoid receptors are located.  Previous linkers investigated for the polymeric conjugation 
of treprostinil79,138,339,399 have consisted of esters which are labile to ubiquitous 
carboxylesterases. As discussed in Chapter 3, premature release of treprostinil was exhibited 
and thus the conjugates were unsuccessful in reducing site pain. Upon the successful design 
of a treprostinil linker which achieves PAH specific release, the potential to be employed on a 
varied of structures, including; prodrug conjugates, antibody drug conjugates, polymer drug 
conjugates, dendritic drug conjugates is opened. 
The expected benefit to patients of a treatment option which localised treprostinil to the lung 
is expected to not only increase quality of life, but also increase the efficacy of treatment by 
raising the maximum tolerated dose. Therefore, both a strategy for actively directing a 
conjugate to the lung and a strategy to selectively release the drug at the disease site were 
pursued. A targeting peptide was identified, synthesised and tested. Enzyme specific peptides 
were designed, synthesised and modified for a peptidic prodrug conjugation of polymer and 
treprostinil.  
 
Following reports of the disulfide cyclised peptide sequence CARSKNKDC452,453 the sequence 
was investigated as a method to target a polymeric conjugate. To be certain of the specificity 
of CAR peptide towards PAH, it was desirable to conduct some assays to verify its utility, 
before attempting to include CAR in a larger conjugate.  
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Figure 5-6. Structure of fluorescein (FITC)-conjugated disulfide cyclised 
CARSKNKDC peptide which has been shown to possess specific binding and uptake 
in cells in an inflammatory state.452,453  
As reported in the original literature, CAR was conjugated with FITC 75 to aid the visualisation 
of the CAR peptide 73 homing in the intended site. Chromophores by nature possess 
delocalised electrons which denote their colour. The delocalised or conjugated system often 
renders the molecule hydrophobic, which is associated with increased non-specific binding.471 
The non-specific accumulation of fluorescein-labelled conjugates in cells and tissues is 
particularly prominent when the ratio of fluorescein to the substrate or peptide is increased.472 
In testing the homing ability of CAR peptide, a small chromophore would be ideal to limit non-
specific binding. However, FITC 75 is a common chromophore used in tissue visualisation 
studies. Furthermore, the original CAR papers used FITC 75, so to verify their results, the 
same FITC chromophore was employed here to synthesise 73. 
In terms of conjugation, both the amine and carboxyl terminus of the peptide were accessible 
to conjugation and had been described previously.77 The disulfide cyclisation is a feature of 
the phage display method used to identify CAR peptide. Cyclic peptides exhibit greater stability 
than their linear counterparts.473 The disulfide link is subject to reductive conditions to form the 
two thiols so reductive conditions should be avoided. Conjugation to a polymer should be 
carefully considered as the presence of two lysine amines and carboxylic acid additional to 
the terminal groups hinders the potential for controlled amide bond formation. In negotiation 
with several companies offering quotes for the peptide, it seems that the FITC conjugation was 
an expensive step in an already expensive purchase. Therefore, rather than ordering FITC-
Ahx-CARSKNKDC-NH2 73, as the original CAR papers suggest, a non-FITC conjugated 
precursor which contained lysine masking groups was settled on as a compromise. Such a 
structure would allow for the solution-phase FITC conjugation and subsequent lysine 
deprotection to obtain the desired structure in a two-step reaction. No by-products would be 
formed in the FITC conjugation and only the protecting group would require removal from the 
peptide. The intermediate would also be available for conjugation to other structures, via the 
terminal amine.  
FITC conjugation to cyclised CAR  
Initial strategies utilised a bespoke-made CAR peptide 74. Cyclisation was accomplished by 
disulfide bond formation between the two cysteines. The N-terminus was unprotected for 
further conjugation and as described in the literature, the C-terminus was amidated. With the 
72 
Targeting of drug release 
230 
  
exception of lysine, the side chain residues (alanine, arginine, serine, asparagine, aspartic 
acid were unprotected. To ensure site-specific conjugation to the N-terminus amine, lysine 
sidechains were protected with 1-(4,4-dimethyl-2,6- dioxacyclohexylidene)ethyl (Dde) groups. 
Alternative protecting groups considered were allyloxycarbonyl (alloc) and 1-(4,4-dimethyl-2,6-
dioxocyclohex-1-ylidene)isovaleryl (ivDde) groupswhich are both orthogonal protecting groups 
stable to the conditions employed by the manufacturers to couple the amino acids and isolate 
the peptide. 
 
Table 5-2. Considered protecting groups for amines of lysine side 
chains. Alloc = allyloxycarbonyl; Dde = N-(1-(4,4-dimethyl-2,6-
dioxocyclohexylidene)ethyl); ivDde = 1-(4,4-dimethyl-2,6-dioxocyclohex-
1-ylidene)isovaleryl; TFA = trifluoroacetic acid; AcOH = acetic acid; NMM 
= N-methylmorpholine; CHCl3 = chloroform; DMF = dimethylformamide; 
NMP = N-methyl-2-pyrrolidinone; DCM = dichloromethane; Pd(Ph3P)4 = 
palladium-tetrakis(triphenylphosphine). 
Lysine 
protecting 
group 
Structure 
Stable 
conditions 
Deprotection 
conditions 
Alloc 
 
Piperidine 
TFA 
Hydrazine 
3 eq. Pd(Ph3P)4 in 
CHCl3/AcOH/NMM 
(37:2:1) 
Dde 
 
Piperidine 
TFA 
2% hydrazine in 
DMF or  
20% hydroxylamine 
/15% imidazole in 
NMP/DCM (5:1) 
ivDde 
 
Piperidine 
TFA 
2% hydrazine in 
DMF or  
20% hydroxylamine 
/15% imidazole in 
NMP/DCM (5:1) 
Protection with an alloc group forms an allyl carbamate and is cleaved catalytically with either 
palladium or tin. The presence of trace metal was however of concern for later evaluation in 
biological assays, so alloc- and allyl-based protection groups were not considered to be 
suitable at this stage. Dde and ivDde groups are both removed by treatment of 2% hydrazine 
(Scheme 5-3). During Fmoc removal steps Dde can migrate to other amine side chains which 
can be problematic in the synthesis of large peptides.474 The hindered nature of ivDde was 
thought to provide an alternative to Dde as it would circumvent these drawbacks making it 
more robust but harder to cleave.475 In the case of CARSKNKDC, only two lysine groups were 
present, both of which required protection so the benefits of ivDde would not be utilised and a 
struggle in removing the protecting groups was anticipated. Therefore, lysines were protected 
with the more easily cleaved Dde groups (Figure 5-7). 
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Figure 5-7. Structure of disulfide cyclised H-CARSK(Dde)NK(Dde)DC-NH2 74. Yellow 
indicates the 1-(4,4-dimethyl-2,6- dioxacyclohexylidene)ethyl (Dde) groups, blue 
shows the free amine terminus and the green highlights the disulfide link. 
Fluorescein conjugation to the terminal amine (highlighted blue in Figure 5-7) was conducted 
using fluorescein isothiocyanate 75 under basic conditions (Scheme 5-2).476 Isothiocyanates 
are readily reactive owing to the electrophilic carbon, so anhydrous conditions were employed. 
The carbon of an isothiocyanate is electrophilic owing to the electronegativity of the 
heteroatoms sulfur and nitrogen. The nucleophilic free amine of the peptide will attack the 
isothiocyanate carbon breaking the carbon-nitrogen π-bond resulting in the formation of a 
thiourea adduct 77 (Scheme 5-1). 
 
Scheme 5-1. Mechanism for the nucleophilic addition of CAR amine 74 into 
fluorescein isothiocyanate 75 to form thiourea product 77. 
Non-nucleophilic base, diisopropylethylamine (DIPEA), was employed to deprotonate the 
trifluoroacetate salt the peptide is supplied as. A slight excess of FITC 75 was used to ensure 
complete consumption of the peptide and to account for possible side reactions of FITC 75 
with water or other nucleophile contaminants. The reaction was monitored by RP-TLC and 
completion of the reaction was indicated by the formation of a fluorescent spot with an 
increased Rf value (0.15 versus. 0.59). A sample of the reaction (0.5 mL) was dried and the 
triethylamine hydrochloride salt was precipitated addition of THF. A pale precipitate was 
filtered through a cotton wool plugged pipette. 
73 
75 
73 
74 
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Scheme 5-2. Fluorescein isothiocyanate (FITC) 75 conjugation of cyclised CARSKNKDC 74 
with 1-(4,4-dimethyl-2,6- dioxacyclohexylidene)ethyl (Dde) lysine side chain protecting 
groups, in the presence of diisopropylethylamine (DIPEA). 
Whilst all the CAR amines were protected, attempts were made to purify FITC-CAR(Dde) 77 
before deprotection of the Dde protected lysine side chains. Isolation of FITC-CAR(Dde) 77 
was attempted using automated RP-chromatography with acetonitrile and water as the mobile 
phase. However, despite multiple attempts, resolution between the different components was 
not obtained. Eluted fractions were analysed by HPLC. Compared to retention time of the 
starting CAR(Dde) 74 at 6.2 minutes, the HPLC trace of the reaction solution contained no 
starting peptide and the presence of a new and large absorbance at 14.8 minutes. The longer 
retention time indicates an increase in lipophilicity consistent with the expected FITC 
conjugation in the desired product 77. The presence of salts in the solution was not deemed 
a problem for HPLC analysis when aqueous solvents are employed, so attempts to remove 
the salt were not repeated for subsequent samples. 
 
Figure 5-8. Chromatogram of suspected FITC-CAR(Dde) 77 analysed by HPLC using 
a gradient of 10-60% acetonitrile/water over 22 minutes. An attempt to isolate the 
product was attempted using automated RP- column, however all components of the 
crude mixture eluted together. 
The reaction was repeated on a 20 mg scale and after 18 hours the mixture split into two 
portions. The first was dried and the residue dissolved in THF to facilitate removal of 
73 
74 
76 
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triethylamine hydrochloride salt by precipitation. The yellow solution was filtered through cotton 
wool but resulted in a very pale filtrate. The cotton wool was flushed through with a 50% 
methanol/water solution. Both fractions were dried over air and analysed by 1H NMR 
spectroscopy (δ6-DMSO) but no peptide resonances were observed in the spectra. 
The remaining sample of  reaction solution was also dried. Redissolution in acetonitrile formed 
a precipitate which was filtered off through cotton wool. Serial flushing of the cotton wool with 
different solvents into different vials was conducted. A RP-TLC of each vial was conducted in 
40% acetonitrile/water. Most product was located in the first acetonitrile flush (vial 1). It was 
decided that the reaction would be carried forward with impurities still present. 
 
Figure 5-9. A sample of the cloudy solution in which fluorescein conjugation of 
CARSK(Dde)NK(Dde)DC-NH2 had been attempted was filtered through a cotton wool 
plugged pipette. A series of solvents were passed through the pipette to solubilise any 
compounds removed by filtration or interaction with the cotton. The filtrate of each flush 
was collected and analysed by thin-layer chromatography (40% acetonitrile/water). 
Most product was obtained in the first fraction in acetonitrile.j 
A trial deprotection of the Dde groups of the starting CAR(Dde) 74 was attempted using 
hydrazine hydrate 78 on a 2 mg scale (Scheme 5-3). Tracking by RP-HPLC from the starting 
material showed a decrease in retention time from 10.4 minutes to 8.2 minutes, which was 
consistent with an increase in polarity expected for lysine deprotection. 
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Scheme 5-3. Deprotection of lysine protecting group, 1-(4,4-dimethyl-2,6- 
dioxacyclohexylidene)ethyl (Dde) of cyclised CARSKNKDC 75 with hydrazine 78 to 
release the free amine peptide 79, forming a pyrazole side product 80.  
The reaction solution was dried under a stream of air and the crude residue was analysed by 
1H NMR spectroscopy. The spectra showed a change in the resonance corresponding to the 
methyl group of the Dde group from a doublet at 2.57 ppm in the starting CAR(Dde) 74 to a 
broad singlet at 2.46 ppm (labelled pink in Figure 5-10). This suggested a reaction at the 
alkene had occurred (Scheme 5-3). Additionally, a singlet at 2.39 ppm, corresponding to the 
four identical protons on the Dde cyclohexyl ring before treatment with hydrazine 78, was split 
into two different singlets at 2.36 and 2.71 ppm. This suggested that the Dde structure was no 
longer symmetrical and the downfield shift is consistent with the formation of the pyrazole 
group 80. This evidence suggested that the reaction had occurred as desired but still contained 
the pyrazole by-product, 80. Successful conditions for forming free amine CAR 79 by Dde 
removal of CAR(Dde) 74 were verified so the conditions were transferred to FITC-CAR(Dde) 
77 without further purification.  
 
79 
77 78 
74 
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Figure 5-10. 1H NMR spectrum of cyclised CAR 79 before and after 1-(4,4-dimethyl-
2,6- dioxacyclohexylidene)ethyl (Dde) cleavage by hydrazine hydrate 78 showing the 
presence of pyrazole by-product 80. 
A small sample of FITC-CAR(Dde) 77 was then allowed to react with hydrazine hydrate 78 to 
remove the Dde groups. The reaction was monitored by HPLC. Impure starting material 77 
was used so to be able to achieve better separation of peaks on the HPLC chromatogram, a 
slower gradient than previously used for the deprotection of the starting CAR(Dde) 74 was 
employed.  
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Scheme 5-4. Deprotection of lysine 1-(4,4-dimethyl-2,6- dioxacyclohexylidene)ethyl 
(Dde) groups of FITC-CARSKNKDC 77 to the lysine side chain product 81 by 
hydrazine hydrate 78. 
The reaction was monitored by HPLC using a solvent gradient 25-50 acetonitrile/water over 
15 minutes and then retaining 50% acetonitrile for a further 15 minutes. Treatment of the FITC 
labelled peptide 77 with hydrazine hydrate 78 resulted in the formation of a new HPLC 
absorbance at 7.0 minutes and decrease of the starting peptide 77 absorbance at 15.1 min. 
The change in the HPLC elutogram was consistent with the decrease in retention time 
observed for the deprotection of the starting CAR(Dde) 74.  
 
Figure 5-11. Comparison of chromatographs obtained of FITC-
CARSK(Dde)NK(Dde)DC-NH2 77 before (A) and after (B) treatment with hydrazine 
hydrate to afford free amines of FITC-CARSKNKDC-NH2. 81 Peptide were analysed 
by HPLC using 25-50% acetonitrile/water mobile phase. 
The hydrazine 78 deprotection of FITC-CAR(Dde) 77 was again conducted on a 5 mg scale 
in acetonitrile. Upon addition of hydrazine hydrate 78, a precipitate was formed and collected 
by filtration through cotton wool. The filtrate was retained, and precipitate flushed with water 
and the filtrate collected. Both solutions were analysed by HPLC (Figure 5-12), using a solvent 
gradient 40-70% acetonitrile/water over 15 minutes and plateauing at 70% for 15 minutes. The 
peptidic product was found in the first acetonitrile solution (A). Flushing with water released 
very little compound as indicated by the much smaller scale. 
76 
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Figure 5-12. HPLC elutograms of filtered FITC-CAR peptide 77 upon treatment of 
hydrazine hydrate 78. (A) shows filtrate in acetonitrile and (B) shows water soluble 
precipitate.  
It was questioned whether the difficulty in isolating the deprotonated FITC-CAR 81 was a result 
of the presence of FITC 75 or residual impurities from the FITC-conjugation step (Scheme 
5-2). For this reason, an attempt was made to remove residual impurities. FITC-CAR(Dde) 77 
(20 mg) was dissolved in acetonitrile and a drop of trifluoracetic acid added to form the 
triethylamine salt. The triethylammonium trifluoroacetate salt precipitate formed was filtered 
through cotton wool. Upon addition of hydrazine hydrate 78 fumes were observed, and a 
precipitate formed. After 10 minutes the solution was filtered through cotton wool and the 
filtrate collected. The precipitate was flushed with water and both filtrates analysed by HPLC. 
(A and B of Figure 5-13, respectively). An unidentified peptide product was observed by 
increased absorbance at 217 nm in the acetonitrile layer which produced a sharp peak at 5.3 
minutes. The aqueous flush fraction also contained a peak at 4.5 minutes but with a reduced 
intensity (25%, as shown by the different scales). 
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Figure 5-13. HPLC elutograms of reaction with FITC-CAR 75 with hydrazine hydrate 
78 following triethylamine salt removal with trifluoroacetic acid. The reaction was 
filtered through cotton wool with acetonitrile and the filtrate retained (A). The precipitate 
collected was flushed through with water and analysed (B). 
The main hindrance experienced during the synthesis is the small scale of the reactions 
undertaken which eliminated the possibility of analysis by 1H NMR or by multiple techniques. 
Therefore, after several unsuccessful attempts to isolate the product by precipitation and 
dissolution in different solvents, fractions obtained thus far were analysed by TLC to confirm 
the presence of possible products (Figure 5-14). The fractions which contained the visibly 
orange product with were then pooled together and isolation by automated RP column 
chromatography attempted. However, separation of the peaks was not achieved as 
determined by TLC, which showed the same compounds in all the fractions.  
 
Figure 5-14. All fractions retained from FITC-CAR(Dde) deprotection with hydrazine 
hydrate until this point were analysed by simultaneous thin layer chromatography 
employing 50% acetonitrile/water, represented as an accurate drawing of the TLC 
observed. Purification of small quantities was challenging and combining relevant 
fractions was anticipated to increase sensitivity of detection. All fractions contained the 
orange compound and so were combined for further purification. 
Employing a shallower solvent gradient (from 12-80% acetonitrile in the first run to 5-40% 
acetonitrile over double the time) facilitated partial separation by collection of compounds into 
one of two populations. The two slightly overlapping peaks on the chromatogram were both 
UV active allowing for detection, however the compounds with a shorter retention time 
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possessed a spot which was coloured yellow in white light on a TLC plate (Rf =0.35). The 
fractions obtained from the automated RP chromatography were split into two populations 
(Figure 5-15); those containing the yellow spot and those with a lower Rf without the yellow 
spot. Owing to the overlapping retention times, compounds thought to be side products 
appearing at different Rfs were also unavoidably collected. The pooled fractions were dried by 
lyophilisation and analysed by 1H NMR spectroscopy. Both spectra showed the presence of 
FITC 75 resonances but a lack of resonances observed corresponding to the peptide 74, 
indicating the peptide was still bound to the stationary phase. Repeat flushing using methanol, 
acetonitrile and water did not isolate the peptide, as determined by 1H NMR spectroscopy.  
 
Figure 5-15. Accurate drawing of the thin layer chromatogram observed showing 
fractions from column chromatography of pooled fluorescein-XCARSKNKDC reaction 
mixtures. Separation achieved was poor and to maintain reasonable concentrations 
for 1H NMR spectroscopy, the fractions were split into two populations labelled in blue 
and purple. 
FITC-conjugation of the pre-made peptide 74 was achievable and easy to deprotect as 
determined by tracking of the reaction using TLC. HPLC indicated both reactions went to 
completion, although the isolation the peptides proved problematic. Purification of both the 
FITC 75 conjugation (Scheme 5-2) and Dde removal steps (Scheme 5-4) proved problematic 
as it was difficult to determine the location of the peptidic compound because of the small 
scales employed. An alternative method of deprotection has been reported using imidazole 
and hydroxylamine.477 However, it was assumed that the issue in purification would remain. 
At the time, only analytical HPLC columns were available which made separation attempts 
tedious. Loading high concentrations of reaction mix onto the column made UV detection 
virtually impossible as for all wavelength monitored, the concentration was too high and the 
signal was off scale preventing accurate resolution and measurement. Additional to this, too 
high loading would result in poor dissolution and the impure product would exhibit poor column 
interaction and the risk on precipitation on the column. Upon seeking advice from colleagues, 
the opportunity to synthesise the desired peptide by solid phase peptide synthesis (SPPS) 
was presented. 
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Solid phase peptide synthesis of FITC-CAR 
SPPS allows for a controlled stepwise conjugation of amino acids. Choosing the correct side 
chain and N-terminal protecting groups, conjugation can preferentially be conducted. 
Furthermore, reaction on the solid phase allows for easy removal of excess reagents and 
unconjugated by-products by simple filtration after each step. With the use of an automated 
system, a short peptide such as CAR peptide could be synthesised within 24 hours, followed 
by a FITC 75 conjugation and a cyclisation step (Figure 5-16). In light of the struggle 
encountered with solution phase work-up, SPPS was considered simpler and predictable. For 
this reason, synthesis of CAR peptide on-resin from its constituent amino acids was pursued. 
The variety of different protecting groups, coupling reagents and the number of unwanted side 
reactions possible (Described earlier in Chapter 3, Scheme 3-3), necessitates a thorough 
plan for SPPS synthesis (Figure 5-16).  
 
Figure 5-16. Considerations for synthesis of FITC-XCARSKNKDC using solid phase 
peptide synthesis. 
N-terminal growth of peptides using Fmoc-protected amino acids was employed as it is a 
robust, reliable and widely used methodology for peptide synthesis and had previously been 
reported to be possible with CAR peptide 73.478 The literature reportedly synthesised CAR on 
a polystyrene (PS) resin with surface PEG chains and terminated with a peptide amide linker 
(PAL).452,479 Polystyrene is a cost-efficient resin matrix which can be used on small to large 
scale. PS has good swelling properties in organic solvents but for long sequences can facilitate 
peptide aggregation. Polar supports, such as polyethylene glycol (PEG) are better for such 
peptides and so to combine both properties, PEG-PS composites are often employed. A 
comparable resin for the synthesis of CAR peptide 73 was sought. 
PAL-Novasyn® TentaGel® resin fitted the resin description employed in the literature and 
consists of: (a) a core copolystyrene with mesh size 100-200 for organic swelling; (b) an outer 
layer of water soluble PEG chains to aid swelling and interactions with the solvent; and (c) an 
aminomethyl-dimethoxyphenoxyvaleric acid terminal peptide amide linker (PAL) which will 
conjugate to the carboxylic acid of the first amino acid, cysteine (Scheme 5-5). Upon TFA-
catalysed cleavage of the peptide from the PAL-resin, the primary amide derivative of the 
peptide carboxyl terminus 103 would be generated (Scheme 5-5.). The loading for PAL-
Novasyn TG resin was 0.22 mmol/g which is low for a standard resin but will facilitate potential 
cyclisation of the thiols, whilst on resin which will be easier to purify than cyclisation in solution. 
Targeting of drug release 
241 
  
Complete coupling with 100 mg of resin, will yield a maximum of 0.022mmol of product. For 
the desired peptide with molecular mass 1523 g/mol, this will result in a maximum of 34 mg of 
product.  
 
Scheme 5-5. Proposed mechanism for acid-mediated peptide cleavage from peptide 
amide linker (PAL) resin to form a primary amide on the peptide C-terminus, 81. 
Fmoc-amino acids, except cysteines, were employed possessing acid-sensitive side chain 
protecting groups so deprotection could occur during the final resin cleavage step. Disulfide-
linked peptides (highlighted blue in structure 74) exist in nature, for example in the hormones 
oxytocin and somatostatin (Figure 5-17) and also between keratin strands in hair follicles. 
However, their synthesis is often very sensitive to the oxidation technique, peptide structure, 
and solvent employed during the disulfide bond formation leading to peptide cyclisation.  
 
Figure 5-17. Structure of naturally occurring disulfide linked cyclic peptide hormones; 
oxytocin 82 and somastatin 83 Disulfide bonds are highlighted in blue.  
Anticipating a need to explore cyclisation both on- and off-resin, an orthogonal thiol protecting 
group was sought. The ideal protecting group would be stable to peptide formation and resin 
cleavage conditions and be removed by conditions which all other protecting groups and resin 
linker would be stable to. The thiol protecting group, acetamidomethyl (Acm), was employed 
for cysteine protection as it is stabile to 95% TFA and will cleave and be simultaneously 
oxidised to the disulfide in the presence of oxidising agents such as iodine.  
 
82 81 
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Figure 5-18. Structure of Fluorenylmethyloxycarbonyl-(Acetamidomethyl) Cysteine. 
On resin FITC 75 conjugation at the N-terminus undergoes a cyclisation during acid-mediated 
resin cleavage which cleaves the last amino acid (Scheme 5-6).480 To prevent this a long 
enough spacer can be introduced which does not readily form the cyclisation product. An 
aminohexanoic acid (Ahx) spacer was included in the sequence at the N-terminus (denoted X 
in Scheme 5-7) to aid on-resin conjugation in later steps. 
 
Scheme 5-6. Possible cyclisation upon acid-mediated resin cleavage of N-terminal 
Fluorescein-conjugated amino acid resulting in removal of cyclised conjugate of 
fluorescein and terminal amino acid. 
The coupling to form CAR peptide 84 was carried out in quintuplet using 100 mg resin per 
vessel. As recommended for all polystyrene resins, the resin was swollen in dichloromethane 
(DCM) and reaction was carried out in DMF using an automated synthesiser. Coupling using 
HBTU and DIPEA is most widely employed, so these conditions were examined first. Amino 
acids were added to the resin in order of the carbonyl terminal amino acid to the amine-terminal 
amino acid (Scheme 5-7). The resin was treated with 5 equivalents of both the first amino acid 
(Fmoc-Cys(Acm)-OH) (Figure 5-18) and HBTU and 10 equivalents of DIPEA. The coupling 
reaction was conducted twice for each amino acid before removal of the Fmoc group on the 
growing peptide on the resin. Fmoc deprotection was conducted using a solution of 40% 
piperidine in DMF. Although Fmoc is labile to piperidine, it is stable to DIPEA owing to the 
hindered tertiary amine. The final automated step involved deprotection of the Fmoc group 
after the coupling of the Ahx amino acid 105 of resin-bound CAR peptide 84. 
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Scheme 5-7. Proposed fluorenylmethyloxycarbonyl (Fmoc)-protected solid phase 
peptide synthesis (SPPS) of Fluorescein-XCARSKNKDC from corresponding amino 
acids. The process is automated up until the formation of 84 which is Fmoc-
deprotected using piperidine to render the free amine terminus. Fluorescein 
isothiocyanate (FITC) is then reacted and the cysteine thiols are deprotected and 
cyclised. TFA = trifluoroacetic acid; TIS = triisopropyl silane; water. Pbf = 2,2,4,6,7-
pentamethyldihydrobenzofuran-5-sulfonyl; OtBu = tertiary butyl ester; Boc = tert-
butyloxycarbonyl; Trt = trityl; PAL-PEG-PS = peptide amide linker-poly(ethylene 
glycol)-polystyrene; NMP = N-methylpyrrolidinone; DIPEA = diisopropylethylamine; 
DMF = dimethylformamide; [O] = oxidising agent. HBTU =3-
[Bis(dimethylamino)methyliumyl]-3H-benzotriazol-1-oxide hexafluorophosphate. 
Confirmation of a free terminal amine of 84 was checked with the Kaiser test which involves 
treating a sample of beads with ninhydrin 85. Primary amines form an imine compound when 
treated with ninhydrin (Scheme 5-8). The imine is hydrolysed to form a primary amine 86 and 
aldehyde. The primary amine formed 86 can react with another molecule of ninhydrin 85 to 
83 
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from an imine-bridging conjugated dimer 87 which results in the solution exhibiting an intense 
blue colour. 
 
Scheme 5-8. Reaction between primary amine of amino acid on resin solid support 
and ninhydrin 85 to produce a solution of blue dimer 87 via primary amine intermediate 
86. In the absence of a resin-bound amine the reaction cannot proceed and the 
solution remain colourless. 
The resin bound peptide 84 was then conjugated to FITC 78 in DIPEA/DMF and an aliquot of 
the reaction cleaved from the resin using standard TFA procedure. After drying, HPLC analysis 
confirmed the presence of one product with the mass of the desired linear CAR(Acm) peptide 
89 as the [M+2H]2+ ion with mass of 834.3 m/z.  
 
Scheme 5-9. Isolation of linear fluorescein-CARSKNKDC peptide with 
acetamidomethyl thiol protecting groups 89. On resin fluorescein isothiocyanate 75 
(FITC) conjugation of fluorenylmethyloxycarbonyl (Fmoc) depotected resin bound 
peptide, 84. Followed by resin removal and global deprotection of all side chains other 
than cysteine acetamidomethyl (Acm) thiol protecting group of 88 to form amidated 
fluorescein-conjugated CARSKNKDC peptide 89. TFA = trifluoroacetic acid; TIS = 
triisopropyl silane; Pbf = 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl; OtBu = 
tertiary butyl ester; Boc = tert-butyloxycarbonyl; Trt = trityl; DIPEA = diisopropyl 
ethylamine. 
One reaction vessel was retained and cleaved using standard conditions to obtain linear FITC-
CAR(Acm) 89. The peptide was purified by preparative HPLC and the eluted fractions 
collected. The fractions were analysed by analytical HPLC and the pure fractions combined. 
85 
84 
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The solvent was removed by lyophilisation to yield FITC-CAR(Acm) 89 as an orange glassy 
solid. 
 
Figure 5-19. Chromatogram of FITC-Ahx-C(Acm)ARSKNKDC(Acm) 89 following 
purification by preparative high performance liquid chromatography.  
Disulfide bonds form between thiols under oxidative conditions. The pKa of a thiol is 
approximately 5 units lower than the corresponding alcohol (pKaSH = ~8.5 pKaOH = ~15), 
making thiols weakly acidic.481,482 As a result, in mild oxidative conditions, thiols can oxidise to 
form disulfide bonds. Thiol oxidation can be achieved on resin and off resin, post- or during 
thiol protecting group removal. Depending on the peptide, solution, and concentration, 
disulphide bonds can form mono-cyclic peptides, dimerization of peptides, polymers or a 
combination of all three.  
 
Figure 5-20. Possible cyclisation products, a) monocylised peptide, b) sidulfide CAR 
peptide dimer c) cyclisation of tripeptide and d) polymerisation by disulfide bond 
formation. 
Cys(Acm) is known to oxidise faster in polar protic solvents, such as water and methanol, 
compared to organic aprotic solvents such as DCM and chloroform (CHCl3).483 In rare 
circumstances, migration of Acm groups (shown in red in Figure 5-18) to other side chains 
including Ser, has been reported.484 Different conditions including thallium or mercury salt 
oxidation, presence of acid, trifluoroethanol /chloroform solvent mixtures, are employed to 
circumvent side reactions and encourage the formation of the desired product. In this case, 
the disulphide mono-cyclic peptide was sought. 
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Scheme 5-10. Proposed on-resin cyclisation of fluorescein conjugated CARSKNKDC 
88 (FITC-CAR) to form the disulfide bridge of 90, followed by deprotection of the side 
chains and removal of the resin to form 73. TFA = trifluoroacetic acid; TIS = triisopropyl 
silane; water. Pbf = 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl; OtBu = 
tertiary butyl ester; Boc = tert-butyloxycarbonyl; Trt = trityl 
Cyclisation with iodine 
Iodine is known to oxidise free and Acm-protected thiols. Iodine cyclisation of resin bound 
peptide 88 was attempted twice; once using DIPEA in DMF on a 22 μmol scale, the other 
using ammonium acetate in DMF on a 4.4 μmol scale. Both reactions were left for 1 hour 
before rinsing and drying and removing from resin. The dry yellow solid formed had a mass 
greater than that expected which suggested that the product was impure and either resin-
bound impurities or residual acid may be present. Oxidation of the Acm groups to achieve the 
disulfide bond in the presence of DIPEA produced multiple products observed by HPLC. The 
reaction with ammonium acetate buffer following the method employed by Nishino,485 showed 
fewer products by HPLC, with one main resonance at 14.3 minutes (Figure 5-21). 
 
Figure 5-21. Chromatograms of peptide 88 products after cyclisation attempts. The 
chromatograms show the products formed after on resin cyclisation, A) in the presence 
of diisopropylethylamine (DIPEA) and B), in the presence of ammonium acetate buffer. 
The sample obtained from the cyclisation in the presence of ammonium acetate was analysed 
by LCMS. However, the UV absorbance was less defined, and no spectral signal was detected 
corresponding to either the unclycised peptide (Mr = 1521 m/z) or the expected product (Mr = 
1523 m/z) or its associated salts (Figure 5-22). 
87 
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Figure 5-22. LCMS chromatograph of the product obtained following on-resin 
cyclisation of FITC-CARSKNKDC by simultaneous remocal of (Acm) groups and 
oxidation of the cysteinyl thiols. The mass spectrum of the main peak did not show any 
of the uncyclized starting material, expected cyclised product with mass 1523 m/z or 
its associated salts. 
Cyclisation with thallium  
Heavy metals are known to bind to the polystyrene mesh, which despite repeated washings 
become liberated in the acidic conditions of resin cleavage to contaminate the cleaved peptide. 
Although the use of heavy metals with resin-bound reactions is avoided, thallium had been 
reported to achieve successful on-resin cyclisations, so was used to examined to investigate 
if cyclisation of CAR 88 could be achieved. Cyclisation using thallium trifluoroacetate486 was 
carried out on a 4.4 μmol scale in DMF for 1.5 hours. The peptide was isolated by cleaving 
from resin before analysis by HPLC. Multiple resonances were observed indicating 
unsuccessful cyclisation (Figure 5-23).  
 
Figure 5-23. The chromatogram showing the result of on resin cyclisation of 88 using 
thallium trifluoroacetate (shown in inset). 
Forming the disulfide bond with the peptide bound to the resin was expected to be easier to 
purify owing to the ability to rinse away side-products and unreacted reagents. However, HPLC 
traces revealed multiple products were being formed, thus making it difficult to isolate. Despite 
the low resin loading, this is likely a result of the proximity of peptides to their neighbour, 
enabling dimer, trimers and polymers to form. The separation of the different peptide 
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compounds by HPLC was anticipated to be difficult and time consuming using an analytical 
column, so before purification was attempted, off-resin cyclisations were trialled. 
Linear FITC-conjugated CAR peptide 89 obtained previously was used to attempt the 
simultaneous deprotection and oxidation cyclisation of the cysteine thiols to form desired 
peptide 73. Unlike the on-resin attempts, the side chain protecting groups of amino acids other 
than cysteine in peptide 89 are not present. To prevent intermolecular disulfide bonds forming, 
the reactions were run in dilute solvent systems which kept the concentrations low and 
minimised interaction between peptides. 
 
Scheme 5-11. Proposed cyclisation of linear Fluorescein (FITC)-CAR(Acm) 89 to form 
disulfide bond of 73 through cysteine thiols.  
Off-resin cyclisation with iodine 
A sample of the linear FITC-CAR(Acm) 89 was used to oxidise the thiols in solution. The 
cyclisation was attempted on a 1.2 mg scale using 60 equivalents of iodine in MeOH/H2O (8 
mL).487 The reaction was left for 24 hours and analysed by HPLC. In comparison to linear 
FITC-CAR(Acm) 89 which has a retention time of 10.2 minutes, the product of the cyclisation 
either exhibited no interaction with the column and was eluted at the void volume or was not 
isolated during work-up (Figure 5-24). 
 
Figure 5-24. Chomatogram of the peptide following off resin cyclisation using iodine. 
No peak was observed, suggesting the peptide had been lost during wor-up. 
Cyclisation with Acm-protected thiols was not as straightforward as anticipated and multiple 
products were forming, presumably by the close interaction of peptide chains on resin allowing 
for reactions between different chains. An alternative strategy was sought which would allow 
for thiol deprotection without simultaneous disulfide bond formation. Synthesis of CAR-peptide 
91 was performed using trityl-protected cysteine which is deprotected with mild acid to expose 
free thiol groups which can be oxidised under milder oxidative conditions. The reaction was 
88 72 
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carried out using automated peptide synthesis on a 100 mg scale in duplicate. FITC 75 was 
conjugated as described before and was deemed successful by a clear result upon Kaiser 
test, suggesting full conjugation of amine terminus forming FITC-CAR(trt)-Resin 91 had been 
formed. 
 
Scheme 5-12. Proposed synthesis of fluorescein-XCARSKNKDC-NH2 73 by 
employing tritylated cysteine (Cys(Trt)) for solid phase peptide synthesis. TFA = 
trifluoroacetic acid; TIS = triisopropyl silane; EDT = ethane dithiol; Pbf = 2,2,4,6,7-
pentamethyldihydrobenzofuran-5-sulfonyl; OtBu = tertiary butyl ester; Boc = tert-
butyloxycarbonyl; Trt = trityl; PAL-PEG-PS = peptide amide linker-poly(ethylene 
glycol)-polystyrene; NMP = N-methylpyrrolidinone; DIPEA = diisopropylethylamine; 
DMF = dimethylformamide; [O] = oxidising agent. HBTU =3-[Bis(di-
methylamino)methyliumyl]-3H-benzotriazol-1-oxide hexafluorophosphate. 
90 
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On resin cyclisation of the FITC-CAR 92 using trityl protecting groups for cysteine thiols was 
attempted to investigate whether a more labile cysteine-protecting group results in more 
efficient cyclisation to achieve desired peptide 73 (Scheme 5-13).  
 
Scheme 5-13. Proposed on-resin cyclisation of fluorescein conjugated CARSKNKDC 
92 (FITC-CAR) to form the cyclised peptide 73. The trityl-protected thiols are 
simultaneously deprotected and cyclised by oxidation to form the cyclised peptide 90. 
The remaining side chain protecting groups are removed during the resin cleavage 
step to form desired peptide 73. TFA = trifluoroacetic acid; TIS = triisopropyl silane; 
EDT = ethane dithiol; Pbf = 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl; OtBu 
= tertiary butyl ester; Boc = tert-butyloxycarbonyl; Trt = trityl; [O] = oxidising agent. 
Iodine oxidation of fully protected peptide 92 was conducted on a 2.2 μmol scale in the 
presence of DIPEA in DCM which possesses better resin swelling properties so was thought 
to result in fewer intermolecular disulfide bonds. After two hours, the resin was washed, dried 
and cleaved. HPLC analysis of the peptide product showed multiple absorbances. 
 
Figure 5-25. High performance liquid chromatogram showing multiple compounds are 
formed following on resin cyclisation of fluorescein conjugated XCARSKNKDC peptide 
92 (FITC-CAR) with trityl protected cysteine thiols using iodine. 
Iodine oxidation of FITC-CAR(Trt) 92 was carried out again on the same scale but in DMF 
without the presence of a base. HPLC analysis of the cleaved product obtained showed many 
absorbances, with no obvious major product (Figure 5-26). 
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Figure 5-26 Chromatogram of the products formed following on resin iodine cyclisation 
of the trityl-protected cysteines of fluorescein-XCARSKNKDC 92 (FITC-CAR). Multiple 
products were detected. 
Although cyclisation using thallium is undesirable for reasons explained earlier, the cyclisation 
of FITC-CAR(trt) 92 using thallium trifluoroacetate 93 was performed out of curiosity as to 
whether the cyclised product 73 could be obtained by on-resin cyclisation techniques. 
 
Scheme 5-14. Proposed conversion of fluorescein conjugated XCARSKNKDC (FITC-
CAR) 92 to form desired peptide 73, using thallium trifluoroacetate 93 to form the 
disulfide bond. TFA = trifluoroacetic acid; TIS = triisopropyl silane; EDT = ethane 
dithiol; Pbf = 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl; OtBu = tertiary butyl 
ester; Boc = tert-butyloxycarbonyl; Trt = trityl; 
Protected FITC-CAR(Trt)-Resin 92 on a 2.2 μmol scale was treated with thallium 
trifluoroacetate 93 in DMF for 2 hours. HPLC of the resin-cleaved product showed one main 
resonance at 11.2 minutes (Figure 5-27). The identity of the compound corresponding to the 
main absorbance was not investigated as it was known that the thallium 93 mediated oxidation 
was not viable for the synthesis of a biologically relevant compound. The result however, 
indicated that it was possible to form one product predominantly.  
91 
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Figure 5-27 Chromatogram of the product isolated from resin following on resin 
cyclisation of fluorescein conjugated XCARSKNKDC 92 (FIC-CAR) via disulfide bond 
formation between the two trityl-cysteines with thallium trifluoroacetate 93. Although 
multiple resonances were observed, one peak dominated. 
Meanwhile, investigations were conducted on the solution phase cyclisation of triyl CAR 
peptide 94. The remaining resin bound protected FITC-CAR(Trt) 92 was cleaved from the 
resin using TFA in the presence of triisopropyl silane (TIS), water and ethane dithiol. Treatment 
of TFA with trityl groups as well as all other side chains, results in removal of the protecting 
groups and exposure of the amino acid side chain. The presence of ethane dithiol was 
employed to maintain the reduced state of the trityl-cleaved cysteine thiols and prevent 
alkylation of the thiols. Once cleaved and lyophilised, the free thiols can be oxidised to form a 
disulfide bond. 
 
Scheme 5-15. Resin removal and removal of amino acid side chains of fluorescein 
conjugated CARSKNKDC 92 (FITC-CAR) in the presence of trifluoroacetic acid (TFA), 
triisopropyl silane 95 (TIS), ethane dithiol (EDT) and water. Removal of cysteine trityl 
protecting groups results in peptide with free thiols 94 and trityl cation 96 which is 
sequestered by TIS 95. Pbf = 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl; 
OtBu = tertiary butyl ester; Boc = tert-butyloxycarbonyl; Trt = trityl; 
Oxidation of unprotected thiols can be governed by thermodynamic or kinetic control. 
Formation of the kinetically most favourable product is often achieved with iodine. The addition 
of an iodine solution to the peptide stirring in an organic-aqueous mixture produces a 
permanent yellow colour when oxidation is complete. 
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Scheme 5-16. Proposed solution phase cyclisation of fluorescein conjugated 
CARSKNKDC (FITC-CAR) thiol 94 to form desired cyclised peptide 73. 
Thermodynamic oxidation can be carried out by oxygen. Using atmospheric air is the simplest 
method, requiring dissolution and stirring of the peptide in a volatile aqueous buffer solution 
such as ammonium bicarbonate. The slow reaction and dilute concentration used reduces 
intermolecular reactions and facilitates the cyclisation of peptides. Depending on the peptide 
sequence, the reaction time varies and can be catalysed by the addition of activated charcoal. 
Alternative oxidising conditions such as potassium ferricyanide, can also be employed. A 16 
mg sample of FITC-AHx-CARSKNKDC 93 was oxidised by dissolution in deaerated 
ammonium bicarbonate solution (1 M, 32 mL) and stirred at RT for 16 hours. The reaction was 
monitored by HPLC using a mobile phase 10-60% acetonitrile/water over 20 minutes. The first 
HPLC sample was analysed after 2 minutes of reaction initiation (Figure 5-28). 
 
Figure 5-28. Two chromatograms of the air oxidation of the two cysteine thiols to form 
a disulfide linked, cyclised product. A) is taken immediately after the reaction was 
initiated and B is following 16 hours. The absorbance at 10.6 decreases as that at 10.2 
minutes increases. 
Oxidation of thiol FITC-CAR 94 with air and ammonium bicarbonate was deemed complete by 
HPLC after 16 hours without the need for catalysis. Purification of expected cyclised peptide 
73 was carried out by preparative HPLC and the product-containing fractions were dried in 
vacuo to yield a dry orange powder which contained mostly ammonium carbonate salt, as 
determined by 1H NMR spectroscopy. Upon dilution of the product in water, methanol, 
acetonitrile, DMSO or various combinations, a red precipitate remained, usually on the glass 
surface. The yellow solution was run on an analytical HPLC column but did not show any 
absorption after 20 minutes. Only addition of acetic acid in water solubilised the precipitate. 
The salt was removed by preparative chromatography. The eluted product was collected in 
fractions which were checked for purity by analytical HPLC before combining pure fractions. 
93 72 
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The solvent was then removed in vacuo to yield cyclised FITC-CAR 73 as an orange oil with 
molecular mass 1523.6 g/mol as confirmed by MS. 
Binding of CAR peptide to HUVECs 
The selective binding of FITC-CAR had previously been shown in vitro, using chinese hamster 
ovarian cells (CHO-K) and in an in vivo monocrotaline PAH model in rats.452,453,456 The binding 
site of CAR was shown to be dependant on the presence of heparan glycan chains on the 
cells surface. When a CHO-K cell line with defective glycosaminglycan biosynthesis, pgsA-
745, was incubated with a CAR-expressing phage, a 50-fold decrease in binding was observed 
compared to the CHO-K cells.452 Furthermore, when CHO-K cells were pretreated with 
heparanase I and III, binding was reduced by 80%. However, this was not measured 
comparing relative binding in a healthy state versus inflammatory state. To investigate utility 
of CAR peptide as a disease targeting moiety for the treatment of PAH, an in vitro assay was 
designed to test and compare CAR peptide binding in endothelial cells in a control and pro-
inflammatory state. 
To extend this concept, CAR binding was measured using an endothelial cell line, human 
umbilical venous endothelial cells (HUVECs). TNF-α is an inflammatory mediator upregulated 
in many inflammatory diseases including cancer, irritable bowel disease, depression. 
Proinflammatory TNF-α is released from a variety of cells, including smooth muscle cells and 
fibroblasts to induce an inflammatory response.488 TNF-α is a pro-inflammatory cytokine which 
by inducing numerous signalling cascades, leads to adhesion of leukocytes, migration of 
transendothelial cells, vascular leaks as well as promoting thrombosis in vascular endothelial 
cells.489  In addition, TNF-α has been implicated in contributing to the pathobiology of PAH, as 
evidenced in several in vitro and in vivo models.490–495 Mechanisms for TNF-α participation in 
PAH have been investigated. TNF-alpha reduces expression of bone morphogenetic protein 
type-II receptor (BMPR-II) which is heavily implicated in the progression of PAH. 496 The 
mechanism is thought to involve an upregulation of NOTCH II signalling, a known pro-
inflammatory pathway. Furthermore, TNF-α activates the transcription factor nuclear factor-
kappa B (NF-κB) which is a central driver in inflammatory mediated diseases.497 Antagonism 
of TNF-α is considered a therapeutic approach for such inflammatory diseases.498 TNF-α 
antagonism using recombinant TNF-α receptor II:IgG Fc fusion protein (rhTNFRFc) was 
shown to attenuate mean pulmonany arterial pressure and remodelling in a monocrotaline-
induced PAH model in rats.499  
Owing to the vast mechanistic changes induced by its presence, TNF-α is used to stimulate 
controlled inflammatory states, both in vitro and in vivo. To mimic an aspect of the inflammatory 
response in PAH, TNF-α was used to initiate an inflammatory cellular response in the binding 
assay.  
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Figure 5-29 Fluorescence image of cultured human umbilical vein endothelial cells. 
Nuclei are stained blue using DAPI and the endothelial marker, CD31, is visualised in 
red. 
Initially, the FITC-CAR 73 was added to the solution using the concentration reported in the 
literature (10 μM) as a preliminary investigation into whether fluorescence of the FITC-CAR 
could be detected. Cultured HUVECs were treated with FITC-CAR (10 μM) in diluted in 
endothelial cell media in the absence or presence of TNF-α (10 μg/mL) for 24 hours. After 
staining of the nucleus and fixing of the cells, the slides were analysed by fluorescent 
microscopy within 48 hours. Excitation and emission wavelengths of 525 nm and 495 nm were 
used for fluorescein, and 358 nm and 461 nm were used for DAPI. 
 
Figure 5-30. Fluorescence microscopy of human umbilical vein endothelial cells 
(HUVECs) treated with Fluorescein-labelled cyclised CARSKCNKDC peptide (FITC-
CAR). HUVECs were treated with FITC-CAR at 10 μM for 24 hours in the presence 
and absence of TNF-α. FITC-CAR was observed near nuclear regions suggesting 
internalisation and particularly in the absence of TNF- α, co-localised with DAPI, 
potentially suggesting oversaturation. 
FITC-CAR 73 was visible by fluorescence microscopy and appeared to be localised in the 
nucleus. By eye, there appeared to be limited difference in the amount of accumulation of 
FITC-CAR between healthy and inflamed cells and it was questionable whether the 
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concentration used was oversaturating the cells with FITC-CAR. To investigate this, the 
reaction was repeated using 10-fold decreasing concentrations of FITC-CAR 73.  
A 10-fold decrease in concentration (1 μM) was used and showed a decrease in the binding 
of FITC-CAR, showing preference in HUVECs exposed to TNF-α, acting as a surrogate for 
the inflammation. In comparison to the 10 μM reaction, the CAR-FITC did not seem to 
accumulate in the nuclear regions and also showed the cytosolic vacuoles. 
 
Figure 5-31. Binding of fluorescein-labelled cyclised-CARSKNKDC (FITC-CAR) 73 to 
human umbilical vein endothelial cells (HUVECs) was investigated at a lower 
concentration of FITC-CAR (1 μM). Fluorescent microscopy of HUVECs using 494 nm 
to measure FITC excitation and emission wavelengths of 525 nm and 495 nm emission 
and 358 nm and 461 nm were used to visualise DAPI-stained nuclei. Specific binding 
of FITC-CAR was only observed in cells treated with TNF-α. FITC-CAR appeared to 
be internalised but did not co-localise with DAPI. 
At a lower concentration, a clear difference between FITC-CAR binding in a healthy and TNF- 
α induced inflamed cells was observed. Localisation is not observed in nuclear regions as 
seen in at 10 μM although bright regions in the near nuclear regions were observed in both. 
The close proximity of fluorescent emission to the nuclear region suggests internalisation, as 
previously reported.452,453 The reaction was also conducted at a 10-fold lower concentration 
but no fluorescein emission was observed. With hindsight, more information could have been 
derived from the experiment by employing only half dilution. 
Targeting Peptide Summary 
A previously reported targeting moiety was synthesised and tested for its use in targeting large 
macromolecules to the lung. The ability of CAR to home specifically to cells grown in an 
inflammatory environment, was tested in an in vitro cell assay cell assay (HUVECs). The 
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binding studies were performed using 10 μM of CAR peptide, as conducted in the original CAR 
peptide literature, however binding was observed in the nucleus in the absence of TNF-α. The 
reaction was conducted once more at a concentration 10-fold lower which did not show 
specific binding without TNF- α. At the lower concentration, in the presence of TNF-α, FITC-
CAR was shown to localise nuclear region, suggesting the peptide was internalised.  
With the data suggesting a change in behaviour when cells were incubated in healthy cells to 
those in an inflammatory environment, further experiments were planned. In order to conduct 
a more thorough investigation in the selectivity of CAR binding, a scrambled and polymerised 
version were designed. Unfortunately, work on the synthesis was initiated but not completed 
with enough time to conduct biological assays. 
 
Treprostinil 4 conjugation to a carrier molecule such as a polymer (or an antibody) requires a 
linker that is stable in circulation while being degradable in PAH diseased tissue. Linker 
degradation strategies often employ an enzyme that may be present at the intended site of 
action.270 We therefore considered linkers that could be degraded by a proteolytic enzyme that 
is upregulated in the PAH lung, with minimal expression in healthy tissue. To release 
treprostinil it was necessary that the enzyme must cleave at either end of a peptide linker and 
not between two amino acids (Figure 5-32). 
 
Figure 5-32. Generic tripeptide showing the terminal amine and carboxylic acid 
groups. Chemically, conjugation to a drug molecule can occur at either site. Enzymatic 
cleavage between any two amino acids will not result in drug release. Therefore, a 
suitable enzyme must cleave either the N- or C- terminus. The site of conjugation will 
be determined by the enzyme specificity. AA = amino acid, where the number denotes 
the order of conjugation on resin. 
Tryptase and chymase are both serine proteases released from mast cells upregulated in 
PAH. The tryptase and chymase are released upon mast cell degranulation in response to 
chronic inflammation. They contribute to the inflammatory response by facilitating collagen 
formation and tryptase can induce pulmonary fibrosis and contribute to PAH progression.500,501 
Specific substrates of both enzymes have been identified which cleave at the carboxyl 
terminus. Chromogenic conjugates of the substrates are available for use to identify and 
quantify mast cells in tissue samples and in vitro assays. Upon contact of tryptase, found in 
the mast cells, the hydrophobic chromophore cleaves to produce a bright colour. The 
replacement of the chromophore for treprostinil was considered and a similar tryptase specific 
mechanism for treprostinil released was hypothesised. 
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Direct conjugation of the treprostinil acid terminus 4, to the C-terminus of an amino acid is not 
possible, however a spacer would facilitate conjugation. Tryptase cleaves the amide bond at 
the C-terminus, therefore a spacer must possess on amine group to facilitate an amide bond 
to the peptide.  
 
Figure 5-33. The C-terminus of a peptide linker which can form an amide which can 
be enzymatically cleaved, as well as the C-terminus of treprostinil 4. It is not possible 
to conjugate the two moieties directly, so a spacer must be employed (labelled in red). 
Conjugation to the treprostinil 4 could be achieved with either an amine or a hydroxyl, to form 
the amide and ester, respectively. For ease of synthesis, possessing one amine and one 
hydroxyl will allow for selective reactions at only on end of the molecule. However, conjugation 
of most simple spacers, e.g. hydroxylamine, or amine terminal triethylene glycol, will facilitate 
amide cleavage at the N-terminus to release an inactive esterified treprostinil.  
 
Scheme 5-17. Proposed structure of tryptase substrate-amine linker-treprostinil 
prodrug. Successful enzymatic cleavage by tryptase of amide bond would release the 
linker-treprostinil conjugate at the site of release which would still possess minimal 
activity until treprostinil was released. 
Self-immolative linkers are able to overcome the problem of releasing an inactive drug 
molecule by allowing the first cleavage of tryptase mediated amide cleavage (at the C-
terminus) to initiate the second cleavage of ester cleavage (at the treprostinil acid terminus) to 
release the active drug. Many different immolative linkers have been described in the literature 
(Table 5-3), some using aromatic conjugation to transfer electrons which causes the second 
cleavage and some using cyclisation techniques to cleave the ester.  
  
4 
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Table 5-3. Different self immolative linkers available and described in the literature. 
Release mechanisms and typical conditions for drug release are shown. TBAF = 
tetra-n-butylammonium fluoride , DTT = dithiothreitol. 
Self-immolative structure 
Release 
conditions 
 
TBAF502 
Light503 
 
Plasmin504 
Penicillin-G-
amidase505 
 
DTT506 
 
Hydrogen 
peroxide507 
 
Penicillin-G-
amidase508 
 
1% HCl509510 
Light511 
 
Zn/ethanoic 
acid512 
 
DTT513 
To facilitate conjugation of treprostinil 4 to the C-terminus of a peptide substrate, the 
immolative linker, pABA, was incorporated into the linker design.  
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Figure 5-34. Structure of para-aminobenzyl alcohol (pABA), a self-immolative linker 
which can employed to link two carboxylic acids together such as the C-terminal of a 
peptide substrate with treprostinil acid. 
The amino group forms an amide bond with the enzyme substrate and an ester bond is formed 
with treprostinil 4. Upon cleavage of the amide bond, electrons are transferred through the 
ring, forming the azaquinone, breaking the carbon-oxygen bond, releasing the treprostinil 
carboxylate ion. 
 
Scheme 5-18. Proposed structure of treprostinil-enzyme substrate prodrug, featuring 
self-immolative linker, p-aminobenzyl alcohol. Upon enzymatic degradation of the 
amide bond, electrons are transferred through the aromatic ring to release treprostinil 
4. 
Fluorogenic Tryptase and Chymase substrates 
Peptide substrates of tryptase and chymase can be obtained from commercial suppliers 
(Table 5-4.). Based on most structures available tryptase is dependent on the C-terminal 
amino acid possessing a cationic side chain (i.e. lysine or arginine). The substrates are C-
terminal conjugated to a fluorescent chromophore which when cleaved by their respective 
enzyme releases the chromophore for visualisation. The substrates are used to determine and 
quantify the presence of tryptase or chymase within a tissue. The substrates are expensive 
but could be synthesised readily by SPPS without the chromophore. The presence of the 
chromophore would be an ideal strategy to test the activity of tryptase as a negative control. 
However, as well as cost, purchasing the available substrates would not facilitate an option to 
test the immolative linker between the chromophore and the peptide. Furthermore, solution 
phase conjugation of peptide substrate to an immolative linker and then to either treprostinil 
or a chromophore at the C-terminus would require the amino acid side chains to be protected. 
The unsuccessful experience of conjugating FITC 75 to side chain protected CAR peptide 73 
paired with the ease and cost efficiency of automated solid phase peptide synthesis led efforts 
down an in-house synthesis route. With the intention of using these substrates for a prodrug 
appendage, initial proof was sought that the tryptase/chymase substrates would cleave in the 
presence of their respective enzyme. In addition, an investigation into the relative cleavage 
rates when attached with the drug via a self immolative linker was planned. 
96 
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Table 5-4. Commercially available peptides. AMC = 7-amido-4-
trifluoromethylcoumarin. pNA = para nitrolaniline; Ac = acetyl; Tos = tosyl; Boc = 
tert-butyloxycarbonyl 
Peptide substrates Suppliers 
H-Orn-Phe-Arg-AMC Sigma Aldrich 
Ac-Lys-Pro-Arg-AMC Sigma Aldrich 
Tos-Gly-Pro-Lys-pNa Bachem 
Z-gly-Pro-Arg-pNa Bachem 
Pyr-Pro-Arg-pNA HCl Bachem 
H-Leu-Thr-Arg-pNa Bachem 
H-D-Ile-Phe-Lys-pNA trifluoroacetate Bachem 
Boc-Val-Pro-Arg-AMC HCl Bachem 
Phe-Ser-Arg-AMC acetate Bachem 
Five substrates reported in the literature and listed as commercially available were selected to 
be synthesised by SPPS (below). Initially, the peptides would be conjugated to a chromophore 
and then would be conjugated to treprostinil via a self immolative linker.  
Ac-Orn-Phe-Arg-OH 
Z-Gly-Pro-Arg-OH 
Ac-Lys-Pro-Arg-OH 
H-Ala-Ala-Pro-Ile-Arg-Asn-Lys-OH 
Suc-Phe-Pro-Phe-OH 
Loading of chromophore onto resin 
Many of the commercial substrates contained a fluorescent marker at the C-terminal to make 
quantification of enzymatic cleavage possible. In order to synthesise the substrates, above, 
on-resin, a chromophore with amino acid groups (amine and carboxyl group) was required. 
The amino acid derivative of the common fluorescent chromophore 7-aminocoumarin-4-acetic 
acid (ACA, also known as ACC) was commercially available. The Fmoc derivative 103 (Fmoc-
ACA-OH) was purchased which could be loaded onto a resin using following the usual Fmoc 
based strategy in the presence of coupling agents. Two resins were reported in the literature, 
Wang and Rink amide AM, although better results were reported for Rink amide AM.514 For 
this reason, as well as inefficient yields obtained using Wang resin,515 Fmoc-ACA-OH 103 was 
reacted with rink amide AM resin. The loading of the batch of Rink amide resin was 0.7 mmol/g 
so for totally efficient loading of Fmoc-ACA-OH 103 to 100 mg of resin would result in 31 mg 
immobilised onto the resin. For efficient coupling, the reaction of carried out in duplicate. For 
each coupling, a minimum of 2 equivalent of Fmoc-ACA-OH 103 is required, therefore ~120mg 
of Fmoc-ACA-OH is required to achieve only 30 mg immobilised on the resin. 
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Table 5-5. Chromogenic substrates using 7-amino coumarin acetic acid as the 
chromophore which can be loaded onto the resin and facilitate peptide growth. Ac 
= acetyl; Z = carboxybenzyl; H = free N-terminal amine; Suc = succinic acid. 
 
Substrate 
N-
terminal 
group 
AA7 AA6 AA5 AA4 AA3 AA2 AA1 
97 Ac - - - - Orn Phe Arg 
98 Z - - - - Gly Pro Arg 
99 Ac - - - - Lys Pro Arg 
100 H Ala Ala Pro Ile Arg Asn Lys 
101 Suc - - - - Phe Pro Phe 
Loading of Fmoc-ACA 103 was initially attempted by coupling with disopropyl carbodiimide 
thrice, following the procedure described by the manufacturer.516 The first coupling was 
erroneously conducted in DMF, which was substituted for a mix of DCM/DMF (7:3) for the 
following reactions. DMF has been shown to facilitate formation of the N-acylurea 24 in 
carbodiimide-mediated coupling. Colourimetric Kaiser testing for the presence of the 
unreactive amine produced a positive intense blue result, indicating that the coupling had not 
proceeded as expected. 
 
Scheme 5-19. The proposed method of employing aminocoumarin acetic acid (103) 
as a terminal chromophore amino acid. 
Given the aliphatic nature of the carboxylic acid moiety of Fmoc-ACA 103, coupling to a resin 
was not anticipated to be problematic. Therefore, standard SPPS coupling conditions, 
HBTU/DIPEA, were employed, but coupling was not successful, as determined using the 
Kaiser test. Further attempts with HBTU/DIPEA included the catalytic additive HOBt 27, 
although Kaiser test revealed that the coupling had still not progressed.  
To determine the reason for the unsuccessful resin loading, the resin and coupling reagents 
were investigated. A sample was taken from the failed coupling, rinsed and placed into a 
vessel with a simple amino acid, Fmoc-Ala-OH 146, using the same coupling reagents 
(including same batches). The following morning, the coupling was deemed complete by 
102 
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ninhydrin test. This provided assurance that the resin and reagents were suitable for coupling 
and signalled a problem with the Fmoc-ACA-OH 103.  
 
Figure 5-35. Sample reactions trialled to ascertain whether the failed coupling of 
Fmoc-aminocoumarin acetic acid was a result of the coupling reagents or the acid 
reagent. One sample was treated with additional coupling agent, 
diisopropylcarbodiimide (DIPC) which remained blue when a Kaiser test was 
performed indicating no coupling had occurred. The right-hand arm sample was rinsed 
with dimethylformamide (DMF) and treated to the same reagents (including the same 
batches of HBTU and DIPC) but with an alanine amino acid, in dimethylformamide. 
After 18 hours, Kaiser test revealed a negative result indicating that the coupling had 
occurred successful to leave no unreacted amines. HBTU = 3-
[Bis(dimethylamino)methyliumyl]-3H-benzotriazol-1-oxide hexafluorophosphate; 
DIPEA = diisopropylethylamine 
An investigation into the structure of the chromophore acid 103 was conducted. TLC showed 
one major spot with Rf 0.62 which was UV active but did not stain with bromocresol blue which 
should stain yellow in the presence of protons with pKa < 3. 1H NMR indicated the presence 
of the expected number of protons; the aliphatic and aromatic resonances of the Fmoc group, 
the acidic proton. The broad singlet with chemical shift 12.8 ppm confirmed the presence of 
an acidic proton belonging to a carboxylic acid. However, the methylene proton was not 
observed in the expected region of ~2.9 ppm. A singlet was observed at 3.9 ppm but integrated 
to 1.5 protons instead of 2 (yellow in Figure 5-36).  
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Figure 5-36. 1H NMR spectrum of Fmoc-aminocoumarin acetic acid 103 (Fmoc-ACA-
OH). The expected protons are present but do not integrate to the number expected 
from the structure. Inset image of Fmoc-ACA-OH analysed by thin layer 
chromatography which did not stain yellow, expected of carboxylic acid compounds. 
Resonant structures of Fmoc-ACA-OH 103 are possible (Scheme 5-20), particularly in basic 
conditions (DIPEA), which would explain the reduced peak integration and the observed 
inactivity during coupling. Deprotonation of one of the benzyl methylene (labelled blue, 
Scheme 5-20) could explain the reduced integration as it becomes unsaturated. However, this 
would be accompanied with a singlet resonance found closer to the aromatic region, which 
was not observed. 
 
Scheme 5-20. Possible resonant forms of Fmoc-ACA-OH 103 showing the different 
protons which could alter the 1H NMR spectrum and the structure deduced through its 
interpretation. The acidic proton is labelled in blue and the aromatic proton is labelled 
in red. 
The cyclic alkene proton in the ACA adduct 103 (labelled in red, Scheme 5-20), would also 
be expected to have split into additional downfield resonances, which was also not 
observed.13C NMR showed a short resonance at 162.2 ppm which, may represent the acidic 
carbonyl (Figure 5-37). FTIR confirmed an absorbance at 1735 cm-1 which represents the 
stretching frequency of the acid carbonyl as well as a broad absorbance at 2972 cm-1 which 
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indicates the presence of hydrogen bonding hydroxyl groups including those of a carboxyl 
acid. Additionally, the observed broad band in the region of 2972 nm, corresponding to the O-
H bond stretch of an acid, suggested the compound to have the expected moieties. 
 
Figure 5-37. 13C NMR spectrum of Fmoc-aminocoumarin acetic acid 103 (Fmoc-ACA-
OH) indicating the presence of an acid carbon 
To be certain the acid moiety of Fmoc-ACA-OH 103 was present, a functional test was 
performed by attempting to esterify the acid. Fmoc-ACA-OH 103 was stirred overnight in 
ethanol (with minimal DMF to aid solubilisation) in the presence of catalytic sulphuric acid (2 
drops). Following a 16-hour incubation and work up into ethyl acetate, the proton NMR 
spectrum revealed a triplet at 1.19 ppm and a quadruplet with chemical shift 4.12 ppm, 
corresponding to the expected ethyl ester protons of the esterified acid (Figure 5-38).  
 
Figure 5-38. Proton NMR spectrum for the esterification product of 
Fluorenylmethyloxycarbonyl-7-aminocoumarin-4-acetic acid 103, showing the correct 
integration for methylene and methyl protons, highlighted in pink and green 
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respectively. Successful esterification indicates that the acid group of chromophore 
103 is present. 
It was confirmed that the acid was present on Fmoc-ACA-OH 103, which suggested that either 
the acid was much less active than initially expected or that a steric effect caused by the close 
proximity to the aromatic Fmoc-ACA 103 to the resin loading functionality was preventing 
successful interaction and coupling reactions. To investigate the role of steric hindrance in 
coupling Fmoc-ACA-OH 103 to Rink Amide AM resin, aminohexanoic acid 105 (Ahx), used a 
short chain spacer, was first coupled to the resin. Resin was successfully coupled to Fmoc-
Ahx-OH 105 to afford the free amine Ahx-bound resin 104. The resin bound Fmoc as 
deprotected and Fmoc-ACA-OH 103 was coupled using HBTU/DIPEA chemistry and left for a 
total of three days (Scheme 5-21). Reaction progression by Kaiser test revealed a blue 
solution, indicating negligible coupling to free amine of Ahx moiety.  
 
Scheme 5-21. Coupling of aminohexanoic acid 105 (Ahx) to Rink Amide AM resin to 
afford the resin bound Ahx 104 to reduce steric hindrance for subsequent coupling to 
Fmoc-aminocoumarin acetic acid 103 (Fmoc-ACA-OH) in the presence of N,N,N′,N′-
Tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU) and 
diisopropylethyl amine (DIPEA). 
The reason for the unexpected low reactivity of Fmoc-ACA-OH 103 could not be determined. 
Synthetic efforts to make tryptase substrates 97-101 utilising Fmoc-ACA-OH 103 were 
terminated and an alternative approach was sought. 
Amino acid bound fluorescent moieties 
A chromophore was required to determine cleavage of the peptide substrate. Tryptase cleaves 
its substrates at the C-terminus which during synthesis is where the resin is attached. The 
obvious solution was to employ chromogenic amino acids but one such attempt was not 
successful. Chromogenic amino acids are expensive, so a more cost-effective solution was 
sought (Figure 5-39).  
 
Figure 5-39. Ways considered to append a chromophore to the C-terminus of tryptase 
substrate sequences. A) Direct linkage of the chromophore to the resin and B) 
conjugation of chromophore to a lysine side chain. 
104 103 
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Instead of direct conjugation of the chromophore to the resin from which a peptide substrate 
can be appended, a lysine with a chromophore attached to the side chain can be conjugated 
to the C-terminus (Scheme 5-22). 
 
Scheme 5-22. Proposed synthesis of substrates with fluorescein isothiocyanate 75 
(FITC) conjugated through the side chain of an additional lysine residue 106 to afford 
a resin-bound chromophore 108 to which substrates can be conjugated. Coupling of 
the first lysine derivative is carried out using standard coupling techniques. Lysine side 
chain protecting group 4-methyltrityl (Mtt) is weakly acid labile allowing for lysine 
deprotection without resin cleavage. The resulting side chain amine can be coupled to 
FITC 75. Following fluorenylmethyloxycarbonyl deprotection of resin chromophore 
108, tryptase substrates can be synthesised. 
Mtt sidechain-protected lysine 106 was linked to Rink Amide AM resin using standard 
HBTU/HOBt/DIPEA conditions.517 Once complete, the lysine side chain of resin-bound lysine 
109 was deprotected using TFA/TIS in DCM under an argon environment to afford the free 
amine derivative 107. Removal of Mtt releases methyl trityl cation which is yellow. TIS 95 is 
added to the cleavage cocktail to quench the cation so over time the yellow colour fades. The 
resin was washed with the solution until no yellow colour was produced upon addition. FITC 
75 was then coupled onto the side chain amine in the presence of DIPEA in an argon 
environment. The dried resin 108 was split into 5 equal portions and tryptase and chymase 
substrates were built onto them, incorporating in a final Fmoc deprotection step on the peptide 
synthesiser to liberate the N-terminal amines. 
  
105 
74 
106 
107 
108 
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Table 5-6. Chromogenic substrates using fluorescein conjugated the side chain of 
a C-terminus lysine as the chromophore, allowing for immobilisation on the resin 
and facilitating peptide growth. Ac = acetyl; Z = carboxybenzyl; H = free N-terminal 
amine; Suc = succinic acid. 
 
Substrate N-
terminal 
group 
AA7 AA6 AA5 AA4 AA3 AA2 AA1 
109 Ac - - - - Orn Phe Arg 
110 Z - - - - Gly Pro Arg 
111 Ac - - - - Lys Pro Arg 
112 H Ala Ala Pro Ile Arg Asn Lys 
113 Suc - - - - Phe Pro Phe 
To replicate the substrates commercially available and thus known to be active, of the five 
substrate variations prepared, three required post-sequence N-terminal modifications with 
either acetic anhydride or succinic anhydride. The carboxylbenzyl group (Z) was added by 
coupling Z-glycine. Kaiser test was performed to confirm successful N-terminal capping. 
Peptides were then rinsed, cleaved and isolated using standard procedures. 
Lysine(FITC) substrate derivatives 109-113 were synthesised as an alternative to the ACA 
derivatives attempted unsuccessfully with the immobilisation of Fmoc-ACA-OH 103. Side 
chain conjugation of FITC to lysine was achieved easily without issues. Enzymatic cleavage 
of the C-terminal amide bond of the substrate releases the Lysine-FITC conjugate. However, 
no change in absorption is associated with the release making monitoring enzyme activity, 
and thus substrate specificity, not possible by spectroscopic methods. No changes in UV 
absorption occurs over time. To be able to monitor the rate of substrate cleavage, HPLC 
analysis would be required. In order to measure multiple time points, multiple solutions would 
need to be incubated with enzyme, quenched and analysed. Before committing time to the 
analysis, efforts were dedicated to the conjugation of treprostinil to the substrate. 
Treprostinil-tryptase substrate 
The substrates identified in Table 5-4 were designed for use as a prodrug appendage to the 
carboxylic acid of treprostinil, thus on-resin synthesis of the substrates which could be 
conjugated at the C-terminus to treprostinil, was considered simultaneously (Scheme 5-23).  
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For proof of concept a simple self-immolative linker was sought and the p-aminobenzyl alcohol 
97 was employed. Cleavage of the amide bond by enzymatic degradation allows the amine 
electrons to resonate through the aromatic ring to form the azaquinone methide and break the 
C-O bond, releasing the free acid of treprostinil 4.255 
 
Scheme 5-23. Enzyme initiated cleavage of the amide bond causing electrons to be 
transferred through a resonant form which results in ester cleavage to release 
treprostinil 4. 
To restrict the resonance of the amine electrons into the aromatic ring, the amine must be 
coupled first. Amines are usually more nucleophilic than their hydroxyl counterpart, so 
protection of the alcohol is often not warranted. However, non-nucleophilic, weakly basic 
amines are more similar in pKa and reactivity to an alcohol. This results in the coupling being 
less readily afforded than an aliphatic amine and the requirement of hydroxyl protection to 
afford the correct product. 
 
Figure 5-40. Structure of p-aminobenzyl alcohol 97. Although the pKa2 of the amine 
is greater than that of the alcohol, the available lone pair which can resonate into te 
ring, increases the electronegativity and makes it a better nucleophile.  
For pABA 97, the pKa of the ammonium and alcohol are 9.4 and 15.4, respectively so the 
ammonium is more readily deprotonated owing to the aromatic resonance. Once the amide 
bond is formed and the peptide grown 116, the reaction of the alcohol with treprostinil 4 to 
afford the treprostinil ester 115 can be attempted, which may or not require a deprotection 
step beforehand. It was noted at this point that the final structure would involve a treprostinil 
ester bond in the presence of free amine on the lysine side chains which may undergo 
substitution to cause premature release of treprostinil. Therefore, the protonated salt of the 
compound would need to be considered as the final compound. To support the overall concept 
that treprostinil could be linked to a carboxyl terminus via an immolative linker, the feasibility 
of the required steps was examined (Scheme 5-24).  
 
pKa1 = 4.0 
pKa2 = 25.4 pKa = 15.4 
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Scheme 5-24. Conjugation of para-aminobenzyl alcohol 97 to the carboxylic acid of a 
substrate peptide to form the aromatic amide 116 which can then undergo 
esterification of treprostinil to form the final conjugate 115. 
Coupling of the aniline amine of pABA 97 to a carboxylic acid was not achieved using standard 
coupling agents. Carbodiimide derivative EDCI 33 and the uronium based HBTU did not afford 
complete conversion of the amine to the amide. On-resin coupling of anilines had been 
reported successful by employing the effective, yet relatively expensive uronium derivative, 
HATU 117.518  
 
Scheme 5-25. Conjugation of para-aminobenzyl alcohol 97 to C-terminus of lysine 
119 using 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate 117 (HATU) to form the amide conjugated product 118. 
Coupling of pABA 97 to Fmoc-lysine(boc)-OH 119 on a 200 mg scale, was conducted in 
anhydrous DMF conditions in the presence of HATU 117 and DIPEA. The reaction was 
monitored by TLC using ninhydrin to stain for amines. After 96 hours, a product spot was 
visible (Rf = 0.6) which no longer stained deep purple like the starting material but stained 
brown with heating, indicating the presence of an amide. 1H NMR spectroscopy confirmed the 
desired product 118 had formed and coupling had not occurred involving the alcohol. The 
spectrum showed a shift in the aromatic resonance of aminobenzyl alcohol 97 from 6.97 and 
6.52 ppm to 7.55 and 7.25 ppm for each aromatic pair (Figure 5-41). The proton of the 
aromatic amide is observed at 10.0 ppm. The benzyl protons neighbouring the alcohol did not 
show a shift indicating that the coupling had occurred at the amine terminus and not the 
hydroxyl terminus. 
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Figure 5-41. 1H NMR spectrum of the successful coupling between Fmoc-Lys(Boc)-
OH 119 and p-aminobenzyl alcohol 97 to form the amide derivative 118. 
Coupling of the free hydroxyl of the amide product 118 to the carboxyl acid of treprostinil 4 
was conducted using phenoxyacetic acid 22 as a model (Scheme 5-26). Previous work in 
chapter 3 identified CDI 36 as a suitable coupling agent for the esterification of phenoxyacetic 
acid 22. However, when these conditions were used to couple phenoxyacetic acid 22 and the 
hydroxyl of amide product 118 no reaction was observed after 24 hours. HBTU was utilised 
using several different conditions. Interestingly, the addition of HOBt hydrate 29, did not result 
in coupling. HOBt 29 is understood to increase the rate of reaction by acting as a nucleophilic 
catalyst towards the acid carbonyl, which reduces the likelihood of racemisation. The exclusion 
of HOBt hydrate 29 however, afforded the complete exhaustion of starting materials and 
formation of ester product 120, as determined by TLC.  
 
Scheme 5-26. Esterification of Fmoc-Lys(boc)-amide benzyl alcohol 118 with 
phenoxyacetic acid 22 in the presence of HBTU and diisopropylethyl amine (DIPEA) 
in dimethylformamide (DMF), to afford Fmoc-Lys(boc)-amide benzylphenoxtacetate 
120. 
Isolation of this compound and subsequent 1H NMR analysis (Figure 5-42) indicated the 
formation of the ester 120. A downfield shift in resonance from 4.26 to 5.09 ppm corresponding 
to the benzyl protons of the pABA moiety. Additionally, a shift is observed at 4.56 ppm 
corresponding to the methylene resonance of phenoxyacetic ester 120 which is seen at 4.70 
ppm when in the acid form, giving confidence that the coupling has occurred. HOBt 29 is an 
explosive compound so is often supplied as the hydrate to reduce the associated risk.360 The 
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poor coupling observed when HOBt 29 was employed was unexpected and could be a result 
of the presence of competing water within the reaction mixture. 
 
Figure 5-42. 1H NMR spectrum of the esterified product 120, formed by coupling 
phenoxyacetic acid 22 with the hydroxyl of Fmoc-Lys(boc)-amide benzyl alcohol 118. 
Using HBTU coupling reagent, a route to conjugate the p-aminobenzyl alcohol 97 self-
immolative linker between the C-terminus of an amino acid and an aryl acid such as that of 
treprostinil 4, has been identified.  
A benefit of SPPS is the ease of synthesis and deprotection in the global resin cleavage step 
(cleavage of resin and all standard acid-labile side chain protecting groups). Deprotection of 
the side chains in solution, post-resin cleavage would allow for conjugation of treprostinil linker 
to the carboxylic terminus but requires removal of different side chain protecting groups. 
Additionally, work up of solution phase reactions has the potential for the loss of product 
whereas with a successful solid phase reaction, the product is immobilised on the resin and 
all other reagent, by products and side reactions are removed. Particularly for multistep 
synthetic routes, the ability to immobilise and locate the desired product at each step 
maximises the benefit derived from solid phase reactions.519 Furthermore, the purification after 
each step for solution phase reactions is a time-consuming exercise. SPPS reactions require 
the use of excess reagents to force reactions to completion, although the recycling of precious 
reagents is possible. Therefore, conjugation of treprostinil 4 to the substrate would ideally be 
carried out on-resin, before the amino acid side chains have been deprotected to minimise 
possible side reactions.  
Owing to the lack of suitable functional groups, treprostinil 4 cannot easily loaded onto a resin 
and facilitate peptide conjugation, which ruled out traditional resin loading techniques. To 
overcome this problem, a synthetic route was devised which linked the resin to the amide bond 
between the first and p-aminobenzyl alcohol 97. Such an intermediate bound to the resin, 
would allow the substrate to be grown in the usual manner and render the hydroxyl of p-
aminobenzyl alcohol 97 available to conjugate to treprostinil 4.  
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Scheme 5-27. Desired order of synthesis of treprostinil peptide prodrug 115. Peptide 
is synthesised first, followed by conjugation of p-aminobenzyl alcohol 97 and then by 
treprostinil 4. Cleavage and simultaneous deprotection of the amino acid side chains 
would result in the desired prodrug structure 115. 
In order to link the resin to the two amino acids via a tertiary amide such as 121, a formyl resin 
was employed, and a two-step synthesis required; reductive amination followed by secondary 
amidation (Scheme 5-28). 
 
Scheme 5-28. Linking of p-aminobenzyl alcohol 97 and first amino acid onto formyl 
resin by tertiary amide link. i) Loading of p-aminobenzyl alcohol 97 onto formyl resin 
by reductive amination. ii) Coupling of secondary amine 122 to Fmoc-protected amino 
acid. 
4-(4-Formyl-3-methoxyphenoxy)butyryl (FMPB) resin 123 is a formyl resin which facilitates 
loading by reductive amination. The loading of the resin is 0.52 mmol/g which means for a 
successful 50 mg scale reaction, a maximum of 0.025 mmol of product will be formed. The 
resin terminal is a resin derivative of 2,4-alkoxybenzaldehyde which after formation of the 
tertiary amide on-resin, is cleaved by standard TFA-mediated cleavage conditions to generate 
a secondary amide. 
 
Scheme 5-29. FMPB formyl resin 123 (i) loading of amine 97 and (ii) subsequent 
amidation; iii) when cleaved in standard TFA-mediated conditions, the secondary 
amide is released from the resin. 
The main drawback with SPPS is during method development, the time between running a 
reaction and determining its success can be slow. Additionally, the cleaving and work up 
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process is laborious compared to TLC used in solution phase. Therefore, a solution phase 
reaction was utilised to gain an understanding of the suitable reaction conditions, using 
methods to track the reaction progression such as TLC and NMR. Once conditions were 
identified, they could later be transferred to the solid phase. To mimic the FMBP resin 123 
reactivity as closely as possible in the solution phase, 2,4-dimethoxybenzaldehyde 124 (DMB) 
was employed as the aldehyde function. With the intention of transferring optimised conditions 
to on-resin techniques, only solution phase reducing agent were employed (i.e. palladium, 
platinum and nickel were not considered). 
 
Figure 5-43. Structure of 2,4-dimethoxybenzaldehyde 124 used as a solution phase 
mimic of the terminal group of FMBP resin 123. 
Dissolution of a nucleophilic amine 97 in the presence of benzaldehyde 124 was expected to 
form the imine 125. The instability of the imine 125 makes detection of its formation difficult. 
As a result, the imine formation step was not monitored, but left to react for a sufficient time 
and success later determined by the amine product 126 that formed after reduction. Addition 
of a suitable reducing agent, such as sodium borohydride or 2-methylpyridine borane complex 
127, provides a nucleophilic hydride ion which can attack the imine carbon, resulting in a 
secondary amine. However, reduction of the unreacted aldehyde 124 to an alcohol renders it 
unreactive and prevents imine formation. 
 
Scheme 5-30. Proposed formation of secondary amine 126 through reductive 
amination of 2,4-dimethoxy benzylaldehyde 124 and p-aminobenzyl alcohol 97 via an 
imine intermediate 125 which is reduced by 2-methyl pyridinium borane 127. 
DMB 124 initially underwent reaction with p-ABA 97 and reduced with 2-methyl borane 
complex 127 (Scheme 5-30).520 Addition of the DMB 124, pABA 97 and the reducing agent in 
one step uses a direct reductive approach where the carbinol amine (labelled in blue) is 
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reduced, without the need for imine 125 formation.521 However, tracking by TLC did not 
indicate any change in Rf values 0.6 and 0.3 for DMB 124 and pABA 97 respectively.  
Reductive amination had been shown to be successful at forming the secondary amine 
between aromatic benzaldehyde 124 and an aniline derivative 97 using sodium borohydride 
and Dowex 50WD8 in THF.522 Sodium borohydride is considered a green, environmentally 
friendly reducing agent which is safe and inexpensive to use. Unfortunately, it is able to reduce 
other functional groups including aldehydes so is often used alongside catalysts, such as 
Dowex which assist in the formation of imines. A reaction of DMB 124, pABA 97 and NaBH4 
(1:1:1) in the presence of a catalytic amount of Dowex was performed and after 15 minutes, 
TLC showed no trace of starting aldehyde 124 or amine 97, as well as the appearance of a 
new spot indicating a reaction had progressed. The reaction was worked up by liquid phase 
separation and the products were separated by column chromatography. Unfortunately, only 
the benzyl alcohol derivative 128 was isolated (Scheme 5-31), suggesting the aldehyde 124 
was prematurely reduced before the imine 125 formation could occur. For both the borane and 
sodium borohydride reduction reactions described, only 5 minutes were allowed for the imine 
125 to form before addition of the reducing agent.  
 
Scheme 5-31. Undesired reduction of aldehyde to form the alcohol derivative 128 
when reductive amination of 2,4-dimethoxy benzylaldehyde 124 along with p-amino 
benzyl alcohol 97 in the presence of sodium borohydride 131 and Dowex resin was 
attempted. 
Longer imine formation times were expected to facilitate successful reductive amination 
reactions.521 Imine 125 formation between DMB 124 and pABA 97 was allowed 2 hours to 
form in the presence of Dowex resin, before sodium borohydride 131 was added. However, 
TLC showed only the presence of starting compounds and the alcohol product 128. The 
formation of the alcohol 128 suggested that the imine 125 still did not form after 2 hours. The 
presence of starting materials indicated that the desired stoichiometry was not achieved, likely 
to be a result of sodium borohydride 131 hydrolysis either during transfer to the reaction vessel 
or upon contact with solvent containing residual water. 
Aniline derivates have been reported to undergo reductive aminations,522 however, in the work 
presented, the desired secondary amine could not be achieved. The most successful and 
commonly employed agents were employed521 but the evidence observed suggested that the 
imine did not form. Formation of the imine is hindered by the donation of the aniline lone pair 
into the aromatic ring which reduces the nucleophilicity of the nitrogen. The proximity of the 
moieties to electron dense aromatic rings contribute to steric effects and electron repulsion. 
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Therefore, efforts attempting to achieve reductive amination by nucleophilic addition of p-
aminobenzyl alcohol were terminated and a route to utilise a more nucleophilic amine was 
sought.  
The attachment of the resin mimic, 2,4-dimethoxybenzaldehyde 124, at an amide bond was 
modified to attach between amino acid 1 and 2 instead of between amino acid 1 and pABA 97 
(Scheme 5-32). This would allow an imine to form more readily using a nucleophilic, primary, 
aliphatic amine. 
 
Scheme 5-32. Two proposed schemes for reductive amination of FMBP resin-mimic 
2,4-dimethoxybenzaldehyde 124. A) mimics resin linkage between p-aminobenzyl 
alcohol 97 and first amino acid (AA1); B) mimics resin linkage between the first (AA1) 
and second (AA2) amino acids 129. 
In brief, an esterified derivative of the first amino acid is left to react with aldehyde 124 in the 
presence of base which forms the imine 136. (Scheme 5-33). Addition of a borohydride 
reducing agent (eg. sodium borohydride 131) reduces the imine 136 to the corresponding 
secondary amine product 130, which can couple the next amino acid to give the tertiary amine 
structure 129. 
 
Figure 5-44. Structures of borohydride reducing agents suitable for reductive 
aminations; 2-methylpyridine borane complex 127; sodium borohydride 131; sodium 
triacetoxy borohydride 132; sodium cyanoborohydride 133. The different substituents 
of the borohydrides alter the reductive abilities of the borohydride. 
The amino acid requires a free amine, protected side chain and a protected carboxylic acid. 
The carboxyl-ester derivatised amino acids were employed initially as they were commercially 
available. The hydrochloride salt of β-alanine ethyl ester 135 was allowed to undergo reaction 
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with DMB 124 for 2 hours in methanol (Scheme 5-33). Methanol has been shown to 
successfully form an imine of a primary amine quantitatively when leaving 3 hours for the 
aldimine to form before addition of sodium borohydride. Following conditions successfully 
employed by Abdel-Magid and colleagues, sodium triacetoxyborohydride 132 (STAB) was 
employed as a reducing agent with excess equivalents (1.4) to give the desired amine 134.521 
The acetoxy groups in the reducing agent have an electron withdrawing effect on the boron 
atom resulting in a milder reducing agent than the boro-tetrahydride derivatives. STAB 132 
appears to be more suitable for reductive aminations523 although it is still effective at reducing 
aldehydes to alcohols.524,525  
 
Scheme 5-33. Mechanism for reductive amination via imine formation between 2,4-
dimethoxybenzaldehyde 124 and primary amine of β alanine ethyl ester 135. The 
imine intermediate 136 is reduced by sodium triacetoxyborohydride to form secondary 
amine 134. 
Initially the first reductive amination attempt was conducted in standard methanol. After 4 
hours, TLC indicated DMB 124 and amine 135 were still present. An additional spot was 
observed which stained yellow with ninhydrin, suggesting the desired secondary amine 134 
had formed. Further addition of STAB 132 increased the intensity of the yellow spot but starting 
materials were not completely consumed and the addition of more STAB 132 (0.5 equivalents) 
soon produced a precipitate thought to be insoluble STAB 132. The observed partial success 
of the reaction by TLC was attributed to the amine. The β-alanine ethyl ester 135 was used as 
the hydrochloride salt to avoid the free amine from undergoing intermolecular reaction with the 
ester upon storage. The protonation of the amine eliminates its ability to act as a nucleophile 
and prevents possible polymerisation (Scheme 5-34).  
 
Scheme 5-34. The protonation of the primary amine of β-alanine ethyl ester 135 
prevents nucleophilic substitution reactions between molecules which can potentially 
form dimers to polymers. Therefore, esterified amino acids are supplied as the 
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hydrochloride salt. The ester salt 135 has reduced nucleophile activity until the 
ammonium ion is neutralised. 
To enable imine 136 formation, the reaction was performed using the same conditions as 
before but in the presence of triethylamine in slight excess (1.2 equivalents). Basic conditions 
are known to slow the rate of the competing reduction of the aldehyde 124 and favour 
formation of a secondary amine 134 when a similar reducing agent, lithium cyanoborohydride 
is employed.526 Heat-activated molecular sieves (3 Å) were added to the reaction to remove 
the water produced upon imine 136 formation so as to drive equilibrium forward in methanol. 
A yellow ninhydrin stain spot was present after the first 2 hours, but starting materials were 
only depleted by the addition of a further 1.4 equivalents of STAB 132. The reaction was 
worked up by liquid extraction between ethyl acetate and water, made aqueous by addition of 
sodium hydroxide. 1H NMR spectroscopy of the isolated product revealed the presence of a 
resonance at 3.64 ppm (highlighted in purple in Figure 5-45), corresponding to the benzylic 
protons neighbouring the secondary amine in the desired product 134. 
 
Figure 5-45. 1H NMR spectrum of ethyl 3-((3,5-dimethoxybenzyl)amino)propanoate 
134 following the successful solution phase reductive amination of 2,4-dimethoxy 
benzaldehyde 124 with β-alanine ethyl ester 135. The presence of the reduction 
protons (purple) and the shift in the alanine protons neighbouring the mine (yellow) 
indicate the success of the reaction. 
Having established reductive amination conditions in solution to afford the secondary alcohol, 
the reaction was repeated in the solution phase using conditions more applicable to solid 
phase synthesis. Firstly, the solution phase reaction was repeated using a bulkier amino acid, 
phenylalanine ethyl ester 137, to better mimic the hindrance associated with reactions 
conducted on-resin. Secondly, methanol is not a suitable solvent for solid phase reactions as 
it shrinks polystyrene-based resins, thus limiting the interaction between solution phase 
reagents and resin-bound functional groups. Therefore, the solution phase reductive 
amination was attempted using phenylalanine ethyl ester 137 in DCM using the conditions 
previously successfully optimised (Scheme 5-35). After 2 hours, the reaction seemed to 
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progress, however complete consumption of starting materials to produce an intense yellow 
colour of TLC product spot was only observed after adding excess STAB 132 (2 equivalents).  
 
Scheme 5-35. Reductive amination between 2,4-dimethoxybenzaldehyde 124 and 
bulkier amino acid, phenyl alanine ethyl ester hydrochloride 137 in the presence of 
triethylamine (NEt3) and sodium triacetoxyborohydride (STAB) 132 to form secondary 
amine 138. 
The requirement for excess reducing agent could indicate a slower rate of imine formation or 
the hydrolysis of the reducing agent. After basic work-up into ethyl acetate, 1H NMR 
spectroscopy indicated successful reductive amination. The presence of the phenyl group 
causes more restricted rotation of the bonds between the secondary amine and the dimethoxy-
aromatic ring. This causes the resonance of the methylene protons (highlighted in blue in 
Figure 5-46) to split into a doublet of doublets. Furthermore, the methoxy groups also further 
diverge from each other as a result of the interaction, which limits the free rotation of the 
dimethoxy aromatic ring.  
 
Figure 5-46. 1H NMR spectrum of ethyl (3,5-dimethoxybenzyl)phenylalaninate 138 
formed by reductive amination between 2,4-dimethoxy benzaldehyde 124 and 
phenylalanine ethyl ester 137. Notably, the presence of the phenyl group results in the 
splitting of the resonances corresponding to the methoxy (orange) and the methylene 
groups (blue). 
Reductive amination to load the first amino acid onto an aldehyde compound 124 in solution, 
was achieved using the mild reducing agent, STAB 132. Product was formed in both DCM and 
MeOH (yielding 52% and 47%, respectively), despite the known risk of hydrolysis of STAB in 
methanol. DCM is known to swell polystyrene resin, so the successful reaction optimisation in 
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DCM will be useful in transferring these techniques to resin bound aldehydes. Reaction 
mixtures were easily worked up by liquid phase extraction to yield the desired secondary 
amine compounds. 
Having identified suitable conditions for the solution phase reductive amination, the reaction 
conditions were then attempted for an aldehyde functionalised resin. However, the reaction 
does not involve free primary amines on the resin which excludes the Kaiser test for monitoring 
the reaction progress. To monitor the reaction a colourimetric test for the presence of an 
aldehyde (using the p-anisaldehyde test527) and a secondary amine (using the acetaldehyde 
test528) were employed.  
The p-anisaldehyde test is based on its use for monitoring reactions by TLC.529 Addition of 
acetaldehyde 139 causes a reaction with the resin bound secondary amine 122 forming an 
imine which is in a resonant form with the enamine (Scheme 5-36). When in its enamine form, 
it can undergo Michael addition with the reactive alkene of unreacted dibenzofulvene 140 
(DBF) found in the matrix of polystyrene based resins or derived from Fmoc-amino acids 
present. This initiates a spontaneous and anionic polymerisation and causes colouration of 
the beads to orange/brown. For polystyrene deficient resins, Fmoc-amino acids should be 
added with the aldehyde 139 to form DBF 122 in situ and donate the reactive alkene.528 
 
Scheme 5-36. The proposed mechanism for the acateldehyde 139 colourimetric test 
of secondary amines.528 Imine formation occurs between the resin-bound secondary 
amine and acetaldehyde 139. This can undergo a reaction with Fmoc groups to create 
a dibenzofulvene 140, which reacts with the enamine to initiate a spontaneous anionic 
polymerisation turning beads orange/brown. The polymerisation ends when a proton 
acts as the electrophile. 
The reductive amination of formyl resin 123 was carried out with β-alanine ethyl ester 
hydrochloride 135 neutralised with triethylamine in the presence of STAB 132 in DCM 
(Scheme 5-37). Complete dissolution of the STAB 132 reducing agent was not observed as 
a white precipitate remained. Resin-bound aldehyde 123 was not detected after 3 hours as 
determined by the beads being clear in the presence of p-anisaldehyde. Unfortunately, no 
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secondary amine 142 was detected either as the resin beads were clear in the presence of 
acetaldehyde 139. These observations indicated the resin bound aldehyde 123 was reduced 
to an alcohol before formation of the imine had occurred. New conditions for on-resin reductive 
amination were thus needed. 
 
Scheme 5-37. Imine formation between an aldehyde and primary amine which is then 
reduced by reducing agent sodium borohydride to form the secondary amine. 
To aid solubility, alternative solvents were investigated. Dichloroethane is considered the 
preferred solvent for reductive aminations and is recommended for reductive aminations by 
the suppliers of the formyl resin. Contrary to this assertion, dichloroethane would not dissolve 
the amino acid H-Arg(Pbf)-OMe 143. Also recommended by the suppliers was the use of a 
mixture of DMF/trimethyl orthoformate (TMOF) (2:1) which did successfully dissolve H-
Arg(Pbf)-OMe 143 and was thus employed.530 The formyl resin 123 and basic arginine 143 
solution was allowed 5 minutes to react before the addition of the STAB 132 solvent mixture 
was added. Surprisingly, aldehyde 123 was still detected after 24 hours of reaction, by 
production of purple coloured beads upon treatment with p-anisaldehyde. The presence of 
aldehyde 123 indicated that neither the reductive amination or the reduction to alcohol had 
occurred. To be certain of this unexpected result, the reaction was repeated once more exactly 
on a 50 mg scale but produced the same result, confirming the original observation. 
 
Scheme 5-38. Proposed formation of secondary amine by reductive amination of 
formyl resin and arginine(Pbf) methyl ester via imine intermediate. 
The reductive amination was then attempted using 1% acetic acid/DMF solvent and sodium 
cyanoborohydride 133 (NaBH3CN) as reducing agent.531 Despite releasing HCN/NaCN as a 
by-product, NaBH3CN 133 can reduce imines at a faster rate than the reduction of aldehydes, 
offering a degree of selectivity for the desired secondary amine product.532 Deprotonation of 
the amino acid salt is not necessary in this system as acid is added to the reaction (Scheme 
5-39). The reaction between formyl resin 123 and H-Arg(Pfb)-OMe 143 was conducted for 3 
hours to allow for imine formation before adding the NaBH3CN 133 reducing agent. Testing 
for the presence of resin bound aldehyde with p-anisaldehyde was negative after 16 hours. 
An aliquot of beads was then evaluated in the presence of acetaldehyde 139 which gave an 
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orange colour indicating the presence of a secondary amine 144. These observations were 
consistent with reductive amination having occurred.  
 
Scheme 5-39. Successful reaction conditions for the reductive amidation of 4-(4-
Formyl-3-methoxyphenoxy)butyryl (FMPB) resin 123 to afford secondary amine 144 
with H-Arg(Pbf)-OMe 143 in the presence of sodium cyanoborohydride 133 
(NaBH3CN) and 1% acetic acid (AcOH) in dimethylformamide (DMF). 
Secondary amidation 
Once the conditions were found to attach the first amino acid (AA1) to the resin formyl group 
by reductive amination, the next step required the coupling of an Fmoc protected amino acid 
(AA2) This would produce a tertiary amide at the resin bound secondary amine (Scheme 5-40).  
 
Scheme 5-40. Proposed amide coupling of secondary amine 144 to acid to form 
tertiary amide 145. 
The nucleophilicity of secondary amines in solution is generally greater than primary amines 
owing to the electron donating effects of the alkyl groups compared to hydrogen. The steric 
effects of secondary amines often counter-acts and sometimes significantly reduces the 
expected increase in activity. Although solid-phase reactions offer advantages (e.g. 
purification, automation), one of the biggest limitations is achieving sufficient interaction 
between the resin reactive group and reagents in solution. High concentrations of reagents in 
solvents that facilitate swelling of the resin are employed to overcome this limitation. While 
solid phase coupling of sterically hindered functional groups can be inhibited or incomplete, it 
is possible to couple a tripeptide (Ala-Thr-(ΧMe,MePro)) to a resin bound secondary amine of 
Gly-OMe.531  
Several attempts to achieve tertiary amide derivatives were made in solution phase using the 
secondary amines, although all were unsuccessful (Table 5-7). Given that the conditions 
identified in the solution phase for the reductive amination were not successfully transferred 
to solid phase, solution phase optimisation of the amidation was considered unworthwhile. 
Therefore, attempts were made on resin without successful conditions in solution being 
identified the identified  
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Table 5-7. Unsuccessful reaction conditions employed in attempting to form the 
tertiary amide in solution phase. Both secondary amines formed by reductive 
amination were attempted to couple to Fmoc-alanine 146. DIPEA = 
diisoproylethylamine, Ph = phenyl; Me = methyl; DCC = dicyclohexylcarbodiimide; 
DMAP = dimethylamino pyridine; DMF = dimethyl formamide; THF = 
tetrahydrofuran; DCM = dichloromethane; Fmoc = fluorenylmethyloxycarbonyl; Bz 
= benzyl. 
 
Amine R Reagents Solvent Scale /mg 
138 CH(Bz) HBTU, DIPEA, HOBt DMF 41 
138 CH(Bz) N-methyl morpholine, ethyl 
Chloroformate THF 
90 
134 CH2CH2 N-methyl morpholine, ethyl 
Chloroformate DCM 
59 
134 CH2CH2 N-methyl morpholine, ethyl 
Chloroformate DCM 
50 
138 CH(Bz) DCC, DMAP DCM 113 
Without an optimised method for the solution phase tertiary amidation to transfer, on-resin 
coupling of secondary amide 145 and Fmoc-proline 147 was initially conducted following 
conditions reported.531 Known for its high yielding couplings, compared to other coupling 
reagents, HATU 117 is often employed for coupling of hindered, basic or weakly nucleophilic 
amines.533,534 To test the suggested conditions, resin-bound secondary amine 145 was 
coupled to Fmoc-proline 147 using in situ carboxyl activation by HATU 117 and DIPEA in DMF 
(Scheme 5-41). The reaction was repeated in triplicate, leaving each coupling over 16 hours 
to react.  
 
Scheme 5-41. Proposed amidation of resin-bound secondary amide 145 with 
fluorenylmethyloxycarbonyl proline 147, activating the acid carbonyl with 1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate 117 (HATU) and diisopropyl ethylamine (DIPEA) to form the 
tertiary amide 148. 
The reaction was tracked by a colorimetric acetaldehyde 139 test for the presence of 
secondary amines, however, no reduction in orange colour was observed, indicating the 
remaining presence of secondary amine. To confirm the accuracy of the positive result given 
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by the acetaldehyde the solution was divided into two portions. The first was cleaved from the 
resin using TFA/TIS/water to afford the deprotected lysine side chain amine. The solution was 
re-dissolved in acetonitrile and analysed by LCMS. An impure product was observed, although 
the largest absorbance (44%) was attributed to the desired dipeptide 149 with [M+H]+ 508 m/z. 
The uncoupled deprotected arginine methyl ester was also detected as the potassium salt, 
[M+K]+ = 227 m/z. 
 
Figure 5-47. LCMS analysis of cleaved product following attempt to amidate resin-
bound secondary amine of 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl 
arginine methyl ester 145 to Fmoc-proline 147. 1-[Bis(dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate 117 (HATU) was used as 
coupling reagent and resin cleavage was achieved using trifluoroacetic acid, 
tiisopropyl silane 95 and water. An absorbance was detected corresponding to the 
desired dipeptide 149 with [M+H]+ = 508 m/z. 
To the second portion, resin was treated to 10 equivalents of acetic anhydride to acetylate any 
remaining secondary amine (Scheme 5-42). Upon repeating the acetaldehyde test no colour 
was observed, indicating that although some desired dipeptide had formed, the acetaldehyde 
test result was accurate and the coupling of proline 147 to the secondary amine 145 was only 
partially successful. 
With confidence in the acetaldehyde test, the reaction was repeated using Fmoc-
phenylalanine 152 and leaving HATU 117 to react for longer to attempt to complete the 
coupling. After 72 hours and 3 coupling cycles, the acetaldehyde test remained positive for 
the presence of secondary amine 145, indicating unsuccessful coupling. 
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Scheme 5-42. Acetylation of any remaining secondary amine 145 with treatment of 
acetic anhydride 150, to form the tertiary amide 151, which will provide a negative 
control for the colourimetric test for the presence of secondary alcohols. 
DIPC in the presence of a strong auxillary nucleophile, such as HOAt has been shown to give 
very successful amide couplings.353 In lieu of the expensive HOAt, the cheaper alternative, 
DMAP 32 was used. Using the same 10 equivalents of DMAP 32 as previously employed for 
DIPEA to couple Fmoc-phenylalanine 152 to the resin-bound arginine ester 145, no secondary 
amine was detected after one hour.  
 
Scheme 5-43. Coupling of fluorenylmethyloxycarbonyl (Fmoc) phenyl alanine 152 to 
secondary amine of resin-bound arginine methyl ester 145 using diisopropyl 
carbodiimide (DIPC) and 10 equivalents of 4-(dimethylamino)pyridine 32 (DMAP) to 
form the resin-bound Fmoc-phenylalanine-arginine methyl ester dipeptide 153. 
Once the resin bound product 153 was cleaved from the resin, using standard cleavage 
conditions described in the methods, the isolated product was analysed by LCMS (Figure 
5-48). The chromatogram exhibited 3 peaks, of which the larger peak, with retention time 3.6 
minutes, possessed a mass of 558 m/z, corresponding to the desired Fmoc-Phe-Arg-OMe 
154. When repeated using 10 equivalents of DIPEA and a catalytic amount (0.2 equivalents) 
of DMAP 32, the reaction however, did not progress after 24 hours. The use of DIPC without 
any base is also reported to be successful.535 In our hands, however, the exclusion of base 
resulted in no reaction as detected by the acetaldehyde test for secondary amine which 
remained positive. 
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Figure 5-48. The resin-bound product expected to be fluorenylmethyloxycarbonyl 
(Fmoc) phenylalanine- 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) 
arginine methyl ester 153 was cleaved from the resin using trifluoroacetic acid (TFA), 
triisopropylsilane 95 (TIS) and water. The expected Fmoc protected dipeptide 154 was 
analysed by LCMS. The peak highlighted in pink, with retention time 3.6 minutes 
shows entirely product ion [M+H]+ = 558.2 m/z. 
Despite the unconventional conditions employing 10 equivalents of DMAP 32, the reaction 
progressed as desired, albeit in low yield. The desired peptide made up only 32% of the total 
compounds analysed by UV absorbance. Unfortunately, the success of the reaction was not 
realised until nearing the end of the project after other methods had been pursued. With only 
a few days left to verify the conditions, a repeat was attempted. This required synthesising the 
secondary amine 134 by on resin reductive amination between β-alanine ethyl ester 135 and 
formyl resin 123 using the successful conditions found with sodium triacetoxyborohydride 132. 
The reaction was repeated as before on a 0.058 mmol scale of formyl resin 123. However, the 
aldehyde was found to be reduced as determined by no colour with the acetaldehyde 139 test 
and no bead colouration with the p-anisaldehyde test.  
On-resin reductive amination and subsequent amidation has been successfully reported in the 
literature.536 Although a method to achieve the reductive amination step was found and 
employed, the conditions were not reproducible. Furthermore, coupling of the secondary 
amine formed was not successful. An extensive variety of coupling agents and combinations 
with reaction promoters are available.355. Perhaps with the right combination, the desired 
tertiary amine might be achieved. The limitation with the reaction may also be inherently 
caused by the steric hindrance surrounding the secondary amine and the carboxylic acid, 
although the ability to form the tertiary amide Fmoc-Phe-Arg(Pbf) 153 suggests that the steric 
hindrance is not the limitation 
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The objective of this section of work was to investigate methods to achieve a tryptase substrate 
with a C-terminal treprostinil. The reductive amination method was prone to reduction of the 
aldehyde to the resin which resulted in unreproducible results. Efforts to achieve 
immobilisation of treprostinil and substrate on resin via the reductive amination were 
terminated and alternative approaches were considered. One option would be to link the resin 
to the arginine side chain (Scheme 5-44) as described by Hamźe and colleagues,537 however 
few reports have utilised this method in the literature. Furthermore, arginine side-chain 
immobilisation would only be an option for peptide substrates with arginine as the C-terminal 
amino acid. 
 
Scheme 5-44. Proposed immobilisation of arginine derivative to Rink Amide resin 
allowing for peptide growth at N-terminal and p-aminobenzyl alcohol- and treprostinil 
conjugation at the C-terminus. On resin conversion of the thiourea to guanidyl group 
on resin results in an arginine side group upon cleavage. 
Another route considered was to add a side chain to the p-ABA group which theoretically 
should not interfere with immolative resonance required from drug release (Scheme 5-45). 
 
Scheme 5-45. Proposed side chain immobilisation of p-aminobenzyl alcohol (or 
derivative) on resin to facilitate conjugation of the first amino acid to the N-terminal, 
and the esterification to treprostinil at the hydroxyl terminal. X is any group which can 
link to any resin. 
Side chain immobilisation of p-aminobenzyl alcohol 
Immobilising the peptide-treprostinil on a resin through a side chain possessing derivative of 
p-aminobenzyl alcohol, as shown in Scheme 5-45 was considered the most accessible 
method. No commercially available compounds, such as 155, were identified. However, an 
acid terminal derivative could be obtained by ring opening of phthalide structure 158 (Scheme 
5-46). 
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Scheme 5-46. Proposed reaction scheme for the side chain immobilisation of p-
aminobenzyl alcohol, by ring opening of 4-nitrophthalide 158 and subsequent 
reduction of the immobilised nitro benzyl alcohol 156. The resulting immobilised para-
aminobenzyl alcohol 157 can facilitate both amino acid conjugation (amine terminus) 
and treprostinil conjugation (hydroxyl terminus). 
Ring opening of the phthalide 158, by a resin-bound amine will form an amide bond and 
liberate benzyl alcohol 156 (Scheme 5-46). Following reduction of the resin-immobilised nitro 
group 156 to the amine derivative 157, an amino acid can be conjugated which can grow the 
peptide substrates using standard Fmoc-conjugation (Scheme 5-47). Treprostinil can then be 
conjugated to the resin-bound protected substrate through the benzyl alcohol. The enzyme 
substrate-treprostinil conjugate is isolated following removal from the resin.  
 
Scheme 5-47. Proposed route to conjugate peptide substrate and treprostinil 4 to the 
immobilised para-aminobenzyl alcohol 157. Cleavage of the conjugate from the resin 
will liberate the desired enzyme substrate conjugate of treprostinil 159. 
In the design of the synthetic plan outlined, several potential issues or considerations were 
identified. First, the choice of the resin is partially determined by whether the cleaved product 
is desired as the free acid or the primary amide. As the design is for an enzyme substrate with 
a terminal hydrophobic moiety, treprostinil, it was hypothesised that preservation of as much 
hydrophilic character as possible would be preferred. This involves use of an alcohol terminal 
resin, and Wang resin was available. However, this would mean attempting a ring opening by 
nucleophilic substitution by an alcohol. An alcohol is less nucleophilic than an amine, so in this 
respect an amine terminal resin would be desired. Furthermore, with an alcohol moiety on the 
157 155 156 
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resin and no primary aliphatic amine on the phthalide, detection of the successful reaction 
progression could not easily be determined. Given the lack of certainty surrounding the 
successful ring opening reaction, a desirable reaction would involve an amine which could be 
determined by the robust Kaiser test. Therefore, it was decided that the Wang resin would first 
be conjugated to Fmoc-ala-OH 146 (Scheme 5-48). This would result in an ester link to the 
resin which when cleaved would form the soluble acid. The conjugation of Wang could be 
easily determined by deprotection of a sample a subsequent Kaiser test. Following loading, 
the Fmoc can be cleaved to reveal a primary aliphatic amine which is expected to undergo 
nucleophilic addition of the ester to facilitate ring opening. 
 
Scheme 5-48. Proposed immobilisation of p-amino benzyl alcohol by phthalide ring 
opening by amine of alanine-functionalised Wang resin 160. The 
fluorenylmethyloxycarbonyl (Fmoc)-deprotected alanine 161 amine undergoes ring 
opening of phthalide 158 which when cleaved releases the acid derivative 162. 
Second, upon opening of the lactone ring, a benzyl alcohol is exposed but whether the alcohol 
requires protection whilst the peptide substrate is conjugated, was not yet determined. 
Third, the nitro-phthalide compound 158 is cheaper than the corresponding amine 163 so initial 
attempts were made with the nitro-derivative. On-resin reduction of the nitro group to the amine 
is not common, but a method is described in the literature.538 Failing that, solution phase 
reduction of the nitro phthalide 158 could be attempted to afford the amine-derivative 163 
which could then be used on-resin (Scheme 5-49). 
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Scheme 5-49. Proposed methods to achieve the resin bound aniline derivative 164, 
composing of either on-resin reduction of nitro group after resin-loading, ring opening 
step to form 162 or off resin reduction to form the aniline phthalide 163 and subsequent 
resin-loading by ring opening.  
Fourth, testing the success of nitro reduction of nitro-resin 162 to the aniline derivative 164, 
may or may not be determined with the Kaiser test. An alternative method of testing the 
reaction progression is to couple an Fmoc-amino acid to the nitro/amine group, remove the 
Fmoc group and check the presence of primary amine of the conjugate 165 with the Kaiser 
test (Scheme 5-50). Coupling of the aromatic amine to the C-terminal of an Fmoc-amino acid 
was previously determined using solution phase reagents employing HATU 117 as a suitable 
coupling agent. 
 
Scheme 5-50. Methods of testing progression of reduction of nitro-resin 162 on resin 
using colourimetric Kaiser test. Aromatic amines, such as 164, are difficult to detect 
using the Kaiser test, owing to the changes in electron density. The Kaiser test can be 
used to determine the success of the reduction by detecting for the presence of the 
amine by conjugation of the aniline 164 to a second amino acid. The primary amine 
conjugate 165 produces a strong result using the Kaiser test. 
Fifth, ester coupling conditions were previously described in Chapter 3, using carbonyl 
diimidazole 36 (CDI). Treprostinil 4 could be appended either before or after nitro reduction 
and peptide growth at the N-terminal (Scheme 5-46 and Scheme 5-47). In considering the 
order of conjugation (i.e. should treprostinil be conjugated before or after the peptide has been 
conjugated), the bond stabilities were compared. The ester employed to conjugate treprostinil 
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to the conjugate is less robust than the amide bonds contained in the conjugate. Therefore, 
during the amino acid coupling steps, when the resin is treated with 5 equivalents of Fmoc-
amino acids and coupling agent, the ester bond may be jeopardised which could potentially 
remove treprostinil 4 from the resin. The conjugation of treprostinil was designed to be 
incorporated towards the end of the synthetic. Another consideration, learning from experience 
in Chapter 3, is the potential need for treprostinil hydroxyl protection. Silylation of the alcohols 
and acid of treprostinil prior to conjugation at the acid terminus was shown to be partially 
successful in Chapter 3 and could be employed for conjugation to the resin. Treprostinil 
reagent can be collected after the resin reaction to recover unreacted treprostinil.  
 
Scheme 5-51. Proposed protection of treprostinil with tertiary butyl dimethyl silyl 
(TBDMS) groups which will allow for esterification at the carboxyl terminus. Being acid 
labile, the hydroxyl TBDMS groups are expected to cleave upon resin cleavage. 
Lastly, upon cleavage of the product from the resin, an ester bond requires cleavage, however 
the treprostinil is also linked via an ester. Therefore, cleavage conditions will need to be sought 
to selectively cleave the resin ester, whilst leaving the treprostinil ester intact (Scheme 5-52). 
 
Scheme 5-52. Removal of the tryptase substrate-amidebenzylester-treprostinil 
conjugate from resin. The conditions employed for the ester cleavage of the wang 
resin must leave treprostinil ester in-tact. 
Before the phthalide reduction was conducted on-resin, the reaction was attempted in solution 
to determine the conditions required for phthalide ring opening (Scheme 5-53). A carboxyl-
protected β-alanine ethyl ester hydrochloride 135 was employed to mimic the role of the resin. 
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Scheme 5-53. Ring opening of 6-nitrophthalide 158 by β-alanine ethyl ester 
hydrochloride 135 to form the amide derivative of para-nitrobenzyl alcohol 166. 
Ring opening of 6-nitrophthalide 158 was carried out by nucleophilic attack of β-alanine ethyl 
ester hydrochloride 135 in the presence of triethylamine to neutralise the salt ammonium ion. 
Reagents were refluxed in ethanol at 86 ᵒ to drive the reaction and after 3 hours the desired 
ring opened amide 166 was formed in 60 % yield. Analysis by 1H NMR revealed a shift in the 
singlet resonance (highlighted in blue in Figure 5-49) from 5.4 to 4.8 ppm indicating the loss 
of ester linkage in favour of the alcohol, as well as resonance shift in triplet (highlighted in pink) 
from 3.4 to 3.7 ppm indicating that the amine had undergone reaction to the amide. 
 
Figure 5-49. 1H NMR spectrum of the amide product 166 formed through ring opening 
of 6-nitrophthalide 158 by nucleophilic substitution of β-alanine ethyl ester 
hydrochloride 135. 
To transfer the successful solution phase conditions to solid phase, Fmoc-alanine 146 was 
immobilised onto the resin using standard HATU 117 coupling conditions and confirmed by a 
negative Kaiser test. After deprotection of the Fmoc group, the resin was left to react with 6-
nitrophthalide 158 in the presence of base and refluxed. The reaction was deemed complete 
by a negative, colourless Kaiser test.  
 
Scheme 5-54. Conjugation of fluorenylmethyloxycarbonyl (Fmoc) alanine to Wang 
resin employing 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 
3-oxide hexafluorophosphate 117 (HATU) as coupling agent with the presence of 
diisopropylethylamine (DIPEA) in dimethylformamide (DMF). Following the removal of 
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Fmoc group to produce Ala-Wang 161, the amine can be detected using the Kaiser 
test to produce a blue colour. 
It was considered that the reduction of the nitro- group to the corresponding amine could be 
avoided by repeating the solution phase reaction using the amine derivative, 6-aminophthalide 
163. Employing the same reaction conditions, 6-aminophthalide 163 was allowed to react with 
β-alanine ethyl ester 135, but the ring opened, amide product 167 was not observed by TLC 
(Scheme 5-55). The nitro group of 158 has an electron withdrawing effect on the aromatic ring 
which through inductive effects, weakens the ester bond. The aniline amine however, donates 
electrons to the aromatic ring which results in a strong ester bond.  
 
Scheme 5-55. The proposed ring opening of 6-aminophthalide 163 by amide formation 
with β-alanine ethyl ester 135 to form the amide derivative of para-aminobenzyl alcohol 
167. However, the reaction was unsuccessful. 
Coupling of the aniline 163 to a carboxylic acid to form the corresponding amide was thought 
to remove the electron donating effect of the aniline electrons and allow for successful ring 
opening by nucleophilic substitution of the ester carbonyl. Using conditions previously 
described for the coupling of ACA alinine 97, HATU 117 was employed to activate the carboxyl 
of Fmoc-Lys(Boc)-OH 169 and couple the aniline 163 in solution to form the Lysine-phthalide 
derivative 168. The reaction was conducted in the presence of DMAP 32 catalyst in DMF 
(Scheme 5-56). 
 
Scheme 5-56. Amidation of the aniline phthalide by coupling to 
fluorenylmethyloxycarbonyl (Fmoc)-lysine 169 to form the Fmoc-lysine phthalide 168. 
The reaction was achieved using 1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate 117 (HATU) coupling agent and 
4-(dimethylamino)pyridine 32 (DMAP) in dimethylformamide.. 
1H NMR spectroscopy (Figure 5-50) confirmed a shift in the proton of the aromatic nitrogen 
(labelled in pink) from 5.53 to 10.4 ppm upon amidation. The lactone ring appeared to be intact 
by the presence of the singlet at 5.4 ppm, highlighted in blue. 
162 134 
166 
162 168 167 
Targeting of drug release 
295 
  
 
Figure 5-50. 1H NMR spectrum of amide product 168 formed by amide coupling Fmoc-
Lysine(Boc) 169 and 6-aminephthalide 163. The shift in the aromatic amine (pink) as 
well as the lysine methine (green) confirm conjugation. The persistent methylene 
resonance (blue) indicated that the lactone ring is in-tact. 
The aniline-amide product, Fmoc-Lys(boc) amide phthalide 168 was used to attempt ring 
opening on the resin. The immobilisation of the amino acid-phthalide conjugate on resin in one 
step was considered to be an efficient method to circumvent the requirement for an on-resin 
nitro reduction. 
 
Scheme 5-57. The ring opening and simultaneous resin immobilisation of amidated 
phthalide 168 by nucleophilic substitution of the resin bound alanine 161. The amide 
is not electron withdrawing enough to facilitate ester bond cleavage which would 
otherwise form the amide linked resin bound lysine amidobenzyl alcohol 170. 
Opening of the ring of Fmoc-lys-phthalide 168 lactone ring to form an amide bond on resin 
(161) was unsuccessful, using conditions found to be successful with the nitro derivative 158. 
Lysine-phthalide 168 was refluxed in the presence of resin-bound alanine 161. However, the 
opening of the ring was not observed by Kaiser test, in the case of the resin. The reaction was 
attempted in solution using tyramine 171 an unhindered amine compound to determine if the 
hindrance of the amine resin was preventing ring opening. Refluxing phthalide 168 with 
tyramine 171 in DMF at 175 ᵒC did not afford the amide product. 
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Scheme 5-58. Proposed ring opening of fluorenylmethyloxycarbonyl (Fmoc)Lysine 
phthalide 168 by tyramine 171 to form the amide derivative. 
Hydrolysis of the amide phthalide 168 was attempted using lithium hydroxide ester hydrolysis 
conditions but the acid benzyl alcohol product was not formed (Scheme 5-59). The electron 
withdrawing effect of the aniline is not sufficiently reduced by amidation and ring opening of 
the nitro is the most successful route. Therefore, a route to reduce the nitro moiety on the resin 
was sought. 
 
Scheme 5-59. Proposed hydrolysis of the amidated phthalide 168 by lithium 
hydroxide, to afford the acid-alcohol ring opened product. Fmoc = 
fluorenylmethyloxycarbonyl 
A literature search only identified one method to reduce a nitro group to the amine on a solid 
phase reaction without metal catalysis, although the yields were not reported.538 The reaction 
employed a bi-phasic solvent of DCM and water (9:1). An aqueous solution of hydrogen 
thiosulfate in the presence of potassium carbonate was employed as the reducing agent and 
a phase transfer catalyst was employed to facilitate reaction between the solvent layers. A 
pyridinium halide phase transfer catalyst was used by Scheuermann and colleagues538, 
although n-tetrabutyl ammonium iodide was available so was used in the reaction attempt. 
 
Scheme 5-60. The reduction of resin bound nitro 162 to achieve resin-bound amine 
derivative 164 modified from a reported procedure.538 To facilitate interaction between 
the protic aqueous solvent and the aprotic dichloromethane, n-butyl ammonium iodide 
((n-Bu)4NI) was added as a phase transfer catalyst, instead of the viologen reported 
in the paper. Colourimetric montoring of the reaction was not achieved directly but was 
deemed successful indirectly by further conjugation. 
After 24 hours a Kaiser test was carried out and a pale purple colour solution was observed. 
It was not certain whether the pale colour meant very few amines were present or that the 
aromatic amine presented that colour when treated with the Kaiser test. For this reason, it was 
determined that a further coupling of any amine groups followed by Fmoc deprotection step 
would be needed to clarify the potentially ambiguous result. Coupling of the aniline was shown 
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here to be successful when HATU 117 was employed and similarly previously reported on 
resin.514,516,539. Therefore, for the investigation of nitro group reduction, it was assumed that 
the subsequent coupling of any amines present would be complete. Coupling of a resin sample 
taken from the reduction reaction (162 and/or 164) with Fmoc-Arg(Pbf)-OH was carried out in 
the presence of HATU 117 and DIPEA for 12 hours. After which, a sample was taken and 
treated with piperidine to cleave the Fmoc group (Scheme 5-61). Kaiser test revealed an 
intense blue colour indicating the presence of a coupled primary amine. 
 
Scheme 5-61. Possible structures formed when coupling Fluorenylmethyloxycarbonyl 
(Fmoc) 2,2,4,6,7-Pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) Arginine to a 
potential mixture of nitro resin 162 (X = O)and reduced aniline resin derivative 164 (X 
= H). Both structures produce the same positive Kaiser test; the desired amide 172 via 
the aniline derivative 164; and ester formation by coupling via the hydroxyl 173, or a 
mixture of both. (i) 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxide hexafluorophosphate 117 (HATU), diisopropylethylamine, Fmoc-
arginine(Pbf)-OH; (ii) 20% piperidine/ dimethylformamide; (iii) Kaiser test. 
In the presence of the free hydroxyl of the aniline compound, 164 the coupling could have also 
occurred at the hydroxy terminus to produce a positive result (Scheme 5-61). To circumvent 
this possibility, the nitro derivative 162 was acetylated by treatment of acetic anhydride 150 at 
the hydroxy terminus to prevent unwanted hydroxyl coupling (Scheme 5-62). The resin was 
reduced using the conditions used previously, coupled to Fmoc-Ala-OH and Fmoc-
deprotected. A translucent purple colour was revealed upon treatment with the Kaiser test, 
confirming the suspicion that phenylalanine 152 had previously coupled to the hydroxyl 
terminus. Furthermore, in the presence of excess Fmoc-alanine, the pale purple colour also 
indicated only partial reduction of the nitro group 162 to the amine derivative 164 occurred. To 
facilitate successful reduction of the nitro resin 162, longer reaction times were considered.  
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Scheme 5-62. Acetylation of the resin-bound nitro benzyl alcohol 162 using acetic 
anhydride 150 to prevent coupling at the hydroxyl terminus. The reduction was then 
attempted again. DCM = dichloromethane 
The coupling at the hydroxyl terminus highlighted the need for hydroxyl protection, and for this, 
benzyl groups, THP and trityl groups were all considered. Tetrahydropyran and benzyl groups 
were attempted although a method to detect the presence of alcohols proved difficult, as 
described below. Protection by benzyl ether was also not ideal because of the hydrogenation 
removal step. Trityl protecting groups are frequently used in SPPS for the protection of 
cysteine side chains, because they are so are resistant to the basic conditions employed for 
amide coupling and Fmoc removal. Additionally, they are very sensitive to acidic conditions so 
can be removed selectively leaving the resin ester link and side chain protecting groups intact. 
Tritylation of the nitro-resin 162 was attempted using trityl chloride in a basic environment 
(Scheme 5-63). The presence or absence of the alcohol was not easily determined using a 
colorimetric test. The 4-toluene sulfonyl chloride - p-nitrobenzylpyridine (TosCl-PNBP) test 
often employed for alcohol detection converts the alcohol to its tosylate form which is 
subsequently displaced by the PNBP. Upon treatment with base, the pyridinium salt is formed 
which produces a strong red/purple colour.540 Unfortunately, the preceding phthalide ring 
opening step results in a brown stained resin which makes subtle changes in colour to pale 
red/purple difficult to determine with certainty (Figure 5-51). Wang resin was run as a positive 
control and acetylated wang resin (by treatment with acetic anhydride 150) run as a negative 
control.  
 
Figure 5-51. Ambiguous result of the 4-toluene sulfonyl chloride - p-
nitrobenzylpyridine (TosCl-PNBP) test run in parallel (a) Wang resin as positive 
control; (b) reaction resin when tritylating alcohol of nitro resin 162; (c) acetylated wang 
resin was used as a negative control. 
Another method to determining the presence of hydroxyls is to use bromocresol blue.541 The 
utilisation of trityl protecting groups permitted an alternative approach to test for the hydroxyl 
protection; to test for trityl deprotection. In the presence of 1% TFA in DCM, trityl groups are 
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cleaved and upon liberation of the cation a yellow colour emerges (Scheme 5-63). A sample 
of the nitro resin treated with trityl chloride was swirled in a solution of 1% TFA in 
dichloromethane and a yellow formed. To confirm the yellow colour is a result of the trityl 
cation, TIS 95 was added to quench the cation and remove the yellow colour, which indeed 
turned the solution colourless. This confirmed the conditions required for the tritylation of the 
alcohol.  
 
Scheme 5-63. Tritylation of resin-bound nitro benzyl alcohol 162 by treating alcohol 
with trityl chloride 176. Upon treatment with mild acid, the trityl cation is formed which 
produces a yellow solution. 
The tritylation was carried out on a larger scale (0.680 mmol), using an excess of trityl chloride. 
The trityl-removal step was conducted on a small sample using weak acid to confirm reaction 
success. The nitro group reduction step was carried out in triplicate, leaving the reaction 
mixture to shake for 24 hours for each cycle.  
 
Scheme 5-64. Proposed on-resin reduction of trityl-protected immobilised nitro benzyl 
alcohol derivative 175 to form the aniline derivative 177.  
A test sample was taken and coupled to Fmoc-phenylalanine 152 in duplicate using HATU 
117 and DIPEA. After which, the Fmoc-groups were removed and to half the sample, the 
Kaiser test conducted, revealing an intense blue solution, indicating successful coupling. To 
the remaining test sample, 1% TFA in DCM was added which immediately produce a yellow 
solution, confirming that the trityl groups were still intact and thus coupling had occurred 
through the aniline and not the hydroxyl. The intense blue solution upon Kaiser test, therefore 
indicates that the on-resin reduction had been successful.  
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Figure 5-52. Image of Kaiser test result following coupling of 
fluorenylmethyloxycarbonyl alanine to reduced resin-bound amine 177 and 
subsequent fluorenylmethyloxycarbonyl-deprotection. 
With the trityl protecting group intact and the confirmed aromatic amine of the reduced resin 
product 177, the next step was to split the resin into equal protons to couple the desired first 
amino acid. However, the positive result occurred in the final weeks of the project, during the 
writing phase so the coupling of the substrates remains yet to be conducted. 
 
Scheme 5-65. The proposed conjugation of the amino acid sequence to the trityl-
protected resin-bound aniline 177. 
When discussing the nitro-reduction mechanism employed for the on-resin reduction more 
closely during the work up, previously literature of biphasic reductions using sodium dithionite 
was consulted. The publication followed for the work reported used various pyridyl bromide 
viologens as phase transfer agents, to aid interaction across the biphasic interface.538 When 
designing the nitro reduction described in this chapter, n-butylammonium iodide was already 
in possession so was employed in a similar manner, in the same sub stoichiometric quantity. 
Viologens also possess the ability to transfer electrons between phases.542,543  
 
Scheme 5-66. Mechanism of the viologen (V) in the reduction of resin-bound nitro 
group to the aniline derivative. Viologen is both a phase transfer agent and electron 
transfer agent. V+ carries the electron from the aqueous layer to the chloroform layer 
to donate it to the nitro, becoming V2+ and resulting in the aniline derivative. 
Replenishment of the viologen is achieved by reaction with sodium thiosulfate. 
The phase transfer catalyst employed, n-butylammonium iodide does not possess known 
electron transferring properties, but the evidence suggests that coupling to a nucleophile other 
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than the hydroxyl was successful, suggesting nitro reduction to the aniline. Additionally, when 
n-butylammonium iodide was erroneously forgotten from the reduction reactions, coupling of 
an amino acid did not appear to occur, confirming a role of n-butyl ammonium iodide necessary 
for reduction of the nitro group. The reduction reaction took between 1 and 3 days to complete, 
requiring longer reaction times for larger reaction batches. For any commercial utilisation, the 
reaction time would need to be reduced and the use of an electron transfer agent such as the 
viologen phase transfer catalysts may offer a route to achieve more efficient conversion to the 
aniline derivative.  
Resin Cleavage Conditition Testing 
During the period of developing the method this far, a simultaneous investigation was carried 
out to consider the treprostinil-ester stability (highlighted red in Scheme 5-67) in the resin 
removal and side chain removal steps. This step would also require forming the amine salts 
of the terminal and lysine amines to prevent nucleophilic attack into the ester carbonyl, 
releasing the treprostinil prematurely.  
 
Scheme 5-67. Desired conjugate isolation upon resin cleavage which cleaves the 
Wang resin-linking ester (red) and leaves the treprostinil ester (blue) in-tact. 
An investigation was undertaken to determine resin cleavage and side chain deprotection 
conditions suitable to be employed in the presence of the treprostinil ester. For this, Fmoc-
lys(boc)-pABA-Phenox 120 was synthesised to act as a model which could be tracked in real-
time. Ester 120 was exposed to various conditions known to remove protecting groups and 
compounds from resins. The results are displayed in the table below.  
Table 5-8. Ester stability of lysine-amidobenzyl phenoxyester 
is resin cleavage cocktails. TFA = trifluoroacetic acid; TIS = 
triisopropylsilane; DCM = dichloromethane; HCl = 
hydrochloric acid; HFIP = hexafluoroisopropanol, 1H NMR = 
proton nuclear magnetic resonance. 
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Cleavage 
cocktail 
Time Outcome Analysis Reference 
TFA 2 hours 
Ester 
cleavage 
1H NMR 544 
TFA/TIS/H2O 
(95:2.5:2.5) 
2 hours 
Ester 
cleavage 
1H NMR 544 
1% TFA / DCM 2 hours Ester in tact 1H NMR 545 
0.1 N HCl / 
HFIP / DCM 
(20%) 
1.5 
hours 
Ester in tact 1H NMR 546 
The arginine-phenoxyester conjugate was unstable when exposed to standard TFA-mediated 
resin-cleavage conditions. The experiment was re-run without the addition of water to 
investigate whether the cleavage was a result of hydrolysis. 1H NMR analysis of the two 
products showed a shift in methylene resonances corresponding to the benzyl and phenoxy 
moietyies. A change in both resonances suggests that the bond between them has been 
cleaved. When the ester conjugate was treated to milder cleavage conditions using only 1% 
TFA in DCM, the ester methylene remained unchanged. However, such mild cleavage 
conditions are inadequate in removing robust protecting groups such as the 2,2,4,6,7-
pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) group. Palladino and colleagues had identified 
a mild resin cleavage procedure which avoids TFA but is suitable to remove Pbf groups from 
arginine. The cleavage cocktail consists of HCl, 1,1,1,3,3,3-hexafluoroisopropanol and DCM 
and can remove Pbf groups in 1.5 hours. The arginine ester was treated to the cleavage 
solution and analysis of the crude product after 1.5 hours revealed the ester was still present. 
In the 1H NMR sprectra (Figure 5-53), a resonance at 4.66 ppm corresponding to the 
methylene of the phenoxy moiety is shifted slightly downfield upon cleavage of the ester. 
Furthermore, the peak corresponding to the benzyl methylene protons is visible at 5.2 ppm 
when the ester bond is present. Upon ester cleavage, the protons are detected upfield of 5.2 
ppm, however the number of resonances in the region prevent the exact peak being identified. 
119 
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Figure 5-53. In-line 1H NMR spectra of the products obtained when treating lysine-
phenoxyacetate ester 125 to different resin removal conditions. A small shift in the 
peak corresponding to the phenoxyacetic ester methylene (shown in blue) from 4.66 
to 4.70 ppm is observed upon ester cleavage (shown in green). Furthermore, the 
benzyl methylene resonance (shown in pink) is no longer observed at 5.2 ppm when 
a high proportion of trifluoroacetic acid (TFA) is employed in the mixture, indicating 
that the the ester is cleaved. TIS = triisopropyl silane; HCl = hydrochloric acid; HFIP = 
1,1,1,3,3,3-hexafluoropropanol. 
With ester-stability identified, the resin-cleavage conditions were employed to verify the 
sensitivity to remove peptides from Wang resin. To investigate the success of the nitro 
reduction of the tritylated resin-immobilised nitro benzyl alcohol by amide formation (Scheme 
5-68), the resin-bound product 178, was removed from the resin using HFIP.  
 
Scheme 5-68. Cleavage of expected resin-bound phenylalanide tritylbenzoyl alanine 
using test cleavage conditions 0.1 M hydrochloric acid and 1,1,1,3,3,3-
hexafluoropropanol. The trityl group is expected to cleave simultaneously. 
After 1.5 hours, the resin was filtered off and the crude filtrate dried and analysed by 1H NMR 
spectroscopy (Figure 5-54). The NMR spectrum of the crude product showed peaks similar 
to that of the expected product. Notably, the aromatic resonances of the phenylalanine 
(labelled yellow in Figure 5-54) integrated with that of the alanine resonances (highlighted 
177 
178 
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pink) in a 2:3 ratio which indicated successful coupling. The trityl group peaks are not present, 
as expected, owing to the acidic cleavage conditions. The benzyl alcohol methylene protons 
are no longer a singlet integrating to 2 protons which indicates that coupling may be occurred 
at unprotected alcohol terminals or that the two protons experience two different nuclear 
environments which is detectable by the splitting of the NMR signal. In this case, it might be 
expected to observe splitting resulting from geminal coupling which is not visible in the spectra. 
The methine protons and the phenyl methylene protons did not produce a visible peak, 
although it is possible they are present under the broad resonance at 3.4 ppm. at unprotected 
from the did not show the peaks for the expected product.  
 
Figure 5-54. 1H NMR of the product isolated from the resin removal using hexafluoro-
2-propanol. The protons observed match that of the expected product although the 
methine and benzyl protons are either not present or found beneath the broad 
resonance at 3.4 ppm. Furthermore, the benzyl protons neighbouring the alcohol 
appear to have split into two singlets. 
Cleavage from the resin using HFIP produces a product which shares 1H NMR resonances 
with the expected product. The exact structure is not determined, owing to the lack of methine 
resonances. In order to be certain, a further investagtion is necessitated to confirm efficient 
coupling and determine resin removal efficacy. As a preliminary result, it appears that the HFIP 
conditions remove product from the resin which may be suitable for the removal of a treprostinil 
ester conjugate. 
To localise the release of treprostinil in the PAH lung, the conjugation of treprostinil to an 
enzyme upregulated in PAH was considered. With the reported ease, scalability and 
reproducibility of solid phase synthesis, a method to synthesise such a conjugate on resin was 
considered to offer greater commercial feasibility. Achieving a tryptase or chymase substrate 
conjugate with treprostinil required conjugation at the N-terminus. Conjugation of treprostinil 
to a resin which could then facilitate peptide conjugation was not an option and therefore, a 
synthetic route to accommodate both resin growth and treprostinil on-resin was investigated. 
A route was found (Scheme 5-69) to immobilise a derivative of nitro-benzyl alcohol onto the 
resin which after hydroxyl protection and nitro reduction would facilitate a sequence of amino 
acid conjugation using standard coupling of Fmoc amino acid derivatives. Following hydroxyl 
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deprotection, treprostinil could be conjugated on resin which will facilitate an easy method to 
remove and recycle excess equivalents of treprostinil. Following conjugation, conditions were 
sought for the resin removal step which is mild enough to cleave the conjugate from the resin 
and cleave the side chain protecting groups but leave the treprostinil ester in-tact.  
 
Scheme 5-69. Synthetic steps optimised to achieve the treprostinil-enzyme substrate 
conjugations on resin. Reaction reagents shown in blue have been shown to produce 
the proposed compound, whereas those in red are yet to be determined. Reactions 
conditions shown in green have been attempted but the reaction product ambiguous 
or not confirmed. Purple reaction conditions indicate conditions which have been 
successfully employed in other reaction within this work but not attempted on the 
compound shown. 
Tryptase substrate summary 
On resin techniques were thought to provide a clean and reproducible route to the synthesis 
and purification of C-terminus enzyme substrates. Methods were pursued to achieve a 
chromophore at the C-terminal, for proof-of-concept, and then a method to conjugate 
treprostinil. Conjugation to a chromophore was initially sought as a cheaper alternative to 
purchasing commercially available conjugates. The time taken to synthesise the conjugates 
was anticipated to be negligible, given the automatic programmable synthesis of the peptide. 
The synthesis was hindered by unresolved issues conjugating the amino-acid derivative of 
amino coumarin to the resin. FITC-conjugated derivatives of the substrates were synthesised 
by the addition of a side chain FITC-conjugated lysine derivative at the C-terminus. The 
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synthesis was simple and reproducable, but their degradation does not alter electromagnetic 
absorbance and emission properties sensitively to facilitate real time tracking of the enzymatic 
degradation in the presence of tryptase. Other chromophores are available which could have 
facilitated resin-immobilisation, but efforts were directed from reproducing commercially 
available compounds to the synthesis of treprostinil conjugates. 
To attach the treprostinil carboxyl group and C-terminus of a peptide chain together, a self-
immolative spacer, p-aminobenzyl alcohol, was incorporated into the design which was 
anticipated to facilitate drug release via a self-immolative mechanism. Immobilisation of the 
peptide-treprostinil conjugate on the resin was the first hurdle, as the treprostinil structure does 
not facilitate conjugation exclusively and orthogonally through two moieties. At first, resin-
attachment between the first amino acid and spacer was attempted. Reductive amination of 
p-aminobenzyl alcohol was deemed too poorly nucleophilic to form the imine intermediate 
which could later be reduced, immobilising it onto the resin. Therefore, attaching the resin 
between the first and second amino acids was sought. Attachment of the first amino acid by 
reductive amination was successful both in solution and on-resin. The on-resin reductive 
amination and subsequent amidation step was difficult to monitor using the colourimetric tests 
available and furthermore, results were rarely reproducible.  
Using a method to immobilise derivatives of benzyl alcohol onto the resin were investigated 
and which saw success in the ring opening of 6-nitrophthalide, both in solution and on-resin. 
The need to protect the hydroxyl liberated upon ring-opening was established which was 
achieved by tritylation. In order to facilitate peptide conjugation, the nitro-required reduction 
which is not commonly employed for on-resin strategies. Attempts to negate the reduction step 
were sought but the amine and amide derivatives employed were not electron withdrawing 
enough to facilitate subsequent ring opening. Despite the unconventional approach, reduction 
was achieved without the need for metal catalysis. The aniline product was insensitive to the 
Kaiser test but a method to monitor the success of the reaction was found by coupling and 
deprotection of a reaction sample to a fmoc-amino acid. The process is lengthier than standard 
colourimetic tests but provided unambiguous reaction monitoring. 
The sensitivity of the ester bond achieved upon the expected treprostinil conjugation was 
anticipated and resin cleavage conditions were sought that would not result in ester 
degradation and premature treprostinil release. Resin cleavage using HCl and HFIP in DCM 
was found to be suitable for ester stability and resin cleavage in solution but when employed 
to remove a dipeptide from Wang resin, the expected dipeptide was not detected by 1H NMR. 
 
Polymer drug-conjugates (PDCs) of treprostinil which include a targeting moiety to increase 
specificity for the lung has not previously been attempted. With no prior history of PDCs in the 
treatment of PAH, lessons were taken from the approach applied in treating cancer. PAH and 
cancer have many overlapping mechanisms and features however treprostinil is not as toxic 
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as the cytotoxic compounds used to kill tumour cells. Therefore, treprostinil has a larger 
therapeutic window than cancer therapies and could better exploit the benefit of polymer drug 
conjugates, as a small level of off target effects will not cause the negative effects associated 
with cytotoxic drugs. In the design of a polymer drug conjugate, the targeting moiety and 
releasable linker were considered.  
CAR was investigated as the targeting moiety and a route to synthesise the fluorescein-
conjugated derivative was attempted first using a bespoke made CAR(Dde) moiety and then 
using on-resin synthesis techniques. For both pathways taken, purification required a 
preparative column which, after attempting alternative methods of purification, was purchased. 
With hindsight, the purification of the solution phase peptide could have been made easier to 
read the absorbances by using a different wavelength which could have been achieved by 
employing a diode array spectrometer. FITC-CAR was shown to localise in the near nuclear 
regions of cells in the presence of TNF-α. At higher concentrations FITC-CAR was also shown 
to bind non-specifically to the nuclei of both healthy and inflamed cells. 
Substrate-specific enzymatic degradation of prostacyclins is an approach not previously 
attempted in the published literature. However, its successful employment in treating patients 
could result in the localised release and action of PM’s in diseased lung tissue in PAH. 
Tryptase is an enzyme only found in sites of chronic inflammation, so a tryptase-specific 
substrate will only release drug in the PAH lung. SPPS is a useful tool for the synthesis of 
peptides and small molecule which allows for multiple subsequent steps to be carried out on 
molecule and minimises the work up. However due to the lack of certainty and analysis in each 
step, robust chemistries must be employed to increase the yield of desired product. Testing of 
the pro-drug substrates was attempted using Fmoc-ACA-OH which is designed to link to the 
resin allowing for simple substrate-chromophore dimers. Immobilisation onto the resin was not 
achieved and so Lys(FITC) C-terminal conjugations were sought. Synthesis was readily 
achieved but testing of the release could not readily be tracked using change in chromophore 
absorbance.  
Immobilisation of treprostinil on a resin allows for multiple different oligopeptides to be 
appended to treprostinil. This work covered the on-resin conjugation of treprostinil to tryptase 
and chymase substrates, it is thought that the concept could be applied to oether enzyme 
substrates. Multiple equivalents of treprostinil are required to react with the resin, although the 
excess can be easily recovered. The sensitivity of the ester bond formed to conjugate 
treprostinil is susceptible to nucleophilic substitution so treprostinil is added to the resin last. 
 
PAH patients receiving prostacyclin therapy are burdened by the systemic adverse events. 
Despite the targeted advancements in cancer therapy, polymer-drug conjugates of PMs for 
PAH have not reached the clinic. The synthesis, utility and biocompatibility of HPMA polymers 
is well established. Although a full polymer was not synthesised, the work featured in this 
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chapter builds ideas and synthetic strategies towards incorporation of releasable treprostinil 
and a targeting moiety.  
Despite the homing abilities of the CAR peptide being previously reported, the 4-year period 
in which no further publications or patents had been published, made us sceptical about its 
further utility. We initially set out to confirm some preliminary observations in a different 
inflammation assay, which would help to determine its utility in a drug polymer for PAH. 
Synthesis of the FITC conjugated peptide both in solution and on-resin took longer than 
expected. Although a method was found for the oxidation of the thiols, previous unsuccessful 
oxidation attempts could have been improved by quenching the iodine with ascorbic acid. 
Targeted therapies, including using CAR peptide for the treatment of PAH have been explored 
in the literature but this is the first reported use in a conjugated form. This work is the first 
attempt to incorporate an oligopeptide prodrug approach in PAH. To achieve the prodrug 
structures, on-resin synthesis was pursued. This was the first report of immobilising a PM on 
resin which allows for versatility in the peptide substrates. Ideally, immobilisation of treprostinil 
on the resin would feature in the initial steps, however the lack of suitable handles and the 
sensitivity of esters in the presence of excess amines risks severing the bond linking 
treprostinil to the immolative linker. On the other hand, incorporating treprostinil onto the resin 
last reduces the opportunity for treprostinil to be cleaved during the synthesis. The cost and 
complex synthesis of treprostinil prioritise its preservation.  
Although efforts for the different moieties in the context of a polymeric structure were explored, 
incorporation of the substrate-drug moiety and the targeting peptide into a polymeric structure 
was not attempted. 
 Chapter Conclusion 
In conclusion, both a targeting moiety and releasable linker for a polymer-drug conjugate for 
the delivery of treprostinil to the PAH lung were investigated. Synthetic routes on-resin were 
explored to find reproducible methods which can later be scaled.  
Achieving the derired compounds on resin was not as straight-forward as expected but did 
achieve the cyclised FITC-CAR method when an off-resin method for oxidation of the thiols 
was employed. Progress was made in achieving the first on-resin conjugate of the prostanoids. 
Despite the error made during the nitro reduction, further coupling through a nucleophile other 
than the hydroxyl was observed. The opportunity to test the tryptase substrate conjugates was 
not reached in the time frame, so activity is yet to be determined. The synthetic method 
described is thought to be compatible to any substrate designed to be cleaved at the C-
terminus, which opens the potential to target a variety of disease states involving proteolytic 
degradation. 
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A targeted polymer drug conjugate based on the structure described by Ringsdorf425 (Figure 
5-1) has not been described previously. Here, the design of a targeting moiety and release 
mechanism is presented and progress made on the successful synthesis. 
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 General Discussion 
 Project Approach 
The aims of the PhD project were to investigate methods to reduce adverse events associated 
with treprostinil therapy for the treatment of pulmonary arterial hypertension (PAH). First the 
adverse events associated with treprostinil therapy versus placebo were identified from clinical 
trial data in the meta-analysis described in Chapter 2. The analysis identified drug-mediated 
systemic and local adverse events which varied with administration route and prostacyclin 
mimetic. The conclusions provided a solid clinical rationale for the strategies that are described 
in the subsequent chapters. The work presented in Chapters 3-5 describe the different pro-
drug strategies that were selected to examine how to reduce the adverse reactions associated 
with treprostinil. Many prodrug approaches were considered as described in Chapter 1 but 
were not pursued due to characteristics of PAH as a medical condition or because of the 
inherent structure activity limitations of treprostinil as a molecule or its mode of action as an 
agonist.  
Two strategies that were examined include the preparation and in vitro characterisation of N-
acyl sulfonamide treprostinil (TRE-S) 21 and a polymer-drug conjugate, oligo(PEG-treprostinil 
acetal) 71. A third strategy involved the design of a targeted polymer-treprostinil conjugate. 
Treprostinil 4 was envisaged to be conjugated to a water-soluble polymer by an enzymatically 
cleavable pendent chain much as is described by the Ringsdorf model. Some key conclusions 
from the work described in Chapters 2-5 include:  
1. Subcutaneous treprostinil is limited by site pain. 
2. Treprostinil IP activity can be reduced by using N-acyl sulfonamide prodrug 
3. Treprostinil is limited as a monomer for polyacetal formation. 
4. Inflamed endothelial cells facilitate binding of CAR peptide, compared to healthy cells 
5. A method has been determined to immobilise both a carboxylic acid containing drug 
and enzyme substrate onto a resin. 
Preliminary work was also done for related prodrug strategies but was terminated at early 
initial stages. N-acyl-sulfonamide treprostinil 21 was initially intended for a polyvalent prodrug 
strategy so methods were examined to conjugate treprostinil via its aryl ring. Since progress 
to prepare the CAR targeting moiety and tryptase linker was slower than anticipated, efforts 
were reduced to prepare monomers and co-polymers of N-(2-hydroxylpropyl methacrylamide), 
which was being considered as the polymer to be used for a targeted-treprostinil conjugate.  
The breadth of the strategies examined and described in this thesis was also in part a result 
of the uncertainty of a supply of treprostinil at the beginning of the project, which meant 
treprostinil-specific approaches were not immediately pursued. A supply of treprostinil was 
received in May 2016. While waiting for enough treprostinil to work with, attempts to pursue 
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the CAR-peptide and enzymatically degradable linkages employing a model drug-compound 
(phenoxyacetic acid) were conducted. Once the treprostinil supply (2 g) was received, the 
prodrug TRE-S strategy was initiated using treprostinil as sparingly as possible. Polymer-
treprostinil conjugates were not attempted until it was established that enough treprostinil was 
left to incorporate into a polymer. 
 Critical analysis and future perspective  
For each clinically used dosage form of treprostinil, there are different limitations, e.g. oral 
treprostinil exhibits fluctuating peak and trough concentrations in the blood whereas 
subcutaneous does not. The project primary aim was to decrease adverse events reported in 
the literature owing to non-specific activation of prostanoid receptors. A secondary 
consideration was increasing the duration of action to reduce the frequency of dosing by 
utilising a polymer-based approach.  
Chemical conjugation of treprostinil is not the only method that can reduce adverse events 
associated with treprostinil treatments. Other approaches have recently been developed and 
have entered clinical trials, including; pre-filled 2-day disposable capsules for subcutaneous 
delivery;547 implantable intravascular infusions (FDA approved),548,549 portable, breath-
powered inhalers550 and an inhalable treprostinil lipid nanoparticle prodrug (discussed in 
Chapter 3).136,200 
At the time of the project conception (2014), only work on a PEG-ester derivative of treprostinil 
investigated in the early 2000’s had been published.338,399 The 4-arm PEG derivative 
developed from a collaboration between UT and Ascendis had entered trials33979 but the results 
were not released until 2015.138 No other polymer or prodrug derivatives of treprostinil had 
been published to our knowledge. From the understanding gained from these documented 
works, our work was designed to extend and not duplicate understanding. Thus, ester 
conjugation of treprostinil was avoided, and more site-specific release mechanisms were 
pursued. During the last few months of the project, results of the pharmacokinetic study of an 
inhaled alkyl ester treprostinil prodrug delivered in a lipid nanoparticle formulation in humans135 
revealed that the adverse events experienced were similar to inhaled treprostinil, further 
verifying this decision. 
Analysis using publicly disclosed information of the adverse event profile of treprostinil via the 
different routes of administration was necessary to determine a plausible strategy to reduce 
adverse events that could be addressed utilising a polymer-based approach. Flushing related 
to inhaled treprostinil was the most likely adverse event, followed by site pain associated with 
subcutaneously delivered treprostinil. Furthermore, a comparison between selexipag 6 and 
treprostinil demonstrated no difference in the likelihood of gastrointestinal-associated adverse 
events for orally administered treprostinil. The meta-analysis identified two limiting factors 
associated with treprostinil; (i) activation of prostanoid receptors upon subcutaneous infusion 
causing site pain; and (ii) a lack of specificity for the lung resulting in systemically induced 
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adverse events. Thus, overcoming these limitations by a prodrug approach became the aim 
for developing the strategies described in the experimental Chapters 3-5. 
Treprostinil 4 is a challenging molecule to modify chemically. Early structure activity 
relationships published on the initial design of treprostinil were consulted but limited 
information on the structure activity relationships of treprostinil derivatives were accessible. A 
3-month placement at UT to conduct their synthesis of treprostinil provided an invaluable 
opportunity to gain experience and insights about the history and development of treprostinil. 
Many ideas were considered for derivatising the carboxylic acid and the two hydroxyl groups 
of treprostinil. As described in Chapter 3, several reaction conditions employed to derivatise 
treprostinil were unsuccessful. The hydroxyls were less reactive than first thought which was 
further verified in Chapter 4 by the difficulty experienced forming polyacetal bonds via a 
reactive vinyl ether. The secondary alcohol groups exhibited weak nucleophilicity and were 
not able to displace alkyl halide but were able to silylate using silyl chlorides when the acid 
group was protected which prevented in situ degradation. Acidic reaction conditions 
suppressed the nucleophilic nature of the secondary hydroxyls but standard benzyl protection 
methods using basic conditions were also unsuccessful. Efficient nucleophilic activity of the 
hydroxyls was achieved when the electrophile was activated with charged salts of compounds 
with broken aromaticity. When activating the acid for coupling reactions with carbodiimide 
derivatives, the alcohols were able to undergo reactions. This was deduced by the number of 
reaction products formed when the hydroxyls were unprotected which when protected, were 
not present.The difficulties in derivatising treprostinil to achieve N-acyl sulfonamide treprostinil 
21 were overcome by employing a series of protecting group steps, and then circumvented 
using an intermediate precursor. For the treprostinil coupling, the poor nucleophilicity of 
methane sulfonamide was overcome by employing a coupling agent, CDI, which produced 
imidazole as a by-product which helped to drive the reactions.The reduced pKa of a phenolic 
hydroxyl compared to alkyl hydroxyls facilitated a route to alkylate the aromatic hydroxyl 
without employing protecting group chemistries. Ease of alkylation depended on the activity of 
the electrophile which is affected by acidic neighbouring protons. The use of a strong base 
facilitated greater reaction yields. Although the synthesis of the N-acyl sulfonamide treprostinil  
4 had been independently pursued by our collaborators, the synthesis described in Chapter 
3 from the triol precursor 51 is novel and provides a means to examine further prodrug 
approaches. Using HPLC, no evidence of poor stability was detected in the work described in 
Chapter 3, but it was clear that limitations may exist (e.g. solubility). 
Future conjugation of treprostinil reactions at the acidic group should first consider employing 
the triol precursor to treprostinil. The triol approach does not require protecting group 
strategies to be employed which potentially increases yields. Coupling of prodrug head groups 
which do not possess an acidic alpha proton will likely achieve greater reaction efficacy.  
The N-acyl sulfonamide treprostinil prodrug approach was successful in reducing activity at 
the IP receptor which indicates that further investigation would be worthwhile. The enzymatic 
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degradation required to remove the N-acyl sulfonamide moiety was attempted several times 
using a microsomal assay. Optimising the analysis method using HPLC and then LCMS was 
challenging, and although the data started to show a coherent result towards the end of the 
PhD project, repeat reactions still need to be conducted and analysed to demonstrate a 
reproducible trend. Overall the work described in Chapter 3 did provide for greater 
understanding of the reactivity of treprostinil. The N-acyl sulfonamide prodrug 21 has not yet 
been published, so it is hoped that once the microsome detection methods are refined, the 
analysis can be repeated, and results will be submitted for publication. 
Compared to the polymer-based strategies, a low molecular weight prodrug approach is a 
simpler and possibly more scalable approach that offers more commercially viable alternatives 
but does not reduce systemic permeation. Should a low molecular weight prodrug approach 
be desired, future work should consider a synthetic route using the triol precursor 51. The use 
of the triol 51 offered a method of prodrug synthesis which did not require the treprostinil 
derivative until the last step. As well as minimising losses associated with the protecting group 
strategy, a variety of derivatives could easily be synthesised using this approach. To reduce 
systemic prostanoid receptor agonism, a PAH-specific prodrug-cleavable moiety might be 
considered. An enzymatic approach may offer a method to achieve site-specific cleavage 
The concept of a polymer-drug conjugate of treprostinil that would preferentially localise drug 
to the PAH lung still requires in vivo examination to determine the extent of uptake that may 
be possible in the diseased vasculature. The pathological changes in the PAH diseased lung 
may facilitate uptake of macromonomers which could result in accumulation of a polymer-drug 
conjugate. The endothelial damage of PAH to facilitate uptake of macromolecules into the 
tissue space by an enhanced permeation and retention effect clearly requires further study. 
Furthermore, the specificity of conjugate uptake can be enhanced by the inclusion of a 
selective targeting moiety, which still needs further validation.  
Use of a diol-containing drug as a monomer to prepare a polyacetal that incorporates the drug 
in the main chain is known401,402,416 for synthesising an acid labile, biodegradable polymer-drug 
conjugates. The work described in Chapter 4 shows that this approach may not apply to 
treprostinil as with other molecules that have been described in the literature. Treprostinil was 
the first molecule with secondary diols that to our knowledge has been examined for polyacetal 
synthesis. Although the hydroxyls are known poor nucleophiles, reaction with vinyl ethers to 
form acetal bonds was observed although was likely hindered by the acidic conditions 
employed. The preparation of the treprostinil oligoacetal 71 is still considered a viable 
candidate for further preclinical evaluation because an oligomeric acetal would be expected to 
diffuse from the hypodermis more quickly than a larger molecular weight polyacetal. Clearly 
there are significant in vivo experiments that would need to be conducted to determine 
efficacy. It is unfortunate that progress was hindered by a yet to determine limitation in the 
acid catalysed reaction conditions for preparing treprostinil containing co-polyacetals. It is 
possible that a base-catalysed polymerisation should be examined and compared with the 
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acid catalysed reaction, which may be a feasible strategy for future work. Alternatively, 
functionalising the treprostinil to form acetal containing monomers (e.g. diamino-diacetal 
treprostinil) which could then undergo a more reactive and better controlled polymerisation is 
another potentially successful strategy. 
Since little is known about the possibility for passively targeting PAH tissue and since active 
targeting strategies are clinically proven (e.g. ADCs), a targeting strategy for a polymer-drug 
conjugate to the diseased lung was pursued. An antibody-based approach was beyond the 
scope of what was known at the outset of the project, so the CAR peptide was investigated as 
it appeared from the literature that it could be selective for PAH tissue. First a method to 
synthesise CAR was established which then allowed for the binding to be tested. Fmoc 
coupling of amino acids was achieved on resin and oxidation of the peptide in solution 
facilitated disulphide bond formation intramolecularly and reducing intermolecular bond 
formation. A preliminary study on the binding properties of CAR was conducted and CAR 
binding to HUVEC cells was shown to increase in the presence of TNF-α which is an 
inflammatory promoter. A more extensive investigation into CAR binding and the use of CAR 
over other targeting peptides is warranted. 
Several strategies to prepare an enzymatically degradable peptide linker for treprostinil were 
considered. Of these, a method to conjugate treprostinil to a peptide substrate on-resin was 
investigated. Once established, the method could be applied to synthesise peptide linker-
treprostinil adducts and could be used to prepare an optimised linker-treprostinil on large 
scale. Using an on-resin immobilisation method, other carboxylic acid drugs could be 
considered for conjugation to N-terminal enzyme substrates. 
The biggest obstacle for preparing the enzyme cleavable linker for treprostinil was establishing 
a method to link treprostinil and the peptide to a resin. A base-mediated method wasdeveloped 
which first immobilised the p-aminobenzyl alcohol spacer onto the resin by nucleophilic ring 
opening of a phthalide ester. The reaction was facilitated by the increased  electrophilicity of 
the carbonyl resulting from the electron withdrawing nitro group at the meta position. On-resin 
biphasic reduction of the nitro group was conducted to facilitate peptide coupling. . Although 
the amine derivative was obtained, further efforts to improve the reduction are possible by 
using an electron phase transfer catalyst, rather than an ion phase transfer catalyst, which 
may be a strategy for future studies. Nonetheless, the resin bound aryl amine was prepared, 
but the final conjugation of the enzyme substrate and treprostinil to the resin was not 
conducted owing to time limitations. The method for the final steps to make the desired 
peptide-treprostinil linker have been described for future work and a mild resin-cleavage 
method determined which preserves the treprostinil ester. It is hoped that the synthetic 
approach will be verified and published soon after thesis submission. 
Considering the CAR targeting moiety and the enzymatically degradable peptide linker there 
are significant additional challenges that will need to be addressed. For example, while 
conjugating a CAR peptide to a polymer could result in sub-optimal binding of CAR to its target, 
General Discussion 
315 
  
there may be alternatives for exploiting CAR. For example, a treprostinil-peptide linker-CAR 
prodrug that would localise in PAH diseased tissue could be a plausible candidate. Although 
such a peptide-treprostinil molecule would clear relatively quickly, it would also be expected 
to be less able to bind to the IP, DP1 and EP2 receptors may which cause pain. Treprostinil 4 
release would not be expected to occur in the hypodermis, so a large dose could be given, 
and CAR homing would allow some of the dose to localise in the PAH disease tissue where 
enhanced concentrations of tryptase could release treprostinil.  
As the mechanisms of PAH progression and the pharmacology of treatments become 
elucidated, opportunities to target multiple pathways are presented. Dual therapy for PAH is 
utilised and recommended which offers a way to maximise the efficacy whilst limiting the 
adverse events experienced. Achieving a prodrug dosage form of treprostinil which offers 
enhanced efficacy in the lung whilst mitigating the adverse events allows for a greater number 
of dual therapy combinations. As suggested in Chapter 3, if adverse events could be reduced 
then the concept of co-administering two prostacyclin mimetics working via different receptors 
(e.g. selexipag 5 and treprostinil 4) could also be explored. Further investigation into dual 
combination therapy would be required but the increased tolerability of including a prodrug 
prostanoid receptor agonist has the potential to open more avenues for therapeutic strategies. 
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 Materials and methods 
Pulmonary arterial hypertension is a chronic orphan disease with a complex mechanism and 
poor prognosis. Much attention has been focused on developing safe and efficacious therapies 
to manage disease progression, but current therapies are still dose-limited owing to adverse 
events. The impact of the administration route and adverse events associated with therapy on 
decreasing quality of life is significant. Further investigations are necessitated to improve long 
term therapies, but it is hoped that a polymer-drug conjugate strategy could offer a method to 
prevent off-target receptor interactions and increase efficacy of current drug 
structures.Materials and Methods 
 Materials 
Treprostinil 4 and the treprostinil precursor, benzindine triol 51 were kindly provided by United 
Therapeutics Corp (Silver Spring, USA). Selexipag (Cat. No. 10010411) was purchased from 
Cayman Chemicals (Ann Arbor, USA.) 
Phenoxyacetic acid (Cat. No. 169875000), silica (Cat. No. 419290050) for column 
chromatography, piperidine (Cat. No. 147181000) tyramine (Cat. No. 51-67-2) and 1,1-
carbonyldiimiazole (Cat. No. 151810250) were purchased from Acros Organics (Geel, 
Belgium). Sodium sulfate (Cat. No. 28104.292), N-methyl-2-pyrrolidinone (Cat. No. 25675.3) 
and anhydrous sodium sulfate (Cat. No. 28104.292) were purchased from VWR chemicals 
(Radnor, USA). Sulfuric acid (Cat. No. MFCD00064589) was obtained from BDH chemicals 
(now VWR International). 
Potassium carbonate (Cat. No. P/4080/53), acetic acid (Cat. No. 1332902) and 1M 
Hydrochloric acid (Cat. No. J/4320/15) were bought from Fisher Scientific (Hampton, USA). 
Fluorescein (Cat. No. 46955) and 3Å molecular sieves (Cat. No. 69833) were bought from 
Fluka (now part of Fisher Scientific). 
Trifluoromethyl benzene (Cat. No. B21340), bromoacetyl bromide (Cat. No. A19580), 
trifluoroacetic acid (Cat. No. LO6374-AE), 6-Aminophthalide (Cat. No. A18896-02), 6-
nitrophthalide (Cat. No. B20375), bromocresol (Cat. No. A17090), N-
benzyloxycarbonylglycine (Cat. No. A15928), thallium trifluoroacetate (Cat. No. 43643), acetic 
anhydride (Cat. No, L04295), trifluoroacetic acid (Cat. No. L06374-AE) and anhydrous toluene 
(Cat. No. 41464) were obtained from Alfa Aesar (Haverhill, USA).  
p-anisaldehyde (Cat. No. 15364) were bought from Avocado (Heysham, UK). H-Arg(Pbf)-OMe 
(Cat. No. E3110) was purchased from BaChem (Bubendorf, Switzerland). N-(3-
Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDCI, Cat. No. AS-29855) was 
bought from Cambridge Biosciences (Cambridge, UK). Chloranil (Cat. No. SC-252566) was 
purchased from Chem Cruz (Dallas, USA). Cyclised CARSK(Dde)NK(Dde)DC was supplied 
by China Peptide (Hangzhou, China).  
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Ammonium bicarbonate (Cat. No. A6141) was purchased from Honeywell (Morris Plains, 
USA). 7-(9-Fluorenylmethyloxycarbonylamino)-coumarin-4-acetic acid (Cat. No. RL-1170) 
was purchased from Iris Biotech Gmbt (Marktredwitz, Germany). 4-(dimethylamino)pyridine 
(Cat. No. 8.51055), Fmoc-alanine (Cat. No. 8.52003), Fmoc-arginine(Pbf)-OH (Cat. No. 
8.52067), Fmoc-Asn(trt)-OH (Cat. No. 8.52044), Fmoc-Asp(OtBu)-OH (Cat. No. 8.52005), 
Fmoc-Cys(Acm)-OH (Cat. No. 8.52006), Fmoc-Cys(trt)-OH (Cat. No. 8.52008), Fmoc-D-leu-
OH (Cat. No. 8.52145), Fmoc-e-Ahx-OH (Cat. No. 8.52053), Fmoc-Ile-OH (Cat. No. 8.52010), 
Fmoc-Lys(Boc)-OH (Cat. No. 8.52012), Fmoc-Lys(mtt)-OH (Cat. No. 8.52065), Fmoc-
Orn(Boc)-OH (Cat. No. 8.52015), Fmoc-Phe-OH (Cat. No. 8.52016), Fmoc-Pro-OH (Cat. No. 
8.52017), Fmoc-Ser(tBu)-OH (Cat. No. 8.52019), FMPB Novagel HL (Cat. No. 8.55087), 3-
[Bis(dimethylamino)methyliumyl]-3H-benzotriazol-1-oxide hexafluorophosphate (HBTU, Cat. 
No. 8.51006), PAL-Novasyn TG resin (Cat. No. 8.55137), Rink AM resin (Cat. No. 8.55130) 
and Wang resin (Cat. No. 8.55002) were purchased from Novabiochem (now Merck; 
Kenilworth, USA). Aluminium backed silica thin layer chromatography plates (Cat. No. 
1.05554.0001) and 1M sodium hydroxide solution (Cat. No. 1.09137.1000) were obtained from 
Merck (Kenilworth, USA). 
Magnesium oxide (Cat. No. 203718), sodium Citrate dihydrate (Cat. No. W302600), 
dichlorodiisopropyl silane (Cat. No. 38385), triethylene glycol divinyl ether (Cat. No. 329800), 
polyethylene glycol 3400 (Cat. No. 20,244-4), para-toluene sulfonic acid monohydrate (Cat. 
No. 402885), anhydrous tetrahydrofuran (Cat. No. 401757), pyridine (Cat. No. 270970), 
triethylamine (Cat. No. T0886), Citric acid (Cat. No. C2404), phosphate buffered saline tablet 
(Cat. No. P4417), magnesium sulfate (Cat. No. 208094) 2-benzyloxy-1-methylpyridinium 
triflate (Cat. No. 679674), Celite (Cat. No. 6858), lithium hydroxide (Cat. No 402974), 
methanesulfonamide (Cat. No. 64275), 1,8-diazabicyclo[5.4.0]undec-7-ene (1M in THF; Cat. 
No. 714852), Palladium on Carbon 5% wet (Cat. No. 205680), zinc granules (Cat. No. 31653), 
hydrochloric acid solutions were made from 12 M concentration solution (Cat. No. 320331), 
triethylene glycol mono methyl ether (Cat. No. 317292), tetrabutylammonium iodide (Cat. No. 
140775), sodium hydride (60 % dispersed in mineral oil; Cat. No. 45912) 1,2-Ethanedithiol 
(Cat. No 2390), 1-hydroxybenzotriazole hydrate (Cat. No. 54802), 2,4-
dimethoxybenzaldehyde (Cat. No. D130400), 2-methylpyridine borane complex (Cat. No. 
654213), 4-(4-nitrobenzyl)pyridine (Cat. No. 73210), 4-aminobenzyl alcohol (Cat. No. 191558), 
acetaldehyde (Cat. No. 465380), aluminium chloride (Cat. No. 6220), anhydrous 
dimethylformamide (Cat. No. 227056), hydrazine hydrate (Cat. No. 225819), lithium hydroxide 
monohydrate (Cat. No. 402974), N,N-diisopropylcarbodiimide (Cat. No D125407), N,N-
diisopropylethyl amine (Cat. No. D125806), ninhydrin (Cat. No. 26H2616), p-toluenesulfonyl 
chloride (Cat. No. T35955), sodium bicarbonate (Cat. No. S6014), sodium borohydride (Cat. 
No. 71320), sodium thiosulfate (Cat. No. 217263), sodium triacetoxyborohydride (Cat. No. 
316393), tetrabutylammonium iodide (Cat. No. 140775), ethyl chloroformate (Cat. No. 
185892), 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide 
hexafluorophosphate (HATU; Cat. No. 445460) and succinic anhydride (Cat. No. 239690), 
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triethylamine (Cat. No. T0886), dichoroethane (Cat. No. 28450), L-phenylalanine ethyl ester 
hydrochloride (Cat. No. 22070), phosphomolybdic acid solution (Cat. No. 319279), sodium 
cyano borohydride (Cat. No. 156159), triisopropylsilane (Cat. No. 23378), 
trimethylorthoformate (Cat. No. 108456), pyridine (Cat. No. 270970), β-alanine ethyl ester 
(Cat. No. 306142) and trityl chloride (Cat. No. 93000) were purchased from Sigma Aldrich (St. 
Louis, USA).  
 General Methods 
 
1H and 13C nuclear magnetic resonance (NMR) were determined on either a Bruker 400 MHz 
Avance system with Ultrashield Bruker magnet and broadband probe or Bruker 500 MHz 
Avance system with 500 MHz Oxford magnet and QNP cryoprobe (Billerica, USA). d6- DMSO 
(Cat. No. DLM-10-10), CDCl3 (Cat. No. DLM-7-100MS), MeOD (Cat. No. DLM-24-10), D2O 
(Cat. No. DLM-4-10) were all purchased from Cambridge Isotope Laboratories Inc. (MA, USA). 
NMR data was analysed using Mestrenova software (version 6.0.2; Santiago de Compostela, 
Spain. 
Infrared (IR) data were collected using a Perkin Elmer (Tokyo, Japan) Spectrum 100 FTIR 
spectrometer. Samples were analysed between wavelengths 650-4000 cm-1 at 4 cm-1 
resolution and recorded as an average of 4 scans as percentages transmission.  
High performance liquid chromatography (HPLC) was conducted on a Jasco system (Jasco 
Corp., Oklahoma, US) equipped with a Supelco discovery-HS C18 column (Cat. No. 568522U) 
from Sigma Aldrich and ChromNAV software (version 2.02.05; Jasco Corp). The system 
comprised of a UV detector (Jasco-2077), pump (Jasco-980) and autosampler (Jasco-2055).  
HPLC grade solvents were spiked with 0.1% trifluoroacetic acid (Cat. No. L06374, Alfa Aesar) 
and degassed with a stream of argon (BOC, Guilford, UK) before use. 
Liquid chromatography-mass spectrometry (LC-MS) was carried out on a Shimadzu LC-MS 
2020 (Kyoto, Japan). The LC comprised of a pump (Shimadzu LC-20AD), an autosampler 
(Shimadzu- SIL20AC HT) with loop volume 100 μL, an oven (Shimadzu CTO-20A) set at 40 
ᵒC and a UV detector (Shimadzu-SPD-20A) set to read absorbance at 220-254 nm. The MS 
comprised of a single quadrupole with DL temperature 250 ᵒC and heating block at 300 ᵒC. 
The nebulising gas was flowing at 1.5 L/min and the drying gas flowing at 15 l/min. The system 
was fitted with a Xterra MS C18 column (186000602) from Waters (Milford, USA). Flow rate 
was set at 1.0 mL/min with a a water and acetonitrile mobile phase, both spiked with 0.1% 
formic acid and run in the volume described below. 
Table 7-1. Mobile phase for the 7-minute method used 
for the paired Shimadzu liquid chromatography – mass 
spectroscopy analysis. Both mobile phases were spiked 
with formic acid. 
Time % Water % Acetonitrile 
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0 90 10 
4 5 95 
5 5 95 
5.2 90 10 
7 90 10 
 
Automated column chromatography was carried out on a Isolera one system (Biotage, 
Uppsala, Sweden) equipped with SNAP cartridge (KP-Sil, 25 g). Reagent grade ethyl acetate 
(EA) and hexane were used.  
Liquid chromatography mass spec (LCMS) grade water (Cat. No. 39253) and LCMS grade 
acetonitrile (Cat. No. 34967) were bought from Honeywell (Morris Plains, USA). Solvents were 
spiked using formic acid (Cat. No. F/1900/PB09; Fisher Scientific. Liquid chromatography-
tandem mass spectrometry (LCMS/MS) comprised two systems; LC was carried out on an 
Agilent 1260 Infinity system (Agilent; Santa Clara, USA) equipped with a phenomenex synergi 
hydro column (C18, 150 x 4.6, 4 μm) fitted with guard column. MS was carried out on an Aqilent 
triple Quad 6460 with tandem quadrupole mass spectrometer (Agilent; Santa Clara, USA). 
Peak intensities of characteristic ions (m/z) were measured in multiple reaction monitoring 
(MRM) mode. Mass spec data was analysed using Mass Hunter software (version B.06.00).  
Chemical properties and drawings were made using ChemDraw from Perkin Elmer (Waltham, 
USA). Analysed data was plotted using GraphPad Prism (version 7.04) as mean with standard 
error of the mean (SEM). 
 Methods for Chapter 2 
 
The PRISMA and PRISMA-P checklists for systematic reviews and meta-analyses were 
followed.551,552 Studies were searched for in the online databases: PubMed/Medline, Scopus, 
EMBASE and Cochrane library with no year limits. Highwire, Springer link, Sciencedirect and 
Wiley library online publisher platforms were also searched. The Key words used were; 
iloprost, ilomedine, ventavis, epoprostenol, Flolan, selexipag, Uptravi, beraprost, treprostinil, 
UT15, UT-15, UT 15, Remodulin, Tyvaso, Orenitram, Pulmonary arterial hypertension, human, 
patient, pulmonary arterial hypertension, pulmonary hypertension. MeSH terms used were 
“pulmonary hypertension” and “epoprostenol/analogs and derivatives”. When and where 
necessary, the RCT filters were applied. The search was conducted up until June 2016. Other 
meta-analyses have been released since this time322,553 but no new trial results have been 
published. 
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All trials in all years, conducted pre- and post-marketing worldwide, involving IP receptor 
agonists delivered in any form to adults (aged 16 years or older) for the treatment of PAH 
which complied to the following criteria were considered:  
(1) Randomised controlled trials vs. placebo;  
(2) patients with PAH who had a follow up period > 8 week;  
(3) patients were diagnosed as having PAH according to the WHO/NYHA 
classification system. Individual case studies, open-label studies, trials in healthy 
volunteers, abstracts, letters or trials which had been terminated early due to safety 
concerns were not included.  
 Pulmonary hypertension (PH) was used as an umbrella term to incorporate PH of any sort 
including in association with other diseases. Trials which focussed exclusively on PAH 
secondary to a primary disease were excluded. Only randomised clinical trial studies which 
used PMs were included, whilst trials including other classes of PAH treatments 
(phosphodiesterase-5 inhibitors; PDE-5i and endothelin receptor antagonists; ERAs), without 
PMs, were excluded. No language limits were used. 
 
Two reviewers independently extracted data and assessed the quality of the trials. Uncertainty 
and disagreement was resolved by consulting a third reviewer. The abstracts (or full text, if 
abstract not available) of these results were assessed against the inclusion criteria. The 
investigators then extracted data from the selected studies, including: author, year of 
publication, aim of the study, sample size, mean age, female percentage, study design. 
Change from baseline outcome data for treatment and control groups, including; 6MWD, Borg 
Score, change in quality of life scores, mortality, patients developing right ventricular heart 
failure, patients requiring lung transplant or rescue therapy, discontinuation due to AEs, 
Haemodynamic measures (i.e mixed venous saturation, right atrial pressure, heart rate and 
cardiac index), were collected. AEs were also reported, (site pain, flushing, jaw pain, 
headache, pain in extremities, diarrhoea, vomiting, arthralgia, nausea, peripheral oedema, 
fatigue, cough, upper respiratory tract infection and dyspnea). Analysis of all outcomes 
considers treatment as either monotherapy or combination therapy versus. placebo. The 
quality of studies (risk of bias) was assessed with Cochrane Collaboration’s tool.554 For the 
meta-analysis, studies were examined for P-values, means and standard deviations or other 
metrics depicting the effect of PMs on adverse event in PAH. 
 
The 6MWD test is a clinical measure of functional capacity, used as an indicator of disease 
severity in patients with pulmonary/cardiovascular impairment. Patients walk along a flat 
surface between two markers during a 6-minute period and the total distance recorded 555. 
Discontinuation refers to patients who did not complete the trial due to intolerable adverse 
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events. Rescue therapy describes when patients are advised by medical professionals to 
abandon the study protocol to receive approved medication for the benefit of the patient’s 
health. The death of any patient whilst enrolled in a study was recorded as a fatality. 
Reports of adverse event frequency experienced during the trial period were collected. 
Although site pain was only applicable to parenteral administration formulations, it was 
included in this analysis, owing to its reported frequency and impact. No distinction was made 
between facial and general flushing. Data for adverse events which showed no difference in 
odds ratio (OR) to placebo group in the overall meta-analysis or any of the sub groups was 
not shown.  
 
All outcomes were synthesized with a random effects model556 which was chosen to account 
for differences in the treatment effects from study to study.557 The difference of continuous 
variable or dichotomous data between two groups was estimated by weighted mean difference 
(WMD) with a two-tailed 95% confidence interval (CI) or an OR with two-tailed 95% CI, based 
on the Mantel-Haenszel method.558,559 Standardised mean difference (SMD) was also used as 
a summary statistic for continuous outcomes. SMD values of 0.2, 0.5 and 0.8 were defined as 
small, moderate and large effect size respectively.560,561 Statistical heterogeneity was 
assessed using Cochran’s Q test, which examines the null hypothesis that all studies are 
evaluating the same effect.562 Statistical significance for heterogeneity was set as p ⩽ 0.10. 
Statistic value I2 was used to quantify the degree of heterogeneity with a score of 25, 50, and 
75% representing low, moderate, and high levels of inconsistency, respectively.563 
Heterogeneity was further investigated with subgroup analysis and meta-regression. 
Publication bias was assessed using funnel plots and Egger’s and Begg’s test.564 P < 0.05 
was regarded as statistically significant for the outcomes. RevMan software package (Review 
Manager, Version 5.2, The Cochrane Collaboration, Oxford, UK) and Stata 12.0 (College 
Station, Texas, USA) were employed for statistical analyses. 
Groups for sub group analyses were split to compare the trials firstly into the different drug 
types then into the different routes of administration. To investigate the effect of therapies 
given in the 30 days preceding trial initiation, the trials were split into three groups: those given 
non-PAH specific therapy including oxygen, digoxin, calcium channel blockers, anti-
coagulants and diuretics, termed supportive therapy; those given non-prostanoid PAH-specific 
therapy including ERAs and PDE-5i; and those given prostacyclin therapy which in this case 
included only epoprostenol. Investigating the effect of background therapy meant dividing trials 
into two groups; those who were receiving other PAH-specific treatment at a stable monitored 
dose and those trials in which patients were not. In this case, concomitant therapies included 
ERAs and PDE-5is only. The other groups were not given any PAH-specific therapy on any 
specific dosing regimen but were treated with supportive therapies (as previously defined) 
when necessary. 
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 Methods for Chapter 3 
 
Treprostinil was synthesised during at 3-month visit to UT’s laboratory in Silver Springs, 
Maryland, USA. The large scale synthetic rote as well as the small-scale route were followed 
and compaired. Details of the synthesis can be found in appendix 8.2. 
Preparation of N-(methylsulfonyl)-2-phenoxyacetamide 26 
 
26 
Phenoxyacetic acid 22 (51.0 mg, 0.335 mmol) was added to a stirred solution of N-(3-
dimethylamino)propyl-N’-ethyl carbodiimide hydrochloride 34 (EDCI, 85.1 mg, 0.444 mmol) 
and 4-(dimethylamino)pyridine 32 (DMAP, 96.7 mg, 0.792 mmol) in anhydrous 
dichloromethane (1 mL). After 5 mins, methane sulfonamide 25 (31.6 mg, 0.332 mmol) was 
added and the solution monitored by TLC (silica, 20% Methanol/ethyl acetate, visualised with 
UV and phosphomolybdic acid (PMA)). After 24 hours, TLC showed the presence of a PMA-
staining product spot (Rf = 0.94) paired with a decreased intensity of phenoxyacetic acid spot 
(Rf = 0.45). HCl (1 M, 2 mL) was added to the solution and the product was extracted with 
ethyl acetate (2 mL × 3). The combined organic layers were washed with brine, dried over 
Na2SO4, and the filtrate was concentrated in vacuo to give a white soft solid. Crude product 
was purified by recrystalisation from CDCl3 and hexane (~2:10 mL ratio) to afford purified N-
(methylsulfonyl)-2-phenoxyacetamide 26 (2.7 mg, 4% yield) as a white solid. Melting point = 
131.32 °C.  
1H NMR δH (500 MHz, CDCl3) 8.84 (1 H, s), 7.36 (2 H, dd, J 8.5, 7.5), 7.09 (1 H, t, J 7.4), 
6.93 (2 H, d, J 8.1), 4.60 (2 H, s), 3.37 (3 H, s); 13C NMR δC (126 MHz, DMSO) 168.20, 
157.52, 129.51, 121.25, 114.44, 65.86, 41.14; FTIR (ATR) ν /cm-1:  3255(N-H), 3024-2931 
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(C-H), 1712 (C=O), 1600 (C-H), 1340-1329 (S=O); [M-H]- found: 228.0 m/z.
 
Figure 7-1. Graph showing the melting point of N-acyl sulfonamide phenoxyacetamide 
at 131.32 °C. The compound is stable up to 250°C. 
 
Phenoxyacetic acid 22 (197.2 mg, 1.296 mmol) and 1,1-carbonyldiimidazole 36 (CDI, 232.2 
mg, 1.432 mmol) were dissolved in anhydrous tetrahydrofuran (THF, 2 mL) in a single neck 
10 mL round bottom flask fitted with a septum and the solution stirred at RT for 40 mins, then 
refluxed at 75 ᵒC for 40 mins. The reaction mixture was then allowed to cool to RT over 1 hour 
and methane sulfonamide 25 (126.1 mg, 1.326 mmol) added. After 20 mins, 1,8-
Diazabicyclo[5.4.0]undec-7-ene 31 (DBU) (1 M in THF, 222.6 μL, 1.314 mmol) was added 
dropwise. The solution monitored by TLC and extra CDI 36 added to drive the reaction to 
completion. After 5 days, the reaction was deemed complete by TLC and the solution was 
concentrated in vacuo. HCl (0.2 M, 5 mL) was added and the product extracted in DCM (3 mL 
× 3). The organic layers were combined and washed with NH4Cl (1M, 3mL), dried over 
Na2SO4, and filtrate concentrated in vacuo. Purified product was isolated by crystallisation 
from CHCl3 and recrystallised from cold chloroform. Crystals were dried in vacuo which 
afforded white powder 26 (7.1 mg, 2.4% yield).  
1H NMR δH (500 MHz, CDCl3) 8.91 (1 H, s), 7.39 – 7.30 (2 H, m), 7.07 (1 H, t, J 7.4), 6.93 (2 
H, d, J 8.0), 4.58 (2 H, s), 3.35 (3 H, s). 13C NMR δ C (101 MHz, CDCl3) 167.56 (s), 156.37 (s), 
130.03 (s), 122.96 (s), 114.70 (s), 67.16 (s), 41.68 (s). FTIR (ATR) ν /cm-1:  3257(N-H), 3024-
2930 (C-H), 1713 (C=O), 1600 (C-H), 1341-1329 (S=O); [M-H]- Found: 228.0 m/z. 
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Preparation of phenoxyacetamide 39 
 
39 
In a 25 mL round bottom flask purged with argon and fitted with septum, phenoxyacetic acid 
22 (102.5 mg, 0.674 mmol) and triethylamine (375.6 mL, 2.995 mmol) in anhydrous THF (0.3 
mL) were stirred. The solution was cooled to 0 ᵒC in an ice bath and ethyl chloroformate (90.2 
μL, 0.943 mmol) was added dropwise. After 30 minutes, aqueous ammonium chloride (1 M, 
1.011 mL, 1.011 mmol) was added. The reaction was monitored by TLC (silica, 40% ethyl 
acetate/hexane) and visualised by UV and ninydrin. The reaction was quenched with ice cold 
water (8 mL) and the product extracted with ethyl acetate (2 mL × 3). Organic layers were 
combined, washed with brine, dried over Na2SO4 and solvent was removed in vacuo to afford 
primary amide 39 (84.1 mg, 83%) as pale yellow oil. TLC indicated one product spot (Rf 0.9). 
1H NMR (400 MHz, MeOD) δH 7.33 – 7.25 (2 H, m), 6.97 (1 H, d, J 6.6), 6.95 – 6.91 (2 H, m), 
4.69 (2 H, s); 13C NMR (126 MHz, MeOD) δC 171.05, 159.44, 130.54, 122.57, 115.64, 66.12. 
Preparation of N-acylsulfonamide treprostinil via trimethyl silane treprostinil 
 
In a 2 mL round bottom flask purged with argon was added a solution of treprostinil 4 (50.3 
mg, 0.129 mmol) in anhydrous dimethyl formamide (DMF, 1.0 mL). The solution was cooled 
to 0 ᵒC in an ice bath and N,O-bis(trimethlsilyl)acetamide 41 (50.7 μL, 0.205 mmol) was added 
in two portions using a 25 μL Hamilton syringe. After 16 hours and in a separate argon-purged 
flask, EDCI 34 (32.7 mg, 0.171 mmol) and DMAP 32 (35.4 mg, 0.290 mmol) were dissolved 
in anhydrous DMF (0.9 mL). The solution was cooled to 0 ᵒC and the treprostinil 4 solution 
added dropwise via syringe. A solution of methane sulfonamide 25 (12.2 mg, 0.128 mmol) in 
anhydrous DMF (0.4 mL) was added and stirred at RT for 24 hours. The solution was diluted 
with saturated solution of ammonium chloride (15 mL) and extracted with ethyl acetate (5 mL 
× 3). Combined organic layers were washed with brine, dried over Na2SO4 and solvent 
removed in vacuo. The residue was dissolved in methanol and purified by repeat HPLC using 
analytical column. Mobile phase was 10-90% acetonitrile/water over 20 minutes. Retention 
time = 13.3 minutes. Solvent removed from collected fractions in vacuo to yield 12 mg (20%) 
of N-acyl sulfonamide treprostinil. 13C NMR was not measured but 1H NMR spectrum indicated 
pure compound (Figure 3-22). 
4 20 
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1H NMR (400 MHz, MeOD) δH 7.07 – 6.96 (1 H, m), 6.78 (1 H, d, J 7.3), 6.67 (1 H, d, J 8.3), 
4.67 (2 H, s), 3.75 (3 H, d, J 4.5), 3.66 – 3.55 (2 H, m), 3.49 (2 H, d, J 16.2), 2.80 – 2.58 (5 H, 
m), 2.49 (2 H, dd, J 14.4, 5.7), 2.26 (2 H, d, J 7.1), 2.13 – 1.98 (2 H, m), 1.91 (2 H, dd, J 12.7, 
7.4), 1.69 (1 H, dd, J 11.4, 5.8), 1.57 (2 H, ddd, J 14.8, 12.4, 6.3), 1.45 (4 H, dd, J 17.0, 11.2), 
1.39 – 0.97 (10 H, m), 0.90 (4 H, q, J 6.8).  
Preparation of treprostinil ethyl ester 43 
 
43 
Ethanol (~15 mL) was dried by stirring in the presence of heat-activated 4 Å molecular sieves 
in an argon purged sealed 50 mL round bottom flask (RBF) for 20 minutes before allowing to 
settle. Ethanol was transferred via syringe fitted with a 0.22 mm syringe filter. Treprostinil 4 
(495.8 mg, 1.270 mmol) was dissolved in dry absolute ethanol (9.0 mL) in a 50 mL round 
bottom flask and cooled to 0 ˚C with ice bath. Sulfuric acid (6.8 μL, 0.127 mmol) was then 
added and the solution was refluxed at 86 ˚C for 16 hours. The reaction was monitored by 
TLC (silica, 20% methanol/ethyl acetate, visualised by UV and PMA). Towards the end of 
reaction sodium sulfate was added to remove water. Once complete, the filtrate was 
neutralised by addition of saturated potassium carbonate solution (3 mL) and removed in 
vacuo. Crude product was dissolved in ethyl acetate (10 mL × 3) and extracted 3 times from 
20% aqueous potassium carbonate solution (15 mL). Combined organic layers washed with 
brine and dried over sodium sulfate before solvent removal in vacuo to afford dry white solid 
43 (472.4 mg, 88% yield).  
1H NMR (500 MHz, CDCl3) δH 7.03 (t, J = 7.8 Hz, 1H), 6.78 (d, J = 7.4 Hz, 1H), 6.60 (d, J = 
8.2 Hz, 1H), 4.58 (s, 2H), 4.22 (d, J = 7.1 Hz, 2H), 3.65 (dd, J = 14.5, 11.0 Hz, 1H), 3.53 (s, 
1H), 2.88 (dd, J = 14.7, 6.0 Hz, 1H), 2.72 (dd, J = 14.3, 6.2 Hz, 1H), 2.46 (ddd, J = 21.1, 20.1, 
12.4 Hz, 2H), 2.27 – 2.07 (m, 2H), 1.82 (t, J = 16.5 Hz, 1H), 1.72 – 1.57 (m, 2H), 1.56 – 1.36 
(m, 5H), 1.34 – 1.19 (m, 9H), 1.14 (dd, J = 21.7, 10.4 Hz, 1H), 0.88 (t, J = 6.9 Hz, 3H). 13C 
NMR (CDCl3, 500 Hz) δC 169.31 (s), 154.87 (s), 141.15 (s), 127.90 (s), 126.06 (s), 121.49 (s), 
109.69 (s), 77.42 (s), 72.38 (s), 66.05 (s), 61.24 (s), 52.27 (s), 41.17 (d, J = 8.0 Hz), 37.47 (s), 
35.06 (s), 33.90 (s), 32.74 (s), 31.98 (s), 28.61 (s), 26.06 (s), 25.47 (s), 22.69 (s), 14.16 (d, J 
= 8.6 Hz). FTIR (ATR) ν /cm-1: 3352 (OH), 2931 (CH), 1751 (C=O ester), 1601 (Ar-H), 1179 
(C-O ester). Theoretical mass = 418.6 g/mol; [M-H]- found: 417.3 m/z 
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Figure 7-2. 13C NMR of treprostinil ethyl ester. 
Preparation of bis-benzyl treprostinil ethyl ester 44 
 
44 
Magnesium oxide 47 (88.8 mg, 2.203 mmol) and 2-benzyloxy-1-methylpryridinium triflate 46 
(782.2mg, 2.239 mmol) was added to a solution of treprostinil ethyl ester 43 (283.9 mg, 0.678 
mmol) in trifluoromethyl benzene (6.0 mL) in an argon purged 25 mL round bottom flask fitted 
with septum. The solution was then heated to 83 ˚C for 16 hours. The reaction was monitored 
by TLC (silica, 40% ethyl acetate/hexane, developing by UV and PMA). The reaction was 
cooled, diluted with trifluoromethyl benzene (6 mL), filtered through celite and flushed with 
benzotrifuoride to remove the heterogenous magnesium oxide 47. The solvent was removed 
from the filtrate in vacuo and the crude product purified by automated silica column (10 g, 
Biotage SNAP cartridge) to yield product 45 as a yellow oil (198.2 mg, 49% yield).  
1H NMR (500 MHz, CDCl3) δH 7.42 – 7.16 (11 H, m), 7.03 (1 H, t, J 7.8), 6.76 (1 H, d, J 7.4), 
6.60 (1 H, d, J 8.1), 4.58 (2 H, s), 4.54 (1 H, d, J 11.7), 4.49 (2 H, s), 4.40 (1 H, d, J 11.7), 4.23 
(2 H, q, J 7.1), 3.51 (1 H, d, J 5.7), 3.38 (1 H, s), 2.93 (1 H, dd, J 14.8, 5.9), 2.73 (1 H, dd, J 
14.4, 6.2), 2.53 (1 H, dd, J 14.8, 6.7), 2.46 (1 H, dd, J 14.4, 7.2), 2.29 – 2.16 (2 H, m), 1.84 (1 
H, s), 1.70 (1 H, d, J 17.2), 1.62 (2 H, s), 1.52 (4 H, d, J 5.8), 1.39 (1 H, s), 1.27 (10 H, t, J 7.1), 
0.88 (3 H, q, J 7.0). 13C NMR (126 MHz, CDCl3) δC 169.35 (s), 154.87 (s), 141.11 (s), 139.22 
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(s), 138.80 (s), 126.00 (s), 121.56 (s), 109.66 (s), 84.12 (s), 71.66 (s), 70.77 (s), 66.16 (s), 
61.23 (s), 50.25 (s), 40.80 (s), 37.62 (s), 33.96 (s), 33.74 (s), 33.30 (s), 32.12 (s), 31.57 (s), 
28.54 (s), 26.15 (s), 25.03 (s), 22.70 (s), 14.17 (d, J = 9.2 Hz). IR (ATR) ν /cm-1: 3183 + 3085 
((Ar)C-H), 2928 + 2858 (-C-H), 1759 (C=O), 1732, 1585 (C=C), 1453 (C-H bend), 1276 ((Ar)C-
O-C), 1196 (C-O), 1094 (C-O-C); Theoretical mass = 598.8 g/mol; [M+H]+ found 599.3 m/z. 
  
Figure 7-3. 13C NMR spectra of bis-benzyl treprostinil ethyl ester. 
Preparation of bis-benzyl Treprostinil 49 
 
49 
To a solution of bis-benzyl treprostinil ethyl ester 45 (60.4 mg, 0.101 mmol) dissolved in 
THF/H2O/MeOH (4:1:1, 3.0 mL) in an argon purged 10 mL round bottom flask fitted with 
septum, was added lithium hydroxide (20.3 mg, 0.483 mmol) and stirred at room temperature 
overnight. The reaction was monitored by TLC (silica, 40% ethyl acetate/hexane, developing 
by UV and ninhydrin). Once complete, the reaction solvent was removed in vacuo and the 
remaining residue diluted with HCl solution to pH 2. Product was extracted with ethyl acetate 
(2 mL × 3). The combined organic layers were washed with brine and dried over Na2SO4. 
Solvent removed in vacuo to yield a pale, yellow oil 49. (51.4 mg, 89 % yield).  
1H NMR (500 MHz, CDCl3) δH 9.29 (1 H, s), 7.40 – 7.19 (10 H, m), 7.03 (1 H, t, J 7.8), 6.76 (1 
H, d, J 7.4), 6.60 (1 H, d, J 8.2), 4.60 (2 H, d, J 3.2), 4.53 (1 H, d, J 11.7), 4.49 (2 H, s), 4.38 
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(1 H, d, J 11.7), 3.48 (1 H, dd, J 8.3, 5.8), 3.43 – 3.32 (1 H, m), 2.89 (1 H, dd, J 14.8, 5.9), 2.71 
(1 H, dd, J 14.4, 6.2), 2.47 (2 H, ddd, J 32.9, 14.8, 7.0), 2.29 – 2.12 (2 H, m), 1.83 (1 H, d, J 
8.4), 1.68 (1 H, dd, J 10.2, 5.3), 1.62 – 1.16 (14 H, m), 0.92 – 0.80 (3 H, m). 13C NMR (126 
MHz, CDCl3) δC 173.89 (s), 154.56 (s), 141.22 (s), 138.93 (d, J 41.2), 128.35 (d, J 2.6), 127.93 
– 127.33 (m), 126.18 (s), 121.89 (s), 109.70 (s), 84.09 (s), 79.42 (s), 77.35 (s), 77.09 (s), 76.84 
(s), 71.66 (s), 70.76 (s), 65.59 (s), 50.19 (s), 40.76 (s), 37.61 (s), 33.90 (s), 33.74 (s), 33.27 
(s), 32.13 (s), 31.54 (s), 28.52 (s), 26.16 (s), 25.03 (s), 22.71 (s), 14.16 (s); FTIR (ATR) ν /cm -
1: 3029 ((Ar)C-H), 2927 (-C-H), 2858 (COO-H), 1732 (C=O), 1453 (C-H bend), 1233 (C-O), 
1204 ((Ar)C-O-C), 1113 (C-O-C). [M-H]- found: 569.3 m/z. 
  
Figure 7-4. 13C NMR of bis benzyl treprostinil. 
Treprostinil 4 (49.7 mg, 0.127 mmol) and magnesium oxide 47 (16.6 mg, 0.412 mmol) were 
added to a 25 mL round bottom flask purged with argon and fitted with septum, and stirred 
together with trifluoromethyl benzene (5.0 mL). Once dissolved, 2-benzyloxy-1-
methylpyridinium triflate 46 (143.3 mg, 0.410 mmol) was added. The suspension was refluxed 
at 83 °C in an oil bath for 16 hours and the reaction tracked by TLC (silica, 20% methanol/ethyl 
acetate, developed by UV and PMA). Reaction mix was filtered through a celite pad to remove 
magnesium oxide 47 and the filtrate concentrated in vacuo. The residue was separated 
between DCM (30 mL) and acidifed water (0.1M HCl, 30 mL) and further extracted with DCM 
(20 mL × 2). Organic layers were combined, washed with brine and dried over Na2SO4 before 
concentrating in vacuo to yield unpurified product as yellow cloudy gel 49 (>100% yield); 1H 
NMR of crude mixture indicated desired product present. 
1H NMR δH (500 MHz, CDCl3) 7.30 – 7.13 (10 H, m), 6.97 (1 H, t, J 7.9), 6.70 (1 H, d, J 7.3), 
6.56 (1 H, d, J 8.2), 4.56 (1 H, d, J 19.1), 4.49 (1 H, s), 4.46 (1 H, s), 4.43 (2 H, s), 4.38 (1 H, 
s), 4.33 (1 H, d, J 11.7), 3.50 (1 H, d, J 6.6), 3.48 – 3.38 (1 H, m), 3.36 – 3.24 (1 H, m), 2.85 
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(1 H, dd, J 14.8, 5.9), 2.66 (1 H, dd, J 14.4, 6.1), 2.41 (2 H, ddd, J 32.4, 14.7, 6.8), 2.21 – 2.05 
(2 H, m), 1.83 – 1.70 (2 H, m), 1.70 – 1.58 (4 H, m), 1.58 – 1.49 (4 H, m), 1.49 – 1.37 (2 H, m), 
1.37 – 1.04 (m), 1.04 – 0.92 (m), 0.91 – 0.56 (m). 13C NMR (126 MHz, CDCl3) δC 127.67 – 
126.92 (m), 126.92 – 126.45 (m), 126.35 (d, J 4.8), 78.33 (s), 76.27 (s), 76.02 (s), 75.76 (s), 
69.70 (s), 36.80 – 36.06 (m), 32.68 (d, J 3.2), 31.74 (d, J 3.1), 31.00 (d, J 19.3), 31.23 – 28.94 
(m), 28.88 – 26.71 (m), 23.97 (s), 22.04 – 21.16 (m), 18.69 (dd, J 6.6, 1.9), 13.78 – 12.40 (m). 
FTIR (ATR) ν /cm-1: 3029 ((Ar)C-H), 2924 (C-H), 2858 (COO-H), 1733 (C=O), 1453 (C-H 
bend), 1204 ((Ar)C-O-C), 1112 (C-O-C).Theoretical mass = 570.3 g/mol [M+H]+ found: 571.3 
m/z. 
Preparation of Bis-benzyl-N-acyl sulphonamide treprostinil 50 
 
To a 5 mL RBF fitted with reflux condenser was added bis-benzyl treprostinil 49 (46.4 mg, 
0.081 mmol) and 1,1-carbonyldiimidazole 36 (14.3mg, 0.088 mmol) in anhydrous 
tetrahydrofuran (1.0 mL). The solution was stirred at RT for 40 mins then refluxed at 72 °C for 
30 minutes. Once cooled to RT, methanesulfonamide 25 (7.8 mg, 0.082 mmol) and DBU 31 
(81 µL of 1M in THF solution, 0.081 mmol) were added and reaction stirred for 19 hours. The 
reaction was tracked by TLC (silica, 30% methanol/ethyl acetate, developing by UV and PMA). 
The reaction solvent was removed in vacuo and acidified water (HCl, 1M, 2 mL) added. 
Product extracted with ethyl acetate (1.0 mL × 3). Combined organic layers washed with brine 
(1.0 mL). Crude product (67.0 mg) was separated by column chromatography (silica, 14 g). 
Mobile phase 5 – 100 % ethyl acetate/hexane. Solvent of relevant fractions removed in vacuo 
to yield a clear oil 50 (10.8 mg, 21 % yield).  
1H NMR (400 MHz, CDCl3) δH 7.32 – 7.13 (13 H, m), 7.06 – 7.00 (1 H, m), 6.79 (1 H, d, J 7.4), 
6.59 (1 H, d, J 7.8), 4.50 (2 H, s), 4.47 (1 H, s), 4.43 (2 H, d, J 1.1), 4.36 (1 H, t, J 11.6), 3.51 
– 3.41 (1 H, m), 3.32 (3 H, d, J 5.0), 3.30 (3 H, s), 2.71 (2 H, ddd, J 20.1, 13.2, 6.0), 2.44 (2 H, 
dd, J 14.5, 6.6), 2.26 – 2.11 (2 H, m), 1.89 – 1.76 (1 H, m), 1.71 – 1.37 (11 H, m), 1.33 – 1.08 
(10 H, m), 0.82 (3 H, t, J 7.0); FTIR (ATR) ν /cm-1: 3421-2856 (C-H), 1728 (C=O), 1585 (C-H), 
1454 (C-H), 1345 (S=O); [M-H]- found: 646.3 m/z. 
Under an argon environment, DMAP 32 (11.1 mg, 0.091 mmol) and EDCI 34 (9.4 mg, 0.049 
mmol) were stirred in in DCM (0.3 mL) an argon purged 1 mL reaction vial, fitted with septum. 
Bis-benzyl treprostinil 49 (20.0 mg, 0.0375mmol) was dissolved in DCM (0.6 mL) and added 
to the solution followed by methane sulfonamide 25 (3.9 mg, 0.041 mmol). The reaction was 
stirred for 4 days whilst tracking by TLC and then the solvent was removed in vacuo. The 
49 
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residue was dissolved in HCl (0.5M, 6 mL) and then extracted in ethyl acetate (3 mL × 3), and 
the combined organic layers were then washed with brine and dried over Na2SO4. After 
filtration, the ethyl acetate was removed in vacuo and the crude oily residue purified by column 
chromatography (silica, 20g) using a mobile phase of 50-100% ethyl acetate/hexane to yield 
11.3 mg (46% yield) of the desired product 50 as colourless oil.  
1H NMR (500 MHz, CDCl3) δH 7.36 – 7.19 (46 H, m), 7.07 (4 H, t, J 7.8), 6.83 (3 H, d, J 7.4), 
6.63 (3 H, d, J 8.2), 4.54 (8 H, d, J 2.6), 4.51 (3 H, s), 4.48 (6 H, d, J 1.6), 4.43 (2 H, s), 4.39 
(4 H, d, J 11.6), 3.51 (5 H, dd, J 13.7, 8.2), 3.39 – 3.31 (14 H, m), 2.74 (7 H, ddd, J 23.7, 14.8, 
6.0), 2.47 (9 H, dd, J 15.0, 6.6), 2.29 – 2.17 (9 H, m), 2.02 (2 H, s), 1.87 (5 H, dd, J 15.1, 7.9), 
1.73 – 1.63 (5 H, m), 1.51 (28 H, ddd, J 19.4, 11.7, 4.1), 1.26 (50 H, dt, J 14.3, 5.9), 0.86 (15 
H, q, J 6.9). 13C NMR (126 MHz, CDCl3) δC 166.86 (s), 152.46 (s), 140.52 (s), 138.13 (s), 
137.63 (s), 127.36 (dd, J 15.6, 2.1), 126.67 (d, J 5.1), 126.39 (t, J 10.5), 125.58 (s), 121.99 
(s), 109.18 (s), 82.93 (s), 70.69 (s), 69.75 (s), 67.10 (s), 49.09 (s), 40.67 (s), 39.59 (s), 36.64 
(s), 32.66 (d, J 9.2), 32.21 (s), 31.07 (s), 30.54 (s), 27.47 (s), 25.44 (s), 23.97 (s), 21.66 (d, J 
2.8), 13.10 (d, J 2.4), -0.05 (d, J 11.9); FTIR (ATR) ν /cm-1: 2926-2558 (C-H), 1728 (C=O), 
1584 (C-H), 1343 (S=O); [M-H]- found: 646.3 m/z. 
 
Figure 7-5. 13C NMR spectrum of bis benzyl N-acl sulfonamide treprostinil 
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Preparation of N-acyl sulfonamide treprostinil 21 
 
Into an argon purged chamber of “CO-ware” apparatus, bis-benzyl-N-acyl sulfonamide 
treprostinil 50 (10.8 mg, 0.017 mmol) and 5% palladium on carbon (2.9 mg, 0.357 mmol) were 
stirred in ethanol (3.0 mL). Into the second chamber, zinc pellets (433 mg, 6.623 mmol) were 
added and the chambers stoppered, and air evacuated by vacuum. Via syringe, HCl (4M, 3.3 
mL) was added to the zinc pellets and the solutions left 16 hours, topping up zinc pellets if 
hydrogen evolution ceased. The reaction solution was filtered through celite to remove 
heterogenous catalyst, and then rinsed with ethanol. Filtrate solvent was removed in vacuo to 
produce a clear oil 21 (5.0 mg, 64 % yield).  
1H NMR (400 MHz, CDCl3) δH 7.12 (1 H, t, J 7.8), 6.90 (1 H, d, J 7.4), 6.69 (1 H, d, J 8.2), 4.58 
(2 H, s), 3.77 (2 H, dd, J 9.1, 6.1), 3.62 (1 H, s), 2.83 – 2.67 (2 H, m), 2.57 – 2.44 (2 H, m), 
2.24 (3 H, ddd, J 19.0, 13.2, 6.8), 1.98 – 1.86 (2 H, m), 1.84 – 1.03 (27 H, m), 0.90 (4 H, t, J 
6.8); 13C NMR (126 MHz, CDCl3) δC 167.90, 153.58, 141.55, 127.41, 126.71, 123.04, 110.29, 
72.63, 72.59, 68.17, 52.15, 41.72, 41.43, 41.16, 37.46, 34.92, 33.54, 32.75, 31.91, 29.72, 
28.66, 26.33, 25.39, 22.66, 14.08. [M+H]+ found: 468.2 m/z. 
 
Figure 7-6. 13C NMR spectra of N-acyl sulfonamide treprostinil. 
20 
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Preparation of Bromoacetyl bromide – prodrug intermediate 54 
 
In a 10 mL round bottom flask purged with argon and fitted with septum, a stirred solution of 
triethylene glycol mono methyl ether (97.5 μL, 0.609 mmol) and triethylamine (84.9 μL, 0.609 
mmol) dissolved in diethyl ether (3.0 mL) was cooled to 0 ˚C on ice. Bromoacetyl bromide 53 
(58.2 μL, 0.670mmol) was added dropwise in three portions over 6 minutes. The solution was 
stirred at 0 °C for 15 mins and then at room temperature for 20 minutes. After which, the 
solvent was removed in vacuo and the product extracted from water in DCM (3 mL × 3). The 
combined organic solvents were washed with brine, dried over Na2SO4 and solvent was 
removed in vacuo to yield yellow oil, bromomethyl triethylene acetate 54 in 73 % yield.  
1H NMR (500 MHz, CDCl3-d1) δH 3.33 (s, 3H, OCH3, h); 3.51 (t, 2H, CH2OCH3, J = 9.3 Hz, g); 
3.61 (dd, 6H, CH2OCH2, J = 3.6, 11.1 Hz, d, e, f); 3.69 (t, 2H, CO2CH2CH2O, J = 4.8 Hz, c); 
3.83 (s, 2H, BrCH2, a); 4.28 (t, 2H, CO2CH2CH2, J = 4.7 Hz, b). FTIR (ATR) ν/cm-1 2876 (C-
H), 1736 (C=O), 1285 (C-O), 1098 (C-O-C). [M+Na]+ found: 307.0 m/z. 
Preparation of Bromo N-acyl sulfonamide – prodrug intermediate 55 
 
In an argon-purged 2-neck 50 mL RBF fitted with reflux condenser a suspension of methane 
sulfonamide 25 (245.2 mg, 1.215 mmol) in anhydrous toluene (7.0 mL) was stirred and 
bromoacetyl bromide 53 (140 μL, 1.472 mmol) was added dropwise. The reaction was refluxed 
at 118 °C for 5 hours in an oil bath, then cooled to crystallise from toluene. 2-bromo-N-
(methylsulfonyl)acetamide 55 was recrystallised from toluene to yield clear needles (58.0 mg, 
24%).  
1H NMR (500 MHz, δ6-DMSO) δH 4.04 (s, 2H), 3.27 (s, 3H); 13C NMR (126 MHz, δ6-DMSO) 
δC 172.39 (s), 61.20 (s); FTIR (ATR) ν/cm-1 3163 (N-H), 3022-2942 (C-H), 1706 (C=O), 1470 
(C-H), 1332 (S=O); [M-H]- found: 213.9 m/z. 
53 
54 
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Figure 7-7. 13C NMR spectrum of 2-bromo-N-(methylsulfonyl)acetamide. 
Preparation of Triol-TEG prodrug 56 
 
Bromomethyltriethylene acetate 54 (17.7 mg, 0.062 mmol), potassium carbonate (24.7 mg, 
0.179 mmol), benzindene triol 51 (19.9 mg, 0.060 mmol) and tetrabutyl ammonium iodide (22.4 
mg, 0.061 mmol) were stirred in acetone (4.0 mL) in a 10 mL round bottom flask fitted with 
reflux condenser and refluxed at 58 ˚C for 5 hours. The reaction was tracked by TLC (silica, 
100% ethyl acetate, visualised by potassium permanganate), and once complete, the 
suspension was filtered through celite. The filtrate was condensed in vacuo and product 
isolated by column chromatography. Mobile phase used was 50 – 80% ethyl acetate in 
hexane. Yellow oil 56 (26.6 mg, 82% yield).  
1H NMR (500 MHz, CDCl3) δH 6.99 (t, J = 7.8 Hz, 1H), 6.73 (d, J = 7.4 Hz, 1H), 6.56 (d, J = 
8.2 Hz, 1H), 4.59 (s, 2H), 4.28 (td, J = 4.3, 1.9 Hz, 2H), 3.65 (t, J = 4.7 Hz, 3H), 3.61 – 3.50 
(m, 7H), 3.48 (dd, J = 5.7, 3.6 Hz, 2H), 3.30 (s, 3H), 2.77 (dd, J = 14.7, 6.1 Hz, 1H), 2.67 (dd, 
J = 14.3, 6.2 Hz, 1H), 2.50 (dd, J = 14.8, 6.4 Hz, 1H), 2.39 (dd, J = 14.3, 6.4 Hz, 1H), 2.13 
(ddd, J = 19.4, 14.9, 7.2 Hz, 2H), 1.92 – 1.70 (m, 4H), 1.63 – 1.53 (m, 2H), 1.53 – 1.42 (m, 
3H), 1.42 – 1.30 (m, 4H), 1.30 – 1.14 (m, 11H), 0.83 (t, J = 6.9 Hz, 4H); 13C NMR (126 MHz, 
CDCl3) δC 169.26, 154.88, 141.03, 127.74, 126.12, 121.59, 109.59, 77.36, 72.58, 71.92, 70.59, 
70.57, 70.53, 68.94, 65.85, 64.19, 59.07, 52.22, 41.41, 41.24, 37.43, 35.00, 33.69, 32.76, 
31.93, 28.66, 25.92, 25.40, 22.67, 14.09; FTIR (ATR) ν/cm-1 3392 (O-H), 2924- 2857 (C-H), 
55 
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1759 (C=O), 1585 (C-H), 1469 (C-H bend of TEG), 1195 (C-O ester), 1109 (C-O ether); 
Theoretical mass = 536.7 g/mol [M+Na]+ found = 559.3 m/z. 
Preparation of N-acyl sulfonamide treprostinil 21 from triol intermediate 51 
 
Over an ice bath at 0 ˚C and in an argon purged 5 mL round bottom flask fitted with septum, 
benzindene triol 51 (19.5 mg, 0.059 mmol) was dissolved in DMF (1.0 mL) and sodium hydride 
(1.4 mg, 60% in mineral oil washed in hexane, 0.059 mmol) added. After 5 minutes, 2-bromo-
N-(methylsulfonyl)acetamide 55 (14.1mg, 0.0653 mmol) and the remaining sodium hydroxide 
(1.6 mg, 0.0675 mmol) were added. Immediately the reaction turned orange which was 
subsequently lost during reaction process. The reaction was tracked by TLC (silica, 100% 
ethyl acetate, visualised by UV and PMA), and when deemed complete the reaction was 
diluted with acidified water (25 mL, 0.1M HCl solution, pH 2) and the product extracted in ethyl 
acetate (20 mL × 3), dried over Na2SO4 and solvent removed in vacuo. Crude product was 
separated by column chromatography (silica) using a solvent system comprising of ethyl 
acetate and hexanes (50 – 100%) to yield a purified oil (5.5 mg, 20% yield).  
1H NMR (500 MHz, CDCl3) δH 7.12 (t, J = 7.8 Hz, 1H), 6.90 (d, J = 7.3 Hz, 1H), 6.68 (d, J = 
8.2 Hz, 1H), 4.58 (s, 2H), 3.77 (dd, J = 9.1, 3.0 Hz, 1H), 3.62 (s, 1H), 3.36 (s, 3H), 2.76 (ddd, 
J = 14.7, 6.0, 3.4 Hz, 2H), 2.50 (dt, J = 14.3, 5.8 Hz, 2H), 2.34 – 2.25 (m, 1H), 2.20 (dd, J = 
12.0, 6.5 Hz, 1H), 1.95 – 1.87 (m, 1H), 1.68 – 1.62 (m, 2H), 1.56 (dd, J = 8.8, 4.0 Hz, 2H), 1.48 
– 1.40 (m, 3H), 1.36 – 1.20 (m, 10H), 1.13 (d, J = 11.7 Hz, 1H), 0.92 – 0.84 (m, 4H); 13C NMR 
(126 MHz, CDCl3) δ C 167.92 (s), 153.59 (s), 141.50 (s), 127.42 (s), 126.70 (s), 123.03 (s), 
110.29 (s), 72.58 (s), 68.17 (s), 52.15 (s), 41.70 (s), 41.42 (s), 41.15 (s), 37.46 (s), 34.92 (s), 
33.54 (s), 32.74 (s), 31.91 (s), 30.97 (s), 28.66 (s), 26.33 (s), 25.39 (s), 22.66 (s), 14.08 (s).; 
FTIR (ATR) ν /cm-1: (3262 (O-H), 2926-2856 (C-H), 1722 (C=O), 1585 (C-H), 1467-1403 (C-
H), 1383 (S=O); [M-H]- found: 466.2255 m/z. 
20 
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Figure 7-8. 13C NMR spectrum of N-acyl sulfonamide treprostinil synthesised from triol 
intermediate. 
 
 
Cell Culture 
Human embryonic kidney cells (HEK-293) cells stably transfected with the IP receptor565 were 
grown from frozen in minimum essential growth medium (MEM; Cat. No. 11095080; Thermo 
Fisher; Waltham, USA) containing 10 % foetal bovine serum (FBS; Cat. No. 10270-106; 
Thermo Fisher) and 1% penicillin and streptomycin (PenStrep; Cat. No. 15070-063; Invitrogen; 
Carlsbad, USA).47 Cells were cultured in a T75 flask (Cat. No. 658 170; Sigma Aldrich; St. 
Louis, USA) in 10 mL of warmed growth medium in a temperature and CO2 controlled 
incubator at 37 ˚C and 5% CO2. After 1 day, the medium was replaced with 15 mL of fresh 
medium containing 0.04 % added zeocin (Cat. No. ant-zn-1p; InvivoGen; San Diego, USA) to 
maintain selection of cells expressing the IP receptor. Cells were grown until reaching 80-85% 
confluency, with medium changed every 3-4 days.  
Once confluency was reached, cells were split for further subculture. Media was removed by 
vacuum and cells were washed with 12 mL of warm calcium and magnesium free phosphate 
buffered saline solution (PBS; Cat No. 10010-015; Thermo Fisher) and then removed. 5 mL 
of warm 0.05% trypsin-EDTA (Cat. No. 25300054; Invitrogen) was added to lift adherence 
cells from the flask bottom by incubating the flask at 37 ˚C and 5% CO2 for 1-2 mins. Once 
cells had become detached, growth medium (10 mL) was added to neutralise the trypsin and 
the cell suspension pipetted into a 50 mL falcon tube and centrifuged at 180 × g (Centrifuge 
5804 R; Eppendorf; Hamburg, Germany), 21 ˚C for 5 minutes. The supernatant was removed 
by vacuum and the cell pellet re-suspended in fresh growth medium (4 mL). Once a 
homogeneous suspension of cells was obtained, cells counted were counted using an ADAM 
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Automated Cell Counter (Digital Bio; Seoul, Korea) according to manufacturer instructions. 
Thus, two aliquots (20 µL) were placed in Eppendorf vials containing either the ‘T’ solution (20 
µL), which detects total cell numbers, or ‘N’ solution (20 µL) which detects all non-viable cells. 
Both solutions contain propidium iodide which stains the nucleus of the target cells that have 
been permeabilised or damaged. An aliquot (15 µL) of each mixed solution was placed onto a 
cell counting chip (Cat. No. AD4K-200; Cambridge Bioscience; Cambridge, UK) and loaded 
into the cell counter, which takes 22 fluorescent images of the cells and determines the number 
of cells per millimetre of cell suspension. Using the following equation, the amount of cell 
suspension solution and growth medium was determined to give the desired concentration. 
n1 x v1 = n2 x v2 
n1 – number of cells required for plating  
v1 – volume of cell growth medium in which n1 will be cultured  
n2 - concentration of cells in the total cell suspension (represented by the 20 µL aliquot)  
v2 – volume of cell suspension required for desired plating density.    
Once the cell suspension had been made up according to the required density, the cells were 
added to either 12-well plates or a T75 flask.  
Cyclic-AMP Assay  
HCl (0.1M) was obtained as part of the cAMP ELISA kit (ADI-900-163) from Enzo Life 
Sciences, PierceTM BCA protein assay kit (Cat. No. 23227) was obtained from Thermo Fisher 
Scientific, bovine serum albumin (BSA; Cat. No. A0281) was obtained from Sigma Aldrich. 
The Opsys MR plate-reader was from Dynex Technologies, UK. Data was analysed using 
GraphPad Prism Software, version 7, (CA, USA). 
TRE-S (5.6 mg) was dissolved in 1 mL of 90% MeCN/H2O solution. This was used as a stock 
solution for all biological assays and stored at -20 °C between experiments. 
For the concentration-response experiments, the cell suspension (1 mL) in MEM containing 
10 % foetal bovine serum (FBS) and 1% penicillin and streptomycin (PenStrep) was added to 
each well of a 12-well plate (Cat. No. 734-2324; VWR; Radnor, USA) at a density of 1 x104 
cells mL-1 and incubated for 48 hours at 37 °C / 5% CO2. Following this, the growth medium 
was replaced with fresh growth medium (1 mL) to remove any unattached cells and incubated 
for a further 24 hours at 37°C / 5% CO2. After which, drug concentrations (0.001 -1000nM) 
were made up into media (3 mL) and added to the respective wells in duplicate and cells 
incubated for 15 minutes with the IP receptor agonist (Treprostinil and N-sulfonamide 
treprostinil, TRE-S). When organic solvents were used in the drug stock solutions, equal final 
percentages of solvent (acetonitrile or DMSO) were added to the serial dilution vials to 
maintain consistency in all vials to achieve final amount of 0.1% solvent. The medium was 
removed and replaced with cold HCl (0.1 M, 250 µL) whilst the plate was resting on ice. The 
lysed cells were scraped and collected in 1.5 mL Eppendorf vials. Duplicate concentrations of 
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each drug were pooled together and centrifuged at 10 000 × g at 4 °C for 10 mins to pellet cell 
debris; the supernatant was transferred to new vial and frozen at -80°C until required. 
Before the ELISA was carried out, the supernatant solutions were thawed. The cyclic 
adenosine monophosphate (cAMP) assay kit (ADI-900-163; Enzo Life Sciences; Farmingdale, 
USA) used a competitive binding technique, where each well was coated with a goat anti-
rabbit IgG antibody. Cyclic AMP conjugated to alkaline phosphatase followed by rabbit 
polyclonal antibody was added to each well. The antibody binds competitively to the cAMP. 
The para-nitro phenyl phosphate substrate then reacts with the alkaline phosphatase on the 
cAMP conjugate, releasing a yellow colour. The 96-well plate was read at 405 nm using a 
Dynex Opsys MR plate-reader (Worthing, UK) where the absorbance signal was inversely 
proportional to the concentration of cAMP in the sample. Standard solutions of cAMP were 
made up with known concentrations which are used to generate a standard curve to determine 
levels in HEK-293-IP cells exposed to a particular IP agonist. 
 
Figure 7-9. Standard curve of concentration of cAMP standards versus optical density. 
cAMP is measured using enzyme-linked immunosorbent assay and optical density is 
read at 405 nm. Curve fit uses semi-log cubic spline fit with tails. 
A bovine serum albumin (BCA) protein kit was used to normalise cAMP levels against the level 
of protein. The assay was based on the principle that proteins reduce copper in alkaline 
solution (Cu2+ to Cu1+) producing a colour change which was detected. A standard was 
prepared using a 1 mg / mL solution of bovine serum albumin (BSA) dissolved in distilled 
water. 25 µL of each sample and 200 µL of BCA working solution was added to each well and 
the plate placed on a microplate shaker (VWR, Radnor, USA) for 30 seconds. The plate was 
incubated for 30 minutes at 37°C / 5% CO2 before being cooled to room temperature and read 
at 540 nm using a plate reader. 
Microsomal Degradation Assay 
Sterile distilled water (Cat. No. 15230-071), β- nicotinamide adenine dinucleotide phosphate 
disodium salt (Cat. No. 101166) and PBS tablets (Cat. No. 18912-014) were obtained from 
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Thermo Fisher Scientific, Selexipag (Cat. No. 10010411) was obtained from Cayman 
chemicals (Ann Arbor, USA). Phosphoric acid (Cat. No. 21510-4), indomethacin (Cat. No. I-
7378), ᴅ-Glucose 6-phosphate disodium hydrate (Cat. No. G7250), glucose-6-phosphate 
dehydrogenase (Cat. No. G-4134), potassium phosphate monobasic (Cat. No. P8416) and 
potassium phosphate dibasic (Cat. No. 60353) were bought from Sigma Aldrich, Oasis Prime 
HLB plus lite SPE cartridges (Cat. No. 186005125) were bought from Waters. Papaverine 
(Cat. No. 207220050) was from Acros Organics, rat microsomes (Cat. No. RTMCPL) and 
human microsomes (Cat. No. HMMCPL) were obtained from Life Technologies (Paisley, UK), 
magnesium chloride (anhydrous, Cat. No. 8.14733.0100) was bought from Merck.  
Potassium phosphate buffer (100 mM) was prepared using dibasic potassium phosphate and 
monobasic potassium phosphate. The final solution was filtered through 0.2-mm Nalgene filter 
flask with vacuum assistance and stored at 4 °C. 
The microsome assay is often used as a measure of enzymatic degradation of a prodrug to 
its respective metabolite.278,393 The final assay in each vial includes hepatic microsomes (0.4 
mg/mL), regenerating system (25 mM glucose-6-phosphate, 4 units/mL glucose-6-phosphate 
dehydrogenase, 2.5 mM β-NADP, and 10mM mM MgCl2), test compound (10µM), in 
potassium phosphate buffer at pH 7.4 in a final volume of 500 µL. Rat and human hepatic 
microsomes were obtained as a 20 mg/ mL stock solution. A solution of microsome stock 
suspension (193.5 µL) in the buffer solution (8.8 mL) described above was made. Sample 
solutions (1mM) were prepared. The selexipag solution was prepared by diluting (10 fold) the 
drug stock (5 µL, 10mM) in buffer solution (45 µL). TRE-S (1mM) solution was made by diluting 
stock (4.67 µL, 10.7 mM) in buffer (45.33 µL). Indomethacin (50 µM) was made by diluting 
stock (0.1 µL. 10mM) in buffer (19.9 µL). For the NADPH-regenerating system: glucose-6-
phosphate (190.1 mg) was dissolved in buffer (375 µL); nicotamide adenosine diphosphate 
(49.2 mg) was dissolved in buffer (375 µL); anhydrous magnesium chloride (23.8 mg) was 
dissolved in sterile distilled water (375 µL); a stock of glucose-6-phosphate dehydrogenase 
(114 U, 0.6 mg) was dissolved in buffer (427.5 µL), of which 375 µL used in assay. All NADPH-
generating solutions were kept on ice and immediately before use, the four solutions were 
added together. Portions of microsome solution (465 µL) were aliquoted into 1.5 µL vials for 
incubation which after the designated amount of time would be extracted. Combined NADPH-
regenerating solution (30 µL) was added to each vial and the solutions vortexed then 
preincubated at 37 °C for 5 minutes. The assay was initiated by the addition of drug stock (5 
µL) to achieve a final concentration of 10 µM for selexipag and TRE-S, and 0.5 µM for 
indomethacin. Solutions were vortexed and incubated for various time periods between 0 and 
120 minutes. The reactions were quenched by addition of LCMS grade acetonitrile (100 µL) 
and vortexed. The solutions were then centrifuged at 9279 × g (Eppendorf; Hamburg, 
Germany) for 10 minutes at 4 °C. 
Sample preparation for LCMS/MS involved filtering supernatant (500 µL) through solid phase 
extraction (SPE) cartridges using a 1 mL syringe to remove salts and lipids. The sample was 
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washed of salts by flushing through 500 µL of 5% methanol/water solution. Into a fresh vial, 
drug was eluted from cartridge by addition of 500 µL acetonitrile spiked with internal standard 
(papaverine, 1 pg/mL). Papaverine was chosen as the internal standard as it forms positive 
ion with mass smaller than that of any of the test compounds. Filtrate (20 µL) was analysed 
by LCMS/MS. The mobile phase was a fixed gradient at 55% acetonitrile/water both spiked 
with 0.1% formic acid. The column was operated with a fixed flow rate of 1 mL/minute at a 
temperature of 40 °C. Prodrug masses were identified by electrospray ionisation in positive 
ion mode. Multiple reaction monitoring was used for accurate ion quantification. The most 
abundant ion for each precursor compound was used for quantification. For all compounds; 
dwell was set to 200 and cell accelerator voltage was set to 7 V.  
 
Table 7-2. Most abundant product ions of each drug used in 
microsome assay used for quantification of compound. 
Compound 
Precursor 
ion 
Product 
ion 
Fragmentor 
Collision 
energy 
Papaverine 340.01 324.1 130 30 
Indomethacin 157.9 138.9 155 14 
Selexipag 497.01 377.1 160 30 
TRE-S 467.6 337.2 135 14 
Stability of TRE-S in cell culture media was also carried out using the same procedure as the 
blood stability assay and worked up as below. 
 Methods for Chapter 4 
 
Gel permeation chromatography was carried out by size exclusion by an in-house technician. 
Size exclusion chromatography (SEC) was conducted with DMF as the mobile phase 
containing 5 mM NH4BF4 additive at 70 ˚C with a flow rate of 1.00 mL/min. 100 µL of polymer 
aliquots in DMF (5 mg/mL) were injected in a Viscotek system equipped with a refractive index 
(RI) detector. Poly(methyl methacrylate) (PMMA) standards were used for calibration and 
OMNISEC software was used to determine the average molecular weight (Mn) and index of 
polydispersity (PDI). 
A degradation assay was carried out in an Innova 40 incubator (New Jersey) set to 37 °C. 
Worked up samples were analysed by High performance liquid chromatography (HPLC), on 
system described on page 317.  
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Poly(PEG acetal) 70  
 
In an argon environment, poly(ethylene glycol) 3400 65 (3.5980 g, 1.038 mmol) and p-toluene 
sulfonic acid (5.7 mg, 0.030 mmol) were stirred together in toluene and distilled at 175 °C to 
remove any trace water. Once the solvent had been removed the residue was cooled to 50 °C 
and THF (5 mL) was added. Triethylene glycol di vinyl ether 64 (TEGDVE, 216 μL, 1.058 
mmol) was added to the solution, the flask wrapped in foil and left to stir for 2 hours. 
Triethylamine (289 μL, 2.076 mmol) was added and the reaction solution was slowly added to 
cold hexane (200 mL) to precipitate polyacetal 70. The precipitated solid material was isolated 
by vacuum filtration and washed with hexane, before drying under reduced pressure for 24 
hours to yield (3.43 g, 92% yield) of a white solid; Average molecular weight = 48.7 kDa; PDI 
= 2.0; 1H NMR (500 MHz, D2O) δH 7.67 (1 H, d, J 8.2), 7.36 (1 H, d, J 8.0), 6.50 (1 H, dd, J 
14.3, 6.7), 4.86 (2 H, q, J 5.3), 3.87 – 3.78 (6 H, m), 3.76 – 3.57 (331 H, m), 3.56 – 3.48 (3 H, 
m), 1.33 (6 H, d, J 5.4). 
Oligo(PEG-treprostinil acetal) 71 
 
In a RBF (25 mL) under argon, a solution of PEG 3400 65 (874.5 mg, 0.257 mmol) and pTSA 
(7.4 mg, 0.039 mmol) were stirred in 8 mL toluene. Water was removed by azeotropic 
distillation of toluene by heating to 175 °C. Once a majority of toluene was removed and the 
residue cooled to below 50 °C, treprostinil 4 (100.5 mg, 0.257 mmol) in THF (3 mL) was added 
followed by dropwise addition of TEGDVE 64 (106.2 μL, 0.520 mmol). The reaction mixture 
was stirred in darkness for 3 hours and then precipitated into hexane. Triethylamine (178.5 
μL, 1.281 mmol) was added to the reaction mixture midway through the precipitation step. The 
precipitate collected by vacuum filtration and then dried under vacuum for 24 hours, affording 
oligo(PEG-treprostinil acetal) 71 as a solid (0.8574 g, 80% yield.) Average molecular weight = 
17.4 kDa; PDI = 1.8 kDa; 1H NMR (500 MHz, D2O) δ H 7.67 (1 H, d, J 8.2), 7.35 (1 H, d, J 8.1), 
63 64 
64 63 4 
70 
69 
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7.14 (1 H, d, J 7.8), 6.89 (1 H, d, J 7.2), 6.75 (1 H, d, J 8.2), 4.89 – 4.83 (2 H, m), 4.45 (2 H, 
s), 3.86 – 3.75 (15 H, m), 3.74 – 3.58 (1431 H, m), 3.56 – 3.51 (9 H, m), 2.68 (3 H, q, J 7.2), 
2.58 (1 H, dd, J 13.1, 6.6), 2.50 (1 H, dd, J 13.1, 4.6), 2.38 (2 H, s), 2.32 – 2.24 (1 H, m), 2.24 
– 2.18 (1 H, m), 2.18 – 2.08 (1 H, m), 2.00 – 1.92 (1 H, m), 1.92 – 1.84 (1 H, m), 1.81 – 1.73 
(1 H, m), 1.65 (1 H, s), 1.33 (14 H, d, J 5.3), 0.85 (3 H, t, J 6.5). 
Oligo(treprostinil ethyl ester-PEG acetal) 72 
 
Using a Dean Stark condenser, PEG 3400 65 (436.3 mg, 0.1283 mmol) and pTSA (0.7 mg, 
3.8 μmol) were dissolved in toluene (8 mL) and heated to 175 °C in an argon environment 
whilst stirring for 1 hour. Once all toluene had been removed, treprostinil ethyl ester 43 (51.2 
mg, 0.1223 mmol) and THF (6 mL) were added. The reaction flask was wrapped in foil and 
TEGDVE 64 (54 μL, 0.2670 mmol) added dropwise. After 3.5 hours, the reaction was 
quenched by addition of triethylamine (8.9 μL, 0.0639 mmol) and then precipitated into hexane 
(400 mL). The precipitate collected by vacuum filtration, washed with cold hexane and dried 
under vacuum to yield a white solid (0.3795 g, 81% yield.) Average molecular weight = 7.0 
kDa; PDI = 1.1; 1H NMR (500 MHz, D2O) δ H 7.58 (1 H, d, J 8.2), 7.27 (1 H, d, J 8.0), 7.06 (1 
H, t, J 7.8), 6.80 (1 H, d, J 7.5), 6.66 (1 H, d, J 8.4), 6.42 (2 H, dd, J 14.3, 6.8), 4.77 (4 H, q, J 
5.4), 4.36 (2 H, s), 4.24 (2 H, dd, J 14.3, 2.2), 4.05 (2 H, dd, J 6.7, 2.2), 3.82 (5 H, dd, J 5.4, 
3.3), 3.74 (33 H, dd, J 5.3, 3.5), 3.71 – 3.48 (5006 H, m), 3.48 – 3.27 (44 H, m), 2.72 – 2.63 (2 
H, m), 2.57 (2 H, q, J 7.3), 2.46 (1 H, d, J 6.1), 2.41 (1 H, dd, J 14.5, 5.8), 2.29 (2 H, s), 2.20 
(1 H, d, J 7.5), 2.09 – 1.97 (1 H, m), 1.85 (1 H, s), 1.56 (1 H, s), 1.44 (1 H, d, J 19.4), 1.33 (2 
H, d, J 11.1), 1.24 (12 H, d, J 5.4), 1.08 (4 H, dd, J 12.0, 4.9), 0.96 (3 H, t, J 7.3). 
Poly(silyl PEG)  
 
In an oven dried, argon purged RBF (25 mL), PEG 3400 65 (996.7 mg, 0.2931 mmol) was 
dried by azeotropic removal of toluene (50mL) in vacuo. Once toluene had been removed, 
42 
63 
64 
71 
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THF (12 mL) and pyridine (47.0 μL, 0.5835 mmol) were added and heated slightly to solubilise. 
Whilst stirring vigorously, dichlorodiisopropyl silane (46.0 μL, 0.2549 mmol) was added 
dropwise. The solution was stirred for 16 hours. The cloudy reaction mixture was precipitated 
into hexane and the precipitate collected by vacuum filtration. After drying under vacuum, a 
white powder was afforded (0.9262 g) Average molecular weight = 10.7 kDa; PDI = 1.06. 
Polymerisation was unsuccessful. 
Poly(silyl PEG treprostinil)  
 
PEG 3400 65 (435.4 mg, 0.1281 mmol) was dried by azeotropic removal of toluene from an 
argon-purged 25 mL RBF, in vacuo. The dried residue was dissolved in anhydrous THF aided 
by heating to 40 °C and pyridine (52.0 μL, 0.6468 mmol) added. Treprostinil 4 (50.0 mg, 0.1280 
mmol) was added, followed by dropwise addition of dichloroisopropyl silane (46.2 μL, 0.2560 
mmol). The solution stirred for 16 hours and precipitated into hexane. Precipitate collected and 
dried over partial pressure to afford white powder (0.409 g,) although polymerisation was 
unsuccessful. 
 
PBS buffers were made at pH 7.4, 6.6, by dissolution of a PBS tablet in deionised water (200 
mL). Citrate buffer was made by addition of citric acid solution (0.11 M, 82 mL) and sodium 
citrate solution (0.11 M, 18 mL). All pH measurements were taken using a Hanna HI 2210 pH 
meter (Rhode Island, US) and adjustments were made by dropwise addition of standard HCl 
(0.1 M) or NaOH (0.1M). Oligo(PEG-Treprostinil acetal) solutions were made by dissolving the 
sample in buffers at 5 mg/mL or 2.5 mg/mL. Immediately upon oligomer dissolution, the 
solutions were vortexed and aliquoted into 200 μL samples. The aliquots were incubated at 
37 °C and at predefined time points, the solutions were extracted using ethyl acetate. Briefly, 
treprostinil was extracted into EA (3 × 200 μL) and the combined EA layers washed with brine 
(200 μL). Trace water was removed from the organic layer by filtration through a layer of 
 
4 
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MgSO4 and cotton wool. The filter was flushed with EA (200 μL) and the filtrate dried over a 
stream of air. Once dried, the residue was reconstituted in a 200 μL acetonitrile solution with 
1 mg/mL phenoxyacetic acid as an internal standard. HPLC samples were frozen until 
analysis.  
A 1 mg/mL stock solution of treprostinil was prepared in the same solution of MeCN spiked 
with phenoxyacetic acid as samples. Treprostinil calibrants were prepared by 2-fold serial 
dilution using spiked MeCN as solvent. Samples were analysed by HPLC in duplicate. 
HPLC analysis was conducted using a Supelco Discovery HS RP-C18 column (Cat. No. 
567209-U). Water and acetonitrile spiked with 0.1 % TFA comprised the liquid phase. A 
gradient was run from 40% to 90% MeCN over 8 minutes. An injection volume of 20 μL and a 
flow rate of 1 mL/minute were used and treprostinil was detected by UV (217 nm). 
HPLC analysis was calculated as a ratio between internal standard with retention time 3.6 
minutes and treprostinil concentration with retention time 7.1 minutes. Ratios for calibration 
standards were plotted measuring regression. Ratios of samples with unknown concentrations 
were converted into concentrations (mg/mL) using the linear equation. To compensate for the 
different aliquot and extraction volumes, the concentration calculated was divided by the 
relevant dilution factor.  
Degradation analysis by GPC was conducted on a separate sample (200 μL) for each time 
point. At predefined time points (0, 1, 2, 4, 6, 24 hours), one sample was analysed by HPLC 
as before and the other was flash frozen in an acetone/dry ice bath, stored at -20 °C and 
lyophilised for 24 hours. The samples were then prepared for GPC as described on page 338 
.Methods for Chapter 5 
  Methods for Chapter 5 
 
Peptides were synthesised by automated solid phase peptide synthesis (SPPS) using a 
Biotage Syro (Uppsala, Sweden). Each coupling was carried out in duplicate and 5 equivalents 
of the Fmoc-amino acid were added. Coupling was carried out in peptide grade 
dimethylformamide (DMF) by N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium 
hexafluorophosphate (HBTU, 5 eq) in the presence of diisopropyl ethylamine (DIPEA, 10 eq). 
After duplicate coupling the Fmoc-amine was deprotected by reaction with piperidine (40%). 
Number of moles for each repeat reaction were calculated using the following equation.  
𝑁𝑜. 𝑀𝑜𝑙𝑒𝑠 = 𝑅𝑒𝑠𝑖𝑛 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (
𝑚𝑚𝑜𝑙
𝑔
) ∗ 𝑟𝑒𝑠𝑖𝑛 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑔) 
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Figure 7-10. Image of automated solid phase peptide synthesiser used to make amino 
build amino acid sequences on resin matrices. Solutions of coupling 3-
[Bis(dimethylamino)methyliumyl]-3H-benzotriazol-1-oxide hexafluorophosphate 
(HBTU), piperidine and individual amino acids are made up individually in 
dimethylformamide (DMF). Diisopropylethylamine (DIPEA) is dissolved in N-
methylpyrrolidinone (NMP). Each pre-programmed amino acid sequence is 
synthesised in the respective reaction vessel which is loaded with swollen resin. The 
needle collects the correct amount of each solution and dispenses them in the reaction 
vessel. The vessel is vortexed for 3 minutes for each coupling and each coupling is 
conducted twice.  
Resin drying and removal 
Unless otherwise stated, before different reaction steps (coupling, cyclisation, resin removal), 
resins were rinsed with DMF (6x 3 mL) to rinse any remaining unreacted compounds. 
Dichloromethane (DCM, 6x 3 mL) was used to rinse DMF and 50% DCM/MeOH (6x 3 mL) 
was used to help the resin shrink. The resin was subsequently dried in a vacuum desiccator 
overnight.  
Unless otherwise stated, compounds were removed from resin by the addition of a solution 
containing 95% trifluoroacetic acid (TFA), 2.5% triisopropyl silane 95 (TIS) and 2.5% water.544 
The solution was left to sit for 2 hours with the occasional swirling of the reaction mixture. The 
resin was removed by filtration through a sinter funnel, rinsing with further TFA. The filtrate 
was condensed but not dried in vacuo and the product was precipitated by the addition of ice-
cold diethyl ether. The precipitate was collected on a sinter, washed further with diethyl ether, 
dissolved in a suitable solvent (95% aqueous acetic acid or water) and filtrate collected in a 
RBF. The collected filtrates were lyophilised using one of three options; for acidic solutions a 
Heto Powerdry LL1500 freeze dryer (Thermo Fisher, US) was used; for aqueous solutions, 
the solvent was removed using a Virtis Advantage freeze dryer (-60 ᵒC environment with shelf 
temperature -20 ᵒC), when neither of these were available, a freeze dryer was made using a 
rotary evaporator (Buchi Rotavapor R-200; Flawil, Switzerland) set to no rotation. The sample 
was cooled in salt ice bath (-12 ᵒC), the vapour cooled with ice finger (-78 ᵒC) and system 
depressurised with a vacuum pump.  
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HPLC – Analytical and preparative 
Analytical reverse phase high performance liquid chromatography (RP-HPLC) was carried out 
as described before in the general methods, page 317). UV detector measured absorbances 
at 217 nm (amide bond detection), 254 nm (aromatic detection) and 495 nm (fluorescein 
detection). Unless stated otherwise, samples were analysed using an aqueous mobile phase 
of increasing acetonitrile (10% - 60%) over 22 minutes. The total analysis time was 30 minutes. 
Preparative HPLC was carried out on a Jasco system (Jasco Corp., Oklahoma, US) comprised 
of a pump (Jasco-980), a 2 mL loop volume autosampler (Jasco AS-1555), and a single 
wavelength UV detector (Jasco-1570) set to 217 nm. The system was equipped with a reverse 
phase column Supelco Discovery HS C18 column, (25 cm x 2.1 cm, 5 μm; Cat. No. 568543-U) 
purchased from Sigma Aldrich UK and ChromNAV software (version 2.02.05, Jasco Corp). 
The mobile phase consisted of 0.1% TFA (Cat. No. L06374) buffered water with increasing 
TFA-buffered (0.1%) acetonitrile concentration (10% - 60%) over 90 minutes. The total 
analysis time was 120 minutes.  
Purification by automated column chromatography was carried out on a Biotage system as 
described in Chapter 3. The system was fitted with a Reveleris C18 cartridge (4 g or 12 g, Cat. 
No. 145152990; Buchi; Flawil, Switzerland). A mobile phase of acetonitrile and water, in a 
gradient as described below, was run at 6 mL/min.  
Table 7-3. Mobile phase used for automated chromatography system. Using 
column volumes to measure the solvent allowed for the same method to be applied 
exactly, irrespective of the column cartridge size used. 
Column Volumes % Acetonitrile % Water 
2 5 95 
20 5 – 40 95 – 60 
3 40 60 
Kaiser test for primary amines 
The Kaiser test consists of three solutions and was used to determine the presence of primary 
alcohols on resin.566 
Solution 1: Ninhydrin (5 g) was dissolved in ethanol (100 mL) 
Solution 2: Liquid phenol (80 g) was mixed with ethanol (20 mL) 
Solution 3: Potassium cyanide (0.001 M, aqueous, 2 mL) was mixed with pyridine (98 
mL) 
To prepare the resin, a sample of resin beads (~10 beads) was removed from the reaction, 
placed on a sinter under partial pressure, and washed in the following order; DMF (3 mL) to 
rid any solution phase reagents, DCM (3 mL) to rinse away DMF traces, and DCM/MeOH 
(50%, 3 mL) to shrink the resin. After drying the resin for 2 minutes on the sinter under reduced 
pressure, the beads were transferred into a soda tube. The Kaiser test was performed by 
addition of the following solutions via glass pipette in the order described; solution 1 (1 drop), 
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solution 2 (2 drops) and solution 3 (1 drop). The solution gentle agitated and heated to 110 ᵒC 
for 3-5 minutes. An intense blue solution with blue beads was positive and indicated primary 
amines were present. A colourless or faintly coloured solution with pale beads indicated that 
no primary amines are present. A dark blue solution with pale beads indicates that the coupling 
was nearly complete.  
P-anisaldehyde test for aldehydes 
The presence of aldehydes was determined using a p-anisaldehyde solution.527 Ethanol (4.4 
mL), sulfuric acid (0.45 mL), acetic acid (50 μL) and p-anisaldehyde (127.5 μL) were stirred 
together and stored at 4 ᵒC for up to 5 days. To test for aldehydes, a small sample of resin 
was washed with DMF (3 mL), DCM (3 mL) and a 50% solution of DCM/MeOH (3 mL). Once 
dried under partial pressure for a couple of minutes the beads were transferred to a soda tube 
and the test solution (~300 mL) was added. The solution was heated to 110 ᵒC for 4 minutes 
in a heated block and the colour change was interpreted. In the absence of aldehydes, no 
change in bead colour was observed. In the presence of aldehydes, the beads turn purple/red.  
Acetaldehyde test for secondary amines 
The presence of secondary amines was determined using the acetaldehyde test. A solution of 
2% acetaldehyde 139 in DMF and NMP (1 mL) was mixed together. Sample resin (10-20 
beads) was washed with DMF prior to testing and placed in a soda tube. 2-3 drops of the 
testing solution were added and after 10 minutes the colour noted. The presence of secondary 
amines turned the beads red and no colour change was observed in their absence. 
4-toluene sulfonyl chloride – p-nitrobenzylpyridine (TosCl-PNBP) test for alcohols  
Detection of alcohol was determined using the TosCl-PNBP test567,568 which was comprised 
of three different solutions. 
Solution 1: p-toluenesulfonyl chloride in toluene (0.12M) 
Solution 2: p-nitrobenzylpyridine in toluene (0.30M) 
Solution 3: Piperidine 10% (v/v) in chloroform 
A sample of test resin was washed with DMF (3 mL) and DCM (6 mL). As a suspension in 
DCM, approximately 10 beads were pipetted onto a sheet of silica. Once dry, 1 drop of solution 
1 followed by a drop of solution 2 was added to the beads. The silica plate was heated from 
beneath using a heat gun for 1 minute or until a yellow colour had appeared and disappeared 
again. A drop of solution 3 was then added. The presence of hydroxyls was indicated by a 
purple colouration to the beads which appeared pink when concentrations were low. The 
absence of alcohols and phenols resulted in no colour change. Samples were run alongside 
control tests; using Wang resin as a positive control and acetylated Wang resin as a negative 
control. 
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Figure 7-11. Depiction of results of colourimetirc resin tests for amines. Beads 
produced no colour when no groups are present, became purple when primary amines 
were present and exposed to ninhydrin. A very pale blue colour indicated very few 
amines were present. Orange solution and brown/red beads indicated the presence of 
secondary amines. 
 
FITC-CARSKNKDC synthesis 
In solution CAR peptide conjugation 
 
A solution of DIPEA (155 μL, 122.1 μL) in anhydrous DMF (2.5 mL) was added to disulfide-
cyclised CARSK(Dde)NK(Dde)DC-NH2 74 (50 mg, 37 μmol) and fluoroscein isothiocyanate 
75 (FITC, 19.2 mg, 48 μmol) in an argon purged flask. The flask was wrapped in foil and left 
stirring at RT for 16 hours and monitored by reverse phase thin layer chromatography (RP-
TLC). DMF was removed by passing a stream of air over the solution and redissolving the 
residue in THF. The precipitate was filtered off and the filtrate dried down. HPLC retention time 
of FITC-peptide 77 = 13.7 minutes; Rf = 0.56. Peptide FITC conjugation was conducted 
following previous procedures:569 
 
Disulfide-cyclised H-CARSK(Dde)NK(Dde)DC 74 (2mg, 1.5 μmol) was dissolved in DMF (50 
μL) and hydrazine hydrate 78 (2 μL) added. After 10 minutes, RP-TLC was run in 50% 
MeCN/H2O by drying a sample of reaction solution. The dried solution was analysed by HPLC 
in water; retention time = 8.2 minutes; Rf = 0.5;  
76 
78 
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1H NMR (400 MHz, MeOD) δ 8.18 – 8.13 (1 H, m), 8.07 (1 H, s), 8.02 (1 H, s), 8.00 (1 H, s), 
7.97 (3 H, s), 6.69 (1 H, d, J 7.4), 6.54 (1 H, d, J 8.6), 4.93 (1 H, s), 4.90 (1 H, s), 4.89 – 4.78 
(242 H, m), 4.76 (1 H, s), 4.70 (1 H, s), 4.69 (1 H, s), 4.56 (1 H, dd, J 8.8, 4.9), 4.49 (1 H, d, J 
7.1), 4.36 (1 H, dd, J 14.3, 6.8), 4.31 (1 H, t, J 4.4), 4.24 – 4.18 (1 H, m), 4.14 (1 H, s), 3.95 (1 
H, dd, J 11.2, 4.3), 3.84 (1 H, dd, J 11.1, 4.5), 3.50 – 3.47 (1 H, m), 3.35 (1 H, s), 3.34 – 3.29 
(111 H, m), 3.29 (1 H, s), 3.24 (2 H, dd, J 9.4, 4.0), 3.13 (1 H, dt, J 3.3, 1.7), 3.03 (1 H, d, J 
3.7), 2.99 (1 H, s), 2.95 (3 H, t, J 7.2), 2.90 (1 H, d, J 0.5), 2.86 (2 H, d, J 0.6), 2.80 (2 H, d, J 
6.6), 2.78 (1 H, d, J 5.0), 2.76 – 2.73 (1 H, m), 2.70 (4 H, s), 2.66 (1 H, s), 2.62 (1 H, s), 2.55 
(1 H, d, J 6.4), 2.52 – 2.49 (1 H, m), 2.45 (6 H, s), 2.42 (1 H, s), 2.40 (1 H, d, J 5.8), 2.34 (5 H, 
d, J 2.2), 2.14 (1 H, s), 2.10 (1 H, s), 2.04 (1 H, s), 1.98 (1 H, d, J 5.4), 1.91 (4 H, dt, J 23.3, 
9.1), 1.68 (4 H, s), 1.48 (3 H, d, J 7.0), 1.43 (2 H, d, J 7.0), 1.29 (1 H, s), 1.09 (12 H, s), 1.07 
(1 H, d, J 3.5), 1.05 (1 H, s), 1.02 (1 H, s). 
 
To a solution of crude disulfide-cyclised FITC-XCARSK(Dde)NK(Dde)DC-NH2 77 (3.7 μL) in 
THF (0.5 mL) was added hydrazine hydrate 78 (10 μL, 0.174 mmol). The reaction was tracked 
by HPLC using a solvent gradient of 25-50% acetonitrile over 15 minutes then the 50% 
acetonitrile was maintained for a further 15 minutes. UV detection was carried out at 220 nm. 
HPLC trace showed two sharp absorbances; one at 15.1 minutes expected to be product and 
another at 20.9 minutes indicating an excess of FITC. 
On resin CAR synthesis 
 
H-Ahx-Cys(Acm)-Ala-Arg(Pbf)-Ser(OtBu)-Lys(Boc)-Asn(Trt)-Lys(Boc)-Asp(OtBu)-Cys(Acm) 
84 was synthesised by automated solid phase peptide synthesis. Peptides were grown on 
PAL Novasyn resin (Barany's aminomethyl-dimethoxyphenoxyvaleric acid linker attached to 
NovaSyn® TentaGel® resin,100 mg) in quintuplet. The loading of the batch was 0.22 mmol/g, 
therefore each vial possessed 0.022 mmol of reactive amines. 
 
80 
83 
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Table 7-4. Amounts of reagents required for automated solid phase peptide 
synthesis of CARSKNKDC peptide on PAL NovaSyn® resin using Fmoc chemistry 
and employing Fmoc-Cys(Acm) as the thiol protecting group.  
Code Compound Mol Amount Solvent Vol of solvent 
C Fmoc-Cys(Acm)-OH 414.5 0.476 g DMF 16.37 mL 
A Fmoc-Ala-OH 311.3 0.184 g DMF 8.47 mL 
R Fmoc-Arg(Pbf)-OH 648.8 0.384 g DMF 8.32 mL 
S Fmoc-Ser(OtBu)-OH 383.4 0.227 g DMF 8.43 mL 
K Fmoc-Lys(Boc)-OH 468.2 0.538 g DMF 16.26 mL 
N Fmoc-Asn(Trt)-OH 597.8 0.353 g DMF 8.36 mL 
D Fmoc-Asp(OtBu)-OH 411.5 0.243 g DMF 8.42 mL 
X Fmoc-Ahx-OH 353.4 0.209 g DMF 8.45 mL 
 HBTU 379.3 2.235 g DMF 88.21 mL 
 DIPEA 129.3 2.01 mL NMP 40.99 mL 
 Piperidine 85.15 38.4 mL DMF 57.60 mL 
 
 
H-Ahx-Cys(Trt)-Ala-Arg(Pbf)-Ser(OtBu)-Lys(Boc)-Asn(Trt)-Lys(Boc)-Asp(OtBu)-Cys(Trt) 91 
was synthesised on PAL Novasyn resin (100 mg) in duplicate. Resin loading was 0.22 mmol/g, 
therefore each vial possessed 0.022 mmol of reactive amines. 
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Table 7-5. Amounts of reagents required for SPPS of CAR peptide using Cys(Trt). 
Code Compound 
Mol wt 
(g/mol) 
Amount Solvent 
Total vol of 
solvent 
(mL) 
C Fmoc-Cys(Trt)-OH 585.7 0.286 g DMF 6.89 
A Fmoc-Ala-OH 311.3 0.081 g DMF 3.74 
R Fmoc-Arg(Pbf)-OH 648.8 0.169 g DMF 3.67 
S Fmoc-Ser(OtBu)-OH 383.4 0.100 g DMF 3.373 
K Fmoc-Lys(Boc)-OH 468.2 0.229 g DMF 6.91 
N Fmoc-Asn(Trt)-OH 597.8 0.156 g DMF 3.67 
D Fmoc-Asp(OtBu)-OH 411.5 0.108 g DMF 3.72 
X Fmoc-Ahx-OH 353.4 0.092 g DMF 3.74 
 HBTU 379.3 0.983 g DMF 38.81 
 DIPEA 129.3 0.89 mL NMP 18.11 
 Piperidine 85.15 16.8 mL DMF 25.2 
The last step included a fluorenylmethyloxycarbonyl protecting group (Fmoc)-deprotection 
step, which rendered the amine reactive for further conjugation reactions. 
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On resin FITC-conjugation 
 
H-Ahx-Cys(Acm)-Ala-Arg(Pbf)-Ser(OtBu)-Lys(Boc)-Asn(Trt)-Lys(Boc)-Asp(OtBu)-Cys(Acm) – 
PAL Novasyn resin 88 (0.0044 mmol) was allowed to swell in DCM for 1.5 hours before 
washing with DMF (3 × 3 mL) and purging the vessel with Argon. A solution of FITC 75 (6.9 
mg, 0.0176 mmol) in anhydrous DMF (1 mL) was added followed by DIPEA (1.23 μL, 0.0070 
mmol). The solution was covered in foil and shaken for 3 hours. The reaction was monitored 
by Kaiser test which returned positive. The resin was washed with DMF (3 × 6 mL), DCM (3 × 
6 mL), 50% DCM/MeOH (3 × 6 mL) and dried in a vacuum desiccator overnight. Peptide 89 
was removed from the resin using the standard procedure and isolated by preparative HPLC 
to yield 15.7 mg, 43% yield, 71% column recovery, HPLC retention time = 10.2 minutes; Rf 
value = 0.4 ( acetonitrile/aqueous HCl) 
 
 
H-Ahx-Cys(Trt)-Ala-Arg(Pbf)-Ser(OtBu)-Lys(Boc)-Asn(Trt)-Lys(Boc)-Asp(OtBu)-Cys(Trt) – 
PAL Novasyn resin 91 (0.022 mmol) was swollen in DMF (2 mL) for 45 minutes. The syringe 
vessel was purged with argon and the solvent replaced with a solution of fluorescein 
87 
88 
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isothiocyanate 75 (34.7 mg, 0.089 mmol) in anhydrous DMF (2 mL). DIPEA (6.3 μL, 0.036 
mmol) was added and the reaction covered in foil and shaken for 3 hours. The reaction was 
tracked using the Kaiser test which produced a positive result. The resin was washed and 
dried using the standard method and carried forward to the next reaction. 
 
FITC-CAR resin 92 was cleaved in a cocktail of TFA (1.88 mL), H2O (50 μL), 1,2-ethanedithiol 
(50μL) and TIS 95 (50 μL) which removed side chain protecting groups. The precipitated 
peptide was dissolved in deionised water before lyophilisation. Peptide yield was 28.9 mg, 
(86%); HPLC was conducted using the method described on page 342.  The uncyclised peak 
was observed after 14.2 minutes but the cyclised product was also observed at 10.05 minutes 
so the peptide was taken forward for cysteine cyclisation without further analysis. 
 
 
 
Table 7-6. Unsuccessful cyclisation conditions used to form the disulfide bond 
between cysteine thiols. DIPEA = diisopropylethylamine; DMF = 
dimethylformamide. 
Compound 
Scale 
(mmol) 
Reaction 
medium 
Cyclisation 
conditions 
Outcome 
88 0.022 
On-resin 
in DMF 
Iodine (0.219 
mmol), DIPEA 
(2 eq.) 
Analysed by HPLC (40:60 
MeCN/H2O, isocratic) to show 
many peaks. LCMS (standard 
method) identified the expected ion 
520.8 m/z 
88 0.0044 
On-resin 
in DMF 
Thallium 
trifluoroacetate 
(0.0066 mmol) 
Analysed by HPLC (standard 
procedure) to show two prominent 
peaks amoung many impurities. 
92 0.0022 
On-resin 
in DMF 
Iodine (0.038 
mmol) 
Analysed by HPLC (standard 
method) to show multiple peaks. 
92 0.0022 
On-resin 
in DMF 
Iodine (0.017 
mmol) 
DIPEA (0.017 
mmol) 
Analysed by HPLC (standard 
method) to show multiple peaks. 
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In solution cyclisation 
FITC-Ahx-Cys(SH)-Ala-Arg-Ser-Lys-Asn-Lys-Asp-Cys(SH)-NH2 94 (16.2 mg, 0.022 mmol) 
was dissolved in a deaerated aqueous solution of ammonium bicarbonate (0.1M, 32.4 mL). 
The solution was wrapped in foil and stirred at RT for 1 hour. The reaction was tracked by 
HPLC using the general method described on page 342 and the reaction stopped by removal 
of solvent and salt in vacuo. The elutogram showed a single resonance after 10.05 minutes. 
Preparative HPLC of the peptide afforded a 6% yield (2.1 mg). Theoretical mass = 1523.6 
g/mol; [M+2H]+ = 763.3 m/z; 
Tryptase substrate prodrug 
ACC-different couplings 
Table 7-7. Unsuccessful reaction conditions to attempt to load Fmoc-ACA-OH onto 
resin. DIPC = diisopropylcarbodiimide; HOBt = hydroxybenzotriazole hydrate; DCM 
= dichloromethane; DMF = dimethylformamide; HBTU = N,N,N′,N′-Tetramethyl-O-
(1H-benzotriazol-1-yl)uronium hexafluorophosphate; DIPEA = 
diisoproylethylamine. 
Compound Scale Resin Reaction conditions Outcome 
103 0.0168 
mmol 
Rink amide 
AM (0.0084 
mmol) 
DIPC (0.0168 mmol), 
HOBt (0.0168 mmol) in 
DCM/DMF (7:3; 1 mL). 18 
hours total.533 
Kaiser test remained 
intense blue indicating 
no coupling. 
103 0.700 
mmol 
Rink amide 
AM (0.35 
mmol) 
HBTU (0.7 mmol) and 
DIPEA (1.4 mmol) in DMF 
(1.3 mL). 30 hours total. 
539 
Kaiser test remained 
intense blue indicating 
no coupling. 
103 0.071 
mmol 
104 (0.035 
mmol) 
HBTU (0.069 mmol, 
DIPEA (0.144 mmol), in 
DMF (1 mL). 72 hours 
total. 
Kaiser test remained 
intense blue indicating 
no coupling. 
 
FITC-Lys couplings 
 
Rink amide AM resin (401.0 mg, 0.281 mmol) was swollen and deprotected using standard 
procedures. Fmoc-Lys(mtt)-OH 106 (437.4 mg, 0.700 mmol), HBTU (265.4 mg, 0.700 mmol) 
and DIPEA (243.8 mg, 1.400 mmol) were dissolved in DMF (2.5 mL) and added to the resin. 
After 1 hour, the reagents were refreshed, including HOBt 29 (107.2 mg, 0.700 mmol). After a 
further 3 hours, the Kaiser test was performed revealing a faint purple solution indicating 
successful reaction coupling, affording resin-bound lysine 109. 
105 108 
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Fmoc-Lys(mtt)-Rink amide AM resin 109 (0.281 mmol) was swollen in DCM (3 mL) in an argon 
environment for 40 minutes. The solution was removed, and system purged by an argon 
balloon. A solution (5 mL) of TFA (0.7 mL), DCM (49 mL) and TIS 95 (2.5 mL) was added to 
the resin and stirred for 2 minutes before removing the solution by positive pressure of argon. 
This reaction was repeated 10 more times until no yellow colouration was created upon 
addition. Resin-bound lysine amine 107 was rinsed with DCM and dried in a desiccator 
overnight. 
 
Fmoc-Lys-Rink amide AM resin 107 (0.281 mmol) was swollen using the standard procedure. 
The system was purged with argon and a solution of FITC 75 (436.8 mg, 1.122 mmol) and 
DIPEA (78 μL, 0.448 mmol) in anhydrous DMF (8 mL) was added. The solution was wrapped 
in foil and left shaking for 4 hours. No colour produced with the Kaiser test indicated coupling 
was complete. FITC conjugate 108 was rinsed with DMF, DCM and 50% DCM/MeOH before 
drying under vacuum overnight. 
The following Lys(FITC)-terminated peptide substrates were synthesised in parallel by 
automated peptide synthesis. Fmoc-Lys(FITC)-bound Rink amide AM resin 108 was used to 
grow the peptides by using the reagents described in the table below. Each reaction vessel 
contained 0.056 mmol, by theoretical calculation (0.280 mmol of total Lys(FITC)-Resin split 
between 5 reaction vessels). Couplings were carried in duplicate and Fmoc groups were 
removed with 40% piperidine/DMF.  
Ac-Orn-Phe-Arg-Lys(FITC)-Resin 
Z-Gly-Pro-Arg-Lys(FITC)-Resin 
Ac-Lys-Pro-Arg-Lys(FITC)-Resin 
H-Ala-Ala-Pro-Ile-Arg-Asn-Lys-Lys(FITC)-Resin 
Suc-Phe-Pro-Phe-Lys(FITC)-Resin 
 
106 108 
107 
106 
74 
Materials and methods 
355 
  
Table 7-8. Quantities of each amino acid and coupling reagents required for the 
automated sysnthesis of tryptase substrates on resin using an automated spolid 
phase peptide synthesiser. Mol. Wt – molecular weight. DMF = dimethylformamide; 
NMP = N-methyl pyrrolidinone; DIPEA – diisopropylethylamine. 
Amino 
acid code 
Compound 
Mol wt 
(g/mol) 
Amount Solvent 
Total vol of 
solvent 
(mL) 
A Fmoc-Ala-OH 311.3 0.212 g DMF 3.75 
F Fmoc-Phe-OH 387.4 0.380 g DMF 5.31 
I Fmoc-Ile-OH 353.4 0.136 DMF 2.10 
K Fmoc-Lys(Boc)-OH 468.2 0.320 DMF 3.64 
N Fmoc-Asn(Trt)-OH 597.8 0.230 DMF 2.04 
P Fmoc-Pro-OH 337.4 0.419 DMF 6.79 
R Fmoc-Arg(Pbf)-OH 648.8 0.806 DMF 6.50 
Orn Fmoc-Orn(Boc)-OH 454.5 0.175 DMF 2.08 
G Z-Gly-OH 209.2 0.081 DMF 2.14 
 HBTU 379.3 2.378 DMF 35.72 
 DIPEA 129.3 2.13 mL NMP 15.77 
 Piperidine 85.15 19.60 DMF 29.40 
The programmed sequence finished with a deprotection reaction rendering the terminal 
amines free. Peptides H-Ala-Ala-Pro-Ile-Arg-Asn-Lys-Lys(FITC)-Resin and Z-Gly-Pro-Arg-
Lys(FITC)-Resin were rinsed, dried, cleaved and isolated using standard procedures, yielding 
75.1 mg and 50.9 mg, of modified peptide, respectively. The remaining peptides were left in 
their DMF swollen states for subsequent amine capping. 
A solution of acetic anhydride 150 (211.2 μL, 1.12 mmol) and DIPEA (390.2 μL, 2.24 mmol) in 
DMF (6 mL) was stirred together and split in two. The first portion was added to H-Orn-Phe-
Arg-Lys(FITC)-Resin and left to stir for 30 minutes and the reaction repeated. The Kaiser test 
returned negative, so the resin was rinsed, dried, cleaved and isolated using standard 
conditions, yielding 56.9 mg of isolated peptide. The second portion of acetic anhydride 
solution was added to H-Lys-Pro-Arg-Lys(FITC)-Resin and left to reaction for 30 minutes 
before repeating the reaction. The peptide was isolated using standard drying and resin 
removal procedures to yield 54.2 mg. 
Materials and methods 
356 
  
A solution of succinic anhydride (57.3 mg, 0.573 mmol), HOBt 29 (85.9 mg, 0.560 mmol) and 
DIPEA (97.5 μL, 0.560 mmol) in DMF (3 mL) was added to H-Phe-Pro-Phe-Lys(FITC)-Resin 
and left to react for 3 minutes. The reaction was repeated without addition of HOBt. The 
reaction was rinsed, dried, cleaved and isolated using standard procedure to yield 61.7mg of 
glassy residue. 
109) Ac-Orn-Phe-Arg-Lys(FITC)-OH 
110) Z-Gly-Pro-Arg-Lys(FITC)-OH 
111) Ac-Lys-Pro-Arg-Lys(FITC)-OH 
112) H-Ala-Ala-Pro-Ile-Arg-Asn-Lys-Lys(FITC)-OH 
113) Suc-Phe-Pro-Phe-Lys(FITC)-OH 
Off-resin reductive amination 
 
Reductive amination reactions were attempted between 2,4-dimethoxybenzaldehyde 124 
(DMB) and amine derivatives in solution with a variety of reducing agents (Table 7-9). 
Typically, the aldehyde and amine were stirred together, in the presence of base (or additive 
if used), for between 5 minutes – 3 hours before adding the reducing agent. 
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Table 7-9. Conditions used for reductive aminations. DMB = 2,4-
dimethoxybenzaldehyde; PMHS = polymethylhydrosiloxane; pABA = para-
aminobenzyl alcohol; STAB – sodium triacetoxyborohydride MeOH = methanol, 
NEt3 = triethylamine; EtOH = ethanol; THF = tetrahydrofuran; DCM = 
dichloromethane. Bold indicates successful reaction conditions. 
Aldehyde 
derivative 
Amine 
derivative 
Reducing 
agent 
Additives Solvent 
Reaction 
time 
Ref 
DMB (124) 
70.3 mg 
0.423 
mmol 
pABA (97) 
50.1 mg 
0.407 mmol 
Methyl 
pyridine 
borane (127) 
52.2 mg 
0.487 mmol 
- MeOH 
 
2 mL 
20 mins 520 
DMB (124) 
50.2 mg 
0.301 
mmol 
pABA (97) 
37.1 mg 
0.301 mmol 
NaBH4 (131) 
11.9 mg 
0.315 mmol 
Dowex 
172 mg 
0.301 
mmol 
THF 
 
1 mL 
15 mins 522 
DMB (124) 
50.2 mg 
0.301 
mmol 
pABA (97) 
37.6 mg 
0.305 mmol 
NaBH4 (131) 
12.2 mg 
0.322 mmol 
 
Dowex 
172 mg 
0.301 
mmol 
THF 
 
1 mL 
1 hour 522 
DMB (124) 
50.0 mg 
0.300 
mmol 
Phe-OEt 
(137) 
69.5 mg 
0.303 mmol 
STAB (132) 
89.3 mg 
0.421 mmol 
NEt3 
50.3 μL 
0.361 
mmol 
DCM 
 
1.5 mL 
20 
minutes 
521 
DMB (124) 
150.9 mg, 
0.908 
mmol 
β-Ala-OEt 
(135) 
138.4 mg, 
0.901 mmol 
 
STAB (132) 
381.3 mg, 
1.799 mmol 
NEt3 
150 μL 
1.805 
mmol 
DCM 
 
3 mL 
16 hours 521 
DMB (124) 
149.5 mg 
0.900 
mmol 
 
β-Ala-OEt 
(135) 
147.1 mg 
0.958 mmol 
STAB (132) 
307.0 mg 
1.448 mmol 
 
 - MeOH 
9 mL 
4 hours 521 
DMB (124) 
151.7 mg, 
0.913 
mmol 
β-Ala-OEt 
(135) 
147.1 mg, 
0.958 mmol 
 
STAB (132) 
307.2 mg, 
1.449 mmol 
NEt3 
133 μL 
0.957 
mmol 
MeOH 
 
9 mL 
16 hours 521 
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2,4-dimethoxybenzaldehyde 124 (DMB, 50.0 mg, 0.300 mmol), phenylalanine ethyl ester 137 
(69.5 mg, 0.303 mmol) and NEt3 (50.3 μL, 0.361 mmol) were dissolved in DCM (1.5 mL) and 
stirred for 2 hours. Heat activated 3Å molecular sieves were added and the solution stirred for 
a further 3 hours before sodium triacetoxyborohydride 132 (STAB, 89.3 mg, 0.421 mmol) was 
added. After 16 hours additional STAB (93.0 mg, 0.439 mg) was added and the reaction 
deemed complete after 4 hours by TLC (silica, 30 % ethyl acetate/hexane, UV and ninhydrin 
visualisation). Molecular sieves were removed by filtration and the filtrate solvent removed in 
vacuo. NaHCO3 (1M, 3 mL) was added to the residue and extracted with ethyl acetate (3 × 3 
mL). The combined organic layer was washed with brine, dried over Na2SO4 and the solvent 
removed in vacuo to yield product 138 (40.7 mg, 39% yield).  
1H NMR (500 MHz, CDCl3) δ H 7.18 (2 H, d, J 7.8), 7.08 (2 H, d, J 7.0), 6.96 (1 H, d, J 7.9), 
6.30 (2 H, dd, J 11.3, 2.3), 3.99 (2 H, q, J 7.1), 3.71 (3 H, s), 3.66 (1 H, d, J 13.3), 3.57 (3 H, 
s), 3.54 (1 H, d, J 13.3), 3.41 (1 H, t, J 7.2), 2.87 (2 H, t, J 7.3), 1.08 (3 H, t, J 7.1). Insufficient 
sample for 13C NMR analysis. 
 
DMB 124 (151.7 mg, 0.913 mmol), β-Ala-OEt 135 (147.1 mg, 0.958 mmol) and NEt3 (133 μL, 
0.957 mmol) were dissolved in MeOH (9 mL) in the presence of activated 3Å molecular sieves. 
The solution was stirred for 2.5 hours before adding STAB 132 (307.2 mg, 1.449 mmol) and 
further stirred for 16 hours. The reaction was monitored by TLC (silica, 50% MeOH/ethyl 
acetate, UV and ninhydrin visualisation). The solvent was removed in vacuo, and the residue 
dissolved in EA (10 mL) and 0.1M NaOH (10 mL). Product was extracted a further 2 times. 
Organic layers were combined and washed with brine, dried over Na2SO4 and concentrated 
in vacuo. Secondary amine (134) was afforded (113.3 mg, 47% yield).  
1H NMR (500 MHz, CDCl3) δ H 7.04 (1 H, d, J 8.1), 6.37 (1 H, d, J 2.2), 6.34 (1 H, dd, J 8.1, 
2.3), 4.04 (2 H, q, J 7.1), 3.72 (3 H, s), 3.71 (3 H, s), 3.64 (2 H, s), 2.77 (2 H, t, J 6.7), 2.43 (2 
H, t, J 6.6), 1.16 (3 H, t, J 7.1).  Insufficient sample for 13C NMR analysis. 
 
123 136 
137 
123 
134 133 
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Table 7-10. Unsuccessful reaction conditions used for the amidation between an 
Fmoc-Ala-OH and a secondary amine. DMF = dimethylformamide; DCM = 
dichloromethane; THF = tetrahydrofuran; HBTU =N,N,N′,N′-Tetramethyl-O-(1H-
benzotriazol-1-yl)uronium hexafluorophosphate ; DIPEA = diisoproylethylamine; 
HOBt = 1-Hydroxybenzotriazole hydrate; DCC = dicyclohexylcarbodiimide; DMAP 
= dimethylaminopyridine; NMM = N-methylmorpholine; TLC = thin layer 
chromatography. 
Secondary 
amine 
Scale Solvent Coupling conditions   Outcome 
138 
 
0.119 
mmol 
DMF  
(1.2 mL) 
HBTU (0.142 mmol), DIPEA 
(0.284 mmol), HOBt (0.074 
mmol). 72 hours total. 
No change in TLC. 
Only starting materials 
observed. 
134 0.424 
mmol 
DCM  
(5 mL) 
DCC (0.638 mmol), DMAP 
(0.044 mmol), 0 ᵒC. 16 hours 
total 
No change in TLC. 
Only starting materials 
observed. 
138 0.262 
mmol 
THF  
(1 mL) 
Fmoc-Ala-OH (0.218 mmol), 
and NMM (0.194 mmol) at  
-10ᵒC before 138 added. 
Refluxed for 16 hours. 
TLC indicated new 
product spot but when 
worked up appeared 
to be Fmoc-cleaved  
Ala-OH. 
 
 On resin reductive amination 
 
Typically, FMPB AM resin 123 was swollen in solvent for 1.5 hours before addition of H-
Arg(Pbf)-OMe.HCl 143 (10 equivalents) and base (10 equivalents) if used. The reaction was 
pre-reacted before addition of the reducing agent. Reaction was monitored by colorimetric p-
anisaldehyde test and acetaldehyde test. 
Table 7-11. Conditions employed for reductive amination of FMBP resin 123 by 
arginine (Pbf) methyl ester 143. STAB = sodium triacetoxyborohydride 132; DIPEA 
= diisopropylethylamine; DCE = dichloroethane; TMOF = trimethyl orthoformate; 
DMF = dimethylformamide; DCM = dichloromethane. 
Reducing 
agent 
Additive Solvent 
Pre-reaction 
time /mins 
Time 
/hours 
Reference 
STAB - DCE/TMOF (2:1) 240 16 534 
STAB DIPEA TMOF/DMF (2:1) 5 1.5 534 
STAB DIPEA TMOF/DMF (2:1) 240 16 534 
145 
122 
137 
142 143 
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STAB - DMF 240 2  
STAB DIPEA DCM 90 3 off-resin method 
In an argon environment, FMPB AM resin 123 (53 mg, 0.027 mmol) was swollen in anhydrous 
DMF for 1 hour. The solvent was removed by argon balloon and replaced with a 1% acetic 
acid/DMF solution (3 mL) of H-Arg(Pbf)-OMe 143 (130.8 mg, 0.274 mmol). The resin 
suspension was shaken for 3 hours before the addition of NaBH3CN 133 (18 mg, 0.280 mmol). 
The reaction was shaken for 16 hours. P-anidaldehyde test produced colourless beads 
suggesting aldehyde has been consumed. Secondary amide test using acetaldehyde returned 
beads orange indicating successful reductive amination. Secondary amine 144 was rinsed 
with DMF (9 mL), 10% DIPEA in DMF (9 mL) and DCM (9 mL). 
On resin amidation of secondary amine 
 
FMPB AM resin-Arg(Pbf)-OMe 144 (0.052 mmol) was swollen in DCM for 1 hour and replaced 
with a solution of HATU 117 (100 mg, 0.260 mmol), Fmoc-Pro-OH 147 (87.6 mg, 0.260 mmol) 
and DIPEA (90.6 μL, 0.520 mmol) in a solution of DMF/DCM (1:5, 3.5 mL) and left to react for 
16 hours. The reagents were refreshed and left to react for a further 20 hours. The resin 148 
was rinsed, dried and cleaved using standard procedures, excluding the precipitation step in 
diethyl ether and instead, the filtrate was diluted with acetic acid and lyophilised. The sample 
was analysed by LCMS using the method described on page 317; retention time = 3.56; peak 
area = 44%; Theoretical mass = 507 g/mol [M+H]+ found: 508 m/z 
147 
146 143 
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Table 7-12. Unsuccessful coupling of on-resin secondary amine to acid. HATU = 1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate; DIPEA = diisopropyl ethylamine; DIPC = 
Diisopropylcarbodiimide; DCM = dicloromethane; NMP = N-methylpyrrolidinone. 
Resin Conditions Outcome 
144  
(0.014 mmol) 
Fmoc-phe-OH (0.069 mmol), 
HATU (0.068), DIPEA (0.135 
mmol) in DMF (2 mL) for 1 hour 
and repeated. Total of 72 hours. 
Beads remained orange/brown 
with acetaldehyde test, 
indicating secondary amine did 
not undergo coupling. 
144  
(0.057 mmol) 
Fmoc-Phe-OH (0.285 mmol), 
DIPC (0.285 mmol) and DMAP 
(0.025 mmol) in DCM (5 mL). 
Repeated after 2 hours. Total of 
5 hours. 
Acetaldehyde test returned 
beads orange indicating 
unsuccessful coupling 
144  
(0.057 mmol) 
Fmoc-Phe-OH (0.285 mmol), 
DIPC (0.142 mmol) in DCM/NMP 
(95:5, 2 mL). 16 hours total. 570 
 
Acetaldehyde test returned 
beads positive indicating the 
secondary amine had not 
undergone coupling reaction 
 
FMPB AM resin-Arg(Pbf)-OMe 144 (0.0135 mmol) still swollen from previous reaction was 
rinsed with DCM (3 × 12 mL). A solution of Fmoc-Phe-OH 152 (26.6 mg, 0.069 mmol), DIPC 
(11 μL, 0.070 mmol) and DMAP 32 (17.1 mg, 0.140 mmol) in DCM (2 mL) was added to the 
resin. After 2 hours shaking the, acetaldehyde test returned colourless beads. Resin 153 was 
rinsed, dried and cleaved using standard condition. Dipeptide 154 was extracted in EA from 
water and analysed by LCMS; Retention time = 3.64; Peak Area = 32%, indicating partial 
reaction success but not complete. [M+H]+ found: 558 m/z. 
143 
151 
152 
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Phthalide ring opening for resin-immobilisation 
 
6-Nitrophthalide 158 (1.00 g, 5.581 mmol), β-alanine ethyl ester hydrochloride 135 (1.72 g, 
11.182 mmol) and NEt3 (1.6 mL, 11.165 mmol) were dissolved in ethanol (6 mL) and refluxed 
at 86 °C. The reaction was tracked by TLC (silica, 40% EA/hex, developed by UV and PMA) 
and after 3 hours the reaction was deemed complete. Solvent was removed in vacuo and the 
product extracted in DCM (3 × 30 mL) from acidified water (0.01M HCl, 50 mL). Combined 
organic layers were washed with brine, dried over Na2SO4 and concentrated in vacuo. 
Crystallisation was carried out by dissolving in the minimum amount of ethanol, heated with a 
heat gun, and the maximum amount of water before precipitation. After 16 hours crystals were 
washed with water, redissolved in methanol and concentrated in vacuo to afford ring opened 
amide 166 (1.00 g, 60% yield). Method for phthalide ring opening modified from reference:571 
1H NMR (500 MHz, MeOD) δ H 8.29 (2 H, d, J 8.0), 7.81 (1 H, d, J 8.3), 4.80 (2 H, s), 4.19 (2 
H, q, J 7.1), 3.67 (2 H, t, J 6.6), 2.71 (2 H, t, J 6.6), 1.29 (3 H, t, J 7.2); 13C NMR (126 MHz, 
MeOD) δ C 173.49 (s), 169.62 (s), 148.66 (s), 148.04 (s), 136.94 (s), 130.15 (s), 126.00 (s), 
123.65 (s), 62.53 (s), 61.97 (s), 37.10 (s), 34.87 (s), 14.70 (s). 
 
Wang resin (1.00 g, 1.142 mmol) was swollen in DCM for 1.5 hours and rinsed with DMF (4 x 
4 mL). A solution of Fmoc-Ala-OH 146 (889.0 mg, 2.855 mmol), HBTU (1.08 g, 2.855 mmol), 
HOBt 29 (437.1 mg, 2.855 mmol) and DIPEA (994.4 µL, 5.709 mmol) in DMF (8 mL) was 
added to the resin and shaken for 16 hours. After which, the resin was rinsed with DMF and 
fresh reagents were added. After 4 hours, a few beads were taken, and Fmoc-deprotected 
using a standard procedure. The Kaiser test revealed an intense blue solution and beads. The 
remaining resin 161 was washed with DMF (15 mL), DCM (15 mL) and 50% DCM/MeOH (15 
mL) and dried under vacuum. 
157 134 165 
145 
160 
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Fmoc-Ala-Wang resin 161 (230.9 mg, 0.175 mmol) was swollen in N-Methyl-2- pyrrolidinone 
(NMP) for 16 hours and rinsed with DMF. The resin was Fmoc-deprotected using standard 
procedure and once confirmed by Kaiser test was rinsed with NMP. After transferal into a 50 
mL RBF, a solution of 6-nitrophthalide 158 (63.0 mg, 0.352 mmol) in NMP (15 mL) was added. 
The suspension was refluxed at 124 °C without stirring for 7 hours then stirred at RT for 16 
hours. After a positive Kaiser test, NEt3 (12.2 µL, 0.088 mmol) was added and the suspension 
refluxed for a further 7 hours. After 48 hours of sitting at RT, the suspension refluxed for a 
further 8 hours at higher temperature, 142 °C. Kaiser test indicated synthesis of 162 
successful. Resin washed with DMF (10 mL), DCM (10 mL) and 50% DCM/MeOH (10 mL) 
and dried in vacuum desiccator. 
 
In an argon purged RBF, Fmoc-Lys(Boc)-OH 169 (250.3 mg, 0.534 mmol), HATU 117 (197.3 
mg, 0.519 mmol) and DIPEA (163.4 µL, 0.938 mmol) were stirred together in DMF (5 mL). 
After 40 minutes a catalytic amount of DMAP 32 (3 mg) was added, followed by 6-
aminophthalide 163 (70.1 mg, 0.470 mmol) and left to stir at RT for 18 hours. TLC (silica, 100% 
EA, developed by UV and ninhydrin) was used to track reaction progress which showed 
consumption of starting materials and presence of a new product. The solution was diluted in 
acidified water (50 mL) and extracted with EA (3 × 25 mL). Combined organic layers were 
washed with brine, dried over Na2SO4 and concentrated in vacuo to afford a cream powder. 
Purification was carried out by column chromatography (silica, 40 g), and using a solvent 
gradient EA/hex (10-60%). The column was loaded using dry loading technique, dissolving 
sample in minimum tetrahydrofuran (THF) adding silica and drying then in vacuo. 168 was 
afforded as a cream powder (163.8 mg, 58% yield). 
1H NMR (500 MHz, DMSO) δ H 10.41 (1 H, s), 8.24 (1 H, s), 7.90 (2 H, d, J 7.6), 7.83 (1 H, d, 
J 8.3), 7.74 (3 H, dd, J 13.1, 7.2), 7.62 (1 H, d, J 8.3), 7.42 (2 H, t, J 7.5), 7.33 (2 H, t, J 9.1), 
6.79 (1 H, t, J 5.7), 5.37 (2 H, s), 4.29 (2 H, d, J 6.9), 4.24 (1 H, d, J 6.7), 4.13 (1 H, dd, J 14.5, 
8.6), 2.96 – 2.83 (2 H, m), 1.67 (2 H, d, J 32.7), 1.39 (3 H, s), 1.35 (11 H, s), 1.28 (2 H, d, J 
19.9). 13C NMR (126 MHz, DMSO) δ c 171.70 (s), 170.57 (s), 156.12 (s), 155.54 (s), 143.79 
(d, J 8.0), 141.80 (s), 140.69 (s), 139.61 – 139.50 (m), 127.61 (s), 127.03 (s), 125.36 (d, J 
157 160 161 
168 162 167 
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16.9), 123.34 (s), 120.09 (d, J 2.3), 114.17 (s), 77.30 (s), 69.77 (s), 65.63 (s), 55.48 (s), 46.62 
(s), 31.34 (s), 29.20 (s), 28.22 (s), 22.95 (s). 
 
Table 7-13. Unsuccessful reaction conditions for the opening of amide-phthalide 
168. NEt3 = triethylamine; DCM = dichloromethane; N-methylpyrrolidinone; RT = 
room temperature; AlCl3 = aluminium trichloride; DCE = dichloroethane; TLC = thin 
layer chromatography. 
Nucleophile Scale  Conditions Outcome 
NH2-Ala-
Wang resin 
161 
0.116 
mmol 
Lysine-phthalide (0.232 mmol), 
NEt3 (0.127 mmol) in DCM at 40 ᵒC 
for 16 hours 
Kaiser test produced 
intense blue colour indicting 
unsuccessful coupling. 
NH2-Ala-
Wang resin 
161 
 
0.038 
mmol 
Lysine phthalide (0.057 mmol) in 
NMP (1 mL), refluxed at 123 ᵒC, for 
6 hours then left at RT for 16 hours. 
(heating repeated for 2 days. 
Kaiser test turned intense 
blue indicating no coupling. 
Tyramine 
171  
0.083 
mmol 
AlCl3 (0.108 mmol) in DCE at 0ᵒC 
added, followed by lysine-phthalide 
(0.033 mmol) in DMF (2.5 mL). 18 
hours.572 
TLC showed no change in 
Rf values 
Lithium 
hydroxide 
0.043 
mmol 
Mixed with lysine phthalide (0.025 
mmol) in THF/water/methanol 
(4:1:1, 4 mL). Left at RT for 6 hours 
and refluxed at 60ᵒC for 2 hours. 
Solution turned from clear 
to yellow but only starting 
materials observed by TLC. 
 
 
 
Resin-bound nitrobenzyl alcohol 162 (50.0 mg, 0.046 mmol) was swollen in DCM, rinsed and 
suspended in fresh DCM (3600 µL). A solution of 0.5 M Na2O4S2 (87.1 mg) and K2CO3 (69.1 
mg) in water (1 mL) was made and 400 µL added to the resin. Tetrabutylammonium iodide 
(<1 mg) was added and the suspension shaken for 16 hours. After which, the resin was rinsed 
with DCM then DMF. A solution of Fmoc-Arg(Pbf)-OH (149.4 mg, 0.230 mmol), HATU 117 
(87.5 mg, 0.230 mmol) and DIPEA (80.1 µL, 0.460 mmol) in DMF (3 mL) was added to the 
resin. After 18 hours, reagents were refreshed and left for a further 3 hours. A sample was 
taken and Fmoc-deprotected using standard procedure. The Kaiser test revealed an intense 
blue colour to the solution and beads. A repeat of the reaction in the presence of the acetylated 
benzyl alcohol did not produce the result, suggesting the original Kaiser result described here 
was a false positive. The resin was rinsed and dried in a vacuum desiccator. On-resin 
reduction was conducted following a previously reported method, exchanging the phase 
163 161 
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transfer catalyst:538 The conjugation of the aniline formed was conducted following a previous 
method reported for aniline amidation.514 
 
Resin-bound nitrobenzyl alcohol 162 was swollen in DCM for 16 hours and rinsed with DMF. 
Acetic anhdrydride 150 (14.5 µL, 0.152 mmol) in DMF (1.5 mL) was added to the resin followed 
by pyridine (12 µL, 0.151 mmol). The solution was left for 30 minutes and rinsed with DMF 
then DCM, before carrying on to the reduction step.  
 
Sodium dithionite and potassium carbonate solution, made at a previous step (200 µL) was 
added to acetylated nitro resin 174 in DCM (1800 µL) followed by a catalytic amount of 
tetrabutylammonium iodide (<1 mg). The biphasic solution was shaken for 16 hours and 
reagents refreshed, shaken for a further 18 hours and rinsed with DMF. A solution of Fmoc-
Ala-OH 146 (9.6 mg, 0.031 mmol), HATU 117 (11.8 mg, 0.031 mmol) and DIPEA (10.8 µL, 
0.062 mmol) in DMF (2 mL) was added and the suspension shaken for 18 hours. Reagents 
were refreshed and left for a further 20 hours. A sample was taken, rinsed and Fmoc-
deprotected using a standard procedure. The Kaiser test revealed a pale purple colour of the 
beads and solution.  
 
Resin-bound nitrobenzyl alcohol 162 (50.0 mg, 0.046 mmol) was swollen in DCM and rinsed 
before suspended in anhydrous DCM (2 mL) in an argon environment. A solution of trityl 
chloride 176 (64.3 mg, 0.231 mmol), triethylamine (51.3 µL, 0.368 mmol) and a catalytic 
161 
174 
175 
173 161 
149 
173 
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amount of DMAP 32 (<1 mg) in anhydrous DCM (1 mL) was added. The suspension was 
shaken for 18 hours. A sample of beads were treated and assessed by the TosCl-PNBP test, 
but the orange colour of the beads made the presence of a purple colour to the bead difficult 
to judge. Instead, a sample of resin was taken and rinsed with DMF then DCM. Beads were 
then transferred to a soda tube and a few drops of 1% TFA/DCM solution added. An intense 
yellow colour was seen immediately indicating the release of trityl groups. Addition of the trityl-
scavenging compound, TIS 95 (2-3 drops) removed the yellow. Remaining tritylated resin 177 
was rinsed in DMF, DCM and 50% DCM/MeOH and dried in a vacuum desiccator. Tritylation 
was previously reported.573,574 
 
Resin 175 (0.142 mmol) was swollen in DCM and rinsed before addition of fresh DCM (1800 
μL), an aqueous solution of 0.5 M potassium carbonate and sodium thiosulfate (200 μL) and 
tetra-n-butyl ammonium iodide (6.3 mg, 0.017 mmol).538 The reaction mixture was shaken for 
3 days before the reaction progression was checked. The Kaiser test was employed but did 
not show any purple tint. The resin was washed with DCM and DMF. A sample of resin was 
removed and to it, a solution of Fmoc-Phe-OH 152 (278 mg, 0.716 mmol), HATU 117 (271 
mg, 0.713 mmol) and DMAP 32 (170.2 mg, 1.393 mmol) in DMF (1.5 mL) was added. 
Reagents were refreshed after 3 hours and shaken for a further 3 hours. A sample of resin 
was taken, deprotected using the standard procedure and analysed by the Kaiser test. The 
beads returned intense blue. Upon treatment of a second conjugated-resin sample with 1% 
TFA in DCM a yellow solution was observed The Fmoc-deprotected conjugated resin 178 was 
then dried for 24 hours under vacuum 
 
The Fmoc-deprotected Phe-conjugated resin 178 removed by treatment with a solution of 
hexafluoro-2-propanol (HFIP, 80 μL), TIS 95 (50 μL), dichloromethane (200 μL) and conc. HCl 
(2 drops) for 1.5 hours.546 After which, resin filtered off and washed with DCM. Filtrate 
174 176 177 
177 178 
Materials and methods 
367 
  
collected, and solvent removed by rotary evaporation.1H NMR (500 MHz, DMSO) δ H 13.49 (1 
H, s), 8.62 (1 H, d, J 2.1), 8.59 (2 H, d, J 2.5), 8.57 (2 H, d, J 2.5), 8.53 (1 H, d, J 1.8), 8.50 (1 
H, d, J 2.2), 8.44 (1 H, dd, J 8.7, 2.5), 8.34 (1 H, dd, J 8.4, 2.1), 8.30 (2 H, dd, J 8.4, 2.5), 8.02 
(1 H, d, J 8.6), 7.98 (1 H, d, J 8.6), 7.63 (2 H, d, J 8.5), 7.45 – 7.34 (1 H, m), 5.58 (1 H, s), 4.95 
(2 H, s), 4.71 (1 H, s), 4.10 (1 H, d, J 7.1), 3.53 – 3.46 (1 H, m), 3.46 – 3.40 (2 H, m), 3.39 (2 
H, s), 2.66 (7 H, s), 1.29 (10 H, dd, J 41.7, 21.7). 
 
Table 7-14. Unsuccessful reaction conditions employed to attempt to form an amide 
between the alanine of p-amino benzyl alcohol 97 and the acid of 
Fluorenylmethyloxycarbonyl (Fmoc) and tertiary-butyloxy carbonyl (boc) protected 
lysine 119. ECDI = N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride; 
HBTU = 3-[Bis(dimethylamino)methyliumyl]-3H-benzotriazol-1-oxide 
hexafluorophosphate; HOBT.H2O = hydroxybenzotriazole hydrate; NEt3 = 
triethylamine; DMF = dimethylformamide. 
118 96 117 
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In a RBF (5 mL), purged with argon, Fmoc-Lysine(Boc)-OH 119 (209.4 mg, 0.447 mmol), 
HATU 117 (169.8 mg, 0.447 mmol) and DIPEA (77.8 μL, 0.447 mmol) were dissolved in 
anhydrous DMF (1.8 mL). The solution turned pale yellow and a solution of p-
aminobenzylalcohol 97 (50.4 mg, 0.409 mmol) in DMF (0.7 mL) was added. The reaction was 
left to stir for 18 hours and the reaction tracked by TLC (silica, 100% ethyl acetate, visualised 
by UV and ninhydrin). An absence of red-staining from p-aminobenzylalcohol was noted 
together with the presence of an additional product spot (Rf = 0.51) which stained brown with 
excessive heating. The reaction mixture was diluted with acidified water (0.1M HCl, 10 mL) 
and extracted with excess ethyl acetate (3 × 8 mL). Organic layers were combined, washed 
with brine (10 mL), dried over Na2SO4 and the solvent removed in vacuo and then under 
vacuum. A crude yellow powder was afforded (352.2 mg, >100% yield). Fmoc-Lys(Boc)-OH 
present determined by 1H NMR (10%). 
1H NMR (500 MHz, DMSO) δ H 9.98 (1 H, s), 8.77 (1 H, dd, J 4.3, 1.1), 8.54 (1 H, dd, J 8.4, 
1.2), 7.96 (1 H, s), 7.90 (2 H, d, J 7.5), 7.77 – 7.71 (2 H, m), 7.63 (1 H, d, J 8.0), 7.57 – 7.49 
(2 H, m), 7.43 (2 H, t, J 7.3), 7.34 (2 H, dd, J 12.7, 6.9), 7.24 (2 H, d, J 8.4), 6.80 (1 H, t, J 5.4), 
5.11 (1 H, t, J 5.6), 4.44 (2 H, d, J 5.2), 4.32 – 4.26 (2 H, m), 4.26 – 4.19 (1 H, m), 4.16 – 4.07 
(1 H, m), 2.96 – 2.85 (4 H, m), 1.74 – 1.56 (2 H, m), 1.37 (12 H, d, J 4.4), 1.26 (2 H, dd, J 14.2, 
7.0). 
 
Into an argon purged 5 mL RBF charged with (9H-fluoren-9-yl)methyl tert-butyl (6-((4-
(hydroxymethyl)phenyl)amino)-6-oxohexane-1,5-diyl)dicarbamate 118 (50.2 mg, 0.087 
mmol), was added a solution of phenoxyacetic acid 22 (12.1 mg, 0.079 mmol), DIPEA (27.6 
μL, 0.159 mmol) and HBTU (33.4 mg, 0.088 mmol) in DMF (1 mL). The reaction was left for 5 
days and monitored by TLC (silica, 80% ethyl acetate/hexane, visualised by UV and PMA). 
The solution diluted with HCl acid (0.1M, 8 mL) and extracted with ethyl acetate (3 mL × 6 mL). 
Organic layers were combined, washed with saturated sodium bicarbonate solution (8 mL) 
then brine (8 mL), dried over Na2SO4 and solvent removed in vacuo. Crude product 120 (17.8 
mg, 32% yield).  
Coupling agent Additive Solvent Scale Reference 
EDCI HOBt.H2O DMF 74 mg 575 
EDCI HOBt.H2O DMF 100 mg 575 
HBTU NEt3 DMF 209 mg 576 
117 119 21 
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1H NMR (500 MHz, CDCl3) δ H 8.53 (1 H, s), 7.67 (3 H, d, J 7.4), 7.47 (5 H, dd, J 17.5, 7.2), 
7.30 (3 H, t, J 7.3), 7.27 – 7.13 (8 H, m), 6.91 (1 H, t, J 7.4), 6.81 (2 H, d, J 7.9), 5.63 (1 H, s), 
5.10 (2 H, s), 4.62 (1 H, s), 4.57 (2 H, s), 4.34 (2 H, d, J 6.3), 4.23 (1 H, s), 4.12 (1 H, t, J 6.8), 
3.08 (1 H, d, J 5.6), 3.05 – 2.95 (2 H, m), 1.89 (1 H, s), 1.65 (1 H, s), 1.45 (2 H, s), 1.36 (15 H, 
s), 1.20 (3 H, d, J 14.5). 
HFIP resin cleavage investigation. 
Ester-protecting conditions for the cleavage of peptide resin from resin were investigated. 
Lysine-benzyl-phenoxy ester 120 was used as a test model and was subjected to several resin 
cleavage methods to ascertain which would retain the ester bond. 
Table 7-15. Resin and protecting group cleavage cocktails for 
testing stability of ester. TFA = trifluoroacetic acid; TIS = 
triisopropylsilane; DCM = dichloromethane; HCl = 
hydrochloric acid; HFIP = hexafluoroisopropanol, 1H NMR = 
proton nuclear magnetic resonance. 
Cleavage cocktail Time Reference 
TFA 2 hours 544 
TFA/TIS/H2O (95:2.5:2.5) 2 hours 544 
1% TFA / DCM 2 hours 545 
0.1 N HCl / HFIP / DCM (20%) 1.5 hours 546 
In all cases, a sample of model conjugate 120 (~20 mg, 28 μmol) was dissolved into 
corresponding cleavage cocktail (1 mL) and left stirring for the time recommended for resin 
cleavage (Table 7-15). At the designated time point, TFA was removed in vacuo and the 
solution redissolved in deuterated chloroform (CDCl3) and analysed by 1H NMR without work 
up.  
 
Cell Culture 
Human umbilical vein endothelial cells (HUVECs) cells were thawed at 37 ᵒC and grown from 
frozen in Endothelial growth medium kit (EGM; Cat. No. C-22110; PromoCell Gmbh; 
Heidelberg, Germany). The media contained; fetal calf serum (0.02 ml/mL, Endothelial cell 
growth supplement (4 μL/mL), recombinant human epidermal growth factor (0.1 ng/mL), 
recombinant human basic fibroblast growth factor (1ng/mL), heparin (90 μg/mL) and 
hydrocorticone 1μg/mL. Cells were incubated at 37 ᵒC in a humidified environment with 5% 
CO2 for 24 hours to allow cells to adhere to the flask. Afterwhich, media was replaced every 
2-3 days until cells reached 80% confluency. 
Binding Assay 
Once confluency was reached, cells were split for further subculture. Media was removed by 
vacuum and cells were washed with 12 mL of warm calcium and magnesium free phosphate 
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buffered saline solution (PBS; Cat No. 10010-015; Thermo Fisher) and then removed. 5 mL 
of warm 0.05% trypsin-EDTA (Cat. No. 25300054; Invitrogen) was added to lift adherence 
cells from the flask bottom by incubating the flask at 37 ˚C and 5% CO2 for 1-2 mins. Once 
cells had become detached, growth medium (10 mL) was added to neutralise the trypsin and 
the cell suspension pipetted into a 50 mL falcon tube and centrifuged at 180 × g (Centrifuge 
5804 R; Eppendorf; Hamburg, Germany), 21 ˚C for 5 minutes. The supernatant was removed 
by vacuum and the cell pellet re-suspended in fresh growth medium (4 mL). Once a 
homogeneous suspension of cells was obtained, cells counted were counted using an ADAM 
Automated Cell Counter (Digital Bio; Seoul, Korea), as previously described  
Cells were seeded onto 8-well chamber slides at 10,000 cells per slide in 1 mL of media. The 
cells were grown to 70% confluency in approximately 24 hours. FITC-CAR (1.5 mg, 0.98 μmol) 
was dissolved in sterile water (0.98 mL) and vortexed to dissolve. FITC-CAR solution (1 mM) 
was stored at -80 ᵒC until required. Two solutions were made; 
Non-inflammatory control: FITC-CAR (20 μL) in endothelial cell media (1980 μL) to 
achieve a final concentration of 10 μM 
Pro-inflammatory test solution: FITC-CAR (20 μL) in endothelial cell media (1980 μL) 
with the addition of tumour necrosis factor alpha (TNF- α, 10 µg/mL, 2 µL) with final 
concentration 10 ng/mL. 
When cells were deemed confluent, media was removed and replaced with either of the above 
solutions (1 mL). Lower dilutions were carried out by 1 in 10 dilutions of original solutions in 
EC media. All reactions were run in duplicate.  
The cells were treated for 24 hours, after which the media was removed, and the cells washed 
with PBS solution. After drying, cells were treated with 4% paraformaldehyde (PFA, 500 µL, 
Sigma Aldrich) for 20 minutes and washed with PBS (3x 1mL). The chamber walls were 
removed to leave the fixed cells on a glass slide. A solution of 4',6-diamidino-2-phenylindole 
(DAPI) was added to the cells to stain the nuclei and after 3-4 minutes of air drying, a cover 
slip was placed on the cells and sealed with nail varnish. Cells were stored at -20 °C until 
analysis Fluorescence was visualised within 48 hours of cell fixing, using a confocal 
microscope (Leica TCS SPE; Wetzlar, Germany). Following previous studies, excitation and 
emission wavelengths of 525 nm and 495 nm were used for fluorescein, and 358 nm and 461 
nm were used for DAPI.452  
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 Appendix 
 Meta-Analysis 
Table 8-1. Adverse events associated with treprostinil 
AE Overall OR 
p-
value 
No. 
studies 
Oral Inhaled IV SC 
Any event 
10.3 
(1.1-92.8) 
51%, 0.128 
0.038 3 
26.2 
5.1, 
135.4 
0%,  
 
- 
0.7 
0.1, 
17.7 
- 
 
- 
Site pain 
8.7 
1.6, 45.9 
79%, 0.003 
0.011 4 
 
- 
 
- 
0.7 
0.2, 
3.6 
- 
17.5 
11.1, 27.4 
0% 
Flushing 
4.4 
2.7, 7.1 
30% 0.222 
< 
0.0001 
5 
4.6 
3.2, 6.6 
0% 
20.6 
2.7, 157.9 
- 
 
- 
1.3 
0.2, 7.4 
- 
Jaw Pain 
4.0 
2.9, 5.6 
0%, 0.421 
< 
0.0001 
7 
4.9  
3.3, 7.4 
0% 
1.3 
0.4, 4.3 
- 
11.0 
0.6, 
204.7 
- 
3.1 
1.6, 6.2 
0% 
Headache 
3.3 
1.6-6.8 
88%, 0.0001 
0.001 7 
6.5 
3.4, 
12.4 
77% 
 
- 
6.0 
1.1, 
31.5 
- 
1.5 
0.8, 2.8 
59% 
Pain in 
extremity 
3.3 
2.2, 4.9 
0%, 0.412 
< 
0.0001 
5 
3.1 
2.0, 4.8 
7% 
 
- 
13.0 
1.5, 
112.3 
- 
1.9 
0.2, 22.2 
- 
Diarrhoea 
2.7 
1.9, 3.9 
47%, 0.079 
< 
0.0001 
7 
3.6 
2.7, 4.9 
0% 
1.3 
0.5, 3.3 
- 
6.5 
0.4, 
57.0 
- 
1.8 
1.2, 2.9 
0% 
Vomiting 
2.6 
1.1, 6.1 
79%, 0.0001 
0.024 7 
2.9 
0.9, 9.5 
90% 
 
- 
6.0 
1.1, 
31.5 
- 
1.2 
0.5, 3.1 
12% 
Peripheral 
Oedema 
2.1 
1.2, 3.8 
18%, 0.297 
0.013 3 
1.6 
0.8, 3.0 
0% 
 
- 
 
- 
3.8 
1.5, 9.6 
- 
Nausea 
2.0 
1.3, 3.0 
63%, 0.012 
0.002 7 
3.0 
2.2, 4.0 
8% 
2.0 
0.9, 4.1 
- 
1.1 
0.3, 
4.3 
- 
0.8 
0.2, 3.7 
65% 
Dizziness 
1.2 
0.9, 1.6 
0%, 0.625 
0.172 7 
1.3 
0.7, 2.2 
53% 
1.2 
0.6, 2.4 
- 
1.1 
0.2, 
5.2 
1.1 
0.6, 2.1 
0% 
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- 
Upper 
respiratory 
tract 
infection 
1.0 
0.6, 1.7 
0%, 0.486 
0.923 4 
1.1 
0.6, 2.1 
0% 
0.7 
0.3, 1.7 
- 
 
- 
3.9 
0.4, 41.3 
- 
Insomnia 
2.4 
0.8, 7.4 
0%, 0.919 
0.131 3 
3.0 
0.6, 2.1 
0% 
 
- 
2.0 
0.2, 
19.8 
- 
1.7 
0.2, 19.4 
- 
Abdominal 
pain 
1.2 
0.6, 2.4 
0%, 0.693 
0.579 3 
1.3 
0.6, 
13.6 
- 
 
- 
 
- 
0.5 
0.1, 10.0 
- 
Arthalgia 
1.7 
0.9, 3.4 
0%, 0.628 
0.129 3 
1.7 
0.9, 
3.4,  
0% 
 
- 
 
- 
 
- 
Fatigue 
1.3 
0.9, 1.9 
0%, 0.726 
0.159 4 
1.5 
1.0, 2.2 
0% 
0.9 
0.4, 2.1 
- 
 
- 
 
- 
Palpitations 
0.7 
0.2, 2.4 
72%, 0.028 
0.595 3 
1.0 
0.2, 4.2 
79% 
0.3 
0.1, 1.4 
- 
 
- 
 
- 
Chest pain 
1.0 
0.5, 2.0 
3%, 0.357 
0.948 3 
0.9 
0.4, 2.2 
- 
0.9 
0.5, 6.6 
- 
0.4 
0.1, 
2.3 
- 
 
- 
Dyspnoea 
1.1 
0.5, 2.5 
59%, 0.046 
0.830 5 
1.1 
0.2, 6.9 
87% 
0.7 
0.3, 1.7 
- 
1.8 
0.3, 
10.2 
- 
1.2 
0.1, 15.3 
- 
Cough 
1.5 
0.6, 3.9 
68%, 0.042 
0.372 3 
0.8 
0.3, 1.9 
- 
2.8 
1.7, 4.9 
1.3 
0.3, 
6.0 
- 
 
- 
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 Treprostinil Synthesis 
 
Synthesis of Chiral benzylalkynol 
 
Alkyne coupling with aldehyde in the presence of (+)-N-Methylephridrine: A solution of N-
methylephedrine (1.06 g 5.94 mmol) in anhydrous toluene (7.5 mL) and triethylamine (0.83 
mL, 5.94 mmol) were added to a flask charged with dried zinc triflate (2.19 g, 5.94 mmol) and 
the solution was left stirring at RT under argon for 80 minutes. A solution of anhydrous (S)-1-
decyn-O-tetrahydropyran-2-yl-1-ol 181 (1.42 g, 5.94 mmol) in anhydrous toluene (1.25 mL) 
was added to the orange solution and after a further 25 minutes, 3-benzyl-2-allyl benzaldehyde 
180 (0.5062 g, 1.98 mmol) dissolved in toluene (1.25 mL) was also added. After 21.5 hrs, the 
reaction was monitored by TLC (ethyl acetate/Hexane 1:4) and quenched by addition of water 
(7 mL). Ethyl acetate (5 mL) was added and the two layers separated. The aqueous layer was 
extracted with ethyl acetate and the organic layer washed with brine (5 mL) and saturated 
ammonium chloride solution (2 × 5 mL). The organic layers were combined, dried over Na2SO4 
and the solvent removed in vacuo to yield a dark orange viscous liquid. The crude product was 
chromatographed on silica gel column using a gradient of ethyl acetate in hexane (2-10%) to 
yield an orange viscous liquid 182 (0.53 g, 55% yield). 1H NMR (300 MHz, CDCl3) 7.41-7.38 
(m, 6H), 7.26 (s, 1H), 6.91 (d, 1H), 6.07-5.98 (m, 1H), 5.64 (d, 1H), 5.08 (s, 2H), 5.00 (d, 2H), 
3.89-3.88 (m, 1H), 3.72-3.67 (m, 3H), 3.48-3.44 (m, 1H), 2.40 (q, 2H), 2.29 (t, 1H), 1.77-1.26 
(m, 17H), 0.88 (t, 3H); 13C NMR (300 MHz, CDCl3) 156.8, 140.9, 137.1, 128.6, 127.9, 127.4, 
127.2, 119.6, 115.0, 112.0, 98.0, 97.3, 75.4, 70.3, 62.9, 62.2, 35.3, 34.0, 33.5, 32.1, 31.2, 
29.8, 25.6, 24.8, 22.7, 20.0, 15.6, 15.0, 14.2; IR 3401.3 (O-H), 2930.1 (C-H), 2858.6 (C-H), 
1584.1 (C=C). Purity was determined by HPLC analysis (98% de). 
Alkyne coupling with aldehyde in the presence of (1S, 2S)-3-(t-butyldimethylsilyloxy)-2-
N,N-dimethylamino-1-(p-nitrophenyl)propan-1-ol: To a solution of dry zinc triflate (10.8 g, 
29.73 mmol) in anhydrous THF (20 mL) under argon at 30 °C was added a solution of (1S, 
2S)-3-(t-butyldimethylsilyloxy)-2-N,N-dimethylamino-1-(p-nitrophenyl)propan-1-ol (10.55 g, 
29.73 mmol) in THF (10 mL), then triethylamine (4.14 mL, 2.73 mmol). (S)-1-decyn-O-
tetrahydropyran-2-yl-1-ol 181 (7.10 g, 29.73 mmol) were added and the heat reduced to RT. 
Then 3-benzyl-2-allyl benzaldehyde 180 (0.51 g, 1.98 mmol) was added and the reaction 
stirred at RT for 44 hours and monitored by TLC (ethyl acetate/hexanes 1:4). The solution was 
quenched by addition of saturated ammonium chloride solution (20 mL) and the product was 
extracted with ethyl acetate (4 × 40 mL) until colourless. The combined organic layers were 
179 180 181 
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washed with H20 (2 × 30mL) and brine (12 mL), dried over Na2SO4 and the solvent removed 
in vacuo. The crude product was chromatographed by silica gel column using a gradient of 
ethyl acetate and hexanes (2-10%) to yield an orange viscous liquid 182 (4.98 g, 51.3%). 1H 
NMR (300 MHz, CDCl3) 7.46-7.27 (m, 5H), 7.22 (td, 1H), 6.91 (d, 1H), 6.10-5.94 (m, 1H), 5.64 
(d, 1H), 5.08 (s, 2H), 5.4-4.9 (m, 2H), 4.69-4.62 (m, 1H), 3.94-3.88 (m, 1H), 3.78-3.54 (m, 3H), 
3.52-3.40 (m, 1H), 2.46 (m, 3H), 1.86-1.63 (m, 4H), 1.63-1.40 (m, 5H),1.40-1.18 (m, 6H), 0.87 
(t, 3H); 13C NMR (300 MHz, CDCl3) 156.8, 140.9, 137.4, 137.1, 128.6, 127.9, 127.4, 127.2, 
119.5, 115.0, 112.0, 98.0, 97.3, 87.5, 87.1, 75.9, 75.4, 70.3, 62.8, 62.2, 35.0, 34.0, 33.5, 32.5, 
32.1, 31.2, 29.8, 25.6, 25.4, 24.8, 22.7, 20.0, 15.6, 15.0, 14.2; IR 3391 (O-H), 2930 (C-H), 
2859 (C-H); Purity was determined by HPLC (96% de). 
Synthesis of racemic benzylalkynol 
 
Racemic alkyne coupling with aldehyde: Ethylmagnesium bromide (19.8 mL, 19.8 mmol) 
was added drop-wise to a stirring solution of (S)-1-decyn-O-tetrahydropyran-2-yl-1-ol 181 
(5.00 g, 20.79 mmol) in anhydrous THF (20 mL) under argon and stirred for 90 minutes. The 
reaction was cooled to 0-10 °C and a solution of 3-benzyloxy-2-allyl benzaldehyde 180 (5.00 
g, 19.8 mmol) in anhydrous THF (15 mL) was added drop-wise over 30 minutes. The reaction 
was monitored by TLC (ethyl acetate/hexane 1:4) and after 29 hours the reaction quenched 
by addition of saturated ammonium chloride (2 mL) to form granules and stirred for 10 minutes. 
The precipitate was filtered, the filtrate dried over Na2SO4 and the solvent removed in vacuo. 
The crude product was chromatographed by silica gel column to yield racemic benzyl alkynol 
183 (6.99 g, 72%). 1H NMR (300 MHz, CDCl3) δH 7.43-7.27 (m, 7H), 7.25-7.16 (td, 2H), 6.90 
(d, 1H), 6.10-5.93 (m, 1H), 5.64 (d, 1H), 5.07 (s, 2H), 5.04-4.9 (m, 2H), 4.73-4.59 (m, 1H), 
3.96-3.81 (m, 1H), 3.80-3.62 (m 3H), 3.61-3.54 (m, 1H), 3.54-3.39 (m, 1H), 2.44-2.36 (t, 1H), 
2.36-2.24 (m, 2H), 1.90-1.17 (m, 21H), 0.93-0.80 (t, 3H). 13C NMR (300 MHz, CDCl3) δC 157, 
141, 137.4, 137.0, 128.7, 128.0, 127.5, 127.0, 126.5, 119.5, 115.0, 112.0, 98.0, 97.0, 87.0, 
70.0, 62.5, 62.0, 35.0, 34.0, 33.5, 32.5, 32.0, 31.0, 29.5, 25.5, 24.5, 22.5, 20.0, 14.0. IR 3398 
(O-H), 2930 (C-H), 2859 (C-H), 1582 (C=C). Theoretical mass = 490.3 g/mol. [M+Na]+ Found 
= 513.7 m/z. Purified by HPLC revealing diasteroisomers. 
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Synthesis of aryl alkyne ketone 
 
Alkyne alcohol oxidation of benzyl alkynol: Manganese (IV) oxide (1.23 g, 14.19 mmol) 
was added to a solution of racemic benzylalkynol 183 (0.12 g, 0.252 mmol) in acetone (10 mL) 
and the solution stirred at RT for 20 hours. The reaction was monitored by TLC (ethyl 
acetate/hexane 1:4). The reaction mixture was filtered through Celite® and the filtrate solvent 
removed in vacuo to afford aryl alkyne ketone 184 (0.11 g, 87%). 1H NMR (300 MHz, CDCl3) 
δH 7.75 (t, 1H), 7.54 (m, 9H), 7.20-7.03 (d, 1H), 6.12-5.90 (m, 1H), 5.11 (d, 2H), 5.02 (d, 1H), 
4.98-4.89 (m, 2H), 4.70-4.58 (m, 1H), 3.95-3.80 (m, 3H), 3.80-3.68 (m, 1H), 2.66-2.56 (td, 1H), 
2.51 (t, 1H), 2.18 (s, 1H), 1.94-1.18 (m, 18H), 0.88 (t, 3H); 13C NMR (300 MHz, CDCl3) δC 
180.1, 136.9, 131.0, 128.7, 128.0, 127.2, 126.8, 124.8, 123.0, 116.3, 116.2,3, 115.1, 98.7, 
97.9, 96.1, 95.5, 81.8, 77.2, 76.8, 70.6, 63.2, 53.9, 40.0, 33.7, 32.1, 31.8, 31.3, 30.1, 25.5, 
25.2, 22.7, 20.3, 15.9, 15.1, 14.2; IR 3070 (C-H), 2930 (C-H), 2859 (C-H), 2213 (C≡C), 1644 
(C=O). 
Synthesis of chiral benzylalkynol 
 
CBS reduction of aryl alkynyl ketone: To a solution of aryl alkyne ketone 184 (0.10 g, 0.205 
mmol) in anhydrous THF (2 mL) was added CBS reagent in toluene (1M) (0.25 mL, 0.246 
mmol), drop-wise under argon at RT. After 15 minutes, the solution was cooled to -30 °C by 
acetone/dry ice bath and the borane dimethyl sulfide complex in toluene (2M) (0.15 mL, 0.307 
mmol) was added drop-wise. After 3.5 hours at -30 °C, the reaction was brought up to -20 °C 
for 1 hour. The reaction was monitored by TLC (ethyl acetate/hexane 1:4) and the reaction 
cooled back to -40 °C and quenched by drop-wise addition of methanol (0.18 mL). The reaction 
was allowed to reach 0 °C before ammonium chloride (0.7 mL) and ethyl acetate (2 mL) added. 
The product was extracted from the aqueous phase and the organic layer washed with 
ammonium chloride (5 mL), water (2 × 5 mL) and brine (5 mL), dried over Na2SO4 and the 
solvent removed in vacuo. The crude product was chromatographed through silica gel column 
in Ethyl acetate/hexanes (2-10%) which afforded the chiral benzylalkynol 182 (0.03 g, 30%). 
1H NMR (300 MHz, CDCl3) δH 7.48-7.28 (m, 5H), 7.20 (t, 1H), 7.03 (d, 1H), 6.91 (d, 1H), 6.11-
5.94 (m, 1H), 4.99 (dt, 2H), 4.93 (q, 1H), 4.70 (d, 2H), 3.57 (d, 2H), 1.65-1.52 (m, 2H), 1.25 (s, 
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3H); 13C NMR (300 MHz, CDCl3) δC 156.8, 140.8, 137.1, 128.6, 127.8, 127.2, 119.6, 115.0, 
112.0, 98.0, 76.7, 75.9, 70.3, 62.9, 35.2, 33.9, 32.7, 32.1, 31.2, 29.8, 25.6, 24.8, 22.7, 20.0, 
15.0, 14.2; IR 3398 (O-H), 2928 (C-H), 2857 (C-H); Purity was determined by HPLC (94% de). 
Synthesis of Benzyl alkynyl t-butyldimethylsilyl ether 
 
Silylation of benzylalkynol: To a solution of chiral benzylalkynol 182 (4.50 g, 9.17mmol) in 
anhydrous dichloromethane under argon was added imidazole (0.75 g, 11.004 mmol) and 
dimethylaminopyridine 32 (0.23 g, 1.832 mmol) and stirred. Once dissolved, the solution was 
cooled to 0 °C and t-butyldimethylsilyl chloride (1.66 g 11.004 mmol) was added. The reaction 
was monitored by TLC (ethyl acetate/hexane 1:4) and after 22 hours was quenched by 
addition of H2O (15 mL). The aqueous layer was extracted with DCM (3 × 10mL) and the 
organic layers combined and washed with brine (15 mL) then dried over Na2SO4 and the 
solvent removed in vacuo. The crude product was purified by silica gel column 
chromatography using ethyl acetate in hexanes (1-5%) which afforded a viscous liquid product 
185 (1.30 g, 24%). 1H NMR (300 MHz, CDCl3) 7.48-7.26 (m, 5H), 7.20 (td, 1H), 6.87 (d, 1H), 
6.07-5.90 (m, 1H), 5.60 (s, 1H), 5.08 (s, 2H), 5.02-4.9 (m, 2H), 4.59 (dt, 1H), 3.95-3.80 (m, 
1H), 3.74-3.56 (m, 2H), 3.50-3.38 (m, 1H), 2.37-2.27 (m, 1H), 2.23 (t, 1H), 1.86-1.62 (m, 4H), 
1.62-1.41 (m, 6H), 1.39-1.20 (m, 6H), 0.91 (s, 10H), 0.11 (d, 6H). 
Synthesis of t-butyldimethylsilyl tricyclic enone 
 
Stoichiometric Pauson-Khand cyclisation: To a solution of benzyl alkynyl t-
butyldimethylsilyl ether 185 (2.44 g, 4.028 mmol) in toluene, was added octacarbonyl dicobalt 
(1.38 g, 4.028 mmol) and the brown solution stirred for 48 hours. The reaction was monitored 
by TLC in (ethyl acetate in hexane 1:9) The reaction mixture was filtered through Celite®, 
rinsed with ethyl acetate and solvent removed in vacuo. The crude product was 
chromatographed on silica gel column using a gradient of ethyl acetate in hexanes (2-6%) to 
give pure cyclic enone 186 (1.07 g, 42%). 1H NMR (300 MHz, CDCl3) δH 7.45-7.38 (t, 8H), 
181 184 
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7.38-7.3 (m, 1H), 7.24-7.17 (m, 1H), 6.93 (m, 1H), 6.84 (q, 1H), 5.60 (s, 1H), 5.48 (s, 0.5H), 
5.30 (s, 0.5H), 5.05 (s, 0.5H), 4.54-4.48 (dt, 1H), 3.91-3.71 (m, 1H), 3.65-3.43 (m, 2H), 3.43-
3.29 (m, 2H), 2.69 (dd, 1H), 2.53-2.42 (m, 1H), 2.41-2.10 (m, 2H), 2.04 (s, 1H), 1.83-1.78 (m, 
1H), 1.74-1.39 (m, 9H), 1.36-1.14 (m, 7H), 0.90-0.83 (m, 3H), 0.81 (s, 8H), 0.17 (s, 2H), 0.13 
(s, 1H), 0.08 (d, 3H); 13C NMR (300 MHz, CDCl3) δC 210.0, 172.7, 156.2, 137.4, 137.1, 128.6, 
127.9, 127.4, 122.5, 110.5, 98.0, 97.3, 77.5, 77.2, 76.7, 70.2, 65.6, 62.9, 42.4, 34.0, 33.3, 
32.2, 32.1, 25.8, 22.7, 22.5, 20.0, 19.5, 14.4, 14.0; IR 2927 (C-H), 2855 (C-H), 1702 (C=O), 
1584 (C=C). Theoretical mass = 646.4 g/mol. Mass found: [M+Na]+ = 655.8 m/z. Purification 
and analysis by HPLC rendered the pure compound (90% de). 
Catalytic Pauson-Khand cyclisation using carbon monoxide: To a solution of benzyl 
alkynyl t-butyldimethylsilyl ether 185 (0.21 g, 0.34 mmol) in 1,2-dimethoxyethane, was added 
octacarbonyl dicobalt (0.02 g, 0.0341 mmol) in an argon atmosphere. The system was purged 
with CO gas and stirred for 17 hours at RT. The reaction was then refluxed at 60 °C for 24 
hours. The reaction was monitored by TLC in (ethyl acetate in hexane 1:4). The solvent was 
removed in vacuo and purified by silica gel column chromatography in ethyl acetate/hexane 
(2-6%) to give pure cyclic enone 186 (0.12 g, 58%). 1H NMR (300 MHz, CDCl3) δH 7.45-7.29 
(m, 5H), 7.23-7.17 (m, 1H), 6.93 (q, 1H), 6.84 (q, 1H), 5.60 (s, 1H), 5.48 (s, 1H), 5.05 (s, 2H), 
4.51 (dt, 1H), 3.90-3.81 (m, 1H), 3.80-3.71 (m, 1H), 3.68-3.44 (m, 2H), 3.43-3.28 (m, 2H), 2.69 
(dd, 1H), 2.55-2.11 (m, 4H), 1.92-1.73 (m, 1H), 1.73-1.11 (m, 20H), 0.91-0.76 (m, 12H), 0.15 
(d, 3H), 0.09 (d, 3H); 13C NMR (300 MHz, CDCl3) δC 172.7, 156.1, 138.7, 137.4, 128.7, 128.0, 
127.3, 125.5, 122.4, 110.6, 97.9, 70.0, 65.3, 62.9, 42.3, 33.8, 33.7, 32.2, 31.5, 25.7, 25.6, 
25.3, 24.8, 22.7, 18.2, 14.1; IR 2928 (C-H), 2855 (C-H), 1702 (C=O), 1584 (C=C); Theoretical 
mass = 646.4 g/mol. Mass found: [M+Na]+ = 655.8 m/z. Purity was determined by HPLC (90% 
de). 
Synthesis of tricyclic ketone 
 
Hydrogenation of cyclic enone: To a solution of pure t-butyldimethylsilyl tricyclic enone 186 
(2.07g, 3.2mmol) in ethanol (8 mL) was added potassium carbonate (0.20 g, 10% wt./wt. of 
cyclic enone). Once purged with argon, palladium on activated carbon was added and the 
system purged with hydrogen then stirred at RT for 20 hours. The reaction was monitored by 
TLC (ethyl acetate/hexane 1:4) and IR (peak shift from 1702 to 1732 cm -1). The reaction 
mixture was filtered through Celite® and the solvent removed from the filtrate in vacuo. The 
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crude product was combined with the crude products of two other batches and 
chromatographed together through silica gel column using solvent gradient ethyl acetate in 
hexanes (2-14%) to yield the tricyclic ketone product 187 (0.92 g, 43% of combined theoretical 
yields). 1H NMR (300 MHz, CDCl3) δH 7.06-6.94 (m, 1H), 6.71 (q, 1H), 6.63 (d, 1H), 4.98-4.87 
(m, 1H), 4.71-4.57 (dm, 1H), 3.98-3.80 (m, 1H), 3.70-3.55 (m, 1H), 3.55-3.40 (m, 1H), 3.08-
2.89 (m, 2H), 2.78-2.26 (m, 5H), 2.25-2.12 (dt, 1H), 2.01-1.16 (m, 24H) 13C NMR (300 MHz, 
CDCl3) δC 220.3, 153.9, 152.8, 136.6, 126.4, 122.4, 112.6, 98.1, 97.4, 63.1, 58.2, 51.7, 45.3, 
38.9, 35.0, 32.2, 31.9, 30.6 25.7, 22.7, 19.9, 14.1; IR 3365 (O-H), 2927 (C-H), 2855 (C-H), 
1732 (C=O), 1590 (C=C), Purity was confirmed by HPLC (94%). 
Synthesis of tricyclic diol 
 
Reduction of tricyclic ketone: To a solution of tricyclic ketone 187 (0.11g, 0.26 mmol) in 
ethanol (2 mL) at -10 °C was added dropwise a solution of sodium hydroxide (0.10 g, 0.10 
mmol) in H2O (1mL). The solution was kept at -10 °C and after 30 minutes sodium borohydride 
(0.02 g, 0.54 mmol) was added in 5 portions and the solution allowed to reach RT. The reaction 
was monitored by TLC (ethyl acetate/hexanes 2:5 silica). Additional NaBH4 (10%) was added 
to push the reaction to completion which was reached after 2 hours. The reaction was 
quenched by addition of saturated ammonium chloride solution (1 mL) and the solvent 
removed in vacuo. To the remaining solution was added H2O (2mL) and extracted with t-
butylmethyl ether (3 × 2 mL). The organic layers were combined and washed with H2O (2 × 2 
mL) and brine (3 mL), dried over Na2SO4 and the solvent removed in vacuo. The tricyclic diol 
188 (0.11 g, 94%) was obtained. 1H NMR (300 MHz, CDCl3) δH 6.93 (t, 1H), 6.78-6.55 (m, 2H), 
4.65 (dt, 1H), 4.00-3.85 (m, 1H), 3.80-3.57 (m, 2H), 3.57-3.42 (m, 1H), 2.79 (dd, 2H), 2.41 (m, 
2H), 2.31-2.03 (m, 2H), 1.98-1.02 (m, 25H), 0.88 (t, 3H); 13C NMR (300 MHz, CDCl3) δC 153.2, 
140.9, 126.2, 124.9, 113.1, 98.7, 97.6, 77.6, 73.3, 63.7, 62.7, 52.2, 49.5, 41.2, 40.8, 34.9, 
33.7, 32.9, 32.2, 31.2, 27.1, 25.5, 22.8, 19.9, 14.2; IR 3332 (O-H), 2927 (C-H), 2857 (C-H), 
1589 (C-H); Theoretical mass = 416.3 g/mol. [M+Na]+ found by LCMS: 439.7. Purity was 
determined by HPLC (94%). 
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Synthesis of tricyclic triol 
 
THP cleavage to triol: To a solution of tricyclic diol 188 (0.10 g, 0.252 mmol) in methanol (2.5 
mL) was added dropwise HCl (10%, 3 mL) and the solution stirred at RT. The reaction was 
monitored by TLC (ethyl acetate/hexane 1:1) and after 4 hours, the reaction was quenched 
with saturated sodium bicarbonate solution until the pH reached 7-8. Methanol was removed 
in vacuo and the remaining aqueous solution was extracted with ethyl acetate (2 × 10 mL). 
The organic layers were combined and washed with H2O (2 × 5 mL) and brine (7 mL), dried 
over Na2SO4 and the solvent removed in vacuo to yield tricyclic triol 51 (0.07 g, 86%). 1H NMR 
(300 MHz, CDCl3) δH 6.92 (t, 1H), 6.70-6.57 (q, 2H), 3.71-3.46 (m, 2H), 2,73-2.52 (qn, 2H), 
2.41 (td, 2H), 2.26-1.94 (m, 2H), 1.91-1.73 (m, 1H), 1.69-0.97 (m, 15H), 0.89 (t, 3H); 13C NMR 
(300 MHz, CDCl3) δC 153.1, 140.8, 126.2, 125.0, 120.2, 113.4, 72.8, 60.6, 51.9, 41.1, 40.9, 
37.4, 35.0, 33.7, 32.8, 32.0, 28.6, 26.0, 25.5, 22.8, 14.2; IR 3298 (O-H), 2924 (C-H), 2855 (C-
H), 1588 (C=O); Purity was analysed by HPLC (92% de). 
Synthesis of benzindene nitrile 
 
Alkylation of tricyclic triol by chloroacetonitrile: To a solution of tricyclic triol 51 (0.07 g, 
0.205 mmol) in acetone (3 mL) under argon was added chloroacetonitrile (0.06 g, 0.820 mmol), 
tetrabutylammonium bromide (0.01 g, 0.018mmol) and powdered potassium carbonate (0.17 
g, 1.23 mmol). The mixture was stirred at RT for 36 hours and the reaction monitored by TLC 
(alumina plate, 5% MeOH/DCM). The reaction was filtered through Celite® and the solvent 
removed from filtrate in vacuo. The crude product was chromatographed though silica gel 
column using ethyl acetate in hexanes (10-45%). TLC were carried out in 80% ethyl 
acetate/hexane. The benzindene nitrile product 189 was obtained (0.12 g, 150%). 1H NMR 
(300 MHz, CDCl3) δC 7.13 (t, 1H), 6.90 (d, 1H), 6.81 (d, 1H), 4.75 (s, 2H), 3.80-3.67 (m, 1H), 
3.67-3.52 (m, 1H), 2.48 (qn, 2H), 2.33-2.10 (m, 2H), 2.04 (s, 2H), 1.94-1.05 (m, 21H), 0.89 (t, 
3H); 13C NMR (300 MHz, CDCl3) 153.8, 141.6, 128.4, 126.6, 123.1, 115.5, 110.5, 72.6, 60.5, 
54.5, 52.3, 41.4, 41.2, 37.5, 35.0, 33.7, 32.8, 32.0, 28.7, 26.0, 25.5, 22.7, 14.2; IR 3328 (O-
187 50 
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H), 2926 (C-H), 2856 (C-H), 1732 (C≡N), 1236 (C-O). Chiral purity determined by HPLC (90% 
de). 
Synthesis of treprostinil 
 
Hydrolysis of benzindene: To a solution of tricyclic nitrile 189 (0.12 g, 0.313 mmol) in MeOH 
(3 mL) was added potassium hydroxide (0.10 g, 1.25 mmol) in H2O (0.5 mL) and the reaction 
heated to 80 °C under reflux for 48 hours. The reaction was monitored using TLC (7:3 ethyl 
acetate/hexane. The solvent was removed in vacuo and the remaining solution extracted with 
t-butylmethyl ether (3 × 2 mL). HCl (10%, 2 mL) was added to pH 2 and ethyl acetate (10 mL) 
added. The organic layer was washed with H2O (8 mL) and brine (8 mL) then dried over 
Na2SO4 and solvent removed in vacuo to yield treprostinil 4 (0.07 g, 55%). 1H NMR (300 MHz, 
MeOD) 7.04 (t, 1H), 6.73 (dd, 2H), 4.62 (s, 2H), 3.66-3.40 (dm, 2H), 2.81-2.56 (m, 3H), 2.47 
(dd, 1H), 2.34-2.15 (m, 1H), 1.25-1.96 (m, 1H), 1.96-1.80 (m, 1H), 1.80-1.02 (m, 16H), 1.90 (t, 
3H);13C NMR (300 MHz, MeOD) 155.2, 140.9, 127.4, 125.9, 121.1, 109.4, 76.3, 71.6, 65.2, 
51.3, 41.0, 40.7, 37.0, 34.8, 33.3, 32.8, 31.9, 28.3, 27.6, 25.3, 25.2, 22.5, 13.2; IR 3310 (O-
H), 2925 (C-H), 2856 (C-H), 1729 (C=O); Theoretical mass = 390.5 g/mol. [M+Na]+ found by 
LCMS: 413.6 m/z. Purity was analysed by HPLC (96% de). 
 
Treprostinil 4 was successfully synthesised during a 3-month internship with United 
Therapeutics & Lung Biotechnology at their headquarters in Silver Springs, Maryland, USA 
(Scheme 70). The purpose of this endeavour was to gain an appreciation of the synthetic 
routes used on a commercial level and to investigate common intermediates which could be 
modified for conjugation. Two methods used by United Therapeutics for both large, FDA 
approved (route i)354 and small scale production (route ii) of alkyne addition to aldehyde were 
followed and their diastereomeric purity compared between the alternative steps and overall 
isolated product. The FDA approved synthesis includes the use of a tetrahydropyran protected 
side chain in the first synthetic step which is racemic and sensitive to degradation which limits 
synthetic options and also causes problems in the diastereomeric purity of all intermediates. 
However, FDA approval would need to be re-submitted to change the protecting group used 
so alternative protecting groups have not been introduced into the synthesis route used to 
make the clinical product. Although modification of an intermediate is possible and could 
potentially open up different synthesis and various modifications, the production of the 
intermediate chosen would take a considerable amount of time, taking the project in a different 
direction than intended. Additionally, a certain amount of purified treprostinil has been pledged 
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towards the project saving time and money. This route may be revisited if the other options 
selected involving modification of final treprostinil are unsuccessful. Characterisation data was 
not permitted off UT’s site but as all compounds are known, a comparison of the compounds 
synthesised was conducted against published (where possible) and in-house data. 
 
Scheme 70. Synthetic Scheme for Treprostinil using chiral and non-chiral reagents for 
the addition of the alkyne to aldehyde. 
Treprostinil was prepared following the reactions shown in Scheme 70. Benzyl alkynyl alcohol 
(182) was afforded from the addition of 3-benzyloxy-2-allyl benzaldehyde (180) and (S)-1-
decyn-O-tetrahydropyran-2-yl-1-ol (181) by two different methods; racemically and 
stereoselectively. The racemic Grignard reaction was conducted in the presence of 
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ethylmagnesium bromide to form the alkyne Grignard. This underwent nucleophilic addition to 
the aldehyde 180 to form the racemic alcohol (183) in 72% yield. This benzyl alkynyl alcohol 
(183) was oxidized by MnO2 to afford aryl alkyne ketone (184) in 87% yield which was then 
stereoselectively reduced in the presence of borane dimethyl sulphide complex and (R)-2-
methyl-CBS-oxazaborolidine to afford chiral benzylalkynyl alcohol (182) in 30% yield with 
chiral purity of 94 % de. Alternatively, the stereoselective reduction forms the desired product 
in one step which avoids the need to oxidise and reduce and can be carried out using two 
different chiral agents, both of which were undertaken. The first was carried out in the presence 
of zinc triflate and (+)-N-methylephedrine. Zinc triflate (Zn(OTf)2) coordinates to the alkyne in 
a similar manner to the Grignard rendering it more active towards the aldehyde and the 
methylephedrine, a chiral molecule itself, coordinates to the aldehyde oxygen via hydrogen 
bonding by the oxygen and nitrogen lone pairs and uses the phenyl group to direct the alkyne 
addition to the Re face with 98% de. Due to the cost and restricted supply of (+)-N-
methylephedrine, a second chiral reagent can be used, (1S, 2S)-3-(t-butyldimethylsilyloxy)-2-
N,N-dimethylamino-1-(p-nitrophenyl)propan-1-ol. The reaction is carried out similar as that as 
before, with zinc triflate, but using THF in place of toluene. The reaction required a longer 
period to reach completion and gave the desired product with 96% de. Both of the products 
were identified using 1H NMR spectroscopy with the presence of the resonance at δ 5.6 
corresponding to the proton adjacent to the newly formed alcohol, as well as the aromatic 
proton resonance shift from δ 7.2 to δ 6.9.  
Before cyclisation, the alcohol (182) was protected by reaction with tertiary-butyldimethylsilyl 
chloride (TBDMSCl) in the presence of imidazole and dimethyl aminopyridine (DMAP), to form 
the silyl ether (185) in 42 % yield.  The Pauson-Khand cyclisation of (185) requires the use of 
octacarbonyl dicobalt and occurs by complexation to the alkyne and alkene which facilitates 
cyclic electron transfer with the donation and incorporation of a carbonyl ligand to form the 
tricylic enone (186). This can either be carried out in in stoichiometric amounts of cobalt 
complex or in a catalytic quantity regenerating the catalyst using carbon monoxide gas. Both 
methods were investigated. The silyl ether acts as an important directing group as the bulky 
moiety blocks complexation on the upper face of the molecule and preferentially forms the 5-
membered ring with S configuration. The first reaction used a catalytic amount of octacarbonyl 
dicobalt (0.1 equivalents) in a carbon monoxide atmosphere at 60 °C to afford the tricyclic 
enone (186) in 58 % yield. The alternative uses a stoichiometric amount of octacarbonyl 
dicobalt (1 equivalent) in an argon environment at 80 °C to afford the same product in 94 % 
yield. Despite giving a better yield, the cost of the cobalt complex limits the use of the 
stoichiometric method in scaled up production.  
Both products are identifiable by IR spectroscopy with the observance of the absorbance at 
1702 cm-1 corresponding to the enone carbonyl. In 1H NMR spectroscopy, the absence of the 
characteristic proton resonance at δ 5.9 which corresponds to the non-terminal alkene proton 
of the product is also a clear indicator that cyclisation has taken place. The conformational 
restriction imposed by cyclisation results in the splitting of the resonance at δ 5.6 
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corresponding to the proton adjacent to the alcohol. The presence of the THP group results in 
two diastereomers which are more distinguishable when the molecules loose conformational 
freedom, hence the splitting was not observed in the benzyl alkynyl (181) precursor. The 
reduction of t-butyldimethyl silyl ether and enone as well as the cleavage of the benzyl 
protecting group was conducted in a one-step reaction in the presence of potassium 
carbonate, over palladium carbon in a hydrogen environment for afford (187). The reaction 
was carried out several times on different scales and the crude products combined and 
chromatographed together to afford the tricyclic ketone (187) in 44% yield. The benzyl group 
cleavage and silyl ether reduction are relatively fast compared to the enone reduction which 
alters the polarity of the molecule and makes the reaction appear complete by TLC. The Rf 
value for the de-silylated and de-benzylated enone and the desired ketone are 
indistinguishable by TLC so for this reason, the reaction of monitored by IR spectroscopy.  The 
IR absorption corresponding to the carbonyl will change from enone resonance (1702 cm -1) to 
ketone resonance, (1732 cm-1). The ketone was reduced to the corresponding secondary 
alcohol in the presence of sodium hydroxide and sodium borohydride to afford the tricyclic diol 
(188) in 94% yield. This was determined by the absence of the absorbance of the carbonyl 
bond at 1732 cm-1 by IR spectroscopy. The tetrahydropyran group was cleaved in acid to yield 
triol (51) at 86% which was proven by the absence of the racemic proton resonances at δ 4.6 
and 4.7. The THP cleavage also resulted in an observed upfield peak shift from δ 3.9 to δ 3.6 
corresponding to the proton adjacent to the newly formed alcohol. The triol (51) was alkylated 
by chloroacetonitrile in the presence of tetrabutylammonium bromide (Bu4NBr) and potassium 
chloride to give benzindene nitrile (189). The carbon- chlorine bond is stronger than the 
corresponding bromide bond so the addition of tetrabutylammonium bromide serves to 
displace the chloride on the chloroacetonitrile which increases the rate of alkylation. The bond 
formation was confirmed by 1H NMR with the presence of the OCH2CN proton resonance at δ 
4.7 which had shifted from δ 3.5 in the chloroacetonitrile reagent. The CN bond stretch was 
not observed in the expected nitrile region (2260 – 2220 cm-1) due to the inductive effect of 
the resonant oxygen. The benzindene nitrile (189) was hydrolyzed by potassium hydroxide in 
aqueous methanol to afford crystalline treprostinil (4) in 55% yield which was characterized by 
1H NMR, 13C NMR, IR, purity by HPLC (96% de). The hydrolysis was confirmed by the 
presence of the IR absorbance corresponding to the carboxylic acid carbonyl at 1728 cm -1. A 
summary of the synthesis and the stereochemical outcomes is given in Table 8-2. 
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Table 8-2. Summary of the scales, diasteromeric outcomes, and conditions of the 
synthetic routes used to obtain treprostinil 2.PKC = pauson-Kahn cyclisation; RT= 
room temperature;  
Racemic Stereoselective 
Alkyne coupling with 
grignard THF: 
5 g scale. 
EtMgBr 
Refluxed at RT → 60 
°C for 29 hrs 
25 % impurity by NMR. 
86% de. 
Alkyne coupling 
with grignard in 
diethyl ether: 
0.5 g scale. 
EtMgBr 
Refluxed at RT → 40 
°C for 3.5 hrs. <4 % 
impurity by NMR. 
Alkyne coupling: 
0.5g scale. 
Zinc triflate and  (+)-N-
methylephidrine 
employed to give 98% 
de. 
 
Alkyne coupling: 5g 
scale. 
Zinc triflate and (1S, 
2S)-3-(t-butyl 
dimethylsilyloxy)-2-
N,N-dimethylamino-1-
(p-nitrophenyl) 
propan-1-ol 
96% de. 
Oxidation (from THF reaction): 
0.1 g scale. Oxidation by MnO
2
 at RT 
Chiral CBS reduction: 
CBS reagent in presence of borane complex. 
Ar atmosphere at -30 °C. 
94% de 
Protection by TBDMS group: 
DMAP with imidazole and tertiary-butyldimethylsilyl chloride. 
Catalytic PKC: 
0.2 g scale. 
0.1 eq. Co2(CO)8 in CO atmosphere at 
60 °C for 24 hours. 58% yield. 
Stoichiometric PKC: 
0.2 g scale. 
1 eq. Co2(CO)8 in Ar atmosphere at RT→80 °C for 24 
hours. 55% yield. 
Hydrogenation: 
Pd catalyzed in hydrogen atmosphere at RT. 
Reduction: 
Ketone reduction by sodium borohydride. 
THP hydrolysis: 
Reflux in presence of excess 10 % HCl. 
Alkylation: 
Selective alkylation of phenol using chloroacetonitrile. 
Hydrolysis: 
Base catalyzed hydrolysis in excess KOH. 96% de. 
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Scheme 71. Reduction during the Grignard reaction to produce the alcohol impurity 
190. 
When carrying out the Grignard addition to afford 183, it was noticed that two spots on the 
TLC formed as the product. They were not easily separated on silica gel column and when 
looking back at previous experiments of this type, it was also the case, but had not been 
investigated. The crude product was carried forward to the oxidation step where it appeared 
by TLC that only one product had formed as there was only one spot, however, 1H NMR 
spectra showed the presence of an aldehyde proton which had previously been attributed to 
starting material (180). Upon stereoselective reduction, two spots were again identified which 
led us to believe that an unidentified side product was forming. A small amount was isolated 
of each of the spots and it was determined that the lower spot was an unexpected benzyl 
alcohol derivative (190) present at 25%. Literature reports known competition of the outcomes 
of a Grignard to aldehyde reaction577; addition (desired in this case) and self-reduction 
(undesired) which forms the benzyl alcohol product (Scheme 71). Further reading identified 
the solvent and temperature to be a major factor in the relative outcomes of the reaction. The 
reaction was carried out in both THF (current procedure) and diethyl ether.  
Table 8-3. A comparison of the percentage of impurity 190 formed in the each of 
the different reaction conditions. 
Reaction Impurity 
0.5 g scale in THF at RT 25 % 
0.5 g scale in diethyl ether at RT 3.9 % 
0.5 g scale in diethyl ether, refluxing at 40 °C 3.6 % 
The percentage impurity, detected by 1H NMR spectroscopy, from the reaction carried out in 
THF at room temperature was 25% however, the same reaction in diethyl ether showed only 
3.9% of the self-reducing product. The same reaction in diethyl ether was carried out whilst 
refluxing at 40 °C however the increased temperature made negligible difference with 3.6% 
impurity. The low boiling point (and therefore refluxing temperature) of diethyl ether means 
that the refluxing temperature is similar to room temperature so perhaps the effect of 
temperature would be more pronounced using THF. However, the investigation was deemed 
complete as the impurity had been isolated and a method to reduce it had been determined. 
179 189 
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 Polyvalent Synthesis 
A polyvalent approach takes inspiration from nature to amplify a binding effect by binding 
multiple moieties to a surface simultaneously. When an antibody binds to its respective antigen 
on a cell surface there can be an effector function where the antibody Fc recruits other cells, 
generally from the immune system, to evoke a biological response. The more antibody bound 
to the antigen, the more Fc is present and the stronger can be the effector function.  
Additionally, bacteria interact with cell surfaces using polyvalent interactions to gain entry. A 
polyvalent approach has been used to enhance an anthrax toxin inhibitor which consists of a 
liposome covered in inhibitor ligands. The polyvalent inhibitor extended clearance time and 
blocked anthrax toxin action more potently than free inhibitor.258 Polyvalency has potential for 
the therapeutic activation of cell surface receptors.257 
 
Figure 8-1. Structure of a polyvalent approach which possesses multiple non-
cleavable drug molecules on the same structure. The drugs are conjugated without 
the intention of release as a polyvalent approach requires the drug structures to be 
active upon conjugation. As the first drug ligand bind to the receptor, other ligands are 
in close proximity to other receptors which uses a co-operative binding effect in 
increase lreceptor activation. A targeting moiety can be employed to localise receptor 
binding. 
The prostanoid receptors (IP, EP2, DP1) are present on endothelial cells, smooth muscle cells 
(which infiltrate the vascular lumen in PAH) and platelets. Once in the blood stream, treprostinil 
has exposure to the target receptors, which may present an opportunity to achieve receptor 
activation using a polyvalent approach. 
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Figure 8-2. Modifiable atoms in the treprostinil 4 structure. Modifiable atoms required 
for receptor binding are labelled in orange, and those in green are atoms which are 
not known to interact with the binding pocket. 
A structure possessing multiple treprostinil molecules which are active at the IP, EP2 and DP1 
receptors can be envisaged. A polyvalent strategy is complex for treprostinil 4 because (i) of 
the injection site toxicity displayed by treprostinil 4 and (ii) the need for the carboxylic acid and 
two hydroxyl groups on treprostinil 4 for activity (Figure 8-2). If the treprostinil acid and 
hydroxyls cannot be used to make a polyvalent treprostinil construct, then it would be 
necessary to conjugate treprostinil 4 at one of its aliphatic or aromatic carbons (Figure 8-2). 
Nonetheless it is possible to imagine a polyvalent treprostinil conjugate using a prodrug variant 
of the conjugated treprostinil (Figure 8-3). For example, a polyvalent treprostinil construct 
could contain multiple copies of treprostinil 4 bound to a polymer where either the carboxylic 
acid or hydroxyls on treprostinil 4 are derivatised with a labile moiety to mask the conjugated 
treprostinil 4 during injection.  
 
Figure 8-3. Depiction of a polyvalent approach which requires prodrug moieties to 
prevent receptor activity in other organs. The prodrug would require deprotection in 
the disease tissue to localise the receptor activity. A targeting moiety could be utilised 
to enhance localisation in the pulmonary vessels. 
There are many limitations of a polyvalent strategy using treprostinil which include, multi-step 
synthesis, the need for prodrug activation, the risk that a polyvalent treprostinil 4 would not 
4 
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display higher potency or enhanced PK properties. Conjugating a drug to a polymer via a 
covalent bond to an aromatic or aliphatic carbon on the drug is not a conventional strategy 
and could pose challenges for scaling the synthesis. Nonetheless, preliminary experiments 
were conducted with treprostinil 4 to determine if a polyvalent strategy might be possible. 
 
Scheme 8-72. Proposed methylation of the methylene carbon of ethyl-2-
phenoxyacetate 191 in the presence of base to afford methylated ether 192. 
Initial reactions focused on the derivatisation of phenoxy model via the methylene carbon 
(Scheme 8-72). The pKa of the methylene protons is lower than other carbon-protons which 
may facilitate a route to derivatise using alkyl halide and strong base. To prevent alkylation of 
the acid group, the first attempts were to methylate the methylene proton of ethyl-2-
phenoxyacetate 191 (50 mg) with methyl iodide in the presence of lithium diisopropylamide (1 
equivalent) which has a pKa of 36. The reactions were conducted in THF at -78 ᵒC using a dry 
ice/acetone bath. TLC monitoring did not show change over time. The reactions were repeated 
several times unsuccessfully before attempting with milder potassium tertiary butoxide (pKa 
~17). After 24 hours, a slight shift in the TLC spot from starting material was observed so the 
reaction was worked up and the residue analysed by 1H NMR. The spectra showed starting 
material and no methylation of the methylene carbon, as shown in Figure 8-4.  
 
Figure 8-4. The 1H NMR spectrum obtained following attempts to methylate at the 
methylene carbon using methyl iodide. Only the presence of starting ester was 
indicated. 
191 
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The more robust ester group, tertiary butoxide was employed by reaction of phenoxyacetic 
acid with di-tert-butylcarbonate in tert-butyl alcohol as solvent. The tert-butyl ester product was 
treated with methyl iodide and lithium diisopropylamide as before but following work up in ethyl 
acetate, only starting ester was isolated as determined by 1H NMR. The added bulky groups 
may have prevented the alkylation of the methylene however, a similar result was found with 
the ethyl ester, suggesting that the methylene possess poor reactivity. The alkylated product 
did not seem to be as accessible as possible and the derivatisation of the phenol to achieve 
the alkylated product would be a better route (Scheme 8-73). Phenol could be employed for 
the model reaction but treprostinil triol had not yet been donated. Therefore, efforts to achieve 
the alkylation methylene derivative were terminated. 
 
Scheme 8-73. Suggested method to alkylate the methylene by reaction of phenol 
derivative. Displacement of the iodine would result in the same desired product 192 
but starting with a phenol derivative instead of the acid. 
Alternative to the methylene derivatisation, the aromatic protons can also in principle be 
derivatised. A Friedel Crafts acylation of the benzene ring was considered. The oxygen of the 
phenoxy group has an electron donating effect on the aromatic ring which facilitates 
derivatisation at the ortho and para positions. Only one ortho position is available and is likely 
hindered by the acid moiety. Therefore, it was expected that derivatisation would occur at the 
para position 193 (Scheme 8-74). Formation of a carbon-carbon bond by a Friedel Crafts type 
reaction can be modified to form the acylated or alkylated product. Alkylation would form a 
simple carbon-carbon bond to the benzindene ring, which is an electron donating group. The 
electron donation further activates the ring which results in additional alkylation at the ortho 
positions. To avoid unwanted activity, a Friedel Crafts reaction can form an acylated product 
which results in the addition of an electron withdrawing group which de-activates the ring and 
prevents further acylation. Subsequent reduction of the carbonyl results in the alkyl derivative 
(Scheme 8-74).  
 
Scheme 8-74. Proposed Friedel Crafts acylation of phenoxy acid derivatives at the 
para position. Nucleophilic substitution of the aromatic electrons into the acid chloride 
carbonyl displaces the chloride with the assistance of the aluminium chloride. 
Ethyl-2-phenoxyacetate 191 was used as a model in a preliminary attempt to acylate the 
aromatic ring. It was assumed that the treatment with one equivalent of acetal chloride would 
191 
192 
Appendix 
432 
  
preferentially form the para-derivatised product 193 over the ortho products owing to the steric 
hindrance provided by the acid group. Ethyl-2-phenylacetate (100 mg) was treated to crushed 
aluminium chloride (2 equivalents) in dichloromethane and acetyl chloride (1.5 equivalents) 
was slowly added. Monitoring by TLC in 40% ethyl acetate/hexane showed no presence of 
ester starting material but upon work-up no product was observed. Several repeats were 
conducted, increasing the amount of aluminium chloride and using carbon disulfide as solvent. 
Reaction of the acid 22 and the addition of a refluxing step (70 ᵒC) for 5 hours produced the 
expected product 193 (Figure 8-5). 
 
Figure 8-5. 1H NMR spectra of the acylated phenoxyacetic acid 193 by Friedel Crafts 
acylation. Phenoxyacetic acid 22 (100 mg) was left to react with aluminium chloride (3 
equivalents) in carbon disulfide before the addition of acetyl chloride (1.2 equivalents). 
The reaction solution was refluxed for 5 hours. A change in the aromatic protons 
indicated substitution of the para position and the singlet of the acetyl group was 
present with integral 3. 
Following a successful acylation of the model compound, the reaction was repeated using a 
halide acid with a reactive handle suitable for further conjugation. Ethyl-2-phenoxyacetate 191 
was treated with bromoacetyl bromide 53 in the presence of aluminium chloride. Addition of 
reagents with cooling was conducted as before which was followed by 5 hours of heating to 
70 ᵒC. TLC monitoring indicated the absence of ester starting material 191 and subsequent 
work up gave the desired product 195 (Figure 8-6). 
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Figure 8-6. 1H NMR of the bromoacetylated phenoxyacetate derivative 195 following 
Freidel Crafts acylation. A reaction at the para position of the aromatic ring was 
indicated by the symmetrical remaining aromatic resonances (green and yellow). The 
presence of the bromo methylene peak (red) integrates exactly with the other peaks 
suggesting the reaction occurred as desired. 
The reduction of the acyl group of bromo product 195 was successfully attempted on a 50 mg 
scale using triethyl silane (3 equivalents) and a catalytic amount of trifluoroacetic acid. The 
reaction was heated to 70 ᵒC in ethyl acetate for 4 hours which afforded the desired alkylated 
product 196 (Figure 8-7).  
 
Figure 8-7. 1H NMR spectra of the acyl reduction product 196. Reaction was deemed 
successful by the upfield shift and splitting of the protons neighbouring the bromide 
(red) and the presence of two additional resonances where the acyl group once was 
(grey).  
Following success with ethyl-2-phenoxyacetate, the reaction was attempted using treprostinil. 
Experience gained from the work described Chapter 3 on the interference of the alcohol and 
194 
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acid groups led the decision to test the acylation reaction on the protected bis-benzyl ester 
treprostinil (Scheme 8-75). 
 
Scheme 8-75. Expected acylation of bis-benzyl treprostinil ethyl ester 45 in the 
presence of bromoacetyl bromide 53 and aluminium chloride. 
The acylation reaction was conducted on a 15 mg scale of treprostinil derivative in DCM. 
Reagents were added whilst cooling to -78 ᵒC and reaction solution was heated to 70 ᵒC. After 
16 hours, TLC showed multiple products, including starting treprostinil derivative 45. The 
reaction was worked up by ethyl acetate/aqueous separation and the crude product was 
analysed by 1H NMR. The resulting NMR spectrum showed no difference in the treprostinil 
benzindene aromatic resonances. Unfortunately the benzyl aromatics that were part of the 
hydroxyl protection groups were not observed, indicating that the reaction conditions had 
cleaved the protecting group benzyl ethers. Additional aromatic resonances were seen 
downfield in a small proportion as a pair of doublets which suggested that acylation had 
occurred on the benzyl groups. For future investigations, a more robust hydroxyl protecting 
group will require employment. 
Ultimately the polyvalent approach will result in treprostinil 4 as the active ingredient being 
required to have a modified structure. Whilst forming a carbon-carbon bond to link treprostinil 
on a macromolecule remains challenging, the activity of treprostinil when conjugated at the 
chosen points also remains unknown. Initial efforts were undertaken to understand the 
structure activity relationship (SAR) of treprostinil further were considered. An in-silico 
approach was investigated using previous literature on the IP receptor SAR which described 
the following points as significant for IP receptor binding; carboxylic acid charge pairing to an 
arginine side chain; hydrogen bonding of the hydroxyls to serine and threonine derivatives; 
and a hydrophobic interaction between the alkyl chain and a hydrophobic pocket. 
A model of the IP receptor has been investigated before, but to replicate the binding pocket, 
the homology model using a rhodopsin receptor required reconstructing. In addition, the 
activity of treprostinil at the EP2 receptor is established as therapeutically beneficial so 
replicating the IP receptor binding may not be entirely relevant given the wider context of 
treprostinil binding. 
Although work on the treprostinil derivatisation and in silico binding was initiated, the work was 
not continued owing to the complexity of the polyvalent approach and the lack of accessible 
information including to act as a base from which a structure can be designed. Beyond the 
44 
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challenges in synthesising a prodrug polyvalent molecule that could become active, testing 
the sustained activity of the molecule was also considered to be challenging. The extent of the 
challenges paired with the minimal information suggesting a polyvalent approach might be 
promising, efforts were terminated and were focussed on the pro-drug approaches described 
in Chapters 3-5. 
